



<b>Title</b>	<b>A NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF</b>
<b>Inventor(s)</b>	Yuen, KY; Woo, Chiuyat, Patrick; Lau, Karpui, Susanna; Chan, Kwokhung; Poon, LLM; Guan, Y
<b>Citation</b>	WO Published patent application WO 2006007795. World Intellectual Property Organization (WIPO), PatentScope, 2006
<b>Issued Date</b>	2006
<b>URL</b>	<a href="http://hdl.handle.net/10722/177107">http://hdl.handle.net/10722/177107</a>
<b>Rights</b>	Creative Commons: Attribution 3.0 Hong Kong License For Public Patent Documents

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 January 2006 (26.01.2006)

PCT

(10) International Publication Number  
**WO 2006/007795 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/50**,  
15/63, 7/00, C07K 14/165, A61K 39/215, A61P 11/00,  
G01N 33/53, C12Q 1/68

(CN). GUAN, Yi; 11A, Block 4, Pokfulam Gardens, 180  
Pokfulam Road, Hong Kong (CN).

(21) International Application Number:  
PCT/CN2005/001088

(74) Agent: CHINA PATENT AGENT (H.K.) LTD.; 22/F,  
Great Eagle Centre, 23 Harbour Road, Wanchai, Hong  
Kong (CN).

(22) International Filing Date: 20 July 2005 (20.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/895,064 21 July 2004 (21.07.2004) US  
11/129,741 16 May 2005 (16.05.2005) US

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): THE  
UNIVERSITY OF HONG KONG [CN/CN]; Pokfulam  
Road, Hong Kong (CN).

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: YUEN, Kwokjung; Flat C, 19/F, Block  
20, Baguio Villa, 555 Victoria Road, Hong Kong (CN).  
WOO, Chiuyat, Patrick; Flat B, 23/F, Block 1, Robinson  
Heights, 8 Robinson Road, Hong Kong (CN). LAU,  
Karpui, Susanna; Flat C, 1/F, Block 1, Aquamarine  
Garden, Tuen Mun, New Territories, Hong Kong (CN).  
CHAN, Kwokhung; 3A, Wisteria Mansion, Taikoo shing,  
Quarry Bay, Hong Kong (CN). POON, Litman; Flat  
21H, Block 2, Phase 3, Belvedere Garden, Tsuen Wan,  
Hong Kong (CN). PEIRIS, Joseph, Sriyal, Malik; 19/F,  
Block 29, Baguio Villa, 550 Victoria Road, Hong Kong

Published:  
— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: A NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF

(57) Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus- HKU1 ("HCoV-HKU1"), isolated in Hong Kong. The virus belongs to the order *Nidovirales* of the family *Coronaviridae*, being a single-stranded RN virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by HCoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the HCoV- HKU1 based on the nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1.

A NOVEL HUMAN VIRUS CAUSING  
RESPIRATORY TRACT INFECTION AND USES THEREOF

---

This is a continuation-in-part application of U.S. patent application serial no. 10/895,064 filed July 21, 2004, which is incorporated by reference in its entirety.

5

**SEQUENCE LISTING**

The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on March 21, 2005, are labeled "CRF", "Copy 1" and "Copy 2", respectively, and each contains only one identical 2.84 MB file (V0690044.APP).

10

**1. INTRODUCTION**

The present invention relates to a novel virus causing respiratory tract infection in humans ["coronavirus-HKU1 (CoV-HKU1)"]. Phylogenetic analysis has revealed that the CoV-HKU1 is a new group 2 coronavirus, which has, at least, two (2) genotypes, A and B. The present invention relates to nucleotide sequences comprising the complete genomic sequences of the CoV-HKU1. The invention further relates to nucleotide sequences comprising a portion of the genomic sequences of the CoV-HKU1. The invention also relates to the deduced amino acid sequences of the complete genomes of the CoV-HKU1. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods, such as for immunogens. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequence. Furthermore, the invention relates to vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus as well as protein extracts and subunits of said virus.

25

**2. BACKGROUND OF THE INVENTION**

Since no microbiological cause has been identified in a significant proportion of patients with respiratory tract infections (Macfarlane, J. T. *et al.*, 1993, Prospective study of

aetiology and outcome of adult lower-respiratory-tract infections in the community, *Lancet* 341:511-514; Ruiz, M., S. *et al.*, 1990, Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity, *Am. J. Respir. Crit. Care Med.* 160:397-405), research has been conducted to identify possible novel agent(s). Of the three novel agents identified  
5 in the recent three years, including human metapneumovirus (Van den Hoogen, *et al.*, 2001, A newly discovered human pneumovirus isolated from young children with respiratory tract disease, *Nat. Med.* 7:719-724), Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV) (Peiris, J. S. *et al.*, 2003, Coronavirus as a possible cause of severe acute respiratory syndrome, *Lancet* 361:1319-1325) and human coronavirus NL63 (HCoV-NL63)  
10 (Fouchier, R. A. *et al.*, 2004, A previously undescribed coronavirus associated with respiratory disease in humans, *Proc. Natl. Acad. Sci. USA.* 101:6212-6216; van der Hoek, *et al.*, 2004, Identification of a new human coronavirus, *Nat. Med.* 10:368-373), two were coronaviruses. Coronaviruses possess the largest genome of about 30 kb among all RNA viruses. As a result of the unique mechanism of viral replication, coronaviruses have a high  
15 frequency of recombination.

Based on genotypic and serological characterization, coronaviruses were divided into three distinct groups, with human coronavirus 229E (HCoV-229E) being a group 1 coronavirus and HCoV-OC43 a group 2 coronavirus (Lai, M. M. *et al.*, 1997, The molecular biology of coronaviruses, *Adv. Virus Res.* 48:1-100). They account for 5-30% of human  
20 respiratory tract infections. In late 2002 and 2003, the epidemic caused by SARS-CoV affected over 8000 people with 750 deaths (for example, Peiris, J. S. *et al.*, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, *Lancet* 361:1767-1772). We have also reported the isolation of SARS-CoV-like viruses from Himalayan palm civets, which suggested that  
25 animals could be the reservoir for the ancestor of SARS-CoV (Guan, Y. *et al.*, 2003, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China, *Science* 302:276-278). On the basis of genome analysis, SARS-CoV belongs to a fourth group of coronavirus, or alternatively, a distant relative of group 2 coronaviruses (Eickmann, M. *et al.*, 2003, Phylogeny of the SARS coronavirus, *Science*  
30 302:1504-1505; Marra, M. A. *et al.*, 2003, The Genome sequence of the SARS-associated coronavirus, *Science* 300:1399-1404; Rota, P. A. *et al.*, 2003, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, *Science* 300:1394-1399;



Snijder, E. J. *et al.*, 2003, Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, *J. Mol. Biol.* 331:991-1004; Yeh, S. H. *et al.*, 2004, Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution, *Proc. Natl. Acad. Sci. USA.* 101:2542-2547). Recently, a novel group 1 human coronavirus associated with respiratory tract infections, HCoV-NL63, has been discovered, and its genome sequenced (37).

In January, 2004, a 71-year-old Chinese man was admitted to hospital because of fever and chills for two days associated with sore throat, rhinorrhoea, productive cough with purulent sputum, headache and nausea. He had history of pulmonary tuberculosis more than 40 years ago complicated by cicatrization of right upper lobe and bronchiectasis with chronic *Pseudomonas aeruginosa* colonization of airways. He was a chronic smoker and also had chronic obstructive airway disease, hyperlipidemia, and asymptomatic abdominal aortic aneurysm. He had just returned from Shenzhen of China three days before admission. During his three-day trip to Shenzhen, he had no history of contact with or consumption of wild animals. On admission, his oral temperature was 37.6°C. Physical examination showed tracheal deviation to the right and inspiratory crackles over the anterior left lower zone. His haemoglobin level was 14.7 g/dL, total white cell count  $12.1 \times 10^9/L$ , with neutrophil  $9.7 \times 10^9/L$ , lymphocyte  $1.6 \times 10^9/L$  and monocyte  $0.5 \times 10^9/L$ , and plate count  $303 \times 10^9/L$ . His liver and renal function tests were within normal limits. Chest radiograph showed right upper lobe collapse and new patchy infiltrates over the left lower zone. Blood culture was performed. Empirical oral amoxicillin/clavulanate and azithromycin were commenced. Nasopharyngeal aspirates for direct antigen detection for respiratory viruses, RT-PCR for influenza A virus, human metapneumovirus and SARS-CoV, and viral cultures were negative. Sputum for bacterial culture only recovered *P. aeruginosa*. Sputum for mycobacterial culture was negative. Blood culture was negative. Paired sera for antibodies against *Mycoplasma*, *Chlamydia*, *Legionella*, and SARS-CoV did not show any rise in antibody titres. His fever subsided two days after admission. His cough improved and he was discharged after five days of hospitalization. Amoxicillin/clavulanate and azithromycin were continued for a total of seven days. The present inventors were the group involved in the investigation of this patient. All tests for identifying commonly recognized viruses and bacteria were negative in these patients. The etiologic agent responsible for this disease was

not known until the complete genome of CoV-HKU1 from this patient by the present inventors as disclosed herein. Further studies disclosed herein have revealed that CoV-HKU1 is a human coronavirus and there are, at least, two (2) genotypes, A and B, within CoV-HKU1. The invention is useful in both clinical and scientific research applications.

5

### 3. SUMMARY OF INVENTION

The present invention is based upon the inventor's complete genome sequencing of a novel virus ("CoV-HKU1") causing pneumonia in humans. The virus was first discovered from a patient suffering from pneumonia in Hong Kong. The virus is a single-stranded RNA virus of positive polarity which belongs to the order, *Nidovirales*, of the family, *Coronaviridae*. Further studies based on prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period, have revealed that there are, at least, two (2) genotypes for CoV-HKU1. Accordingly, the invention relates to CoV-HKU1 that phylogenetically relates to known members of *Coronaviridae* and specifically belongs to group 2 coronavirus. In a specific embodiment, the invention provides complete genomic sequences of two (2) genotypes of CoV-HKU1. In a preferred embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides nucleic acids isolated from the virus. The virus preferably comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, in its genome. In a specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement

30

thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:3 or 2919, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or 2919, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. Furthermore, in another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof. In preferred embodiments, such nucleic acid molecules encode amino acid sequences that have biological activities exhibited by the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932,

2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or proteins include those having the amino acid

sequences of SEQ IDNO:2, 34-2918 shown in Figures 2 and 3, and SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in Figures 9. The invention further provides proteins or polypeptides that are isolated from the CoV-HKU1, including viral proteins isolated from cells infected with the virus but not present in comparable uninfected cells. The polypeptides or the proteins of the present invention preferably have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by the nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934. In another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. Furthermore, in another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. In other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000,

7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof.

5           In one aspect, the invention relates to the use of CoV-HKU1 for diagnostic methods. In a specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-HKU1, or any proteins or polypeptides thereof. In another specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-  
10   HKU1-infected cells. In yet another specific embodiment, the invention provides a method of screening for an antibody that immunospecifically binds and neutralizes CoV-HKU1. Such an antibody is useful for a passive immunization or immunotherapy of a subject infected with CoV-HKU1.

          The invention further relates to the use of the sequence information of the isolated  
15   virus for diagnostic methods. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or at least a portion of the nucleotide sequence thereof.  
20   In another specific embodiment, the invention provides nucleic acid molecules which are suitable for hybridization to CoV-HKU1 nucleic acid, including, but not limited to, as PCR primers, Reverse Transcriptase primers, probes for Southern or Northern analysis or other nucleic acid hybridization analysis for the detection of CoV-HKU1 nucleic acids, *e.g.*, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922,  
25   2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof.

          The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924,  
30   2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptide having the amino acid sequence of SEQ ID NO:2 or any one of SEQ ID NOS:34-2918

shown in Figures 2 and 3, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in Figures 9, or encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and/or any CoV-HKU1 epitope, having one or more biological activities of a polypeptide of the invention. The invention further provides antibodies that specifically bind cells or tissues that are infected by CoV-HKU1. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, and so forth. The increased or decreased activity or expression of the CoV-HKU1 in a sample relative to a control sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detecting agents are the antibodies or nucleic acid molecules of the present invention. Antibodies of the invention may also be used to detect and/or treat other coronaviruses, such as Severe Acute Respiratory Syndrome ("SARS") viruses.

In another embodiment, the invention provides vaccine preparations, comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or protein subunits of the virus. In a specific embodiment, the present invention provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific invention, the vaccine preparations of the present invention comprise a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides isolated from or produced from nucleic acid of CoV-HKU1. In a specific embodiment, the vaccine

preparations comprise a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID  
5 NO:2 or any one of SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing or preventing respiratory tract infections caused by CoV-HKU1 by administering to a subject in need thereof the anti-viral agents of the present  
10 invention, alone or in combination with various anti-viral agents as well as adjuvants, and/or other pharmaceutically acceptable excipients.

In another aspect, the present invention provides methods for preventing or inhibiting, under a physiological condition, binding to a host cell, or infection of a host cell, or replication in a host cell, of CoV-HKU1 or a virus comprising a nucleic acid molecule  
15 comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, by administering to the host cell the anti-viral agents of the present invention, alone or in combination with other anti-viral agents. In a specific embodiment, the anti-viral agent of the invention includes the  
20 immunogenic preparations of the invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and/or neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the present invention or a nucleic acid molecule of the invention. In a specific embodiment, the host cell is a mammalian cell, including a cell of human, primates, cows, horses, sheep, pigs, fowl (*e.g.*,  
25 chickens), goats, cats, dogs, hamsters, mice and rats. Preferably a host cell is a primate cell, and most preferably a human cell. Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The invention also provides kits containing a pharmaceutical composition of the present invention.

30

### 3.1 Definitions



The term "an antibody or an antibody fragment that immunospecifically binds a polypeptide of the invention" as used herein refers to an antibody or a fragment thereof that immunospecifically binds to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 5 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, and does not non-specifically bind to other polypeptides. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention may cross-react with other antigens. Preferably, an antibody or a fragment thereof that immunospecifically binds to a polypeptide of the invention does not cross-react with other 10 antigens. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention, can be identified by, for example, immunoassays or other techniques known to those skilled in the art.

An "isolated" or "purified" peptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is 15 derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of a polypeptide/protein in which the polypeptide/protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a polypeptide/protein that is substantially free of cellular material includes preparations of the 20 polypeptide/protein having less than about 30%, 20%, 10%, 5%, 2.5%, or 1%, (by dry weight) of contaminating protein. When the polypeptide/protein is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When polypeptide/protein is produced by chemical synthesis, it is preferably substantially free of 25 chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide/protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than polypeptide/protein fragment of interest. In a preferred embodiment of the present invention, polypeptides/proteins are 30 isolated or purified.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule.

Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment of the invention, nucleic acid molecules encoding polypeptides/proteins of the invention are isolated or purified. The term "isolated" nucleic acid molecule does not include a nucleic acid that is a member of a library that has not been purified away from other library clones containing other nucleic acid molecules.

The term "portion" or "fragment" as used herein refers to a fragment of a nucleic acid molecule containing at least about 10, 15, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, or more contiguous nucleic acids in length of the relevant nucleic acid molecule and having at least one functional feature of the nucleic acid molecule (or the encoded protein has one functional feature of the protein encoded by the nucleic acid molecule); or a fragment of a protein or a polypeptide containing at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,100, 4,200, 4,300, 4,350, 4,360, 4,370, 4,380 amino acid residues in length of the relevant protein or polypeptide and having at least one functional feature of the protein or polypeptide.

The term "having a biological activity of the protein" or "having biological activities of the polypeptides of the invention" refers to the characteristics of the polypeptides or proteins having a common biological activity similar or identical structural domain and/or having sufficient amino acid identity to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the polypeptide having any one of the amino acid sequences of SEQ ID NOS:2, 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236, or a

complement thereof. Such common biological activities of the polypeptides of the invention include antigenicity and immunogenicity.

The term "under stringent condition" refers to hybridization and washing conditions under which nucleotide sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to each other remain hybridized to each other. Such hybridization conditions are described in, for example but not limited to, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.; Basic Methods in Molecular Biology, Elsevier Science Publishing Co., Inc., N.Y. (1986), pp. 75-78, and 84-87; and Molecular Cloning, Cold Spring Harbor Laboratory, N.Y. (1982), pp. 387-389, and are well known to those skilled in the art. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC), 0.5% SDS at about 68°C followed by one or more washes (*e.g.*, about 5 to 30 min each) in 2X SSC, 0.5% SDS at room temperature. Another preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X SSC at about 45°C followed by one or more washes (*e.g.*, about 5 to 30 min each) in 0.2X SSC, 0.1% SDS at about 45-65°C.

The term "variant" as used herein refers either to a naturally occurring genetic mutant of CoV-HKU1 or a recombinantly prepared variation of CoV-HKU1 each of which contain one or more mutations in its genome compared to CoV-HKU1. The term "variant" may also refers either to a naturally occurring variation of a given peptide or a recombinantly prepared variation of a given peptide or protein in which one or more amino acid residues have been modified by amino acid substitution, addition, or deletion.

#### 4. BRIEF DESCRIPTION OF FIGURES

Figure 1 shows a partial DNA sequence (SEQ ID NO:1) and its deduced amino acid sequence (SEQ ID NO:2) obtained from CoV-HKU1 that has 91% amino acid identity to the RNA-dependent RNA polymerase protein of known *Coronaviruses*.

Figure 2 shows the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:34-456; the second-frame translation and amino acid sequences:

SEQ ID NOS:457-723; and the third-frame translation and amino acid sequences: SEQ ID NOS:724-1318.

Figure 3 shows the complement (SEQ ID NO:1319) of the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 in 3'→5' orientation and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:1319-1907; the second-frame translation and amino acid sequences: SEQ ID NO:1908-2453; and the third-frame translation and amino acid sequences: SEQ ID NOS:2454-2918.

Figure 4 shows genome organization of CoV-HKU1. Overall organization of the 29926-nucleotide CoV-HKU1 genomic RNA. Predicted ORFs 1a and 1b, encoding the nonstructural polyproteins (p28, p65 and nsp1-13) and those encoding the hemagglutinin-esterase, spike, envelope, membrane and nucleocapsid structural proteins are indicated. Arrows indicate putative cleavage sites (with the corresponding nucleotide positions) of the replicase polyprotein encoded by ORF 1a and ORF 1b. ATR, PL1<sup>pro</sup> and PL2<sup>pro</sup> represent the acidic tandem repeat and the two papain-like proteases, respectively, in nsp1.

Figure 5A shows the phylogenetic analysis of the chymotrypsin like protease (3CL<sup>pro</sup>), RNA-dependent RNA polymerase (Pol), helicase, and hemagglutinin-esterase (HE); and Figure 5B shows that of the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1. The trees were constructed by the neighbor joining method using the Jukes-Cantor correction and bootstrap values were calculated from 1000 trees. A total of 303, 928, 595, 418, 1356, 75, 225 and 406 amino acid positions in 3CL<sup>pro</sup>, Pol, helicase, HE, S, E, M, and N, respectively, were included in the analysis. The scale bar indicates the estimated number of substitutions per 10 amino acids. HCoV-229E: human coronavirus 229E; PEDV: porcine epidemic diarrhea virus; PTGV: porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63: human coronavirus NL63; HCoV-OC43: human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; SDAV: rat sialodacryoadnitis coronavirus; ECoV: equine coronavirus NC99; PHEV: porcine hemagglutinating encephalomyelitis virus; IBV: infectious bronchitis virus; SARS-CoV: SARS coronavirus.

Figure 6 shows the spike protein of CoV-HKU1 (residues 7-336 of SEQ ID NO: 420) and those of other group 2 coronaviruses (SEQ ID NOS 21-26, respectively, in order of

appearance). The spike protein (1356 amino acids) of CoV-HKU1 is depicted by the horizontal bar [SS = N terminal signal sequence (amino acid residues 1 to 13), HR1 = heptad repeat 1 (amino acid residues 982 to 1083), HR2 = heptad repeat 2 (amino acid residues 1250 to 1297), TM = transmembrane domain (amino acid residues 1301 to 1323)],  
 5 (the seven sequences below the horizontal bar disclose residues 752-766 of SEQ ID NO: 420 and SEQ ID NOS 28-33, respectively, in order of appearance). Alignment of the N-terminal region important for receptor binding (amino acid residues 1 to 330) and the region upstream to the cleavage site between S1 and S2 of CoV-HKU1 and other group 2 coronaviruses was generated with ClustalX 1.83. Residues that match the CoV-HKU1  
 10 exactly are boxed. The three conserved regions (sites I, II, and III) for receptor binding in MHV are shaded. The positions of the four conserved amino acids important for receptor binding in MHV are indicated with arrows. (GenBank accession nos. MHV: P11224; BCoV: NP 150077; HCoV-OC43: NP 937950; SDAV: AAF97738; PHEV: AAL80031; ECoV: AAQ67205).

15 Figure 7 shows the sequential quantitative RT-PCR (closed squares; copies/ml) for CoV-HKU1 in nasopharyngeal aspirates; and serum IgG antibody titers against N protein of CoV-HKU1 (closed triangles).

Figure 8 shows the Western blot analysis of purified recombinant CoV-HKU1 N protein antigen. Prominent immunoreactive protein bands of about 53 kDa (*i.e.*, purified  
 20 recombinant CoV-HKU1 N protein) were detected by the Western blot using the patient's sera obtained during the second and fourth weeks of the illness (lanes 2 and 3). Only very faint bands were observed with the serum samples obtained from the patient during the first week of the illness (lane 1) and two healthy blood donors (lane 4 and 5), respectively.

Figure 9 shows the entire genomic DNA sequence (SEQ ID NO:2919) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (\*)  
 25 indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS: 2970-3474; the second-frame translation and amino acid sequences: SEQ ID NOS: 3475-3721; and the third-frame translation and amino acid sequences: SEQ ID NOS: 3722-4236.

30 Figure 10 shows arrangements of proteins in replicase polyprotein in CoV-HKU1 compared with those in HCoV-OC43, BCoV, and MHV. Alignment of the AC domains of HCoV-OC43 (SEQ ID NO: 4239), BCoV (SEQ ID NO: 4238), and MHV (SEQ ID NO:

4237) and the AC domains and ATR (underlined) of CoV-HKU1 in the two patients (SEQ ID NOS 4240 and 4241) was generated with ClustalX 1.83. AC domain = acidic domain, ATR = acidic tandem repeat. (GenBank accession no. MHV: NC\_001846; BCoV: NC\_003045; HCoV-OC43: AY585229).

5           Fig. 11 shows the multiple alignments of the replicase genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2920 which encodes SEQ ID NO: 2921), 2 (SEQ ID NO: 2922 which encodes SEQ ID NO: 2923), 4 (SEQ ID NO: 2924 which encodes SEQ ID NO: 2925), 5 (SEQ ID NO: 4242 which encodes SEQ ID NO: 4243), 6 (SEQ ID NO: 2926 which encodes SEQ ID NO: 2927), 7 (SEQ ID NO: 2928 which encodes SEQ ID NO: 2929), 8 (SEQ ID NO: 2930 which encodes SEQ ID NO: 2931), 9 (SEQ ID NO: 2932 which encodes SEQ ID NO: 2933) and 10 (SEQ ID NO: 2934 which encodes SEQ ID NO: 2935).

15           Fig. 12 shows the chest radiographs of the two patients who died of community acquired pneumonia associated with CoV-HKU1. The chest radiograph of the first patient (Fig. 12A; patient no. 2 in Table 5) showed patchy airspace shadows in both lungs with predominant involvement of the lower zones. The chest radiograph of the second patient (Fig. 12B; patient no. 10 in Table 5), with Luque instrumentation in situ, showed extensive airspace shadows in both lungs with the middle zones more severely involved.

20           Fig. 13 shows the multiple alignments of the spike genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2936 which encodes SEQ ID NO: 2937), 2 (SEQ ID NO: 2938 which encodes SEQ ID NO: 2939), 4 (SEQ ID NO: 2940 which encodes SEQ ID NO: 2941), 5 (SEQ ID NO: 4244 which encodes SEQ ID NO: 4245), 6 (SEQ ID NO: 2942 which encodes SEQ ID NO: 2943), 7 (SEQ ID NO: 2944 which encodes SEQ ID NO: 2945), 8 (SEQ ID NO: 2946 which encodes SEQ ID NO: 2947), 9 (SEQ ID NO: 2948 which encodes SEQ ID NO: 2949) and 10 (SEQ ID NO: 2950 which encodes SEQ ID NO: 2951).

30           Fig. 14 shows the multiple alignments of the nucleocapsid genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2952 which encodes SEQ ID NO: 2953), 2 (SEQ ID NO: 2954 which encodes SEQ ID NO: 2955), 4 (SEQ ID NO: 2956 which encodes SEQ ID NO: 2957), 5 (SEQ ID NO: 4246 which encodes SEQ ID NO: 4247), 6 (SEQ ID NO: 2958 which encodes SEQ ID NO: 2959), 7 (SEQ ID NO: 2960 which encodes SEQ ID NO: 2961), 8 (SEQ ID NO: 2962 which encodes SEQ ID NO: 2963), 9 (SEQ ID NO: 2964

which encodes SEQ ID NO: 2965) and 10 (SEQ ID NO: 2966 which encodes SEQ ID NO: 2967).

Fig. 15 shows phylogenetic trees and non-synonymous mutations and corresponding amino acid changes of complete *pol*, S and N gene sequences of HCoV-HKU1 from nine patients with community acquired pneumonia. The trees were inferred from *pol* (Fig. 15A), S (Fig. 15B) and N (Fig. 15C) gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The trees were rooted using *pol*, S and N gene sequences of HCoV-OC43, respectively. 2784 nucleotide positions in each *pol* gene, 4071 nucleotide positions in each S gene, and 1326 nucleotide positions in each N gene, were included in the analysis. The scale bar indicates the estimated number of substitutions per 100 (Fig. 15A) and 50 (Figs. 15B and 15C) bases, respectively, using Jukes-Cantor correction. The shaded nucleotides are those that differ from the majority at the corresponding locations. Due to the large number of non-synonymous mutations in the S gene, only the NH<sub>2</sub> terminal 45, out of the total of 306, non-synonymous mutations are shown.

Fig. 16 shows the multiple alignments of nucleotides 1806-1835 and 2229-2258 of the *pol* genes in the nine HCoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV. Marked differences between the 3' ends of the two primers for RT-PCR (LPW1926; SEQ ID NO: 4248 and LPW1927; SEQ ID NO: 4249) and the corresponding bases in HCoV-OC43 (SEQ ID NOS 4250 and 4251), HCoV-229E (SEQ ID NOS 4254 and 4255), HCoV-NL63 (SEQ ID NOS 4256 and 4257) and SARS-CoV (SEQ ID NOS 4252 and 4253) are observed, indicating the high specificity of the two primers for HCoV-HKU1. The positions of LPW1926 (SEQ ID NO: 4248) and LPW1927 (SEQ ID NO: 4249) are boxed. The bases in HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV that were different from those in the sequence of the primers, were shaded.

Fig. 17 show a phylogenetic tree of *pol* gene sequences of the 10 HCoV-HKU1 from patients with community acquired pneumonia. The tree was inferred from *pol* gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The tree was rooted using *pol* gene sequence of HCoV-229E and 393 nucleotide positions (primer sequences excluded) in each *pol* gene were included in the analysis. The scale bar indicates the estimated number of substitutions per 50 bases using Jukes-Cantor correction. HCoV-HKU1: human coronavirus HKU1; HCoV-229E: human coronavirus 229E; HCoV-OC43:

human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; PHEV: porcine hemagglutinating encephalomyelitis virus.

## 5. DETAILED DESCRIPTION OF THE INVENTION

5       The present invention relates to the CoV-HKU1 that phylogenetically relates to known *Coronaviruses*. In a specific embodiment, CoV-HKU1 comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a specific embodiment, the present invention provides isolated nucleic acid  
10       molecules of the CoV-HKU1, comprising, or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof or a portion thereof. In another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent  
15       conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or specific genes of known member of *Coronaviridae*, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a  
20       nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1,  
25       2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150,  
30       1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900,



3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or the proteins of the present invention preferably have one or more biological activities of the proteins encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the native viral proteins containing the amino acid sequences encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides the entire nucleotide sequence of CoV-HKU1 (SEQ ID NO:3 or 2919), or fragments, or complement thereof. Furthermore, the present invention relates to a nucleic acid molecule that hybridizes any portion of the genome of the CoV-HKU1 (SEQ ID NO:3 or 2919) under the stringent conditions. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932,

2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, or a portion thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for use as hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof. The invention further encompasses chimeric or recombinant viruses or viral proteins encoded by said nucleotide sequences.

The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, or any CoV-HKU1 epitope as well as the polypeptides having the amino acid sequences of any one of SEQ ID NO:2, SEQ ID NOS:34-2918 shown in Figures 2 and 3, SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in Figures 9. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, sputum, nasopharyngeal aspirates, and so forth. The presence of the CoV-HKU1 in a sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detection agents are the antibodies of the present invention. In another embodiment, the detection agent is a nucleic acid of the present invention.

In another embodiment, the invention provides vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or subunits of the virus.

The present invention further provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific embodiment, the vaccine preparations of the present invention comprise one or more nucleic acid molecules comprising or consisting of the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing, or preventing respiratory tract infections by administering to a subject in need thereof the anti-viral agents of the present invention, alone or in combination with other antivirals [*e.g.*, amantadine, rimantadine, gancyclovir, acyclovir, ribavirin, penciclovir, oseltamivir, foscarnet zidovudine (AZT), didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, delavirdine, indinavir, ritonavir, vidarabine, nelfinavir, saquinavir, relenza, tamiflu, pleconaril, interferons, etc.], steroids and corticosteroids such as prednisone, cortisone, fluticasone and glucocorticoid, antibiotics, analgesics, bronchodilators, or other treatments for respiratory and/or viral infections. In one aspect, the anti-viral agent of the present invention prevents or inhibit the binding of the virus or viral proteins to a host cell under a physiological condition, thereby preventing or inhibiting the infection of the host cell by the virus. In another aspect, the anti-viral agent of the invention prevents or inhibits replication of the viral nucleic acid molecules in the host cell under a physiological condition by interacting with the viral nucleic acid molecules or its transcription mechanisms. In a specific embodiment, the anti-viral agent of the invention includes the vaccine or immunogenic preparations of the invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and may neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the invention or a nucleic acid molecule of the invention.

In addition, the present invention provides a method of preventing or inhibiting replication in a host cell of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or inhibiting the  
5 activities of the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof, including the polypeptides having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939,  
10 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, by administering to said host cell the anti-viral agent of the invention. In a specific embodiment the host cell is a mammalian cell, such as a cell of humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents. Preferably, the cell is a primate cell and most preferably a human cell.

15 Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The present invention also provides kits comprising pharmaceutical compositions of the present invention.

## 20 5.1 Recombinant and Chimeric CoV-HKU1

The present invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genome of CoV-HKU1 or natural variants thereof. In a specific embodiment, a recombinant virus is one derived from the CoV-HKU1. In a specific embodiment, the virus has a nucleotide sequence of SEQ ID NO:3 or 2919. In  
25 another specific embodiment, a recombinant virus is one derived from a natural variant of CoV-HKU1. A natural variant of CoV-HKU1 has a sequence that is different from the genomic sequence (SEQ ID NO:3 or 2919) of CoV-HKU1, due to one or more naturally occurred mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a  
30 phenotypic change. In accordance with the present invention, a viral vector which is derived from the genome of the CoV-HKU, is one that contains a nucleic acid sequence that encodes at least a part of one ORF of the CoV-HKU1. In a specific embodiment, the ORF

comprises or consists of a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In a specific embodiment, there are more than one ORF within the nucleotide sequence of SEQ ID NO:3 or 2919, or a  
5 fragment thereof. In another embodiment, the polypeptides encoded by the ORF comprises or consists of amino acid sequences of SEQ ID NO:34-2918 shown in Fig. 2 and 8, or SEQ ID NO:2, SEQ ID NO:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or a fragment thereof. In accordance with the present invention these viral  
10 vectors may or may not include nucleic acids that are non-native to the viral genome.

In another specific embodiment, a chimeric virus of the invention is a recombinant CoV-HKU1 which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous  
15 or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

According to the present invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance  
20 with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric virus may be encoded by nucleotide sequences derived from different strains or variants of CoV-HKU1. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides  
25 derived from different strains or variants of CoV-HKU1.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., J. Virol. 72, 2955-2961; Durbin et al., 2000, J. Virol. 74, 6821-6831; Skiadopoulos et al., 1998, J. Virol. 72, 1762-1768 (1998); Teng et al., 2000, J. Virol. 74, 9317-9321). For example, it can be envisaged that a virus  
30 vector derived from the CoV-HKU1 expressing one or more proteins of variants of CoV-HKU1, or vice versa, will protect a subject vaccinated with such vector against infections by both the native CoV-HKU1 and the variant. Attenuated and replication-defective viruses

may be of use for vaccination purposes with live vaccines as has been suggested for other viruses.

In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains or variants of CoV-HKU1.

In certain embodiments, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been inserted or added to the vector.

The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection.

In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by the CoV-HKU1 and natural variants thereof. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses.

The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial antigens, tumor antigens, allergen antigens, and auto antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with CoV-HKU1 and variants thereof.

In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and autoantigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing CoV-HKU1 genes to contain foreign sequences in their respective external domains. Where the

heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

Thus, the present invention relates to the use of viral vectors and recombinant or  
5 chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The present invention also encompasses recombinant viruses comprising a viral vector derived from the CoV-HKU1 or variants thereof which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer  
10 sequences of the virus.

The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of CoV-HKU1 are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing  
15 full-length or partial copies of the CoV-HKU1 genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

20 In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial CoV-HKU1 proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication- defective or chimeric viruses.

25 The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

## 30 5.2 Formulation of Vaccines and Antivirals

In a preferred embodiment, the invention provides a proteinaceous molecule or CoV-HKU1 specific viral protein or functional fragment thereof encoded by a nucleic acid

according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from the virus according to the invention, including envelop protein (E protein), integral membrane protein (M protein), spike protein (S protein), nucleocapsid protein (N protein), hemagglutinin esterase (HE protein), and  
5 RNA-dependent RNA polymerase. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as subunit vaccines. Particularly useful are polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962,  
10 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-2918 in Fig. 2 and 3, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 in Fig. 9, or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly  
15 useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments of the CoV-HKU1 genome; of course preferred are those that are within the preferred bounds and metes of ORFs, in particular, for eliciting CoV-HKU1 specific antibody or T cell responses, whether in vivo (e.g. for protective or therapeutic purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another  
20 technique useful for generating synthetic antibodies).

The invention provides vaccine formulations for the prevention and treatment of infections with CoV-HKU1. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the CoV-HKU1.

In another aspect, the present invention also provides DNA vaccine formulations  
25 comprising a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another specific embodiment, the DNA vaccine formulations of the present invention comprises a nucleic acid or fragment thereof encoding  
30 the antibodies which immunospecifically binds CoV-HKU1. In DNA vaccine formulations, a vaccine DNA comprises a viral vector, such as that derived from the CoV-HKU1, bacterial plasmid, or other expression vector, bearing an insert comprising a nucleic acid



molecule of the present invention operably linked to one or more control elements, thereby allowing expression of the vaccinating proteins encoded by said nucleic acid molecule in a vaccinated subject. Such vectors can be prepared by recombinant DNA technology as recombinant or chimeric viral vectors carrying a nucleic acid molecule of the present invention.

Various heterologous vectors are described for DNA vaccinations against viral infections. For example, the vectors described in the following references may be used to express CoV-HKU1 sequences instead of the sequences of the viruses or other pathogens described; in particular, vectors described for hepatitis B virus (Michel, M.L. *et al.*, 1995, DAN-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans, *Proc. Natl. Aca. Sci. USA* 92:5307-5311; Davis, H.L. *et al.*, 1993, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody, *Human Molec. Genetics* 2:1847-1851), HIV virus (Wang, B. *et al.*, 1993, Gene inoculation generates immune responses against human immunodeficiency virus type 1, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; Lu, S. *et al.*, 1996, Simian immunodeficiency virus DNA vaccine trial in macaques, *J. Virol.* 70:3978-3991; Letvin, N.L. *et al.*, 1997, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, *Proc Natl Acad Sci U S A.* 94(17):9378-83), and influenza viruses (Robinson, H.L. *et al.*, 1993, Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA, *Vaccine* 11:957-960; Ulmer, J.B. *et al.*, Heterologous protection against influenza by injection of DNA encoding a viral protein, *Science* 259:1745-1749), as well as bacterial infections, such as tuberculosis (Tascon, R.E. *et al.*, 1996, Vaccination against tuberculosis by DNA injection, *Nature Med.* 2:888-892; Huygen, K. *et al.*, 1996, Immunogenicity and protective efficacy of a tuberculosis DNA vaccine, *Nature Med.*, 2:893-898), and parasitic infection, such as malaria (Sedegah, M., 1994, Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein, *Proc. Natl. Acad. Sci. USA* 91:9866-9870; Doolan, D.L. *et al.*, 1996, Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8<sup>+</sup> T cell-interferon  $\delta$ , and nitric oxide-dependent immunity, *J. Exper. Med.*, 1183:1739-1746).

Many methods may be used to introduce the vaccine formulations described above. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes. Alternatively, it may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the pathogen for which the vaccine is designed. The DNA vaccines of the present invention may be administered in saline solutions by injections into muscle or skin using a syringe and needle (Wolff J.A. *et al.*, 1990, Direct gene transfer into mouse muscle in vivo, *Science* 247:1465-1468; Raz, E., 1994, Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses, *Proc. Natl. Acad. Sci. USA* 91:9519-9523). Another way to administer DNA vaccines is called "gene gun" method, whereby microscopic gold beads coated with the DNA molecules of interest is fired into the cells (Tang, D. *et al.*, 1992, Genetic immunization is a simple method for eliciting an immune response, *Nature* 356:152-154). For general reviews of the methods for DNA vaccines, see Robinson, H.L., 1999, DNA vaccines: basic mechanism and immune responses (Review), *Int. J. Mol. Med.* 4(5):549-555; Barber, B., 1997, Introduction: Emerging vaccine strategies, *Seminars in Immunology* 9(5):269-270; and Robinson, H.L. *et al.*, 1997, DNA vaccines, *Seminars in Immunology* 9(5):271-283.

### 5.3 Adjuvants and Carrier Molecules

CoV-HKU1-associated antigens are administered with one or more adjuvants. In one embodiment, the CoV-HKU1-associated antigen is administered together with a mineral salt adjuvants or mineral salt gel adjuvant. Such mineral salt and mineral salt gel adjuvants include, but are not limited to, aluminum hydroxide (ALHYDROGEL, REHYDRAGEL), aluminum phosphate gel, aluminum hydroxyphosphate (ADJU-PHOS), and calcium phosphate.

In another embodiment, CoV-HKU1-associated antigen is administered with an immunostimulatory adjuvant. Such class of adjuvants, include, but are not limited to, cytokines (*e.g.*, interleukin-2, interleukin-7, interleukin-12, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon- $\gamma$  interleukin-1 $\beta$  (IL-1 $\beta$ ), and IL-1 $\beta$  peptide or Sclavo Peptide), cytokine-containing liposomes, triterpenoid glycosides or saponins (*e.g.*, QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), Muramyl Dipeptide (MDP) derivatives, such as N-acetyl-muramyl-L-threonyl-D-isoglutamine

(Threonyl-MDP, sold under the trademark TERMURTIDE), GMDP, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxy phosphoryloxy)-ethylamine, muramyl tripeptide phosphatidylethanolamine (MTP-PE), unmethylated CpG dinucleotides and  
5 oligonucleotides, such as bacterial DNA and fragments thereof, LPS, monophosphoryl Lipid A (3D-MLA sold under the trademark MPL), and polyphosphazenes.

In another embodiment, the adjuvant used is a particular adjuvant, including, but not limited to, emulsions, *e.g.*, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalane oil-in-water adjuvant formulations, such as SAF and MF59, *e.g.*,  
10 prepared with block-copolymers, such as L-121 (polyoxypropylene/polyoxyethylene) sold under the trademark PLURONIC L-121, Liposomes, Virosomes, cochleates, and immune stimulating complex, which is sold under the trademark ISCOM.

In another embodiment, a microparticulate adjuvant is used. Microparticulate adjuvants include, but are not limited to biodegradable and biocompatible polyesters, homo-  
15 and copolymers of lactic acid (PLA) and glycolic acid (PGA), poly(lactide-co-glycolides) (PLGA) microparticles, polymers that self-associate into particulates (poloxamer particles), soluble polymers (polyphosphazenes), and virus-like particles (VLPs) such as recombinant protein particulates, *e.g.*, hepatitis B surface antigen (HbsAg).

Yet another class of adjuvants that may be used include mucosal adjuvants,  
20 including but not limited to heat-labile enterotoxin from *Escherichia coli* (LT), cholera holotoxin (CT) and cholera Toxin B Subunit (CTB) from *Vibrio cholerae*, mutant toxins (*e.g.*, LTK63 and LTR72), microparticles, and polymerized liposomes.

In other embodiments, any of the above classes of adjuvants may be used in combination with each other or with other adjuvants. For example, non-limiting examples  
25 of combination adjuvant preparations that can be used to administer the CoV-HKU1-associated antigens of the invention include liposomes containing immunostimulatory protein, cytokines, or T-cell and/or B-cell peptides, or microbes with or without entrapped IL-2 or microparticles containing enterotoxin. Other adjuvants known in the art are also included within the scope of the invention (see *Vaccine Design: The Subunit and Adjuvant*  
30 *Approach*, Chap. 7, Michael F. Powell and Mark J. Newman (eds.), Plenum Press, New York, 1995, which is incorporated herein in its entirety).

The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing a CoV-HKU1 polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

- 5       The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid additional salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic
- 10       bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

- 15       Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, *e.g.*, using a bifurcated needle).

- 20       The patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (*e.g.*, chickens), goats, cats, dogs, hamsters, mice and rats.

#### 5.4 Preparation of Antibodies

- 25       Antibodies which specifically recognize a polypeptide of the invention, such as, but not limited to, polypeptides comprising the sequence of SEQ ID NO:2 or any of SEQ ID NOS: 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or CoV-HKU1 epitope, or antigen-binding fragments thereof, can be used for
- 30       detecting, screening, and isolating the polypeptide of the invention or fragments thereof, or similar sequences that might encode similar enzymes from the other organisms. For example, in one specific embodiment, an antibody which immunospecifically binds CoV-

HKU1 epitope, or a fragment thereof, can be used for various in vitro detection assays, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, Western blot, etc., for the detection of a polypeptide of the invention or, preferably, CoV-HKU1, in samples, for example, a biological material, including cells, cell culture media (e.g.,  
5 bacterial cell culture media, mammalian cell culture media, insect cell culture media, yeast cell culture media, etc.), blood, plasma, serum, tissues, sputum, nasopharyngeal aspirates, etc.

Antibodies specific for a polypeptide of the invention or any epitope of CoV-HKU1 may be generated by any suitable method known in the art. Polyclonal antibodies to an  
10 antigen-of-interest, for example, the CoV-HKU1 epitopes or polypeptides encoded by a nucleotide sequence of SEQ ID NO:1 or 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides shown in Fig. 2 (SEQ ID NOS:34-1318), Fig. 3 (SEQ ID NOS:1319-2918), as well as SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931,  
15 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, can be produced by various procedures well known in the art. For example, an antigen can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc., to induce the production of antisera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase  
20 the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful adjuvants for humans such as BCG (Bacille Calmette-Guerin) and Corynebacterium parvum. Such  
25 adjuvants are also well known in the art (*see* Section 5.4, *supra*).

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow  
30 et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, pp. 563-681 (Elsevier, N.Y., 1981) (both of which are incorporated by reference in their entireties). The

term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

5           Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are  
10 then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by inoculating mice intraperitoneally with positive hybridoma clones.

15           Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and  $F(ab')_2$  fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce  $F(ab')_2$  fragments).  $F(ab')_2$  fragments contain the complete light chain, and the variable region, the CH1 region and the hinge region of the  
20 heavy chain.

The antibodies of the invention or fragments thereof can be also produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

The nucleotide sequence encoding an antibody may be obtained from any  
25 information available to those skilled in the art (i.e., from Genbank, the literature, or by routine cloning and sequence analysis). If a clone containing a nucleic acid encoding a particular antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable  
30 source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A<sup>+</sup> RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic

primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., supra; and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence by, for example, introducing amino acid substitutions, deletions, and/or insertions into the epitope-binding domain regions of the antibodies or any portion of antibodies which may enhance or reduce biological activities of the antibodies.

Recombinant expression of an antibody requires construction of an expression vector containing a nucleotide sequence that encodes the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art as discussed in the previous sections. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The nucleotide sequence encoding the heavy-chain variable region, light-chain variable region, both the heavy-chain and light-chain variable regions, an epitope-binding fragment of the heavy- and/or light-chain variable region, or one or more complementarity determining regions (CDRs) of an antibody may be cloned into such a vector for expression. Thus-prepared expression vector can be then introduced into appropriate host cells for the expression of the antibody. Accordingly, the invention includes host cells containing a polynucleotide encoding an antibody specific for the polypeptides of the invention or fragments thereof.

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature*, 322:52, 1986; and Kohler, *Proc. Natl. Acad. Sci. USA*, 77:2 197, 1980). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

In another embodiment, antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods*, 182:41-50, 1995; Ames et al., *J. Immunol. Methods*, 184:177-186, 1995; Kettleborough et al., *Eur. J. Immunol.*, 24:952-958, 1994; Persic et al., *Gene*, 187:9-18, 1997; Burton et al., *Advances in Immunology*, 57:191-280, 1994; PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including



human antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in  
5 PCT publication WO 92/22324; Mullinax et al., *BioTechniques*, 12(6):864-869, 1992; and Sawai et al., *AJRI*, 34:26-34, 1995; and Better et al., *Science*, 240:1041-1043, 1988 (each of which is incorporated by reference in its entirety). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology*, 203:46-88, 1991; Shu et  
10 al., *PNAS*, 90:7995-7999, 1993; and Skerra et al., *Science*, 240:1038-1040, 1988.

Once an antibody molecule of the invention has been produced by any methods described above, it may then be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A or Protein G purification, and  
15 sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for the purification of proteins. Further, the antibodies of the present invention or fragments thereof may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

For some uses, including in vivo use of antibodies in humans and in vitro detection  
20 assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison,  
25 *Science*, 229:1202, 1985; Oi et al., *BioTechniques*, 4:214 1986; Gillies et al., *J. Immunol. Methods*, 125:191-202, 1989; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties. Humanized antibodies are antibody molecules from non-human species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and  
30 framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework

substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al.,  
5 Nature, 332:323, 1988, which are incorporated herein by reference in their entireties.

Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology, 28(4/5):489-498, 1991; Studnicka et al., Protein  
10 Engineering, 7(6):805-814, 1994; Roguska et al., Proc Natl. Acad. Sci. USA, 91:969-973, 1994), and chain shuffling (U.S. Patent No. 5,565,332), all of which are hereby incorporated by reference in their entireties.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art  
15 including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol., 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal  
25 antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entireties. In addition, companies such as Abgenix, Inc. (Fremont, CA), Medarex  
30 (NJ) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology*, 12:899-903, 5 1988).

Antibodies fused or conjugated to heterologous polypeptides may be used in in vitro immunoassays and in purification methods (e.g., affinity chromatography) well known in the art. See e.g., PCT publication Number WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.*, 39:91-99, 1994; U.S. Patent 5,474,981; Gillies et al., *PNAS*, 89:1428-10 1432, 1992; and Fell et al., *J. Immunol.*, 146:2446-2452, 1991, which are incorporated herein by reference in their entireties.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the polypeptides of the invention or fragments, derivatives, analogs, or variants thereof, or similar molecules having the similar enzymatic activities as 15 the polypeptide of the invention. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

### 5.5 Pharmaceutical Compositions and Kits

The present invention encompasses pharmaceutical compositions comprising anti-20 viral agents of the present invention. In a specific embodiment, the anti-viral agent is an antibody which immunospecifically binds CoV-HKU1 or variants thereof, or any proteins derived therefrom. In another specific embodiment, the anti-viral agent is a polypeptide or nucleic acid molecule of the invention. The pharmaceutical compositions have utility as an anti-viral prophylactic agent and may be administered to a subject where the subject has 25 been exposed or is expected to be exposed to a virus.

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu and Wu, 1987, *J. Biol. Chem.* 262:4429 30 4432). Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus

injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In a preferred embodiment, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, by means of nasal spray, or by means of an implant, said implant being of a porous, non porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) infected tissues.

In another embodiment, the pharmaceutical composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, *Science* 249:1527-1533; Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

In yet another embodiment, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald et al., 1980, *Surgery* 88:507; and Saudek et al., 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., 1985, *Science* 228:190; During et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, i.e., the lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of recombinant or chimeric CoV-HKU1, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a

hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline  
5 can be provided so that the ingredients may be mixed prior to administration.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium,  
10 ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2 ethylamino ethanol, histidine, procaine, etc.

The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In  
15 addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500  
20 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose response curves derived from in vitro or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.  
25

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of  
30 pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a preferred embodiment, the kit contains an anti-viral agent of the invention, e.g., an antibody specific for the polypeptides

encoded by a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966 or any CoV-HKU1 epitope, or a polypeptide or protein of the present invention, including those shown in Fig. 2 (SEQ ID NOS:34-1318), Fig. 3 (SEQ ID  
5 NOS:1319-2918), Fig. 9 (SEQ ID NOS: 2970-4236) and SEQ ID NO:2, or a nucleic acid molecule of the invention, alone or in combination with adjuvants, antivirals, antibiotics, analgesic, bronchodialaters, or other pharmaceutically acceptable excipients.

The present invention further encompasses kits comprising a container containing a pharmaceutical composition of the present invention and instructions for use.

10

### 5.6 Detection Assays

The present invention provides a method for detecting an antibody, which immunospecifically binds to the CoV-HKU1, in a biological sample, for example blood, serum, plasma, saliva, urine, etc., from a patient suffering from respiratory tract infection.

15 In a specific embodiment, the method comprising contacting the sample with the polypeptides or protein encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-1318 shown in Fig. 2, SEQ ID NOS:1319-  
20 2918 shown in Fig. 3, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 shown in Figs. 9, directly immobilized on a substrate and detecting the virus-bound antibody directly or indirectly by a labeled heterologous anti-isotype antibody. In another specific embodiment, the sample is contacted with a host cell  
25 comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and expressing the polypeptides encoded thereby, and the bound antibody can be detected by immunofluorescent assay.

30 An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of

detecting an epitope or nucleic acid (e.g., mRNA, genomic RNA) of CoV-HKU1 such that the presence of CoV-HKU1 is detected in the sample. A preferred agent for detecting CoV-HKU1 mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof, or a complement thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1,000 or more contiguous nucleotides in length and sufficient to specifically hybridize under stringent conditions to a CoV-HKU1 mRNA or genomic RNA.

In another preferred specific embodiment, the presence of CoV-HKU1 is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the genome of CoV-HKU1 or a genomic nucleic acid sequence of SEQ ID NO:3 or 2919, or based on a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a non-limiting specific embodiment, preferred primers to be used in a RT-PCR method are: 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5), or 5'-AAAGGATGTTGAC-AACCTGTT-3' (LPW1926; SEQ ID NO: 2968) and 5'-ATCATCATACTAAAATGCT-TACA-3' (LPW1927; SEQ ID NO: 2969), in the presence of 3 mM MgCl<sub>2</sub> and the thermal cycles are, for example, but not limited to, 94°C for 8 min followed by 40 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min. In more preferred specific embodiment, the present invention provides a real-time quantitative PCR assay to detect the presence of CoV-HKU1 in a biological sample by subjecting the cDNA obtained by reverse transcription of the extracted total RNA from the sample to PCR reactions using the specific primers, such as those having nucleotide sequences of SEQ ID NOS:4, 5, 2968 and 2969, and a fluorescence dye, such as SYBR<sup>®</sup> Green I, which fluoresces when bound non-specifically to double-stranded DNA. The fluorescence signals from these reactions are captured at the end of extension steps as PCR product is generated over a range of the



thermal cycles, thereby allowing the quantitative determination of the viral load in the sample based on an amplification plot.

A preferred agent for detecting CoV-HKU1 is an antibody that specifically binds a polypeptide of the invention or any CoV-HKU1 epitope, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact  
5 antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used.

The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by  
10 reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The detection method of the invention can be used to detect mRNA, protein (or any epitope), or genomic RNA in a sample in vitro as well as in vivo. For  
15 example, in vitro techniques for detection of mRNA include northern hybridizations, in situ hybridizations, RT-PCR, and RNase protection. In vitro techniques for detection of an epitope of CoV-HKU1 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic RNA include northern hybridizations, RT-PCR, and RNase protection.  
20 Furthermore, in vivo techniques for detection of CoV-HKU1 include introducing into a subject organism a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in the subject organism can be detected by standard imaging techniques, including autoradiography.

25 In a specific embodiment, the methods further involve obtaining a control sample from a control subject, contacting the control sample with a compound or agent capable of detecting CoV-HKU1, e.g., a polypeptide of the invention or mRNA or genomic RNA encoding a polypeptide of the invention, such that the presence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide is detected in the sample,  
30 and comparing the absence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide in the control sample with the presence of CoV-HKU1, or the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

The invention also encompasses kits for detecting the presence of CoV-HKU1 or a polypeptide or nucleic acid of the invention in a test sample. The kit, for example, can comprise a labeled compound or agent capable of detecting CoV-HKU1 or the polypeptide or a nucleic acid molecule encoding the polypeptide in a test sample and, in certain  
5 embodiments, a means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for use.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g.,  
10 attached to a solid support) which binds to a polypeptide of the invention or CoV-HKU1 epitope; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic  
15 acid sequence encoding a polypeptide of the invention or to a sequence within the CoV-HKU1 genome or (2) a pair of primers useful for amplifying a nucleic acid molecule containing an CoV-HKU1 sequence. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can  
20 also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for use.

25

## 6. EXAMPLES

The following examples illustrate the identification of the novel CoV-HKU1. These examples should not be construed as limiting.

## METHODS AND RESULTS

30

As a general reference, Wiedbrauk DL & Johnston SLG. (Manual of Clinical Virology, Raven Press, New York, 1993) was used.

## 6.1 Example 1

### 6.1.1 Clinical subject

The patient is an in-patient of the United Christian Hospital in Hong Kong.

- 5 Nasopharyngeal aspirates were collected from the patient weekly from the first till the fifth week of the illness, stool and urine in the first and second week of the illness, and sera in the first, second, and fourth weeks of the illness.

### 6.1.2 Antibody detection

- 10 To produce a fusion plasmid for protein purification, primers, 5'- TTTTCCTTTT GCGGCCGCTTAAGCAACAGAGTCTTCTA-3' (SEQ ID NO:6) and 5'- CGGAATTC GATGTCTTATACTCCCGGT-3' (SEQ ID NO:7) were used to amplify the gene encoding the N protein of the CoV-HKU1 by RT-PCR. The sequence coding for amino acid residues 1 to 441 of the N protein was amplified and cloned into the *EcoRI* and *NotI* sites of  
15 expression vector pET-28b(+) (Novagen, Madison, WI, USA) in frame and downstream of the series of six histidine residues. The (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein was expressed in *E. coli* and purified using the Ni<sup>2+</sup>-loaded HiTrap Chelating System (Amersham Pharmacia, USA) according to the manufacturer's instructions.

- Western blot analysis was performed as follows: Two-hundred ng of purified (His)<sub>6</sub>-  
20 tagged (SEQ ID NO:27) recombinant N protein of CoV-HKU1 were loaded into each well of a sodium dodecyl sulfate (SDS)-10% polyacrylamide gel and subsequently electroblotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The blot was cut into strips and the strips were incubated separately with 1:2000 dilution of serum samples obtained during the first, second, and fourth weeks of the patient's illness. Serum samples of two  
25 healthy blood donors were used as controls. Antigen-antibody interaction was detected with an ECL fluorescence system (Amersham Life Science, Buckinghamshire, UK).

- Several prominent immunoreactive bands were visible for serum samples collected during the second and fourth weeks of the patient's illness (Fig. 8, lanes 2 and 3). The sizes of the largest bands were about 53 kDa, consistent with the expected size of 52.8 kDa for  
30 the full-length (His)<sub>6</sub>-tagged (SEQ ID NO:27) N protein, whereas the other bands were consistent with the degradation products of the (His)<sub>6</sub>-tagged (SEQ ID NO:27) N protein.

Only very faint bands were observed for serum samples obtained from the patient during the first week of the illness (Fig. 8, lane 1) and two healthy blood donors (Fig. 8, lanes 4 and 5).

ELISA was performed using the recombinant N protein of CoV-HKU1 prepared as described above. Each well of a Nunc immunoplate (Roskilde, Denmark) was coated with  
5 20 ng of purified (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein for 12 h and then blocked in phosphate-buffered saline with 2% bovine serum albumin. The serum samples obtained from the patient during the first, second, and fourth weeks of the illness were serially diluted and were added to the wells of the (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein-coated plates in a total volume of 100 µl per well and incubated at  
10 37°C for 2 h. After washing with washing buffer five times, 100 µl per well of 1:4000 diluted horse radish peroxidase-conjugated goat anti-human IgG antibody (Zymed Laboratories Inc., South San Francisco, CA, USA) were added to the wells and incubated at 37°C for 1 h. After washing with washing buffer five times, 100 µl of diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at  
15 room temperature for 15 min. One hundred microliters of 0.3 M H<sub>2</sub>SO<sub>4</sub> were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

Box titration was carried out with different dilutions of (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein coating antigen and serum obtained from the fourth week of  
20 the patient's illness. The results identified 20 ng and 80 ng of purified (His)<sub>6</sub>-tagged recombinant N protein per ELISA well as the ideal amount for plate coating and 1:1000 and 1:20 as the most optimal serum dilution for IgG and IgM detection, respectively.

To establish the baseline for the tests, serum samples (diluted at 1:1000 and 1:20 for IgG and IgM, respectively) from 100 healthy blood donors were tested in the CoV-HKU1 antibody ELISA. For the 100 sera from healthy blood donors, the mean ELISA  
25 OD<sub>450</sub> values for IgG and IgM detection were 0.178 and 0.224, with standard deviations of 0.070 and 0.117. Absorbance values of 0.387 and 0.576 were selected as the cutoff values (that equal the sum of the mean value from the healthy control and three times the standard deviation) for IgG and IgM, respectively. Using these cutoff values, the titers for IgG of the  
30 patient's serum samples obtained during the first, second, and fourth weeks of the illness were <1:1000, 1:2000, and 1:8000, respectively (Fig. 7), and those for IgM were 1:20, 1:40, and 1:80, respectively (data not shown).

### 6.1.3 RT-PCR and real time quantitative PCR

#### RT-PCR Assay

An RT-PCR was developed to detect the CoV-HKU1 sequence from NPA samples.

- 5 Total RNA from clinical samples was reverse transcribed using random hexamers and cDNA was amplified using primers 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5), which were constructed based on the RNA-dependent RNA polymerase-encoding sequence (SEQ ID NO:1) of the CoV-HKU1 in the presence of 2.5 mM MgCl<sub>2</sub> (94°C for 8 min followed by 40  
10 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min).

The summary of a typical RT-PCR protocol is as follows:

#### 1. RNA extraction

- RNA from 140 µl of NPA samples was extracted by QIAquick<sup>®</sup> viral RNA  
15 extraction kit and was eluted in 50 µl of elution buffer.

#### 2. Reverse transcription

- |                                       |         |
|---------------------------------------|---------|
| RNA                                   | 11.5 µl |
| 0.1 M DTT                             | 2 µl    |
| 20 5x buffer                          | 4 µl    |
| 10 mM dNTP                            | 1 µl    |
| Superscript II, 200 U/µl (Invitrogen) | 1 µl    |
| Random hexamers, 0.3 µg/ µl           | 0.5 µl  |

- 25 Reaction condition 42°C, 50 min  
94°C, 3 min  
4°C

#### 3. PCR

- 30 cDNA generated by random primers was amplified in a 50 µl reaction as follows:

- |      |      |
|------|------|
| cDNA | 2 µl |
|------|------|

	10 mM dNTP	0.5 $\mu$ l
	10x buffer	5 $\mu$ l
	25 mM MgCl <sub>2</sub>	5 $\mu$ l
	25 $\mu$ M Forward primer	0.5 $\mu$ l
5	25 $\mu$ M Reverse primer	0.5 $\mu$ l
	Ampli <sup>Taq</sup> Gold <sup>®</sup> polymerase, 5U/ $\mu$ l (Applied Biosystems)	0.25 $\mu$ l
	Water	36.25 $\mu$ l

Thermal-cycle condition: 95°C, 10 min, followed by 40 cycles of 95 °C, 1 min;  
 10 50°C 1 min; 72 °C, 1 min.

#### 4. Primer sequences

Primers were designed based on the RNA-dependent RNA polymerase encoding sequence (SEQ ID NO:1) of the CoV-HKU1.

15 Forward primer: 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4)  
 Reverse primer: and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5)  
 Product size: 440 bps

#### Real-Time Quantitative PCR Assay

20 Total RNA from 140  $\mu$ l of nasopharyngeal aspirate (NPA) was extracted by QIAamp<sup>®</sup> virus RNA mini kit (Qiagen) as instructed by the manufacturer. Ten  $\mu$ l of eluted RNA samples were reverse transcribed by 200 U of Superscript<sup>®</sup> II reverse transcriptase (Invitrogen) in a 20  $\mu$ l reaction mixture containing 0.15  $\mu$ g of random hexamers, 10 mmol/L DTT, and 0.5 mmol/L dNTP, as instructed. Complementary DNA was then amplified in a  
 25 SYBR<sup>®</sup> Green I fluorescence reaction (Roche, IN) mixtures. Briefly, 20  $\mu$ l reaction mixtures containing 2 $\mu$ l of cDNA, 3.5 mmol/L MgCl<sub>2</sub>, 0.25  $\mu$ mol/L of forward primer [5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4)] and 0.25  $\mu$ mol/L reverse primer [5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5)] were thermal-cycled by a LightCycler<sup>®</sup> (Roche) with the PCR program, [95°C, 10 min followed by 50 cycles of 95°C,  
 30 10 min; 57°C, 5 sec; 72°C 9 sec]. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were captured at the end of extension step in each cycle. To determine the specificity of the assay, PCR products (440

base pairs) were subjected to a melting curve analysis at the end of the assay (65°C to 95°C, 0.1°C per second) (data not shown).

The amount of CoV-HKU1 RNA in the nasopharyngeal aspirates was followed weekly. Quantitative RT-PCR showed that the amounts of CoV-HKU1 RNA were  $8.5 \times 10^5$  and  $9.6 \times 10^6$  copies per ml in two nasopharyngeal aspirates collected in the first week of the illness,  $1.5 \times 10^5$  copies per ml of NPA, respectively, at two time points collected in the second week of the illness, but CoV-HKU1 RNA was undetectable in the NPA collected in the third, fourth and fifth weeks of the illness (Fig. 7). CoV-HKU1 RNA was also undetectable in the urine and stool of the patient collected in the first and second weeks of the illness.

## **DISCUSSION**

The genome of CoV-HKU1 is a 29926-nucleotide long, polyadenylated RNA. The G + C content is 32%, which is the lowest among all known coronaviruses with genome sequences available, with a GC skew of 0.19. Table 1 shows comparison of genomic features of CoV-HKU1 and other coronaviruses and amino acid identities between the predicted chymotrypsin-like protease (3CL<sup>pro</sup>), RNA dependent RNA polymerase (Pol), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses

Tabke 1

Coronaviruses <sup>a</sup>	Genome features		Pairwise amino acid identity (%)						
	Size (bases)	G + C content	3CL <sup>pro</sup>	Pol	Hel	HE	S	E	
Group 1									
HCoV-229E	27317	0.38	45	54	55	-	31	26	35
PEDV	28033	0.42	44	56	55	-	30	34	37
PTGV	28586	0.38	45	57	57	-	32	34	37
CCoV	-	-	-	-	-	-	31	32	36
HCoV-NL63	27553	0.34	43	54	54	-	30	28	32
Group 2									
CoV-HKU1	29926	0.32	-	-	-	-	-	-	-
HCoV-OC43	30738	0.37	82	87	88	57	60	54	76
MHV	31357	0.42	85	90	89	50	61	57	84
BCoV	31028	0.37	84	88	88	56	61	55	76
SDAV	-	-	-	-	-	50	61	60	77
ECoV	-	-	-	-	-	53	61	56	78
PHEV	-	-	-	-	-	54	61	54	77
Group 3									
IBV	27608	0.38	41	60	57	-	32	28	38
SARS-CoV	29751	0.41	48	65	63	-	33	27	34
<sup>a</sup> HCoV-229E, human coronavirus 229E; PEDV, porcine epidemic diarrhea virus; PTGV, porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63, human coronavirus NL63; HCoV-OC43, human coronavirus OC43; MHV, murine hepatitis virus; BCoV, bovine coronavirus; SDAV, rat sialodactyoadenitis coronavirus; ECov, equine coronavirus NC99; PHEV, porcine hemagglutinating encephalomyelitis virus; IBV, infectious bronchitis virus; SARS-CoV, SARS coronavirus									



The genome organization is the same as other coronaviruses, with the characteristic gene order 5'-replicase, S, E, M, N-3'. Both 5' and 3' ends contain short untranslated regions. The 5' end of the genome consists of a putative 5' leader sequence. A putative transcription regulatory sequences (TRS) motif, 5'-CUAAAC-3', was found at the 3' end of the leader sequence and precedes each translated ORF except ORF4 and ORF6 which encodes the putative E protein. Table 2 shows the putative transcription regulatory sequences in the genome of CoV-HKU1.

**Table 2**

Number of base upstream of AUG	ORF	TRS sequence	SEQ ID NO.
-140	Leader	UUAAAUCUAAACUUUUUAA (127) AUG	8
-7	Hemagglutinin esterase	UUAAAUCUAAACUAUG	9
-6	Spike	UUAAAUCUAAACAUG	10
-13	ORF 5	UUAAAUCUAAACUUUAUUUAUG	11
-9	Membrane	CUAAAUCUAAACAUAUG	12
-13	Nucleocapsid	UUAAAUCUAAACUAUUAGGAUG	13
-35	ORF 9	UUAAAUCUAAACUAUUAGGAUGUCUUAU ACUCCCGGUCAUAUG	14

10

As in SDAV (Sialodacryoadenitis virus) and MHV (mouse hepatitis virus), ORF6 may share the same TRS with ORF 5, suggesting that the translation of the E protein is cap-independent, possibly via an internal ribosomal entry site. The 3' untranslated region contains a predicted pseudoknot structure 59-119 bp downstream of N gene. This pseudoknot structure is highly conserved among coronaviruses and plays a role in coronavirus RNA replication.

15

The coding potential of the CoV-HKU1 genome is shown in Fig. 4 and Table 3 and the phylogenetic analyses of the chymotrypsin-like protease (3CL<sup>Pro</sup>), replicase, helicase, haemagglutinin-esterase (HE), S, E, M and N, are shown in Figures 5A and 5B.

20

Table 3

ORFs	Start-end (base)	No. of bases	No. of amino acids	Frame	Candidate TRS
ORF 1a	206-13600	13395	4465	+2	-
ORF 1b	13600-21753	8154	2717	+1	-
HE (ORF 2)	21773-22933	1161	386	+2	Strong
S (ORF 3)	22942-27012	4071	1356	+1	Strong
ORF 4	26960-27070	111	36	+2	None
ORF 5	27051-27380	330	109	+3	Strong
E (ORF 6)	27373-27621	249	82	+1	None
M (ORF 7)	27633-28304	672	223	+3	Strong
N (ORF 8)	28320-29645	1326	441	+3	Strong
ORF 9	28342-28959	618	205	+1	Strong

The replicase 1a ORF (bases 206-13600) and replicase 1b ORF (bases 13600-21753) occupy 21.5 kb of the CoV-HKU1 genome. Similar to other coronaviruses, a frame shift interrupts the protein-coding regions and separates the 1a and 1b ORFs. This ORF encodes a number of putative proteins, including papain-like protease (PLP) with two copies of the PLP domain, PLP1<sup>pro</sup> and PLP2<sup>pro</sup>, 3CL<sup>pro</sup>, replicase, helicase, and other proteins of unknown functions. These proteins are produced by proteolytic cleavages of a large polyprotein (Fig. 4). The sequence of the resulting putative proteins is the same as that in the MHV genome. This polyprotein is synthesized by a -1 ribosomal frameshift at a conserved site (UUUAAAC) upstream of a pseudoknot structure at the junction of ORF 1a and ORF 1b. This ribosomal frameshift would result in a polyprotein of 7182 amino acids, which has 75-77% amino acid identities with the polyprotein in other Group 2 coronaviruses and 43-47% amino acid identities with the polyprotein in other non-Group 2 coronaviruses. The replicase gene of CoV-HKU1, which encodes 928 amino acids, has 87-89% amino acid identities with the replicase of other Group 2 coronaviruses and 54-65% amino acid identities with the replicase of other non-Group 2 coronaviruses (Table 4 and Fig. 5A). Table 4 shows amino acid identities between the predicted chymotrypsin-like protease (3CL<sup>pro</sup>), replicase (Rep), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses.

Table 4

Group	Virus	Pairwise amino acid identity (%)							
		3CL <sup>pro</sup>	Rep	Hel	HE	S	E	M	N
1	HCoV-229E	45	54	55	-	31	26	35	28
	PEDV	44	56	55	-	30	34	37	37
	PTGV	45	57	57	-	32	34	37	27
	CCoV	-	-	-	-	31	32	36	27
	HCoV-NL63	43	54	54	-	30	28	32	28
2	HCoV-OC43	82	87	88	57	60	54	76	58
	MHV	85	89	87	50	58	55	78	60
	BCoV	84	88	88	56	61	55	76	57
	SDAV	-	-	-	50	61	60	77	62
	ECoV	-	-	-	53	61	56	78	59
	PHEV	-	-	-	54	61	54	77	57
3	IBV	41	60	57	-	32	28	38	27
	SARS-CoV SARS-CoV	48	65	63	-	33	27	34	31

HCoV-229E=human coronavirus 229E; PEDV=porcine epidemic diarrhea virus;

PTGV=porcine transmissible gastroenteritis virus; CCoV=canine enteric coronavirus;

5 HCoV-NL63=human coronavirus NL63; HCoV-OC43=human coronavirus OC43;

MHV=murine hepatitis virus; BCoV=bovine coronavirus; SDAV=rat sialodacryoadenitis coronavirus; ECoV=equine coronavirus NC99; PHEV=porcine hemagglutinating

encephalomyelitis virus; IBV=infectious bronchitis virus; SARS-CoV=SARS coronavirus

10 The catalytic histidine and cysteine amino acid residues, conserved among the  
3CL<sup>pro</sup> in all coronaviruses, are present in the predicted 3CL<sup>pro</sup> of CoV-HKU1 (amino acids  
His<sup>3375</sup> and Cys<sup>3479</sup> of ORF 1a). In the N-terminal of the putative PLP (amino acid residues  
945 to 1104 of ORF 1a), there are 14 tandem copies of a 30-base repeat, which encode  
NDDDEDVVTGD (SEQ ID NO:15), followed by two 30-base regions that encode  
15 NNDEEIVTGD (SEQ ID NO:16) and NDDQIVVTGD (SEQ ID NO:17), located upstream  
to the first copy of PLP domain, PLP1<sup>pro</sup>. This repeat is not observed in other coronaviruses.

ORF 2 (bases 21773-22933) encodes the predicted HE glycoprotein with 386 amino  
acids. The HE protein of CoV-HKU1 has 50-57% amino acid identities with the HE  
proteins of other Group 2 coronaviruses (Table 4 and Fig. 5A). PFAM and InterProScan  
20 analyses of the ORF show that amino acid residues 1 to 349 of the predicted protein is a  
member of the haemagglutinin esterase family (PFAM accession no.: PF03996 and

INTERPRO accession no. IPR007142). This family contains membrane glycoproteins that are present on viral surface and are involved with the cell infection process. It contains haemagglutinin chain 1 (HE1) and haemagglutinin chain 2 (HE2), and forms a homotrimer with each monomer being formed by two chains linked by a disulphide bond. Furthermore, PFAM and InterProScan analyses of the ORF show that amino acid residues 122 to 236 of the predicted protein are the haemagglutinin domain of HE-fusion glycoprotein family (PFAM accession no.: PF02710 and INTERPRO accession no. IPR003860). HE is also present in other Group 2 coronaviruses and influenza C virus. SignalP analysis reveals a signal peptide probability of 0.738, with a cleavage site between residues 13 and 14.

Although TMPred and TMHMM analyses of the ORF show four and three transmembrane domains, respectively, PHDhtm analysis of the ORF shows only one transmembrane domain at positions 354 to 376. This concurs with only one transmembrane region reported in the C terminal of the HE of BCoV (bovine coronavirus) and puffinosis virus. PrositeScan analysis of the HE protein of CoV-HKU1 reveals eight potential N-linked glycosylation (six NXS and two NXT) sites. These are located at positions 83 (NYT), 110, (NGS), 145 (NVS), 168 (NYS), 193 (NFS), 286 (NSS), 314 (NVS, and 328 (NFT). The putative active site for neuraminate O-acetyl-esterase activity, FGDS (SEQ ID NO:18), is located at positions 31-34.

ORF 3 (bases 22942-27012) encodes the predicted S glycoprotein (PFAM accession no. PF01601) with 1356 amino acids. The S protein of CoV-HKU1 has 58-61% amino acid identities with the S proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the S proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B). InterProScan analysis predicts it as a type I membrane glycoprotein. Important features of the S protein of CoV-HKU1 are depicted in Fig. 6. PrositeScan of the S protein of CoV-HKU1 reveals 28 potential N-linked glycosylation (12 NXS and 16 NXT) sites. SignalP analysis reveals a signal peptide probability of 0.909, with a cleavage site between residues 13 and 14. By multiple alignments with the S proteins of other Group 2 coronaviruses, a potential cleavage site located after RRKRR (SEQ ID NO:19), between residues 760 and 761, where S will be cleaved into S1 and S2, is identified. Immediately upstream to RRKRR (SEQ ID NO:19), there is a series of five serine residues that are not present in any other known coronaviruses (Fig. 6). Most of the S protein (residues 15 to 1300) is exposed on the outside of the virus, with a transmembrane domain at the C

terminus (TMHMM analysis of the ORF shows one transmembrane domain at positions 1301 to 1356), followed by a cytoplasmic tail rich in cysteine residues. Two heptad repeats (HR), located at residues 982 to 1083 (HR1) and 1250 to 1297 (HR2), identified by multiple alignments with other coronaviruses, are present. In MHV, it has been confirmed that the receptor for its S protein binding is CEACAM1, a member of the carcinoembryonic antigen (CEA) family of glycoproteins in the immunoglobulin superfamily. Furthermore, it has been shown, by site-directed mutagenesis, that three conserved regions (sites I, II, and III) and some amino acid residues (Thr<sup>62</sup>, Thr<sup>212</sup>, Tyr<sup>214</sup>, and Tyr<sup>216</sup> in MHV) in the N-terminal of the S protein are particularly important for its receptor-binding activity. By multiple alignments with the N-terminal 330 amino acids of the S protein of MHV and other group 2 coronaviruses, it is observed that these conserved regions and amino acids are present in CoV-HKU1 (Fig. 6). This infers that the receptor for CoV-HKU1 could be a member of the CEA family on the surface of the cells in the respiratory tract. On the other hand, for HCoV-OC43, it has been shown in vitro that the receptor for the S protein is a sialic acid. However, the amino acid residues on the S protein of HCoV-OC43 that are important for receptor binding are not well defined.

ORF 4 (bases 26960-27070) encodes a predicted protein with 36 amino acids. This ORF overlaps with the ORF that encodes the S protein. This ORF is not present in other coronaviruses and BlastP analysis of the ORF does not show any hits.

ORF 5 (bases 27051-27380) encodes a predicted protein with 109 amino acids. This ORF overlaps with the ORF that encodes the E protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus non-structural protein NS2 family (PFAM accession no.: PF04753). TMpred and TMHMM analysis do not reveal any transmembrane helix. This predicted protein of CoV-HKU1 has 44-51% amino acid identities with the corresponding proteins of other Group 2 coronaviruses.

ORF 6 (bases 27373-27621) encodes the predicted E protein with 82 amino acids. The E protein of CoV-HKU1 has 54-60% amino acid identities with the E proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the E proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B). PFAM and InterProScan analyses of the ORF show that the predicted E protein is a member of the non-structural protein NS3/Small envelope protein E (NS3\_envE) family (PFAM accession no.: PF02723). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.995).

TMpred analysis of the ORF shows two transmembrane domains at positions 16 to 34 and 39 to 59, and TMHMM analysis of the ORF shows two transmembrane domains at positions 10 to 32 and 39 to 58, consistent with the anticipated association of the E protein with the viral envelope. Both programs predict that both the N and C termini are located on the surface of the virus.

ORF 7 (bases 27633-28304) encodes the predicted M protein with 223 amino acids. The M protein of CoV-HKU1 has 76-78% amino acid identities with the M proteins of other Group 2 coronavirus, but has fewer than 40% amino acid identities with the M proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B). PFAM analysis of the ORF shows that the predicted M protein is a member of the coronavirus matrix glycoprotein (Corona\_M) family (PFAM accession no.: PF01635). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.926). TMpred analysis of the ORF shows three transmembrane domains at positions 21 to 42, 53 to 74, and 77 to 98. TMHMM analysis of the ORF shows three transmembrane domains at positions 20 to 39, 46 to 68, and 78 to 100. The N terminal 19-20 amino acids are located on the outside and the C terminal 123-125-amino acid hydrophilic domain on the inside of the virus.

ORF 8 (bases 28320-29645) encodes the predicted N protein (PFAM accession no.: PF00937) with 441 amino acids. The N protein of CoV-HKU1 has 57-62% amino acid identities with the N proteins of other Group 2 coronaviruses, but has fewer than 40% amino acid identities with the N proteins of Group 1, Group 3, and SARS-CoV (Table 4 and Fig. 5B).

ORF 9 (bases 28342-28959) encodes a hypothetical protein (N2) of 205 amino acids within the ORF that encodes the predicted N protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus nucleocapsid I protein (Corona\_I) family (PFAM accession no.: PF03187). This hypothetical N2 protein of CoV-HKU1 has 32-39% amino acid identities with the N2 proteins of other Group 2 coronaviruses.

We report the characterization and complete genome sequence of a novel coronavirus detected in the nasopharyngeal aspirates of patients with pneumonia. The clinical significance of the virus in the first patient was evident by the high viral loads in the patient's nasopharyngeal aspirates during the first week of his illness, which coincided with the acute symptoms developed in the patient. The viral load decreased during the second week of the illness and was undetectable in the third week of the illness. In addition, the

fall in viral load was accompanied by the recovery from the illness and development of specific antibody response to the recombinant N protein of the virus. Similar to other recently discovered viruses, such as hepatitis C virus, GB virus C, transfusion transmitted virus, and SEN virus, the present virus could not be recovered from cell cultures using the standard cell lines. This could be related to the inherently low recovery rate of coronaviruses. Human coronaviruses are particularly difficult to culture in vitro. Many decades after the recognition of HCoV-229E and HCoV-OC43, there are still only a handful of primary virus isolates available and organ culture is required for primary isolation of HCoV-OC43. In our experience, SARS-CoV can only be recovered from less than 20% of patients with serologically and RT-PCR documented SARS-CoV pneumonia. Therefore, it is not surprising that the new coronavirus CoV-HKU1 has been so far proven difficult to culture in vitro. After the discovery of CoV-HKU1 in the first patient, we conducted a preliminary study on 400 nasopharyngeal aspirates that were collected last year during the SARS epidemic period. Among these 400 nasopharyngeal aspirates, CoV-HKU1 was detected in one specimen, with a viral load comparable to that of the first patient. These results have suggested that CoV-HKU1 is not only incidentally found in one patient, but a previously unrecognized coronavirus associated with pneumonia.

Genomic analysis has reveals that CoV-HKU1 is a Group 2 coronavirus. The genome organization of CoV-HKU1 concurs with those of other coronaviruses, with the characteristic gene order, *i.e.*, 5'-replicase, S, E, M, N-3', short untranslated regions in both 5' and 3' ends, 5' conserved coronavirus core leader sequence, putative TRS upstream to multiple ORFs, and conserved pseudoknot in the 3' untranslated region. In contrast to coronaviruses of other groups, CoV-HKU1 contains certain features that are characteristics of Group 2 coronaviruses, including the presence of HE, ORF 5, and N2. Phylogenetic analysis of the 3CL<sup>pro</sup>, replicase, helicase, S, E, M, and N proteins showed that these genes of CoV-HKU1 were clustered with the corresponding genes in other Group 2 coronaviruses. However, the proteins of CoV-HKU1 formed distinct branches in the phylogenetic trees, indicating that CoV-HKU1 is a distinct member of the group, and is not very closely related to any other known members of Group 2 coronaviruses (Figures 4A and 4B).

In addition to phylogenetic analysis of the putative proteins, CoV-HKU1 exhibits certain features that are distinct from other Group 2 coronaviruses. Compared to other Group 2 coronaviruses, there is a deletion of about 800 bps between the replicase ORF 1b

and the HE ORF 2 in CoV-HKU1. In other Group 2 coronaviruses, including MHV, SDAV, HCoV-OC43 and BCoV, an ORF of 798-837 bp (273-278 amino acids) is present between the replicase 1b ORF and the HE ORF 2. This ORF encodes a protein of the coronavirus non-structural protein NS2a family (PFAM accession no.: PF05213). The absence of this ORF in CoV-HKU1 indicates that this is probably a non-essential gene of coronavirus. In addition to the deletion, the N-terminal of the putative PLP in ORF 1a contains 14 tandem copies of a 30-bp repeat that codes for a highly acidic domain. Similar repeats, with different amino acid compositions, have been found in the genomes of human, rat and parasites, but have not been found in other coronaviruses. The function of these repeats is not well understood, although some authors have suggested that the repeats could be important antigens, and their biological role may be related to their special three-dimensional structures. The vitellaria antigenic protein of *Clonorchis sinensis* contains 23 tandem copies of a 30-bp repeat that codes for DGGAQPPKSG (SEQ ID NO:20). In the case of *Plasmodium falciparum*, it has been shown that the antigenicity of the circumsporozoite protein is due to its repeating epitope structure. It has also been suggested that the tandemly repeated peptide may induce strong humoral immune response in the infected host and thus may also be useful in serological diagnosis. Further experiments should be performed to delineate the antigenic properties, biological role, and possible clinical usefulness of the repeat in the PLP of CoV-HKU1.

The geographical, political, and economic location of Hong Kong makes it a unique place for the study of emerging infectious disease. Hong Kong, as the gateway of southern China, with thousands of people crossing the border on surface and by air every day, has a high potential of importing and exporting infectious diseases to and from China, countries in Southeast Asia and from the rest of the world. In 1997, the first 18 human cases of avian influenza A H5N1 virus infection were reported in Hong Kong. In early 2003, two cases of human infection caused by avian influenza A (H5N1) that was acquired in Fujian, were diagnosed in Hong Kong, which provided an early warning of the impending disease threat for humans and poultry in Southeast Asia that followed in 2004. For the SARS epidemic, although both epidemiological and genomic evidence revealed that the disease had first occurred in southern China in November 2002, it did not receive as much international attention until the disease was spread to Hong Kong and through Hong Kong to Singapore, Toronto, Vietnam, and the United States of America. As for emerging bacterial infections,



50% of the patients with gastroenteritis associated with the recovery of *Laribacter hongkongensis* had recent history of travel to southern China. In this report, one of the patients also had recent history of travel to Shenzhen of China prior to the development of the respiratory illness. We speculate that he might have contacted the virus in Shenzhen.

5 More intensive surveillance of emerging infectious pathogens in this locality is warranted.

## 6.2 Example 2

We prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period. A 453-bp fragment of the *pol* gene of CoV-HKU1 was amplified from the extracted RNA by RT-PCR using CoV-HKU1 specific primers. The epidemiological, clinical, laboratory and radiological features of patients with pneumonia associated with CoV-HKU1 were analyzed. Specific antibodies were detected using a recombinant CoV-HKU1 N protein based ELISA. The complete *pol*, S and N genes of the CoV-HKU1 were amplified and sequenced. RNA extracted from 208 nasopharyngeal swabs and fecal samples from 56 wild and domestic animals in Hong Kong and southern China were subject to RT-PCR of *pol* gene of CoV-HKU1 using CoV-HKU1 specific primers.

10  
15

### 6.2.1 Patients and microbiological methods

All prospectively collected NPAs from patients with community-acquired pneumonia sent to the clinical microbiology laboratories of four regional hospitals in Hong Kong during a 12-month period [March 22 2003 (beginning of SARS epidemic in Hong Kong) – March 21 2004] for detection of SARS-CoV but negative for SARS-CoV RNA by RT-PCR were included in the study. Community-acquired pneumonia is defined as symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which there is no other explanation that develop prior to or within 48 h after presentation to hospital. Once CoV-HKU1 was detected from NPAs, the hospital records, laboratory results and chest radiographs of the corresponding patients were retrieved and examined by two infectious disease physicians. The RNA extracted from the NPAs was subject to RT-PCR for influenza A virus and human metapneumovirus (Peiris JSM *et.al.*, *Lancet* 2003; 361: 1319-25). Available stored serum samples were

20  
25  
30

subject to serological assays for detection of antibodies against *Mycoplasma*, *Chlamydia*, *Legionella* and SARS-CoV by SERODIA-MYCO II (Fujirebio Inc., Tokyo, Japan), *Chlamydia pneumoniae* MIF IgG (Focus technologies, Cypress, CA, USA), indirect immunofluorescence (MRL, San Diego, CA, USA) and our recently developed enzyme-linked immunosorbent assay (ELISA), respectively (Woo PCY *et al.*, *Lancet* 2004; 363:841-5).

To determine the possible risk factors associated with CoV-HKU1 pneumonia, two age- and sex-matched controls per patient with CoV-HKU1 pneumonia were randomly selected from those with community-acquired pneumonia but their NPAs negative for CoV-HKU1. Controls were within five years older or younger than the corresponding patients with CoV-HKU1 pneumonia, and were admitted within 15 days before or after admission of the corresponding patients with CoV-HKU1 pneumonia. The hospital records, laboratory results and chest radiographs of the controls were retrieved and examined by the two infectious disease physicians.

#### 6.2.2 RNA extraction

Viral RNA was extracted from NPAs using QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions within 10 h upon receipt of specimens. The eluted RNA was used as the template for RT-PCR. All extracted RNA was stored immediately at -70°C until use.

#### 6.2.3 RT-PCR of RNA-dependent RNA polymerase gene of coronavirus-HKU1 using coronavirus-HKU1 specific primers and DNA sequencing

A 453-bp fragment of the RNA dependent RNA polymerase (*pol*) gene of CoV-HKU1 was amplified by RT-PCR using CoV-HKU1 specific primers, 5'-AAAGGATGT-TGACAACCCTGTT-3' (LPW1926; SEQ ID NO:2968) and 5'-ATCATCATACTAAAATGC-TTACA-3' (LPW1927; SEQ ID NO:2969) designed by multiple alignment of the nucleotide sequences of the *pol* genes of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and those of the available *pol* genes of other known human coronaviruses. RT was performed using the SuperScript II kit (Invitrogen, San Diego, CA, USA) according to manufacturer's instructions. The PCR mixture (50 µl)

contained cDNA, PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 3 mM MgCl<sub>2</sub> and 0.01% gelatin), 200 µM of each dNTPs and 1.0 U *Taq* polymerase (Boehringer Mannheim, Germany). The mixtures were amplified in 40 cycles of 94°C for 1 min, 48°C for 1 min and 72°C for 1 min, and a final extension at 72°C for 10 min in an automated thermal cycler (Perkin-Elmer Cetus, Gouda, The Netherlands). Distilled water was used as the negative control. To ensure the high specificity of the CoV-HKU1 specific primers, RNA extracted from 200 NPAs positive for influenza A and B viruses, parainfluenza viruses 1-3, respiratory syncytial virus (RSV), or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV were also subject to RT-PCR using the two CoV-HKU1 specific primers.

Ten microlitres of each amplified product was electrophoresed in 1.5% (w/v) agarose gel, with a molecular size marker (ΦX-174 DNA *Hae*III digest, Boehringer Mannheim, Germany) in parallel. Electrophoresis in Tris-borate-EDTA buffer was performed at 100 V for 1.5 h. The gel was stained with ethidium bromide (0.5 µg/ml) for 15 minutes, rinsed and photographed under ultraviolet light illumination.

The PCR products were gel-purified using the QIAquick gel extraction kit (QIAGEN, Hilden, Germany). Both strands of the PCR products were sequenced twice with an ABI Prism 3700 DNA Analyzer according to manufacturers' instructions (Applied Biosystems, Foster City, CA, USA), using the two PCR primers. The sequences of the PCR products were compared with the sequences of the *pol* genes of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and those of the *pol* genes of coronaviruses in the GenBank database.

#### 6.2.4 ELISA using recombinant nucleocapsid protein of CoV-HKU1

The ELISA-based IgG and IgM antibody tests were performed according to our published protocol (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). Briefly, each well of a Nunc immunoplate (Roskilde, Denmark) was coated with purified (His)<sub>6</sub>-tagged recombinant N protein (20 ng for IgG and 80 ng for IgM) for 1 h and then blocked in phosphate-buffered saline with 5% skim milk. The serum samples obtained from the patients during the acute and convalescent phase of the illness were serially diluted and were added to the wells of the (His)<sub>6</sub>-tagged (SEQ ID NO: 27) recombinant N protein-coated plates in a total volume of 100 µl and incubated at 37°C for 2 h. After washing with

washing buffer five times, 100 µl of diluted horse radish peroxidase-conjugated goat anti-human IgG (1:4000) and mouse anti-human IgM (1:1000) antibodies (Zymed Laboratories Inc., South San Francisco, CA, USA) were added to the wells and incubated at 37°C for 1 h. After washing with washing buffer five times, 100 µl diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at room temperature for 15 min. One hundred microlitres of 0.3 M H<sub>2</sub>SO<sub>4</sub> were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

#### 6.2.5 RT-PCR and sequencing of the complete RNA-dependent RNA polymerase, spike and nucleocapsid genes of coronavirus-HKU1 and phylogenetic analysis

The complete *pol*, spike (S) and N genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced using the RNA extracted from the NPAs as template. The RNA was converted to cDNA by a combined random-priming and oligo(dT) priming strategy. The cDNA was amplified by degenerate primers designed by multiple alignment of the regions encoding the *pol*, S and N genes in the genomes of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and those of other group 2 coronaviruses and additional primers designed from the results of the first and subsequent rounds of sequencing. Sequences were assembled and manually edited to produce the complete sequences of the *pol*, S and N genes of CoV-HKU1 from different patients. The nucleotide and the deduced amino acid sequences of the *pol*, S and N genes were compared to those of the two CoV-HKU1 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895) and other group 2 coronaviruses. Phylogenetic tree construction was performed using PileUp method with GrowTree (Genetics Computer Group, Inc.).

#### 6.2.6 Animal surveillance

Two hundred and eight nasopharyngeal swabs and faecal samples from 56 wild and domestic animals [including Chinese ferret-badger (*Melogale moschata*), domestic cat (*Felis catus*), hog-badger (*Arctonyx collaris*), masked palm civet (*Paguma larvata*), racoon dog (*Nyctereutes procyonoides*), Chinese pygmy dormouse (*Typhlomys cinereus*), common pangolin (*Manis pentadactyla*), nutria (*Myocastor coypus*), dog (*Canis familiaris*), rabbit

(*Leporidae* family), snake (*Serpentes* suborder) and bat (*Microchiroptera* suborder)] in Hong Kong and southern China (Guan Y, et al., *Science* 2003; **302**: 276-8) were subjected to RNA extraction and RT-PCR of *pol* gene of CoV-HKU1 using the CoV-HKU1 specific primers (LPW1926; SEQ ID NO:2968 and LPW1927; SEQ ID NO:2969) and protocol  
5 described above.

## 6.2.7 Results

### Clinical and laboratory characteristics

During the 12-month period, NPAs from 418 patients [male:female = 198:220, age  
10 (mean  $\pm$  SD) =  $49 \pm 26$ ] with community-acquired pneumonia, for detection of SARS-CoV but were negative for SARS-CoV RNA by RT-PCR, were identified in the four hospitals. A 453-bp fragment of the *pol* gene of CoV-HKU1 was amplified and sequenced in 10 (2.5%) patients. Sequence analysis revealed 0-2% nucleotide differences between the sequences of the fragments and the sequence of the *pol* gene of the CoV-HKU1 from the  
15 reported index patient (patient no. 5) described in Example 1 above (Fig. 11) (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). In contrast, using our CoV-HKU1 specific primers, none of the 200 NPAs that were positive for influenza A and B viruses, parainfluenza viruses 1-3, RSV, or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV, was RT-PCR positive.

20 The epidemiological, clinical and radiological characteristics of the 10 patients, including patient no. 5 (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895), with community-acquired pneumonia associated with CoV-HKU1 are summarized in Table 5. No epidemiological linkage was identified among the 10 cases. All cases occurred in either winter or spring (January – May). The median age was 71.5 (range: 13-96). Seven were  
25 males and three were females. Nine were Chinese and one was an Arabian. Eight had underlying diseases, and four had underlying diseases of the respiratory tract. Four had recent travel histories to southern China. Five were smokers. Clinically, the illness was not distinguishable from other community-acquired pneumonia. Fever, productive cough and dyspnoea were common presenting symptoms. Upper respiratory tract symptoms were  
30 present in only two patients (patient nos. 1 and 5). One patient (patient no. 7) had loose stool diarrhea. Oxygen saturation on room air upon admission was <95% in two. Airspace shadows were observed in the right lungs of six patients and the left lungs of six patients.

The upper, middle and lower zones were affected in two, four and nine patients respectively. All patients, except patient no. 10, had normal platelet counts and normal liver and renal function tests. Bacterial or mycobacterial pathogens were not detected in any of the sputum samples from the patients. Direct antigen detection for influenza A and B viruses, parainfluenza viruses 1-3, RSV, adenovirus (Woo PCY *et al.*, *J Clin Microbiol* 1997; 35: 1579-81) and RT-PCR for influenza A virus and metapneumovirus, was negative in all NPAs. Antibodies against *M. pneumoniae*, *C. pneumoniae*, *C. psittaci*, *L. pneumophila* and SARS-CoV were negative in all the six patients (patient nos. 1, 4, 5, 6, 8 and 9) whose serum samples were available. All these six patients showed a four-fold change in IgG titer (patient nos. 4, 5 and 6) and/or the presence of IgM (patient nos. 1, 5, 8 and 9) against CoV-HKU1.

Table 5

Characteristics	Patient no.									
	1	2	3	4	5	6	7	8	9	10
Month/Year	Mar/03	Apr/03	May/03	Jan/04	Jan/04	Jan/04	Jan/04	Jan/04	Mar/04	Mar/04
Sex/Age	F/35	M/66	M/13	M/75	M/71	E/96	M/78	M/68	F/83	M/72
Ethnic origin	Chinese	Arabian	Chinese	Chinese	Chinese	Chinese	Chinese	Chinese	Chinese	Chinese
Underlying diseases	-	Diabetes mellitus, old myocardial infarction, gastric lymphoma	Asthma, situs inversus, dextrocardia	Hypertension	Chronic obstructive airway disease, hyperlipidemia, abdominal aortic aneurysm	Hypertension	Chronic obstructive airway disease, diabetes mellitus	-	Chronic obstructive airway disease, parathyroid adenoma, dementia	Prostate carcinoma, cerebrovascular accident, diabetes mellitus
History of travel within two weeks of disease onset	-	-	Shenzhen, China	Guangdong, China	Shenzhen, China	-	-	Guangdong, China	-	-
History of smoking	-	-	-	+	+	-	+	-	+	+
Clinical features										
Fever	+	-	+	-	+	+	+	+	+	+
Chills	-	-	-	-	+	-	-	-	-	-
Rigor	-	-	-	-	-	-	-	-	-	-
Myalgia	-	-	-	-	-	-	-	-	-	-
Headache	-	-	-	-	+	-	-	-	-	-
Cough	+	-	+	+	+	-	+	+	-	+
Sputum production	-	-	+	+	+	-	+	+	+	+
Dyspnoea	-	+	-	+	-	-	+	+	+	+
Pleurisy	-	-	-	-	-	-	-	-	-	-
Rhinorrhoea	-	-	-	-	+	-	-	-	-	-
Sore throat	+	-	-	-	+	-	-	-	-	-
Oxygen saturation on room air (%)	99	83	100	99	99	97	97	95	99	88
Chest radiograph features	RLZ airspace shadows	Bilateral airspace shadows	LMZ and LLZ airspace shadows	LLZ airspace shadows	LLZ airspace shadows	RLZ airspace shadows	LLZ airspace shadows	RMZ airspace shadows	RLZ airspace shadows	Bilateral airspace shadows
Outcome	Survived	Died	Survived	Survived	Survived	Survived	Survived	Survived	Survived	Died
Duration of hospitalization (no. of days)	2	Died on day 12	3	7	5	7	13	5	6	Died on day 6

+ = present; - = absent; RLZ = right upper zone; LUZ = left upper zone; LMZ = right middle zone; LLZ = left middle zone; RMZ = right lower zone; LLZ = left lower zone

In comparison with age- and sex-matched controls with non-CoV-HKU1 pneumonia, no epidemiological, clinical, haematological, serum biochemical and radiological risk factors were identified in patients with CoV-HKU1 pneumonia (Table 6).

5

Table 6

Characteristics	Pneumonia*		P value
	HCoV-HKU1 (n=10)	Non-HCoV- HKU1 (n=20)	
Underlying diseases	8	12	0.42
History of travel within two weeks of disease onset	4	6	0.69
History of smoking	5	7	0.46
Clinical features			
Fever	8	14	0.68
Cough	7	17	0.37
Sputum production	6	12	1.00
Dyspnoea	6	6	0.12
Rhinorrhoea	1	2	1.00
Sore throat	2	2	0.58
Haematological features			
Haemoglobin (g/dl)	12.4	13.2	0.27
Leukocyte count ( $\times 10^9/l$ )	9.9	9.7	0.95
Neutrophil count ( $\times 10^9/l$ )	7.35	7.4	0.71
Lymphocyte count ( $\times 10^9/l$ )	0.95	1.02	0.48
Monocyte count ( $\times 10^9/l$ )	0.55	0.65	0.35
Platelet count ( $\times 10^9/l$ )	240	292	0.20
Serum biochemical features			
Sodium (mmol/l)	136	137	0.59
Potassium (mmol/l)	3.9	4.0	0.42
Creatinine ( $\mu\text{mol/l}$ )	92	76.5	0.06
Urea (mmol/l)	5.25	4.9	0.62
Albumin (g/l)	37	38	0.59
Globulin (g/l)	36.5	30	0.07
Bilirubin ( $\mu\text{mol/l}$ )	12	10	1.00
ALT (U/l)	20	17	0.42
Alkaline phosphatase (U/l)	102	91	0.95
Oxygen saturation on room air (%)	96	98	0.86
Radiological features			
Bilateral involvement	2	5	1.00
No. of zones involved	1	1	0.81
Mortality	2	0	0.10

\*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.



- Two of the 10 patients died of CoV-HKU1 pneumonia. The first patient (patient no. 2) was a 66-year old man who presented with dyspnoea for one day. He had type 2 diabetes mellitus, old myocardial infarction and gastric lymphoma with total gastrectomy in 2002 and was put on chemotherapy. He had severe lymphopenia ( $0.2 \times 10^9/L$ ) and an oxygen saturation of only 83% on admission. Chest radiograph revealed patchy airspace shadows in both lungs with predominant involvement of the lower zones (Fig. 12A). He died 11 days after admission. The other patient (patient no. 10) was a 72-year old man who presented with fever and productive cough for one week. He had type 2 diabetes mellitus, cerebrovascular accident and prostatic carcinoma with bone metastasis complicated by spinal cord compression with laminectomy and Luque instrumentation performed. He had lymphopenia ( $0.9 \times 10^9/L$ ), thrombocytopenia ( $33 \times 10^9/L$ ), deranged liver and renal function tests and an oxygen saturation of only 88% on admission. Chest radiograph revealed extensive airspace shadows in both lungs, with the middle zones more severely involved (Fig. 12B). He died 5 days after admission.
- The clinical, laboratory and radiological characteristics of patients who survived and those who died with community acquired pneumonia associated with CoV-HKU1 were compared (Table 7). Patients who died had lower hemoglobin concentration ( $P=0.04$ ), monocyte count ( $P=0.04$ ), serum albumin ( $P=0.04$ ) and oxygen saturation on admission ( $P=0.03$ ) and bilateral involvement ( $P=0.003$ ) and more number of zones involved ( $P=0.01$ ) on chest radiograph.

Table 7

Characteristics	Outcome*		P value
	Survived (n=8)	Died (n=2)	
Sex (M:F)	5:3	2:0	1.00
Age	73	69	0.60
Underlying diseases	6	2	0.45
History of travel within two weeks of disease onset	4	0	0.24
History of smoking	4	1	1.00
Clinical features			
Fever	7	1	0.26
Cough	6	1	0.51
Sputum production	5	1	0.76
Dyspnoea	4	2	0.22
Rhinorrhoea	1	0	0.62
Sore throat	2	0	0.45
Haematological features			
Haemoglobin (g/dl)	13.4	9	0.04
Leukocyte count ( $\times 10^9/l$ )	9.7	7.85	0.43
Neutrophil count ( $\times 10^9/l$ )	7.4	6.9	0.79
Lymphocyte count ( $\times 10^9/l$ )	1.35	0.55	0.15
Monocyte count ( $\times 10^9/l$ )	0.7	0.3	0.04
Platelet count ( $\times 10^9/l$ )	292	200.5	0.79
Serum biochemical features			
Sodium (mmol/l)	137.5	134	0.11
Potassium (mmol/l)	3.9	4.5	0.06
Creatinine ( $\mu\text{mol/l}$ )	79	76.5	0.69
Urea (mmol/l)	4.6	10.75	0.19
Albumin (g/l)	38.5	26	0.04
Globulin (g/l)	30	30	1.00
Bilirubin ( $\mu\text{mol/l}$ )	10	30.5	0.79
ALT (U/l)	16.5	30.5	0.36
Alkaline phosphatase (U/l)	86	190.5	0.07
Oxygen saturation on room air (%)	99	85.5	0.03
Radiological features			
Bilateral involvement	0	2	0.003
No. of zones involved	1	6	0.01

\*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

**RT-PCR and sequencing of the complete RNA-dependent RNA polymerase, spike and nucleocapsid genes of coronavirus-HKU1 and phylogenetic analysis**

The complete *pol* (Fig. 11), S (Fig. 13) and N (Fig. 14) genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced. The phylogenetic trees and non-synonymous mutations and the corresponding amino acid changes are shown in Fig. 15. In all three genes, the phylogenetic trees using nucleotides or amino acids for construction showed the same topologies. For the S gene, there were 317 and 306 nucleotide positions with synonymous and non-synonymous mutations respectively (Fig. 15B). For the N gene, there were 42 and 53 nucleotide positions with synonymous and non-synonymous mutations respectively (Fig. 15C). The nucleotide sequences of seven of the nine S or N genes showed similar sequences (genotype A, Figs. 16B and 16C) and those of the other two also showed similar sequences (genotype B, Figs. 16B and 16C). For the CoV-HKU1 from patient 1, two peaks (T and C) were consistently observed at nucleotide position 1300 of the N gene, suggesting the presence of quasi-species (Fig. 15C). For the *pol* gene, there were 95 and 13 nucleotide positions with synonymous and non-synonymous mutations respectively (Fig. 15A). The nucleotide sequences of the *pol* genes in the seven CoV-HKU1 of genotype A were also clustered together (Fig. 15A). Interestingly, the seven CoV-HKU1 of genotype A were from seven patients with underlying diseases and the two of genotype B were from the two patients without underlying diseases (Table 5). Furthermore, multiple alignments of the nucleotides sequences of the *pol* genes of the nine CoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV revealed that the primers we used in the present study should be specific for CoV-HKU1 (Fig. 16).

**Animal surveillance**

None of the 208 nasopharyngeal swabs and faecal samples from 56 wild and domestic animals in Hong Kong and southern China was positive for CoV-HKU1 RNA.

**6.2.8 Discussion**

CoV-HKU1, a novel group 2 coronavirus, is associated with community-acquired pneumonia. Since the SARS epidemic in 2003, we have started to prospectively collect NPAs and store the extracted RNA from patients with community-acquired pneumonia so

that when a novel virus is discovered, the epidemiology and hence the clinical, laboratory and radiological features of the disease can be studied timely. In January 2004, we discovered a novel coronavirus, CoV-HKU1, from a patient with community-acquired pneumonia (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). The RNA extracted from prospectively collected NPAs were immediately retrieved and the presence of CoV-HKU1 RNA looked for. Ten of the 418 NPAs were positive for RNA of CoV-HKU1, giving an incidence of 2.5%. The presence of CoV-HKU1 RNA in these specimens was genuine, instead of due to contamination, as amplification and sequencing of multiple genes (*pol*, S and N) of CoV-HKU1 indicated the presence of CoV-HKU1 with different nucleotide sequences in the NPAs from the different patients. Moreover, the clinical significance of CoV-HKU1 was further confirmed by the presence of specific antibody responses in all six patients whose serum samples were available.

Similar to HCoV-229E, HCoV-OC43 and HCoV-NL63, CoV-HKU1 is probably a human coronavirus that is endemic in human. Similar to other human coronavirus infections, cases of CoV-HKU1 pneumonia also occurred in winter and spring. Most patients with CoV-HKU1 pneumonia were old (80% older than 65) with major underlying diseases, especially those of the respiratory and cardiovascular systems. In order to study the phylogeny and relationships among the 10 CoV-HKU1, we sequenced the *pol*, S and N genes of the nine CoV-HKU1 cases which provided adequate amount of RNA. Combined with the data of partial sequencing of the *pol* genes of the 10 CoV-HKU1 (Fig. 17), results showed that unlike the epidemiology of SARS-CoV, the 10 CoV-HKU1 were not clonal and the topology of the phylogenetic trees did not follow the pattern of a clonal outbreak (Fig. 15). Interestingly, the phylogenetic trees constructed using the sequences of both the S and N genes showed that CoV-HKU1 of genotype B was associated with the two patients without underlying diseases, but CoV-HKU1 of genotype A was associated with patients with underlying diseases (Table 5; and Figs. 16B and 16C). Sequencing of more CoV-HKU1 may reveal the presence of genotypes or clades of CoV-HKU1 with differential virulence. To investigate for the possibility of an animal reservoir of CoV-HKU1, we tried to look for the presence of CoV-HKU1 RNA from wild and domestic animals in Hong Kong and southern China by RT-PCR. Our results revealed that none of the specimens showed the presence of CoV-HKU1 RNA. With the results of these clinical epidemiology, molecular epidemiology and eco-epidemiology studies, we conclude that CoV-HKU1 is

probably a human coronavirus, and propose to rename CoV-HKU1 as human coronavirus HKU1 (HCoV-HKU1).

Compared with SARS-CoV pneumonia, HCoV-HKU1 pneumonia is a monophasic disease and most patients had relatively mild symptoms that were localized to the respiratory tract and were only briefly hospitalized. SARS-CoV pneumonia is often described as a biphasic disease, with the first phase due to cell lysis as a result of active viral replication, and the second phase may be due to immunopathological damage (Peiris JSM *et al.*, *Lancet* 2003; 361: 1319-25; Peiris JSM *et al.*, *Lancet* 2003; 361: 1767-72). On the other hand, all 10 patients with HCoV-HKU1 pneumonia showed the pattern of a monophasic disease. Although dyspnoea was present in half of the patients with HCoV-HKU1 pneumonia at initial presentation, as compared to only about 20% of patients with SARS-CoV pneumonia at initial presentation (Peiris JSM *et al.*, *Lancet* 2003; 361: 1319-25), patients with HCoV-HKU1 pneumonia often recovered quickly, but patients with SARS-CoV pneumonia deteriorated after 7-10 days (Peiris JSM *et al.*, *Lancet* 2003; 361: 1319-25; Peiris JSM *et al.*, *Lancet* 2003; 361: 1767-72). For the eight patients who recovered, the median duration of hospitalization was only 5.5 days. This rapid recovery of patients with HCoV-HKU1 pneumonia could be related to the rapid control of the virus by the immune system. This is in line with our previous study showing the index patient (patient 5) with HCoV-HKU1 pneumonia had his peak viral load at around day 3 after onset of illness (Woo, PC. *et al.*, *J. of Virol.*, 2005, p.884-895). Moreover, only one of the patients had extrapulmonary symptoms and all available extrapulmonary specimens (stool, urine and serum) were RT-PCR negative for CoV-HKU1 (unpublished data). On the other hand, for SARS-CoV pneumonia, patients usually had their peak viral loads 7-10 days after the onset of illness (Peiris JSM *et al.*, *Lancet* 2003; 361: 1767-72). Furthermore, the virus can be readily detected in extrapulmonary specimens, in which the viral loads correlated with the manifestations in the corresponding systems (Hung, IFN *et al.*, *Emerg Infect Dis* 2004; 10: 1550-1557). These imply that the virus was not well controlled by the immune system in the initial phase of the illness.

Despite the relatively mild disease in most patients, HCoV-HKU1 pneumonia is associated with mortality in a minority of patients who had lower haemoglobin concentration, monocyte count, serum albumin and oxygen saturation on admission and more extensive involvement on chest radiograph. As in most cases of pneumonia, more

- extensive involvement in the lungs will result in poor gaseous exchange and hence hypoxia and eventually fatality. The lower haemoglobin concentration, monocyte count and serum albumin could represent poorer premorbid states and narrower margins to fight against infections. Both patients who died had underlying diabetes mellitus, malignancy (gastric lymphoma in one and carcinoma of the prostate in the other) and cardiovascular disease (old myocardial infarct in one and cerebrovascular accident in the other).
- 5

## 7. MARKET POTENTIAL

The two genomic types of CoV-HKU1 are completely sequenced. These sequences allow the development of various diagnostic tests and therapeutic methods as described hereinabove. In addition, the genetic information of CoV-HKU1 is extremely important  
5 and valuable for clinical and scientific research applications.

## 8. EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain many equivalents to the specific embodiments of the invention described herein using no more than routine  
10 experimentation. Such equivalents are intended to be encompassed by the following claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification.

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

## CLAIMS

### WHAT IS CLAIMED:

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.
2. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.
3. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2 or a complement of said nucleotide sequence.
4. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3 or a complement thereof.
5. An isolated nucleic acid molecule comprising the nucleotide sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, or 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or a complement thereof.
6. An isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, or a complement thereof, wherein the nucleic acid molecule encodes an amino acid sequence which has a biological activity exhibited by a polypeptide encoded by the nucleotide sequence of SEQ ID NO:1 or 3.
7. The nucleic acid molecule of any one of claims 1-6, wherein the molecule is RNA.
8. The nucleic acid molecule of any one of claims 1-6, wherein the molecule is DNA.
9. A vector comprising the nucleic acid molecule of claim 8.



10. A host cell comprising the vector of claim 9
11. A host cell comprising the nucleic acid molecule of claim 8 operably linked to a heterologous promoter.
12. The host cell of claim 11 being a prokaryotic cell.
13. The host cell of claim 11 is an eukaryotic cell.
14. The host cell of claim 13 is a mammalian cell.
15. A method for producing a polypeptide comprising expressing the polypeptide encoded by the DNA from the host cell of claim 10, and recovering the polypeptide.
16. A method for producing a polypeptide comprising expressing the polypeptide encoded by the DNA from the host cell of claim 11, and recovering the polypeptide.
17. A method for preparing a cell or progeny thereof capable of expressing a polypeptide comprising transfecting the cell with the vector of claim 9.
18. An isolated polypeptide encoded by the nucleic acid molecule of any one of claims 1-6.
19. An isolated polypeptide comprising the amino acid sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110 and 120 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.
20. An isolated polypeptide comprising the amino acid sequence having any one of the amino acid sequence of SEQ ID NOS:34-2918.
21. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 18.
22. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of claim 19 or 20.
23. A method for detecting the presence of the polypeptide of claim 18 in a biological sample, said method comprising:

- (a) contacting the biological sample with a compound that selectively binds to said polypeptide; and
- (b) detecting whether the compound binds to said polypeptide in the sample.

24. The method of claim 23, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

25. The method of claim 23, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.

26. A method for detecting the presence of the polypeptide of claim 19 or 20 in a biological sample, said method comprising:

- (a) contacting the biological sample with a compound that selectively binds to said polypeptide; and
- (b) detecting whether the compound binds to said polypeptide in the sample.

27. The method of claim 26, wherein the biological sample is selected from the group consisting of cells, blood, serum, plasma, saliva, urine, stool, sputum, and nasopharyngeal aspirates.

28. The method of claim 26, wherein the compound that binds to said polypeptide is an antibody or an antigen-binding fragment thereof.

29. A method for detecting the presence of a first nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a fragment thereof, or a complement thereof in a biological sample, said method comprising:

- (a) contacting the biological sample with a compound that selectively binds to said first nucleic acid molecule; and
- (b) detecting whether the compound binds to said nucleic acid molecule in the sample.

30. The method of claim 29, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.

31. The method of claim 29, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

32. A method for detecting the presence of a first nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3 or a fragment thereof or a complement thereof in a biological sample, said method comprising:

- (a) contacting the biological sample with a compound that selectively binds to said first nucleic acid molecule; and
- (b) detecting whether the compound binds to said nucleic acid molecule in the sample.

33. The method of claim 32, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.

34. The method of claim 32, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

35. The method of claim 32, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000 or 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or a complement thereof.

36. A method of preventing or inhibiting a replication in a host cell of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 and/or 3, or a portion thereof, or a complement thereof, comprising administering to the host cell an effective amount of a compound that selectively binds to said first nucleic acid molecule under a physiological condition.

37. The method of claim 36, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.

38. The method of claim 36, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300 or 350 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof.

39. The method of claim 36, wherein the compound that binds to said first nucleic acid molecule is a second nucleic acid molecule comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000 or 29,000 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or a complement thereof.

40. A method of preventing or inhibiting a binding to a host cell of the polypeptide encoded by a nucleotide sequence of SEQ ID NO:1 or 3, or a fragment thereof, or a complement thereof, comprising administering to the host cell an effective amount of a compound that specifically binds to the polypeptide under a physiological condition.

41. The method of claim 40, wherein the compound that specifically binds to the polypeptide is an antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide.

42. A method for detecting the presence of an antibody in a biological sample that immunospecifically binds the polypeptides of claim 18, said method comprising:

- (a) contacting the biological sample with the polypeptide of claim 18; and

- (b) detecting the antibody bound to the polypeptide.
43. A method for detecting the presence of an antibody in a biological sample that immunospecifically binds the polypeptides of claim 19 or 20, said method comprising:
- (a) contacting the biological sample with the polypeptide of claim 19; and
  - (b) detecting the antibody bound to the polypeptide.
44. A method for identifying a subject infected with CoV-HKU1, comprising:
- (a) obtaining total RNA from a biological sample obtained from the subject
  - (b) reverse transcribing the total RNA to obtain cDNA; and
  - (c) amplifying the cDNA using a set of primers derived from the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.
45. The method of claim 44, wherein the set of primers have the nucleotide sequence of SEQ ID NOS:4 and 5, respectively.
46. The method of claim 44, wherein the set of primers have the nucleotide sequence of SEQ ID NOS:6 and 7, respectively.
47. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 18, and a pharmaceutically acceptable carrier.
48. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 19 or 20, and a pharmaceutically acceptable carrier.
49. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, a complement thereof or a fragment thereof, and a pharmaceutically acceptable carrier.
50. An immunogenic formulation comprising an immunogenically effective amount of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:3, a complement thereof or a fragment thereof, and a pharmaceutically acceptable carrier.

51. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2919, a complement thereof, or a fragment thereof.
52. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a replicase gene of CoV-HKU1.
53. The nucleic acid molecule of claim 2 comprising the nucleotide sequence of SEQ ID NO:2920, 2922, 2924, 2926, 2928, 2930, 2932 or 2934.
54. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a spike gene of CoV-HKU1.
55. The nucleic acid molecule of claim 4 comprising the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948 or 2950.
56. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a nucleocapsid gene of CoV-HKU1.
57. The nucleic acid molecule of claim 6 comprising the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964 or 2966.
58. An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes an amino acid sequence which has a biological activity exhibited by a polypeptide encoded by the nucleic acid molecule of claim 51.
59. A vector comprising the nucleic acid molecule of claim 51.
60. A vector comprising the nucleic acid molecule of claim 52.
61. A vector comprising the nucleic acid molecule of claim 54.
62. A vector comprising the nucleic acid molecule of claim 56.
63. A host cell comprising the vector of claim 59.
64. A host cell comprising the vector of claim 60.

- 65. A host cell comprising the vector of claim 61.
- 66. A host cell comprising the vector of claim 62.
- 67. An isolated polypeptide encoded by the nucleic acid molecule of claim 51.
- 68. An isolated polypeptide encoded by the nucleic acid molecule of claim 52.
- 69. An isolated polypeptide encoded by the nucleic acid molecule of claim 54.
- 70. An isolated polypeptide encoded by the nucleic acid molecule of claim 56.
- 71. A nucleic acid molecule encoding the polypeptide of claim 67.
- 72. A nucleic acid molecule encoding the polypeptide of claim 68.
- 73. A nucleic acid molecule encoding the polypeptide of claim 69.
- 74. A nucleic acid molecule encoding the polypeptide of claim 70.

1/201

SEQ:1	1	TCGTGCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTGGCCCGCAAACAT	58
SEQ:2	1	R A M P N I L R I V S S L V L A R K H	19
	59	GAATTTTGTGTTTCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTT	118
	20	E F C C S H G D R F Y R L A N E C A Q V	39
	119	TTGAGTGAAATAGTTATGTGTGGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGT	178
	40	L S E I V M C G G C Y Y V K P G G T S S	59
	179	GGTCATGCAACTACTGCTTTTGCTAATTCGTGTTTAAATATATGTCAGGCTGTTACTGCT	238
	60	G D A T T A F A N S V F N I C Q A V T A	79
	239	AATGTTTGTTCCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTAAGTATACGCAAT	298
	80	N V C S L M A C N G H K I E D L S I R N	99
	299	TTACAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTT	358
	100	L Q K R L Y S N V Y R T D Y V D Y T F V	119
	359	AATGAGTATTATGAATTTTATGTAAGCATTTTAG	393
	120	N E Y Y E F L C K H F	130

FIG. 1



2/201

SEQ:3 1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGAGATCTCAT 60  
E \* E R I A S V P S I S L R S L V R S H  
N K S E L R P Y R L S A Y D L L S D L I  
I R A N C V R T V Y Q L T I S C Q I S

61 TAAATCTAAACTTTTAAACAAGATCCCTGTTATCCATGCTTGTGAGTGTGTTAATC 120  
\* I \* T F \* T R F P V I H A C E C G L I  
K S K L F K Q D S L L S M L V S V V \* S  
L N L N F L N K I P C Y P C L \* V W F N

121 ATAATCTTGTTATTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTTGGTTGTC 180  
I I L Y F T F H T F H L S A S D V L V V  
\* S C I L L S T L F I S L P V T C W L S  
H N L V F Y F P H F S S L C Q \* R V G C

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAAAACAGCAAATACGGTCTCGGCTTCAA 240  
L S V P P I G R N D \* N Q Q I R S R L Q  
S A S L P \* V A M I K T S K Y G L G F K  
P Q R P S H R S Q \* L K P A N T V S A S

241 GTGGGCGCCAGAATTTGTTGGCTGCTTCCGGATGCAGCGGAGAGTTGGCTAGTCCTAT 300  
V G A R I S L A A S G C S G G V G \* S Y  
W A P E F R W L L P D A A E E L A S P M  
S G R Q N F V G C F R M Q R R S W L V L

301 GAAGTCAGATGAGGGTGGGTTATGCCCCTCTACTGGTCAAGCGATGGAAGTGTGGATT 360  
E V R \* G W V M P L Y W S S D G K C W I  
K S D E G G L C P S T G Q A M E S V G F  
\* S Q M R V G Y A P L L V K R W K V L D

361 CGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420  
R L \* \* S C E D R L S L H S W T R M A C  
V Y D N H V K I D C R C I L G Q E W H V  
S F M I I M \* R \* I V A A F L D K N G M

421 GCAGTCAAATCTTATCCGTGATATTTTGTTCATGAAGATCTACATGTTGTAGAAGTTCT 480  
A V K S Y P \* Y F C S \* R S T C C R S S  
Q S N L I R D I F V H E D L H V V E V L  
C S Q I L S V I F L F M K I Y M L \* K F

481 AACTAAAACAGCCGTAAAGTCCGGTACGGCAATTTTAATTAATCACCTTTGCATAGCTT 540  
N \* N S R K V R Y G N F N \* I T F A \* L  
T K T A V K S G T A I L I K S P L H S L  
\* L K Q P \* S P V R Q F \* L N H L C I A

FIG. 2

3/201

541 GGGTGGTTTTCTTAAAGGGTATGTTATGGGCTTGTCCGTTTCATACAAGACTAAACGTTA 600  
G W F S \* R V C Y G L V P F I Q D \* T L  
G G F P K G Y V M G L F R S Y K T K R Y  
W V V F L K G M L W A C S V H T R L N V

601 TGGTGTACATCATCTTTCTATGACTACATCTACTACTAATTTTGGTGAAGATTTTTGGG 660  
C C T S S F Y D Y I Y Y \* F W \* R F F G  
V V H H L S M T T S T T N F G E D F L G  
M L Y I I F L \* L H L L L I L V K I F W

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTCAAAATGGTTTCAATTCGTAG 720  
L D C T F W F Y A I L C S Q M V S I L \*  
W I V P F G F M P S Y V H K W F Q F C R  
V G L Y L L V L C H L M F T N G F N S V

721 GTTGTATATTGAAGAGAGTGATTAAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780  
V V Y \* R E \* F N N F K F \* I \* \* L \* F  
L Y I E E S D L I I S N F K F D D Y D F  
G C I L K R V I \* \* F Q I L N L M I M I

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAAATATTCACAAAA 840  
\* C R R C L C \* G S C \* A \* R \* I F T K  
S V E D A Y A E V H A E P K G K Y S Q K  
L V \* K M L M L R F M L S L K V N I H K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAACCCGTAATTTTGTAGACCAGTA 900  
S L C E T \* T I S W Y \* T R T F C R P V  
A Y A L L R Q Y R G I K P V L F V D Q Y  
K L M L Y L D N I V V L N P Y F L \* T S

901 TGGTGTGACTATTCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATTCCTT 960  
W L \* L F W \* I S R L S S S L W S L F F  
G C D Y S G K L A D C L Q A Y G H Y S L  
M V V T I L V N \* Q I V F K L M V I I L

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGTGACTTTGATATTGTACT 1020  
A R Y E T K A V C M A C Q L \* L \* Y C S  
Q D M R Q K Q S V W L A N C D F D I V V  
C K I \* D K S S L Y G L P I V T L I L \*

1021 GGCTTGGCATGTAGTTCGTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080  
G L A C S S \* F T I C Y A P A D Y S Y Y  
A W H V V R D S R F V M R L Q T I A T I  
W L G M \* F V I H D L L C A C R L \* L L

FIG. 2 CONT.

4/201

1081 TTGTGGTATTAAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGATGTAGTTAT 1140  
L W Y \* I C C T T Y R R C S R W R C S Y  
C G I K Y V A Q P T E D V V D G D V V I  
F V V L N M L H N L Q K M \* \* M E M \* L

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTAAAGCTTCCTAGTTTGAT 1200  
T \* T C T F I I C \* C N S F K A S \* F D  
R E P V H L L S A D A I V L K L P S L M  
Y V N L Y I Y Y L L M Q \* F \* S F L V \*

1201 GAAAGTTATGACTCATATGGATGATTTTCTATTAAATCTATATATAATGTTGATTTGTG 1260  
E S Y D S Y G \* F F Y \* I Y I \* C \* F V  
K V M T H M D D F S I K S I Y N V D L C  
\* K L \* L I W M I F L L N L Y I M L I C

1261 TGATTGTGGTTTGTATGCAGTATGGTTATGTAGATTGTTTAAATGATAATTGTGATTT 1320  
\* L W F C Y A V W L C R L F \* \* \* L \* F  
D C G F V M Q Y G Y V D C F N D N C D F  
V I V V L L C S M V M \* I V L M I I V I

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTCTTGTCATTGTGTGTACAGT 1380  
L W L G F R \* Y D G W F F L S I V L Y S  
Y G W V S G N M M D G F S C P L C C T V  
F M V G F Q V I \* W M V F L V H C V V Q

1381 TTATGACTCTAGCGAAGTTAAAGCCCAATCATCTGGTGTTATTCCTGAAAATCCTGTGTT 1440  
L \* L \* R S \* S P I I W C Y S \* K S C V  
Y D S S E V K A Q S S G V I P E N P V L  
F M T L A K L K P N H L V L F L K I L C

1441 ATTTACTAATAGTACTGATACTGTTAACCATGATTCTTTTAATTGTATGGTTATTCTGT 1500  
I Y \* \* Y \* Y C \* P \* F F \* F V W L F C  
F T N S T D T V N H D S F N L Y G Y S V  
Y L L I V L I L L T M I L L I C M V I L

1501 CACACCATTTGGTTCTTGTATATATTTGGTCGCCCGTCCGATTGTGGATTCTCTATAAT 1560  
H T I W F L Y I L V A A S W I V D S Y N  
T P F G S C I Y W S P R P G L W I P I I  
S H H L V L V Y I G R R V L D C G F L \*

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTCAGGTGTAGTAGTTGTAAATC 1620  
\* I F S Q V L \* \* F G L F R C S R L \* I  
K S S V K S Y D D L V Y S G V V G C K S  
L N L Q S S L M M I W F I Q V \* \* V V N

FIG. 2 CONT.

5/201

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACTTTACTTAGATTATGTTCAATGTAA 1680  
Y C \* R N C S Y Y S C T L L R L C S M \*  
I V K E T A L I T H A L Y L D Y V Q C K  
L L L K K L L L L L M H F T \* I M F N V

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGCGTTAATAATTCTTGGTGTAGGCAACT 1740  
V W \* S \* T K S Y S W R \* \* F L V \* A T  
C G N L E Q N H I L G V N N S W C R Q L  
S V V I L N K I I F L A L I I L G V G N

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTCTAAAAATATTGACTTGTGTTAAGCG 1800  
V A \* \* R \* L \* Y A S K K Y \* L V C \* A  
L L N R G D Y N M L L K N I D L F V K R  
C C L I E V I I I C F \* K I L T C L L S

1801 TCGTGCTGATTTTGCTTGCAAGTTTGCAGTTTGTGGAGATGGTTTTGTACCTTTTACT 1860  
S C \* F C L Q V C S L W R W F C T F F T  
R A D F A C K F A V C G D G F V P F L L  
V V L I L L A S L Q F V E M V L Y L F Y

1861 AGATGGTTTAATTCCTCCGTTAGTTATTTCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920  
R W F N S P \* L L S N S E W Y F L Y I F  
D G L I P R S Y Y L I Q S G I F F T S L  
\* M V \* F P V V I I \* F R V V F S L H L

1921 GATGCTCAATTTTCACAAGAAGTTTCTGATATGTGTTTAAAAATGTGTATTTTGTGTTAT 1980  
D V S I F T R S F \* Y V F K N V Y F V Y  
M S Q F S Q E V S D M C L K M C I L F M  
\* C L N F H K K F L I C V \* K C V F C L

1981 GGACAGAGTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040  
G Q S F S C Y I L Y R A L C \* \* V G Y S  
D R V S V A T F Y I E H Y V N R L V T Q  
W T E F Q L L H F I \* S I M L I G W L L

2041 ATTTAAGTTATTGGGTACTACACTTGTTAATAAAATGGTTAATGTTTAAATACCATGTT 2100  
I \* V I G Y Y T C \* \* N G \* L V \* Y H V  
F K L L G T T L V N K M V N W F N T M L  
N L S Y W V L H L L I K W L I G L I P C

2101 AGATGCTAGTGCACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTGT 2160  
R C \* C T C Y R L A S L P I I E W S F C  
D A S A P A T G W L L Y Q L L N G L F V  
\* M L V H L L Q A G F F T N Y \* M V F L

FIG. 2 CONT.

6/201

2161 AGTATCTCAAGCCAACTTTAATTTTGTGCTTTAATACCTGATTATGCTAAAATTTTAGT 2220  
S I S S Q L \* F C C F N T \* L C \* N F S  
V S Q A N F N F V A L I P D Y A K I L V  
\* Y L K P T L I L L L \* Y L I M L K F \*

2221 TAATAAATTTTACACTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTTAA 2280  
\* \* I L H F F \* V I I R V C Y S \* C F K  
N K F Y T F F K L L L E C V T V D V L K  
L I N F T L F L S Y Y \* S V L Q L M F \*

2281 AGATATGCCTGTCTTAAACTATTAATGGTTTAGTTTGTATTGTAGGCAATAAGTTT 2340  
R Y A C S \* N Y \* W F S L Y C R Q \* V L  
D M P V L K T I N G L V C I V G N K F Y  
K I C L F L K L L M V \* F V L \* A I S F

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTGTGTTTACCATGTAATGCACAGGAACA 2400  
\* R \* Y R V N S W F C F T M \* C T G T T  
N V S T G L I P G F V L P C N A Q E Q Q  
I T L V Q G \* F L V L F Y H V M H R N N

2401 AATTTATTTTTTTGAAGGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAG 2460  
N L F F \* R R C R I C Y S R R \* C Y \* E  
I Y F F E G V A E S V I V E D D V I E N  
K F I F L K A L Q N L L \* \* K M M L L R

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAT 2520  
C Q I F F I I L \* V L S T T \* I C R K N  
V K S S L S S Y E Y C Q P P K S V E K I  
M S N L L Y H L M S I V N H L N L \* K K

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTCCCTATTGTCAT 2580  
L Y Y R \* Y V H G \* V W \* \* I F P Y C H  
C I I D N M Y M G K C G D K F F P I V M  
F V L \* I I C T W V S V V I N F S L L S

2581 GAATGATAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTTCCATGTGCAGGTAGAAA 2640  
E \* \* K Y L S F R S G L A F S M C R \* K  
N D K N I C L L D Q A W R F P C A G R K  
\* M I K I F V F \* I R L G V F H V Q V E

2641 AGTTAATTTTAACGAGAAACCTGTTGTTATGGAGATTCCGCTCTTTGATGACAGTTAAGGT 2700  
S \* F \* R E T C C Y G D S V F D D S \* G  
V N F N E K P V V M E I P S L M T V K V  
K L I L T R N L L L W R F R L \* \* Q L R

FIG. 2 CONT.

7/201

2701 TATGTTTGATTAGATTCTACTTTTGATGATATTTTAGGTAAAGTTTGTTCAGAATTGA 2760  
Y V \* F R F Y F \* \* Y F R \* S L F R I \*  
M F D L D S T F D D I L G K V C S E F E  
L C L I \* I L L L M I F \* V K F V Q N L

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTGCTGTGTTTGTGATGCTATAGAGAA 2820  
S R K G C Y C R \* F C C C C L \* C Y R E  
V E K G V T V D D F V A V V C D A I E N  
K \* K R V L L \* M I L L L L F V M L \* R

2821 TGCTTTAAACTCTTGTAAGAGCATCCAGTGGTTGGTTATCAAGTTCGTGCATTTTAA 2880  
C F K L L \* R A S S G W L S S S C I F K  
A L N S C K E H P V V G Y Q V R A F L N  
M L \* T L V K S I Q W L V I K F V H F \*

2881 TAACTTAATGAGAATGTTGTTTATTTATTTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940  
\* T \* \* E C C L F I \* \* G W \* \* S N G L  
K L N E N V V Y L F D E A G D E A M A S  
I N L M R M L F I Y L M R L V M K Q W P

2941 TCGTATGTATTGTACTTTTGCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000  
S Y V L Y F C Y \* G C \* R R Y Q \* \* S C  
R M Y C T F A I E D V E D V I S S E A V  
L V C I V L L L L R M L K T L S V V K L

3001 CGAAGATACTATTGATGGTGTCTGTTGAAGACACTATTAATGACGATGAAGATGTTGTTAC 3060  
R R Y Y \* W C R \* R H Y \* \* R \* R C C Y  
E D T I D G V V E D T I N D D E D V V T  
S K I L L M V S L K T L L M T M K M L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3181 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

FIG. 2 CONT.

8/201

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3361 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3420  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
L V T M T M K M L L L V T M T M K M L L

3421 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATAACGATGAAGAGATTGTTAC 3480  
W \* Q \* R \* R C C Y W \* Q \* R \* R D C Y  
G D N D D E D V V T G D N N D E E I V T  
L V T M T M K M L L L V T I T M K R L L

3481 TGGTGACAATGATGACCAAATTGTTGTTACTGGTGATGATGTAGATGATATTGAAAGTAT 3540  
W \* Q \* \* P N C C Y W \* \* C R \* Y \* K Y  
G D N D D Q I V V T G D D V D D I E S I  
L V T M M T K L L L L V M M \* M I L K V

3541 TTATGACTTTGATACTTATAAGCTCTTTTAGTTTTTAATGATGTCTATAATGATGCTTT 3600  
L \* L \* Y L \* S S F S F \* \* C L \* \* C F  
Y D F D T Y K A L L V F N D V Y N D A L  
F M T L I L I K L F \* F L M M S I M M L

3601 GTTTGTAGTTATGGTTCTAGTGTGAAACAGAAACATATTTTAAAGTTAATGGTTATG 3660  
V C \* L W F \* C \* N R N I F \* S \* W F M  
F V S Y G S S V E T E T Y F K V N G L W  
C L L V M V L V L K Q K H I L K L M V Y

3661 GTCACCTACTATTACATACTAATTGTTGGTTGCGTTCTGTGTTACTTGTAAATGCAGAA 3720  
V T Y Y Y T Y \* L L V A F C V T C N A E  
S P T I T H T N C W L R S V L L V M Q, K  
G H L L L H I L I V G C V L C Y L \* C R

3721 ATTACCTTTTAAAGTTTAAAGGATTAGCTATTGAAAATATGTGGTTATCTTATAAGGTGGG 3780  
I T F \* V \* G F S Y \* K Y V V I L \* G G  
L P F K F K D L A I E N M W L S Y K V G  
N Y L L S L R I \* L L K I C G Y L I R W

FIG. 2 CONT.

9/201

3781 TTATAATCAAAGTTTGTGATTATTTACTGACCACTATTCCTAAAGCTATTGTTTTGCC 3840  
L \* S K F C \* L F T D H Y S \* S Y C F A  
Y N Q S F V D Y L L T T I P K A I V L P  
V I I K V L L I I Y \* P L F L K L L F C

3841 TCAAGGTGGTTTTGTAGCTGATTTTGCTTATTGGTTTTTAAACCAGTTTGATATTAATGC 3900  
S R W F C S \* F C L L V F K P V \* Y \* C  
Q G G F V A D F A Y W F L N Q F D I N A  
L K V V L \* L I L L I G F \* T S L I L M

3901 GTATGCTAATTGGTGTGTTTAAATGTGGTTTTCTTTTGATTTAAATGGTTTGGATGC 3960  
V C \* L V L F K M W F F F \* F K W F G C  
Y A N W C C L K C G F S F D L N G L D A  
R M L I G V V \* N V V F L L I \* M V W M

3961 TTTGTTTTTTATGGAGATATTGTGTCATGTTTGTAAAGTGTGGACATAATATGACTCT 4020  
F V F L W R Y C V S C L \* V W T \* Y D S  
L F F Y G D I V S H V C K C G H N M T L  
L C F F M E I L C L M F V S V D I I \* L

4021 AATAGCAGCGGACTTACCTTGTACATTACATTTTCATTATTGATGACAATTTTGTGC 4080  
N S S G L T L Y I T F F I I \* \* Q F L C  
I A A D L P C T L H F S L F D D N F C A  
\* \* Q R T Y L V H Y I F H Y L M T I F V

4081 TTTTGCACCCCTAAAAAATTTTATTGCTGCATGCTGCTGGATGTAAACGTTTGTCA 4140  
F L H P \* K N F Y C C M C C G C K R L S  
F C T P K K I F I A A C A V D V N V C H  
L F A P L K K F L L L H V L W M \* T F V

4141 TTCTGTAGCTGTTATAGGTGATGAACAAATAGATGGTAAGTTTGTACTAAATTTAGTGG 4200  
F C S C Y R \* \* T N R W \* V C Y \* I \* W  
S V A V I G D E Q I D G K F V T K F S G  
I L \* L L \* V M N K \* M V S L L L N L V

4201 TGATAAATTTGATTTTATAGTAGGTTATGGAATGTCATTTAGTATGCTTCTTTTGAGTT 4260  
\* \* I \* F Y S R L W N V I \* Y V F F \* V  
D K F D F I V G Y G M S F S M S S F E L  
V I N L I L \* \* V M E C H L V C L L L S

4261 ACCTCAATTGTATGGTTTGTGTATAACACCTAATGTATGTTTTGTTAAAGGTGATATTAT 4320  
T S I V W F V Y N T \* C M F C \* R \* Y Y  
P Q L Y G L C I T P N V C F V K G D I I  
Y L N C M V C V \* H L M Y V L L K V I L

FIG. 2 CONT.



10/201

4321 AAATGTTGCTAGACTTGTTAAGCTGATGTTATTGTTAATCCTGCTAATGGGCATATGCT 4380  
K C C \* T C \* S \* C Y C \* S C \* W A Y A  
N V A R L V K A D V I V N P A N G H M L  
\* M L L D L L K L M L L L I L L M G I C

4381 CCATGGTGGTGGAGTTGCAAAAGCTATAGCTGTAGCTGCAGGTAAAAAATTTCTAAAGA 4440  
P W W W S C K S Y S C S C R \* K I F \* R  
H G G G V A K A I A V A A G K K F S K E  
S M V V E L Q K L \* L \* L Q V K N F L K

4441 AACTGCTGCTATGGTTAAATCTAAAGGTGTTGCCAAGTAGGAGATTGTTATGTTTCTAC 4500  
N C C Y G \* I \* R C L P S R R L L C F Y  
T A A M V K S K G V C Q V G D C Y V S T  
K L L L W L N L K V F A K \* E I V M F L

4501 CGGTGGTAAATTATGTAAACAATTCTTAATATTGTAGGCCCTGATGCTAGACAAGATGG 4560  
R W \* I M \* N N S \* Y C R P \* C \* T R W  
G G K L C K T I L N I V G P D A R Q D G  
P V V N Y V K Q F L I L \* A L M L D K M

4561 AAGACAATCTTATGTTTGTAGCACGTGCTTATAAGCATCTTAATAATTATGATTGTTG 4620  
K T I L C F V S T C L \* A S \* \* L \* L L  
R Q S Y V L L A R A Y K H L N N Y D C C  
E D N L M F C \* H V L I S I L I I M I V

4621 TTTGTCTACTCTCATATCGGCTGGTATATTTAGTGTTCTGCTGATGTGTCATTAACCTA 4680  
F V Y S H I G W Y I \* C S C \* C V I N L  
L S T L I S A G I F S V P A D V S L T Y  
V C L L S Y R L V Y L V F L L M C H \* L

4681 CCTTCTAGGTGTTGTTGATAAACAGTTATCCTTGTTAGTAATAATAAGAAGATTTTGA 4740  
P S R C C \* \* T S Y P C \* \* \* \* R R F \*  
L L G V V D K Q V I L V S N N K E D F D  
T F \* V L L I N K L S L L V I I K K I L

4741 TATTATTCAAAAATGTCAAATTACTTCAGTTGTTGGTACTAAAGCATTGGCTGTTAGATT 4800  
Y Y S K M S N Y F S C W Y \* S I G C \* I  
I I Q K C Q I T S V V G T K A L A V R L  
I L F K N V K L L Q L L V L K H W L L D

4801 AACTGCTAATGTAGGCCGTGTTATTAAATTTGAGACAGATGCATACAAACTTTTTTTGAG 4860  
N C \* C R P C Y \* I \* D R C I Q T F F E  
T A N V G R V I K F E T D A Y K L F L S  
\* L L M \* A V L L N L R Q M H T N F F \*

FIG. 2 CONT.

11/201

4861 TGGTGATGATTGTTTTGTTTCAAATTCCTCTGTTATACAAGAAGTTTTATTGCTTCGTCA 4920  
W \* \* L F C F K F F C Y T R S F I A S S  
G D D C F V S N S S V I Q E V L L L R H  
V V M I V L F Q I L L L Y K K F Y C F V

4921 TGATATACAATTGAATAATGACGTTTCGTGATTATTTGTTGTCTAAGATGACTAGTCTTCC 4980  
\* Y T I E \* \* R S \* L F V V \* D D \* S S  
D I Q L N N D V R D Y L L S K M T S L P  
M I Y N \* I M T F V I I C C L R \* L V F

4981 TAAAGATTGGCGTCTTATCAATAAATTTGATGTTATTAAACGGTGTTAAACTGTTAAGTA 5040  
\* R L A S Y Q \* I \* C Y \* R C \* N C \* V  
K D W R L I N K F D V I N G V K T V K Y  
L K I G V L S I N L M L L T V L K L L S

5041 TTTTGAGTGTCTTAATCTATTTATATATGTTAGTCAGGGTAAAGACTTTGGTTATGTATG 5100  
F \* V S \* F Y L Y M \* S G \* R L W L C M  
F E C P N S I Y I C S Q G K D F G Y V C  
I L S V L I L F I Y V V R V K T L V M Y

5101 TGATGGTTCTTTTTATAAGCAACTGTTAATCAAGTTTGTGTTTATTAGCTAAGAAGAT 5160  
\* W F F L \* S N C \* S S L C F I S \* E D  
D G S F Y K A T V N Q V C V L L A K K I  
V M V L F I K Q L L I K F V F Y \* L R R

5161 AGATGTTTGGCTTACTGTAGATGGTGTAAATTTTAAATCTATTTCTTCTACTGTAGGTGA 5220  
R C F A Y C R W C \* F \* I Y F S Y C R \*  
D V L L T V D G V N F K S I S L T V G E  
\* M F C L L \* M V L I L N L F L L L \* V

5221 AGTTTTTGGTAAATACTTGTAATGTTTCTGTGATGGCATTGATGTTACTAAGTTAAA 5280  
S F W \* N T W \* C F L \* W H \* C Y \* V K  
V F G K I L G N V F C D G I D V T K L K  
K F L V K Y L V M F S V M A L M L L S \*

5281 GTGTAGTGATTTTTATGCCGATAAAATTTTATATCAGTATGAAAATTTGTCTTTAGCTGA 5340  
V \* \* F L C R \* N F I S V \* K F V F S \*  
C S D F Y A D K I L Y Q Y E N L S L A D  
S V V I F M P I K F Y I S M K I C L \* L

5341 TATTTCTGCTGTACAAAGTTCATTGGGTTTGATCAGCAACAATTGCTTGCTTATTATAA 5400  
Y F C C T K F I W V \* S A T I A C L L \*  
I S A V Q S S F G F D Q Q Q L L A Y Y N  
I F L L Y K V H L G L I S N N C L L I I

FIG. 2 CONT.

12/201

5401 TTTTAAACAGTATGTAAATGGTCTGTAGTTGTTAACGGTCCATTTTTCTTTGAACA 5460  
F F N S M \* M V C S C \* R S I F F F \* T  
F L T V C K W S V V V N G P F F S F E Q  
I F \* Q Y V N G L \* L L T V H F F L L N

5461 GTCTCATAATAATTGTTATGTGAATGTAGCTTGTCTTATGTTGCAGCATATTAATCTTAA 5520  
V S \* \* L L C E C S L S Y V A A Y \* S \*  
S H N N C Y V N V A C L M L Q H I N L K  
S L I I I V M \* M \* L V L C C S I L I L

5521 ATTTAATAAATGGCAGTGGCAGGAAGCATGGTATGAATTCGTGCTGGCAGACCACATAG 5580  
I \* \* M A V A G S M V \* I S C W Q T T \*  
F N K W Q W Q E A W Y E F R A G R P H R  
N L I N G S G R K H G M N F V L A D H I

5581 GTTAGTTGCTCTTGTGTTTAGCTAAAGGTCATTTTAAATTTGATGAACCATCAGATGCTAC 5640  
V S C S C F S \* R S F \* I \* \* T I R C Y  
L V A L V L A K G H F K F D E P S D A T  
G \* L L L F \* L K V I L N L M N H Q M L

5641 TGATTTTATTCGTGTTGTTTGAACAAGCTGATTATCAGGTGCAATTTGTGAATTAGA 5700  
\* F Y S C C F E T S \* F I R C N L \* I R  
D F I R V V L K Q A D L S G A I C E L E  
L I L F V L F \* N K L I Y Q V Q F V N \*

5701 ACTTATTTGTGATTGTGGTATTAAACAAGAAAGTCGTGTTGGTGTGATGCTGTTATGCA 5760  
T Y L \* L W Y \* T R K S C W C \* C C Y A  
L I C D C G I K Q E S R V G V D A V M H  
N L F V I V V L N K K V V L V L M L L C

5761 TTTTGGTACATTAGCAAAGACTGATCTTTTAAATGGTTATAAGATTGGCTGTAATTGTGC 5820  
F W Y I S K D \* S F \* W L \* D W L \* L C  
F G T L A K T D L F N G Y K I G C N C A  
I L V H \* Q R L I F L M V I R L A V I V

5821 AGGTAGAATTGTCCATTGTACTAAATTGAATGTACCATTTTGTATTGTTCTAATACTCC 5880  
R \* N C P L Y \* I E C T I F D L F \* Y S  
G R I V H C T K L N V P F L I C S N T P  
Q V E L S I V L N \* M Y H F \* F V L I L

5881 TCTGAGTAAGGATTTACCTGATGATGTTGTTGCAGCTAACATGTTTATGGGTGTAGGTGT 5940  
S E \* G F T \* \* C C C S \* H V Y G C R C  
L S K D L P D D V V A A N M F M G V G V  
L \* V R I Y L M M L L Q L T C L W V \* V

FIG. 2 CONT.

13/201

5941 AGGCCATTATACACATTGAAATGTGGTTCACCTTACCAACATTATGATGCTTGTAGTGT 6000  
R P L Y T F E M W F T L P T L \* C L \* C  
G H Y T H L K C G S P Y Q H Y D A C S V  
\* A I I H I \* N V V H L T N I M M L V V

6001 TAAAAAATATACAGGTGTTAGTGGTTGTTAACTGACTGCTTGTATCTTAAAAATTTAAC 6060  
\* K I Y R C \* W L F N \* L L V S \* K F N  
K K Y T G V S G C L T D C L Y L K N L T  
L K N I Q V L V V V \* L T A C I L K I \*

6061 CCAGACTTTTACATCTATGTTGACTAATTATTTTTGGATGATGTTGAAATGGTGGCTTA 6120  
P D F Y I Y V D \* L F F G \* C \* N G C L  
Q T F T S M L T N Y F L D D V E M V A Y  
P R L L H L C \* L I I F W M M L K W L L

6121 TAACCTGATCTTTTACAATATTATTGTGATAATGGTAAGTATTATACAAAACCTATTAT 6180  
\* P \* S F T I L L \* \* W \* V L Y K T Y Y  
N P D L S Q Y Y C D N G K Y Y T K P I I  
I T L I F H N I I V I M V S I I Q N L L

6181 AAAGGCTCAGTTTAAACCATTGCTAAAGTTGACGGTGTATATACTAACTTTAAGTTAGT 6240  
K G S V \* T I C \* S \* R C L Y \* L \* V S  
K A Q F K P F A K V D G V Y T N F K L V  
\* R L S L N H L L K L T V F I L T L S \*

6241 TGGACATGATATTTGTGCTCAATTGAATGATAAGTTAGGTTTTAATGTAGATTGCCGTT 6300  
W T \* Y L C S I E \* \* V R F \* C R F A V  
G H D I C A Q L N D K L G F N V D L P F  
L D M I F V L N \* M I S \* V L M \* I C R

6301 TGTGAGTACAAAAGTAACAGTCTGGCCTGTAGCTACTGGTGATGTTGTTTGGCATCTGA 6360  
C \* V Q S N S L A C S Y W \* C C F G I \*  
V E Y K V T V W P V A T G D V V L A S D  
L L S T K \* Q S G L \* L L V M L F W H L

6361 TGATTATATGTGAAACGTTATTTTAAAGGATGTGAAACTTTTGGTAAGCCTGTTATTG 6420  
\* F I C E T L F \* R M \* N F W \* A C Y L  
D L Y V K R Y F K G C E T F G K P V I W  
M I Y M \* N V I L K D V K L L V S L L F

6421 GTTTTGTGATGATGAAGCATCATTGAATTCTCTTACTTATTTTAAATAAACCTAGTTTAA 6480  
V L S \* \* S I I E F S Y L F \* \* T \* F \*  
F C H D E A S L N S L T Y F N K P S F K  
G F V M M K H H \* I L L L I L I N L V L

FIG. 2 CONT.

14/201

6481 ATCTGAAAATAGATATAGTGTGTTTGTCTGTTGATTCTGTATCTGAGGAGTCACAAGGTAA 6540  
I \* K \* I \* C F V C \* F C I \* G V T R \*  
S E N R Y S V L S V D S V S E E S Q G N  
N L K I D I V F C L L I L Y L R S H K V

6541 TGTGGTTACTTCTGTTATGGAATCGCAGATTAGTACTAAAGAGGTTAAGTTAAAGGGTGT 6600  
C G Y F C Y G I A D \* Y \* R G \* V K G C  
V V T S V M E S Q I S T K E V K L K G V  
M W L L L L W N R R L V L K R L S \* R V

6601 TAGAAAGACTGTAAATAGAAGATGCTATTATTGTTAATGATGAAAATAGTTCTTATTAA 6660  
\* K D C \* N R R C Y Y C \* \* \* K \* F Y \*  
R K T V K I E D A I I V N D E N S S I K  
L E R L L K \* K M L L L L M M K I V L L

6661 GGTGTGTTAAAGTTTATCTTTAGTTGATGTTTGGGATATGTATTTGACAGGTTGTGATTA 6720  
G C \* K F I F S \* C L G Y V F D R L \* L  
V V K S L S L V D V W D M Y L T G C D Y  
R L L K V Y L \* L M F G I C I \* Q V V I

6721 TGTGTGTTGGGTTGCTAATGAATTGTCACGCCTAGTTAAATCACCAACAGTTAGGGAATA 6780  
C C L G C \* \* I V T P S \* I T N S \* G I  
V V W V A N E L S R L V K S P T V R E Y  
M L F G L L M N C H A \* L N H Q Q L G N

6781 TATACGATATGGTATTAAACCTATTACTATACCTATAGATTTGTTATGTTTAAGAGATGA 6840  
Y T I W Y \* T Y Y Y T Y R F V M F K R \*  
I R Y G I K P I T I P I D L L C L R D D  
I Y D M V L N L L L Y L \* I C Y V \* E M

6841 TAATCAAACCTCTTTAGTTCCTAAAATTTTAAAGCAAGAGCTATAGAATTTTATGGTTT 6900  
\* S N S F S S \* N F \* S K S Y R I L W F  
N Q T L L V P K I F K A R A I E F Y G F  
I I K L F \* F L K F L K Q E L \* N F M V

6901 TTTGAAGTGGTGTGTTTATTATGTTTTAGTTTATTACATTTTACAAATGATAAAACCAT 6960  
F E V V V Y L C F \* F I T F Y K \* \* N H  
L K W L F I Y V F S L L H F T N D K T I  
F \* S G C L F M F L V Y Y I L Q M I K P

6961 TTTTATACTACAGAAATAGCTTCTAAGTTTACTTTTAATTTGTTTGTGTTGGCTCTTAA 7020  
F L Y Y R N S F \* V Y F \* F V L F G S \*  
F Y T T E I A S K F T F N L F C L A L K  
F F I L Q K \* L L S L L L I C F V W L L

FIG. 2 CONT.

15/201

7021 AAATGCTTTTCAGACATTTAGATGGAGTATATTTATAAAAGGTTTTCTTGTGTAGCCAC 7080  
K C F S D I \* M E Y I Y K R F S C C S H  
N A F Q T F R W S I F I K G F L V V A T  
K M L F R H L D G V Y L \* K V F L L \* P

7081 TGTGTTTTGTTTTGGTTAATTTTTGTATATAAATGTTATTTTAGTGACTTTTATCT 7140  
C V F V L V \* F F V Y K C Y F \* \* L L S  
V F L F W F N F L Y I N V I F S D F Y L  
L C F C F G L I F C I \* M L F L V T F I

7141 TCCTAATATTAGTGTTCCTATTTTGTGGGAAGAATTGTTATGTGGATAAAGGCTAC 7200  
S \* Y \* C F S Y F C G K N C Y V D K G Y  
P N I S V F P I F V G R I V M W I K A T  
F L I L V F F L F L W E E L L C G \* R L

7201 TTTTGGTTTGGTTACAATTTGTGATTTTATCTAAGTTAGGTGTAGGTTTACAAGTCA 7260  
F W F G Y N L \* F L F \* V R C R F Y K S  
F G L V T I C D F Y S K L G V G F T S H  
L L V W L Q F V I F I L S \* V \* V L Q V

7261 TTTTGTAAATGTTAGTTTATATGTGAATTGTGTCATCTGGTTTGTATGTGGATAC 7320  
F L \* W \* F Y M \* I V S F W F \* Y V G Y  
F C N G S F I C E L C H S G F D M L D T  
I F V M V V L Y V N C V I L V L I C W I

7321 ATATGCAGCTATAGATTTTGTTCAGTATGAAGTAGATAGACGTGTTTTATTGATTATGT 7380  
I C S Y R F C S V \* S R \* T C F I \* L C  
Y A A I D F V Q Y E V D R R V L F D Y V  
H M Q L \* I L F S M K \* I D V F Y L I M

7381 TAGTTTAGTCAAATTAATTGTTGAACCTCGTTATTGGTTATTCAATTATACACAGTATGGTT 7440  
\* F S Q I N C \* T R Y W L F I I H S M V  
S L V K L I V E L V I G Y S L Y T V W F  
L V \* S N \* L L N S L L V I H Y T Q Y G

7441 TTATCCATTATTTTGTCTTATTGGTTTACAATTATTTACTACATGGTTGCCTGATTGTT 7500  
L S I I L S Y W F T I I Y Y M V A \* F V  
Y P L F C L I G L Q L F T T W L P D L F  
F I H Y F V L L V Y N Y L L H G C L I C

7501 TATGTTAGAACTATGCATTGGTTGATTAGATTTATTGTATTTGTAGCTAATATGTTACC 7560  
Y V R N Y A L V D \* I Y C I C S \* Y V T  
M L E T M H W L I R F I V F V A N M L P  
L C \* K L C I G \* L D L L Y L \* L I C Y

FIG. 2 CONT.

16/201

7561 TGCTTTTGTCTTGTTCGGTTTTATATAGTTGTTACTGCTATGTATAAAGTAGTTGGTTT 7620  
 C F C L V A V L Y S C Y C Y V \* S S W F  
 A F V L L R F Y I V V T A M Y K V V G F  
 L L L S C C G F I \* L L L L C I K \* L V

7621 TATTAGGCATATTGTCTATGGTTGTAATAAAGCTGGTTGTTATTTTGTATATAACGAAA 7680  
 Y \* A Y C L W L \* \* S W L F I L L \* T K  
 I R H I V Y G C N K A G C L F C Y K R N  
 L L G I L S M V V I K L V V Y F V I N E

7681 TTGTAGTGTTCGTGTTAAGTGTAGTACTATTGTTGGTGGTGAATTCGTTATTATGATAT 7740  
 L \* C S C \* V \* Y Y C W W C N S L L \* Y  
 C S V R V K C S T I V G G V I R Y Y D I  
 I V V F V L S V V L L L V V \* F V I M I

7741 TACTGCTAATGGTGGTACTGGTTTTTGTGTTAAACATCAATGGAATTGTTTAAATGCCA 7800  
 Y C \* W W Y W F L C \* T S M E L F \* L P .  
 T A N G G T G F C V K H Q W N C F N C H  
 L L L M V V L V F V L N I N G I V L I A

7801 TTCTTTTAAACCAGGTAACACTTTTATAACTGTAGAAGCTGCTATAGAAGTTTCTAAAGA 7860  
 F F \* T R \* H F Y N C R S C Y R T F \* R  
 S F K P G N T F I T V E A A I E L S K E  
 I L L N Q V T L L \* L \* K L L \* N F L K

7861 GCTTAAACGACCTGTAAATCCAAGTATGCTTACATTATGTAGTTACTGATATTAAGCA 7920  
 A \* T T C K S N \* C F T L C S Y \* Y \* A  
 L K R P V N P T D A S H Y V V T D I K Q  
 S L N D L \* I Q L M L H I M \* L L I L S

7921 AGTTGGTTGTATGATGCGTTTGTCTATGATAGAGATGGACAGCGTTTACGATGATGT 7980  
 S W L Y D A F V L \* \* R W T A C L R \* C  
 V G C M M R L F Y D R D G Q R V Y D D V  
 K L V V \* C V C S M I E M D S V F T M M

7981 TGATGCTAGTTTATTTGTAGATATTAATAATCTGTTACATTCTAAAGTTAAAGTTGTTCC 8040  
 \* C \* F I C R Y \* \* S V T F \* S \* S C S  
 D A S L F V D I N N L L H S K V K V V P  
 L M L V Y L \* I L I I C Y I L K L K L F

8041 TAATTTGTATGTAGTTGTAGTAGAGAGTGTGCTGATAGAGCTAATTTTCTGARTGCTGT 8100  
 \* F V C S C S R E \* C \* \* S \* F S E C C  
 N L Y V V V V E S D A D R A N F L N A V  
 L I C M \* L \* \* R V M L I E L I F \* M L

FIG. 2 CONT.

17/201

8101 TGTGTTTTATGCACATCATTGTATAGGCCTATATTACTTGTAGACAAAAAGTTAATTAC 8160  
C V L C T I I V \* A Y I T C R Q K V N Y  
V F Y A Q S L Y R P I L L V D K K L I T  
L C F M H N H C I G L Y Y L \* T K S \* L

8161 TACAGCTTGTAAATGSTATCTCTGTAACCCAGACTATGTTTGATGTTTATGTTGATACTTT 8220  
Y S L \* W Y L C N P D Y V \* C L C \* Y F  
T A C N G I S V T Q T M F D V Y V D T F  
L Q L V M V S L \* P R L C L M F M L I L

8221 TATGTCCTATTTTGATGTTGATAGAAAGAGTTTAAATAATTTTGTAAACATTGCTCATGC 8280  
Y V S E \* C \* \* K E F \* \* F C \* H C S C  
M S H F D V D R K S F N N F V N I A H A  
L C L I L M L I E R V L I I L L T L L M

8281 TTCTCTTAGAGAGGGTGTGCAATTAGAAAAGGTTTATAGATACTTTTGTGGGATGTGTACG 8340  
F S \* R G C A I R K G F R Y F C G M C T  
S L R E G V Q L E K V L D T F V G C V R  
L L L E R V C N \* K R F \* I L L W D V Y

8341 TAAATGTTGTTCCATTGATTCAGATGTTGAAACAAGATTTATTACTAAATCTATGATATC 8400  
\* M L F H \* F R C \* N K I Y Y \* I Y D I  
K C C S I D S D V E T R F I T K S M I S  
V N V V P L I Q M L K Q D L L L N L \* Y

8401 TGCAGTAGCTGCTGTTTGGGAATTTACTGATGAAAATTATAACAATTTGGTACCTACATA 8460  
C S S C W F G I Y \* \* K L \* Q F G T Y I  
A V A A G L E F T D E N Y N N L V P T Y  
L Q \* L L V W N L L M K I I T I W Y L H

8461 TTTAAAGAGTGATAATATTTGTAGCTGCTGATTTAGGTGTTCTTATACAGAATGGTGCTAA 8520  
F K E \* \* Y C S C \* F R C S Y T E W C \*  
L K S D N I V A A D L G V L I Q N G A K  
I \* R V I I L \* L L I \* V F L Y R M V L

8521 GCATGTACAGGGTAATGTTGCTAAGGCAGCTAATATTTCTTGTATATGGTTTATTGATGC 8580  
A C T G \* C C \* G S \* Y F L Y M V Y \* C  
H V Q G N V A K A A N I S C I W F I D A  
S M Y R V M L L R Q L I F L V Y G L L M

8581 TTTTAATCAACTTACTGCTGATTTACAGCATAAATTAATAAAGCATGTGTTAAACTGG 8640  
F \* S T Y C \* F T A \* I K K S M C \* N W  
F N Q L T A D L Q H K L K K A C V K T G  
L L I N L L L I Y S I N \* K K H V L K L

FIG. 2 CONT.



18/201

8641 CTTGAAGTTAAAATTGACTTTTAAATAAGCAAGAGGCAAGTGTCCTATTCTTACAAACACC 8700  
L E V K I D F \* \* A R G K C P Y S Y N T  
L K L K L T F N K Q E A S V P I L T T P  
A \* S \* N \* L L I S K R Q V S L F L Q H

8701 CTTTTCACCTTAAAGGAGGTGTTGATTGAGTAATTTGTTATATATATTATTTTTGTTAG 8760  
L F T \* R R C C I E \* F V I Y I I F C \*  
F S L K G G V V L S N L L Y I L F F V S  
P F H L K E V L Y \* V I C Y I Y Y F L L

8761 TTTAATCTGTTTTATATTATTTGTTGGGCTTTATTGCCTACATATAGTGTTTATAAGTCTGA 8820  
F N L F Y I I V G F I A Y I \* C L \* V \*  
L I C F I L L W A L L P T Y S V Y K S D  
V \* S V L Y Y C G L Y C L H I V F I S L

8821 TATTCATTTGCCTGCTTATGCTAGTTTTAAAGTTATTGATAATGCTGTTGTTAGAGATAT 8880  
Y S F A C L C \* F \* S Y \* \* W C C \* R Y  
I H L P A Y A S F K V I D N G V V R D I  
I F I C L L M L V L K L L I M V L L E I

8881 TTCAGTTAATGATTTATGTTTTGCTAATAAATTTTCCAATTTGATCAATGGTATGAGTC 8940  
F S \* \* F M F C \* \* I F P I \* S M V \* V  
S V N D L C F A N K F F Q F D Q W Y E S  
F Q L M I Y V L L I N F S N L I N G M S

8941 CACTTTTGGGCTGTTTACTATCATAATTCTATGGATTGCCCTATTGTAGTGGCAGTTAT 9000  
H F W V C L L S \* F Y G L P Y C S G S Y  
T F G S V Y Y H N S M D C P I V V A V M  
P L L G L F T I I I L W I A L L \* W Q L

9001 GGATGAAGATATCGGTTCTACTATGTTTAAATGTTTCCTACTAAAGTTTGTAGACATGGCTT 9060  
G \* R Y R F Y Y V \* C S Y \* S F E T W L  
D E D I G S T M F N V P T K V L R H G F  
W M K I S V L L C L M F L L K F \* D M A

9061 TCATGTTTACATTTTAACTTATGCATTGCTAGTGATAGTGTTCAGTGCTATACACC 9120  
S C F T F F N L C I C \* \* \* C S V L Y T  
H V L H F L T Y A F A S D S V Q C Y T P  
F M F Y I F \* L M H L L V I V F S A I H

9121 ACATATTCAGATTTCTTATAATGATTTTTATGCTAGTGGTTGTGTTTATCATCTTTGTG 9180  
T Y S D F L \* \* F L C \* W L C F I I F V  
H I Q I S Y N D F Y A S G C V L S S L C  
H I F R F L I M I F M L V V V F Y H L C

FIG. 2 CONT.

19/201

9181 TACTATGTTTAAAGAGGTGATGGTACACCACATCCTTATTGTTATTCAGATGGTGTAT 9240  
Y Y V \* K R \* W Y T T S L L L F R W C Y  
T M F K R G D G T P H P Y C Y S D G V M  
V L C L K E V M V H H I L I V I Q M V L

9241 GAAGAATGCTTCTTTGTATACATCTTTGGTCCACATACAGTTATAGCCTTGCTAATC 9300  
E E C F F V Y I F G S T Y T L \* P C \* F  
K N A S L Y T S L V P H T R Y S L A N S  
\* R M L L C I H L W F H I H V I A L L I

9301 TAATGGTTTATAAGATTTCTTGATGTTATTAGTGAAGGTATTGTACGTATTGTAAGAAC 9360  
\* W F Y K I S \* C Y \* \* R Y C T Y C K N  
N G F I R F P D V I S E G I V R I V R T  
L M V L \* D F L M L L V K V L Y V L \* E

9361 GCGCTCTATGACTTATTGTAGAGTGGGTGCATGTGAATACGCCGAGAGGGTATATGTTT 9420  
A L Y D L L \* S G C M \* I R R R G Y M F  
R S M T Y C R V G A C E Y A E E G I C F  
R A L \* L I V E W V H V N T P K R V Y V

9421 TAATTTTAATAGTTCCTGGGTTTGAATAATGATTATTATAGAAGTATGCCTGGAACTTT 9480  
\* F \* \* F L G F E \* \* L L \* K Y A W N F  
N F N S S W V L N N D Y Y R S M P G T F  
L I L I V P G F \* I M I I I E V C L E L

9481 TTGTGGTAGAGATCTTTTGATTTGTTTATCAATTTTTAGTAGTTTAATTCGTCCTAT 9540  
L W \* R S F \* F V L S I F \* \* F N S S Y  
C G R D L F D L F Y Q F F S S L I R P I  
F V V E I F L I C F I N F L V V \* F V L

9541 AGATTTCTTTCTTACTGCTAGTCTATTTTGGAGCTATATTGGCTATAGTTGTTGT 9600  
R F L F S Y C \* F Y F W S Y I G Y S C C  
D F F S L T A S S I F G A I L A I V V V  
\* I S F L L L L V L F L E L Y W L \* L L

9601 CTGCGTTTTTATTATTTAATAAACTTAAGCGTGCTTTTGGAGATTACTAGTGTGT 9660  
L G F L L F N K T \* A C F W R L Y \* C C  
L V F Y Y L I K L K R A F G D Y T S V V  
S W F F I I \* \* N L S V L L E I I L V L

9661 AGTTATAAATGTTGTTGTTGGTGTATTAATTTCTATGCTTTTGTTTTCAAGTTA 9720  
S Y K C C C L V Y \* F S Y A F C F S S L  
V I N V V V W C I N F L M L F V F Q V Y  
\* L \* M L L F G V L I F L C F L F F K F

FIG. 2 CONT.

20/201

9721 TCCTATTTGTGCATGTGTTTATGCTTGTTTATTTTATGTAACATTGTATTTTCCTTC 9780  
S Y L C M C L C L F L F L C N I V F S F  
P I C A C V Y A C F Y F Y V T L Y F P S  
I L F V H V F M L V F I F M \* H C I F L

9781 TGAAATTAGTGAATTATGCATTTGCAATGGATTGTTATGTATGGTGCATAATGCCTTT 9840  
\* N \* C N Y A F A M D C Y V W C Y N A F  
E I S V I M H L Q W I V M Y G A I M P F  
L K L V \* L C I C N G L L C M V L \* C L

9841 TTGGTTTTGTGTCACATATGTAGCTATGGTTATTGCAAACCATGTTTATGGTTATTTTC 9900  
L V L C H I C S Y G Y C K P C F M V I F  
W F C V T Y V A M V I A N H V L W L F S  
F G F V S H M \* L W L L Q T M F Y G Y F

9901 ATATTGTAGGAAAATTGGTGTTAATGTATGTAGTGATAGTACATTTGAAGAAACATCTCT 9960  
I L \* E N W C \* C M \* \* \* Y I \* R N I S  
Y C R K I G V N V C S D S T F E E T S L  
H I V G K L V L M Y V V I V H L K K H L

9961 TACTACTTTTATGATTACTAAAGATTCTTATTGTAGATTAAAGAATTCTGTTTCTGATGT 10020  
Y Y F Y D Y \* R F L L \* I K E F C F \* C  
T T F M I T K D S Y C R L K N S V S D V  
L L L L \* L L K I L I V D \* R I L F L M

10021 TGCCTACAATAGATATTTGAGTTTGTATAATAAGTATCGTTACTATAGTGGTAAATGGA 10080  
C L Q \* I F E F V \* \* V S L L \* W \* N G  
A Y N R Y L S L Y N K Y R Y Y S G K M D  
L P T I D I \* V C I I S I V T I V V K W

10081 TACTGCTGCCATAGAGAAGCGCGTGTCTCAGTTAGCTAAAGCTATGGAACATTTAA 10140  
Y C C L \* R S G V F S V S \* S Y G N I \*  
T A A Y R E A A C S Q L A K A M E T F N  
I L L P I E K R R V L S \* L K L W K H L

10141 TCACAATAATGGTAATGATGCTTATACCAACCTCCTACAGCATCTGTTTCTACATCTTT 10200  
S Q \* W \* \* C L I P T S Y S I C F Y I F  
H N N G N D V L Y Q P P T A S V S T S F  
I T I M V M M S Y T N L L Q H L F L H L

10201 TTTGCAATCAGGTATTGTAAAGATGGTATCTCCTACGTCAAAAATTGAACCTTGATTGT 10260  
F A I R Y C K D G I S Y V K N \* T L Y C  
L Q S G I V K M V S P T S K I E P C I V  
F C N Q V L \* R W Y L L R Q K L N L V L

FIG. 2 CONT.

21/201

10261 TAGTGTTACTTATGGTAGTATGACTTTGAATGGTTATGGTTAGATGACAAAGTTTATTG 10320  
 \* C Y L W \* Y D F E W F M V R \* Q S L L  
 S V T Y G S M T L N G L W L D D K V Y C  
 L V L L M V V \* L \* M V Y G \* M T K F I

10321 TCCTCGTCATGTTATATGTTTCCTCTAATATGAACGAACCTGATTATTCTGCCTTATT 10380  
 S S S C Y M F I L \* Y E R T \* L F C L I  
 P R H V I C S S S N M N E P D Y S A L L  
 V L V M L Y V H P L I \* T N L I I L P Y

10381 GTGTAGAGTTACTCTAGGTGATTTTACTATAATGTCTGGTCGGATGAGTTTAACAGTTGT 10440  
 V \* S Y S R \* F Y Y N V W S D E F N S C  
 C R V T L G D F T I M S G R M S L T V V  
 C V E L L \* V I L L \* C L V G \* V \* Q L

10441 GTCTTACCAGATGCAGGGCTGTCAACTTGTTTTGACAGTCTCTTTACAAAATCCTTACAC 10500  
 V L P D A G L S T C F D S L F T K S L H  
 S Y Q M Q G C Q L V L T V S L Q N P Y T  
 C L T R C R A V N L F \* Q S L Y K I L T

10501 TCCAAAATATACTTTTGGTAATGTTAAACCTGGTGAAACTTTTACTGTTTTAGCTGCGTA 10560  
 S K I Y F W \* C \* T W \* N F Y C F S C V  
 P K Y T F G N V K P G E T F T V L A A Y  
 L Q N I L L V M L N L V K L L L F \* L R

10561 TAATGGCCGACCACAAGGGGCATTTTCATGTTACTATGCGTAGTAGTTATACTATTAAAGG 10620  
 \* W P T T R G I S C Y Y A \* \* L Y Y \* R  
 N G R P Q G A F H V T M R S S Y T I K G  
 I M A D H K G H F M L L C V V V I L L K

10621 TTCTTTTTTGTGTGGTCATGTGGATCTGTGGTTATGTATTAACAGGTGATAGTGTAA 10680  
 F F F V W V M W I C W L C I N R \* \* C \*  
 S F L C G S C G S V G Y V L T G D S V K  
 V L F C V G H V D L L V M Y \* Q V I V L

10681 GTTGTATATATGCATCAATTAGAGCTCAGTACTGGTTGTCACACTGGCACTGATTTTAC 10740  
 V C I Y A S I R A Q Y W L S H W H \* F Y  
 F V Y M H Q L E L S T G C H T G T D F T  
 S L Y I C I N \* S S V L V V T L A L I L

10741 TGGTAATTTTATGGTCCATATAGAGATGCTCAAGTTGTACAGTTGCCAGTTAAGGACTA 10800  
 W \* F L W S I \* R C S S C T V A S \* G L  
 G N F Y G P Y R D A Q V V Q L P V K D Y  
 L V I F M V H I E M L K L Y S C Q L R T

FIG. 2 CONT.

22/201

10801 CGTCCAGACTGTTAATGTTATTGCTTGGCTCTATGCAGCTATACTTAATAATGTGCTTG 10860  
R P D C \* C Y C L A L C S Y T \* \* L C L  
V Q T V N V I A W L Y A A I L N N C A W  
T S R L L M L L L G S M Q L Y L I I V L

10861 GTTTGTACAAAATGATGTTTGTCTACTGAAGATTTAATGTTGGGCTATGGCAAATGG 10920  
V C T K \* C L F Y \* R F \* C L G Y G K W  
F V Q N D V C S T E D F N V W A M A N G  
G L Y K M M F V L L K I L M F G L W Q M

10921 TTTTAGCCAAGTAAAAGCAGATCTTGTCTTAGATGCTTTGGCTTCAATGACAGGTGTTTC 10980  
F \* P S K S R S C L R C F G F N D R C F  
F S Q V K A D L V L D A L A S M T G V S  
V L A K \* K Q I L S \* M L W L Q \* Q V F

10981 TATTGAACTTTATTGGCTGCTATTAAGCGTCTATATATGGGATTTCAGGTCGTCAAAT 11040  
Y \* N F I G C Y \* A S I Y G I S R S S N  
I E T L L A A I K R L Y M G F Q G R Q I  
L L K L Y W L L L S V Y I W D F K V V K

11041 ACTAGGAAGTTGTACTTTTGAAGATGAATTGGCACCTTCTGACGTTTATCAACAATTGGC 11100  
T R K L Y F \* R \* I G T F \* R L S T I G  
L G S C T F E D E L A P S D V Y Q Q L A  
Y \* E V V L L K M N W H L L T F I N N W

11101 TGGTGTAAATTGCAATCTAAAACAAAAGATTATTAAAGAAACAATTTATTGGATTTT 11160  
W C \* I A I \* N K K I Y \* R N N L L D F  
G V K L Q S K T K R F I K E T I Y W I L  
L V L N C N L K Q K D L L K K Q F I G F

11161 GATATCTACATTTTGTAGTTGTATAATTTCTGCATTGTTAAATGGACTATATTTAT 11220  
D I Y I F V \* L Y N F C I C \* M D Y I Y  
I S T F L F S C I I S A F V K W T I F M  
\* Y L H F C L V V \* F L H L L N G L Y L

11221 GATATTAATACACATATGATTGGTGTACATTATGTGTACTTTGTTTTGTAGTTTTAT 11280  
V Y \* Y T Y D W C Y I M C T L F C \* F Y  
Y I N T H M I G V T L C V L C F V S F M  
C I L I H I \* L V L H Y V Y F V L L V L

11281 GATGTTACTAGTTAAACATAAGCATTTTATTGACTATGTATATAATTCCTGACTCTG 11340  
D V T S \* T \* A F L F D Y V Y N S C T L  
M L L V K H K H F Y L T M Y I I P V L C  
\* C Y \* L N I S I F I \* L C I \* F L Y S

FIG. 2 CONT.

23/201

11341 TACCTTGTTTATGTAAATTATTTAGTTGTTTATAAGGAAGGTTTATAGAGGTTTACTTA 11400  
Y L V L C K L F S C L \* G R F \* R F Y L  
T L F Y V N Y L V V Y K E G F R G F T Y  
V P C F M \* I I \* L F I R K V L E V L L

11401 TGTCTGGCTCTCATATTTTGTTCCTGCTGTGAATTTACTTATGTTTATGAAGTATTTTA 11460  
C L A L I F C S C C E F Y L C L \* S I L  
V W L S Y F V P A V N F T Y V Y E V F Y  
M S G S H I L F L L \* I L L M F M K Y F

11461 TGGTTGATTTTATGTGTTTTGCTATTTTATAACTATGCATAGTATTAAATCATGACAT 11520  
W L Y F M C F C Y F Y N Y A \* Y \* S \* H  
G C I L C V F A I F I T M H S I N H D I  
M V V F Y V F L L F L \* L C I V L I M T

11521 TTTTCTTTGATGTTTTGTTGGTAGAATAGTTACTTTAATTTCTATGTGGTATTTTGG 11580  
F F F D V F G W \* N S Y F N F Y V V F W  
F S L M F L V G R I V T L I S M W Y F G  
F F L \* C F W L V E \* L L \* F L C G I L

11581 GTCGAATTTAGAAGAGGATGTTTTGTTATTTATTACAGCCTTTTATAGTACTTATACATG 11640  
V E F R R G C F V I Y Y S L F R Y L Y M  
S N L E E D V L L F I T A F L G T Y T W  
G R I \* K R M F C Y L L Q P F \* V L I H

11641 GACCACTATTTTGTCTATAGCTATAGCAAAAATTGTTGCTAATTGTTGCTCTGTTAATAT 11700  
D H Y F V I S Y S K N C C \* L V V C \* Y  
T T I L S L A I A K I V A N W L S V N I  
G P L F C H \* L \* Q K L L L I G C L L I

11701 ATTTTATTTTACAGATGTACCTTATATTAATGATTCTCTTGAGTTACTTATTTATAGG 11760  
I L F Y R C T L Y \* I D S L E L L I Y R  
F Y F T D V P Y I K L I L L S Y L F I G  
Y F I L Q M Y L I L N \* F S \* V T Y L \*

11761 GTATATTTTATCTTGTTATGSGGATTTTCTCTCTTTTAAACAGTGTTTTATAGATGCC 11820  
V Y F I L L L G I F L S F K Q C F \* N A  
Y I L S C Y W G F F S L L N S V F R M P  
G I F Y L V I G D F S L F \* T V F L E C

11821 TATGGGTGTTTATAATTATAAAATTTCTGTTCAAGAATTGCGTTATATGAATGCTAATGG 11880  
Y G C L \* L \* N F C S R I A L Y E C \* W  
M G V Y N Y K I S V Q E L R Y M N A N G  
L W V F I I I K F L F K N C V I \* M L M

FIG. 2 CONT.

24/201

11881 CTTACGTCCACCTCGTAATAGTTTGGAGGCTATTTGTAAATTAAAACTGCTTGGAAAT 11940  
L T S T S \* \* F \* G Y F V K F K T A W N  
L R P P R N S F E A I L L N L K L L G I  
A Y V H L V I V L R L F C \* I \* N C L E

11941 AGGTGGCGTGCCAGTTATTGAAGTCTCCCAAATTCANTCAAAATTGACTGATGTGAAATG 12000  
R W R A S Y \* S L P N S I K I D \* C E M  
G G V P V I E V S Q I Q S K L T D V K C  
\* V A C Q L L K S P K F N Q N \* L M \* N

12001 TGCTAATGTTGTTTGTAAATTGTTTACAGCATTGTCATGTTGCTTCTAATTCTAAGTT 12060  
C \* C C F V K L F T A F A C C F \* F \* V  
A N V V L L N C L Q H L H V A S N S K L  
V L M L F C \* I V Y S I C M L L L I L S

12061 GTGGCAGTATTGTAGTGTTTACATAATGAAATACTATCTACTTCAGATTGAGTGTAGC 12120  
V A V L \* C F T \* \* N T I Y F R F E C S  
W Q Y C S V L H N E I L S T S D L S V A  
C G S I V V F Y I M K Y Y L L Q I \* V \*

12121 TTTTGATAAGCTTGCTCAATTATTGATTGTTTTATTGCGCAATCCTGCTGCAGTTGATAC 12180  
F \* \* A C S I I D C F I R Q S C C S \* Y  
F D K L A Q L L I V L F A N P A A V D T  
L L I S L L N Y \* L F Y S P I L L Q L I

12181 TAAGTGCTTGCAAGTATAGATGAAGTTAGCGATGATTATGTTCAAGATAGTACCGTTTT 12240  
\* V S C K Y R \* S \* R \* L C S R \* Y R F  
K C L A S I D E V S D D Y V Q D S T V L  
L S V L Q V \* M K L A M I M F K I V P F

12241 GCAGGCTTTGCAAAGTGAGTTTGTAATATGGCTAGTTTGTGTAATATGAAGTCGCAAA 12300  
A G F A K \* V C K Y G \* F C \* I \* S R K  
Q A L Q S E F V N M A S F V E Y E V A K  
C R L C K V S L \* I W L V L L N M K S Q

12301 GAAAAATTTGGCTGATGCTAAAAATAGTGGTTCTGTTAATCAACACAGATAAAACAGTT 12360  
E K F G \* C \* K \* W F C \* S T T D K T V  
K N L A D A K N S G S V N Q Q Q I K Q L  
R K I W L M L K I V V L L I N N R \* N S

12361 AGAAAAAGCATGTAATATAGCTAAGTCTGTGTATGAACGTGATAAAGCTGTAGCTCGCAA 12420  
R K S M \* Y S \* V C V \* T \* \* S C S S Q  
E K A C N I A K S V Y E R D K A V A R K  
\* K K H V I \* L S L C M N V I K L \* L A

FIG. 2 CONT.

25/201

12421 ACTTGAACGTATGGCAGACCTAGCACTTACTAACATGTATAAAGAGGCTCGGATTAATGA 12480  
 T \* T Y G R P S T Y \* H V \* R G S D \* \*  
 L E R M A D L A L T N M Y K E A R I N D  
 N L N V W Q T \* H L L T C I K R L G L M

12481 TAAGAAGAGTAAAGTTGTTTCGCTTTGCAGACAATGCTTTTTCATGATGGTTCGTAAATT 12540  
 \* E E \* S C F R F A D N A F \* H G S \* I  
 K K S K V V S A L Q T M L F S M V R K L  
 I R R V K L F P L C R Q C F L A W F V N

12541 GGATAATCAGGCTTTAAATTCATTCTGGATAATGCTGTTAAAGGTTGTGTACCTTTGAG 12600  
 G \* S G F K F Y S G \* C C \* R L C T F E  
 D N Q A L N S I L D N A V K G C V P L S  
 W I I R L \* I L F W I M L L K V V Y L \*

12601 TGCTATTCCAGCATTGGCTGCTAATACTTTAACTATAGTAATACCAGATAAACAAGTTTT 12660  
 C Y S S I G C \* Y F N Y S N T R \* T S F  
 A I P A L A A N T L T I V I P D K Q V F  
 V L F Q H W L L I L \* L \* \* Y Q I N K F

12661 TGATAAAGTTGTTGATAATGTTTATGTTACATATGCTGGTAGTGTATGGCATATACAGAC 12720  
 \* \* S C \* \* C L C Y I C W \* C M A Y T D  
 D K V V D N V Y V T Y A G S V W H I Q T  
 L I K L L I M F M L H M L V V Y G I Y R

12721 TGTTCAAGATGCTGATGGTATTAATAACAGTTAACTGATATTAGTGTGATTCTAATTG 12780  
 C S R C \* W Y \* \* T V N \* Y \* C \* F \* L  
 V Q D A D G I N K Q L T D I S V D S N W  
 L F K M L M V L I N S \* L I L V L I L I

12781 GCCTCTTGTTATCATTGCGAACAGGTATAATGAAGTTGCTAATGCTGTTATGCAGAATAA 12840  
 A S C Y H C E Q V \* \* S C \* C C Y A E \*  
 P L V I I A N R Y N E V A N A V M Q N N  
 G L L L S L R T G I M K L L M L L C R I

12841 TGAGTTGATGCCTCATAAATTAAAAATACAAGTTGTTAATAGTGGTTCTGATATGAATTG 12900  
 \* V D A S \* I K N T S C \* \* W F \* Y E L  
 E L M P H K L K I Q V V N S G S D M N C  
 M S \* C L I N \* K Y K L L I V V L I \* I

12901 TAATATTCCCTACTCAATGTTATTATAAATAATGGTAGTAGTGGTAGAATAGTTTATGCTGT 12960  
 \* Y S Y S M L L \* \* W \* \* W \* N S L C C  
 N I P T Q C Y Y N N G S S G R I V Y A V  
 V I F L L N V I I I M V V V V E \* F M L

FIG. 2 CONT.



26/201

12961 TCTTAGTGATGTTGATGGTCTTAAGTATACTAAGATAATGAAAGATGATGGAAATTGTGT 13020  
S \* \* C \* W S \* V Y \* D N E R \* W K L C  
L S D V D G L K Y T K I M K D D G N C V  
F L V M L M V L S I L R \* \* K M M E I V

13021 TGTTTGTAGAGCTTGATCCTCCTTGTAATTTTCTATACAAGATGTTAAGGGACTTAAAT 13080  
C F R A \* S S L \* I F Y T R C \* G T \* N  
V L E L D P P C K F S I Q D V K G L K I  
L F \* S L I L L V N F L Y K M L R D L K

13081 TAAGTATCTTTATTTTATTAAGGATGTAACACTTTAGCTAGAGGGTGGGTTGTGGTAC 13140  
\* V S L F Y \* R M \* H F S \* R V G C W Y  
K Y L Y F I K G C N T L A R G W V V G T  
L S I F I L L K D V T L \* L E G G L L V

13141 TTTATCTTCAACAATTAGATTGCAGGCTGGTGTGCTACTGAGTATGCAGCTAATTCTTC 13200  
F I F N N \* I A G W C C Y \* V C S \* F F  
L S S T I R L Q A G V A T E Y A A N S S  
L Y L Q Q L D C R L V L L L S M Q L I L

13201 TATACTTTCATTATGTGCATTTTCTGTAGATCCTAAGAAAACCTTATTAGATTATATACA 13260  
Y T F I M C I F C R S \* E N L F R L Y T  
I L S L C A F S V D P K K T Y L D Y I Q  
L Y F H Y V H F L \* I L R K L I \* I I Y

13261 ACRAAGGTGGTGACCTATAATTAATTGTGTTAAATGCTCTGTGATCATGCTGGTACTGG 13320  
T R W C T Y N \* L C \* N A L \* S C W Y W  
Q G G V P I I N C V K M L C D H A G T G  
N K V V Y L \* L I V L K C S V I M L V L

13321 TATGGCCATTACTATTAAACCTGAGGCTACTATTAACCAAGATTCTTATGGTGGTGCCTC 13380  
Y G H Y Y \* T \* G Y Y \* P R F L W W C L  
M A I T I K P E A T I N Q D S Y G G A S  
V W P L L L N L R L L L T K I L M V V P

13381 AGTTTGTATTTATTGCCGTGCACGTGTAGAGCATCCAGATGTAGATGGTATATGTAATT 13440  
S L Y L L P C T C R A S R C R W Y M \* I  
V C I Y C R A R V E H P D V D G I C K L  
Q F V F I A V H V \* S I Q M \* M V Y V N

13441 ACGTGGTAAATTGTACAAGTCCCTTTGGGTATAAAGATCCTATTCTTTATGTGTTAAC 13500  
T W \* I C T S P F G Y K R S Y S L C V N  
R G K F V Q V P L G I K D P I L Y V L T  
Y V V N L Y K S L W V \* K I L F F M C \*

FIG. 2 CONT.

27/201

13501 ACATGATGTTTGTCAAGTCTGTGGTTTTTGGAGAGATGGCAGTTGTTCTGTGTAGGTTC 13560  
T \* C L S S L W F L E R W Q L F L C R F  
H D V C Q V C G F W R D G S C S C V G S  
H M M F V K S V V F G E M A V V P V \* V

13561 AAGTGTGCTGTTCATCTAAAGATTTAAATTTTTTAAACGGGTTGCGGGTACTAGTGTG 13620  
K C R C S I \* R F K F F K R V R G T S V  
S V A V Q S K D L N F L N G F G V L V \*  
Q V S L F N L K I \* I F \* T G S G Y \* C

13621 AATGCCCGGCTAGTACCCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATT 13680  
N A R L V P C A S G L S T D V Q L R A F  
M P G \* Y P V L V V Y L L M F N \* G H L  
E C P A S T L C \* W F I Y \* C S I K G I

13681 GACATTTGTAATACCAATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGT 13740  
D I C N T N R A G I G L Y Y K V N C C R  
T F V I P I E L V \* V Y I I K \* I V A V  
\* H L \* Y Q \* S W Y R F I L \* S E L L P

13741 TTTGAGCGTATAGATGACGACGGTAATAAATGGATAAGTTCTTTGTTGTCAAAGAAGT 13800  
F Q R I D D D G N K L D K F F V V K R T  
F S V \* M T T V I N W I S S L L S K E L  
F S A Y R \* R R \* \* I G \* V L C C Q K N

13801 AATTTAGAAGTTTATAATAAGAGAAAAGTATTATGAGTTGACTAAAAGTTGTTGGTGT 13860  
N L E V Y N K E K T Y Y E L T K S C G V  
I \* K F I I K R K L I M S \* L K V V V L  
\* F R S L \* \* R E N L L \* V D \* K L W C

13861 GTGGCTGAACATGATTCTTTACATTGATATTGATGGTAGTCGCGTGCCACATATAGTT 13920  
V A E H D F F T F D I D G S R V P H I V  
W L N M I S L H L I L M V V A C H I \* F  
C G \* T \* F L Y I \* Y \* W \* S R A T Y S

13921 CGTAGGAATCTTTCAAAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGAT 13980  
R R N L S K Y T M L D L C Y A L R H F D  
V G I F Q S I L C \* I F A M H C V I L I  
S \* E S F K V Y Y V R S L L C I A S F \*

13981 CGTAATGATTGTTCAATATTGTGTGAAATCTTTGTGAGTATGCTGATTGTTAAAGAATCC 14040  
R N D C S I L C E I L C E Y A D C K E S  
V M I V Q Y C V K F F V S M L I V K N P  
S \* \* L F N I V \* N S L \* V C \* L \* R I

FIG. 2 CONT.

28/201

14041 TACTTTTCTAAGAAAGATTGGGTATGATTTTGTGAAAATCCTGATATTATTAATATATAT 14100  
Y F S K K D W Y D F V E N P D I I N I Y  
T F L R K I G M I L L K I L I L L I Y I  
L L F \* E R L V \* F C \* K S \* Y Y \* Y I

14101 AAAAAATTAGGCCCTATTTTAAATAGAGCTTTACTTAATACTGTCAATTTTGCAGACACC 14160  
K K L G P I F N R A L L N T V I F A D T  
K N \* A L F L I E L Y L I L S F L Q T P  
\* K I R P Y F \* \* S F T \* Y C H F C R H

14161 TTAGTTGAAGTAGGTTTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAA 14220  
L V E V G L V G V L T L D N Q D L Y G Q  
\* L K \* V \* L V F \* L \* I T K I C M V N  
L S \* S R F S W C F N F R \* P R F V W S

14221 TGGTATGATTTTGGTGATTTTATACAAACAGCCCCAGGGTTGGTGTGGCAGTTGCAGAT 14280  
W Y D F G D F I Q T A P G F G V A V A D  
G M I L V I L Y K Q P Q G L V W Q L Q I  
M V \* F W \* F Y T N S P R V W C G S C R

14281 TCTTACTATTCTTATATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTA 14340  
S Y Y S Y M M P M L T M C H V L D C E L  
L T I L I \* C L C \* L C V M Y \* I V N Y  
F L L F L Y D A Y V D Y V S C I R L \* I

14341 TTTGTTAATGATAGTTATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTACAAG 14400  
F V N D S Y R Q F D L V Q Y D F T D Y K  
L L M I V I D N S I L Y S M I L L I T S  
I C \* \* \* L \* T I R S C T V \* F Y \* L Q

14401 TTAGAGTTGTTTAAATAAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTG 14460  
L E L F N K Y F K Y W G M K Y H P N T V  
\* S C L I S I L S I G V \* S I I L I L W  
V R V V \* \* V F \* V L G Y E V S S \* Y C

14461 GATTGTGATAATGATAGGTGTATTATTCATTGTGCTAATTTTAAATATACTATTAGTATG 14520  
D C D N D R C I I H C A N F N I L F S M  
I V I M I G V L F I V L I L I Y Y L V W  
G L \* \* \* \* V Y Y S L C \* F \* Y T I \* Y

14521 GTTTTACCTAATACTTGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCG 14580  
V L P N T C F G P L V R Q I F V D G V P  
F Y L I L V L V P L L D K F L \* M V Y R  
G F T \* Y L F W S P C \* T N F C R W C T

FIG. 2 CONT.

29/201

14581 TTTGTTGTTTCTATTGGTTACCATTACAAAGAGTTAGGTGTAGTTATGAAGTTAGATGTT 14640  
F V V S I G Y H Y K E L G V V M N L D V  
L L F L L V T I T K S \* V \* L \* T \* M L  
V C C F Y W L P L Q R V R C S Y E L R C

14641 GACACACACCGTTATCGTTTGTCTCTTAAAGATTACTTCTTTATGCAGCAGATCCTGCT 14700  
D T H R Y R L S L K D L L L Y A A D P A  
T H T V I V C L L K I Y F F M Q Q I L L  
\* H T P L S F V S \* R F T S L C S R S C

14701 ATGCACGTTGCATCTGCTAGTGCTCTGCTTGATTACGAAGTTGTTGTTTGTAGGTAGCT 14760  
M H V A S A S A L L D L R T C C F S V A  
C T L H L L V L C L I Y E L V V L V \* L  
Y A R C I C \* C S A \* F T N L L F \* C S

14761 GCCATTACAAGTGGTATAAAATTTCAAAGTGTAAACAGGTAAGTTTAAACCAAGACTTT 14820  
A I T S G I K F Q T V K P G N F N Q D F  
P L Q V V \* N F K L \* N Q V T L T K T F  
C H Y K W Y K I S N C K T R \* L \* P R L

14821 TACGAGTTTGTTAAAGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTGAAACAT 14880  
Y E F V K S K G L F K E G S T V D L K H  
T S L L K V K A C L K R V V Q L I \* N I  
L R V C \* K \* R L V \* R G \* Y S \* F E T

14881 TTTTCTTTACTCAAGATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAAT 14940  
F F F T Q D G N A A I T D Y N Y Y K Y N  
F S L L K M V M L Q L L I I I I I S I I  
F F L Y S R W \* C C N Y \* L \* L L \* V \*

14941 TTACCTACTATGGTTGATATTAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATAT 15000  
L P T M V D I K Q L L F V L E V V Y K Y  
Y L L W L I L S S Y C L Y \* K L F I N I  
F T Y Y G \* Y \* A V I V C I R S C L \* I

15001 TTTGAAATTTATGATGGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGAT 15060  
F E I Y D G G C I P A S Q V I V N N Y D  
L K F M M V V V Y Q H H K L L L I I M I  
F \* N L \* W W L Y T S I T S Y C \* \* L \*

15061 AAAAGTGTGGTTATCCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTA 15120  
K S A G Y P F N K F G K A R L Y Y E A L  
K V L V I H L I N L V K P D F I M R H Y  
\* K C W L S I \* \* I W \* S Q T L L \* G I

FIG. 2 CONT.

30/201

15121 TCATTGAGGAACAGAATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTA 15180  
S F E E Q N E I Y A Y T K R N V L P T L  
H L R N R M K F M H I L N V M F C P P \*  
I I \* G T E \* N L C I Y \* T \* C S A H L

15181 ACTCAAATGAATTTAAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGT 15240  
T Q M N L K Y A I S A K N R A R T V A G  
L K \* I \* N M L S V L R I E L A L \* Q V  
N S N E F K I C Y Q C \* E \* S S H C S R

15241 GTTCTATTCTTAGTACTATGACAGGCCGAATGTCCATCAAAATGTTTGAAGAGTATA 15300  
V S I L S T M T G R M F H Q K C L K S I  
F L F L V L \* Q A E C S I K N V \* R V \*  
C F Y S \* Y Y D R P N V P S K M F E E Y

15301 GCAGCTACCCGAGGTGTTCTGTTTATAGGAACCACTAAATTTATGGTGGTGGGAC 15360  
A A T R G V P V V I G T T K F Y G G W D  
Q L P E V F L L L \* E P L N F M V V G T  
S S Y P R C S C C Y R N H \* I L W W L G

15361 GATATGTTACGTCATCTTATAAAGGATGTTGACAACCTGTTCTTATGGGTGGGATTAT 15420  
D M L R H L I K D V D N P V L M G W D Y  
I C Y V I L \* R M L T T L F L W V G I I  
R Y V T S S Y K G C \* Q P C S Y G L G L

15421 CCTAAATGTGATCGTGCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTGGCC 15480  
P K C D R A M P N I L R I V S S L V L A  
L N V I V L C Q I F C V L L V V \* F W P  
S \* M \* S C Y A K Y F A Y C \* \* F S F G

15481 CGCAAACATGAATTTTGTGTTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGT 15540  
R K H E F C C S H G D R F Y R L A N E C  
A N M N F V V H M V I D F I A L R M N V  
P Q T \* I L L F T W \* \* I L S P C E \* M

15541 GCTCAAGTTTGTAGTGAAATAGTTATGTGTGGCGGTGCTATTATGTTAAGCCTGGTGGT 15600  
A Q V L S E I V M C G G C Y Y V K P G G  
L K F \* V K \* L C V A V A I M L S L V V  
C S S F E \* N S Y V W R L L L C \* A W W

15601 ACTAGCAGTGGTGATGCAACTACTGCTTTTGCTAATTCTGTTTTAATATATGTCAGGCT 15660  
T S S G D A T T A F A N S V F N I C Q A  
L A V V M Q L L L L L I L F L I Y V R L  
Y \* Q W \* C N Y C F C \* F C F \* Y M S G

FIG. 2 CONT.

31/201

15661 GTTACTGCTAATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGT 15720  
V T A N V C S L M A C N G H K I E D L S  
L L L M F V L L W P V M A I R L K I \* V  
C Y C \* C L F S Y G L \* W P \* D \* R F K

15721 ATACGCAATTTACAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTAT 15780  
I R N L Q K R L Y S N V Y R T D Y V D Y  
Y A I Y K N A Y T L M F I V Q I M L I I  
Y T Q F T K T L I L \* C L S Y R L C \* L

15781 ACATTTGTTAATGAGTATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGT 15840  
T F V N E Y Y E F L C K H F S M M I L S  
H L L M S I M N F Y V S I L V \* \* F \* V  
Y I C \* \* V L \* I F M \* A F \* Y D D F E

15841 GATGATGGTGTGTCTGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATA 15900  
D D G V V C Y N S D Y A S K G Y I A N I  
M M V L S V I T L I M L V R V I \* L I \*  
\* \* W C C L L \* L \* L C \* \* G L Y S \* Y

15901 AGTGTITTTCAACAAGTTTGTACTATCAGAATAATGTCTTTATGCTCTGAATCTAAATGT 15960  
S V F Q Q V L Y Y Q N N V F M S E S K C  
V F F N K F C T I R I M S L C L N L N V  
K C F S T S F V L S E \* C L Y V \* I \* M

15961 TGGGTTGAAAATGATATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTA 16020  
W V E N D I T N G P H E F C S Q H T M L  
G L K M I L L M V L M N F V P N I L C \*  
L G \* K \* Y Y \* W S S \* I L F P T Y Y V

16021 GTTAAGATAGATGGTGATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTTAGGA 16080  
V K I D G D Y V Y L P Y P D P S R I L G  
L R \* M V I M F I Y H I Q I L L E F \* E  
S \* D R W \* L C L F T I S R S F \* N F R

16081 GCTGGTTGTTTGTGATGATTTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTT 16140  
A G C F V D D L L K T D S V L L I E R F  
L V V L L M I Y \* R L T V F F \* \* S A L  
S W L F C \* \* F I E D \* Q C S F D R A L

16141 GTAAGTCTAGCTATAGATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAAA 16200  
V S L A I D A Y P L V H H E N E E Y Q K  
\* V \* L \* M L T L \* Y I M K M K N T K K  
C K S S Y R C L P F S T S \* K \* R I P K

FIG. 2 CONT.

32/201

16201 GTCTTTCGTGTATATTTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATC 16260  
V F R V Y L E Y I K K L Y N D L G T Q I  
S F V Y I \* N I \* K N C I M I L V L R S  
S L S C I F R I Y K K T V \* \* S W Y S D

16261 TTAGATAGTTATAGTGTATTTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCA 16320  
L D S Y S V I L S T C D G L K F T E E S  
\* I V I V L F \* V L V M V \* S L L K N H  
L R \* L \* C Y F K Y L \* W F K V Y \* R I

16321 TTTTACAAGAATATGTATTTAAAAAGTGCCGTGATGCAGAGTGTAGGTGCATGCCGTTGTT 16380  
F Y K N M Y L K S A V M Q S V G A C V V  
F T R I C I \* K V P \* C R V \* V H A L F  
I L Q E Y V F K K C R D A E C R C M R C

16381 TGTTCATCACAACTTCTTTGCGTTGTGGCAGTTGTATACGTAAGCCTTTGTTATGTTGT 16440  
C S S Q T S L R C G S C I R K P L L C C  
V H H K L L C V V A V V Y V S L C Y V V  
L F I T N F F A L W Q L Y T \* A F V M L

16441 AAATGTTGTTATGACCATGTTATGGCACTAATCATAAATATGTTTGTAGTGTCTCACCT 16500  
K C C Y D H V M A T N H K Y V L S V S P  
N V V M T M L W Q L I I N M F \* V S H L  
\* M L L \* P C Y G N \* S \* I C F E C L T

16501 TACGTTTGTAAATGCACCTAACTGTGATGTGAGTGTGTCACCAAATTATATTTGGGCGGT 16560  
Y V C N A P N C D V S D V T K L Y L G G  
T F V M H L T V M \* V M S P N Y I W A V  
L R L \* C T \* L \* C E \* C H Q I I F G R

16561 ATGTCTTACTATTGTGAAAACCATAAACCCATTATTCATTTAAGTTAGTTATGAATGGT 16620  
M S Y Y C E N H K P H Y S F K L V M N G  
C L T I V K T I N P I I H L S \* L \* M V  
Y V L L L \* K P \* T P L F I \* V S Y E W

16621 ATGGTCCTTGGTTTGTATAAACAATCTTGCACGGGTTACCTTATATAGATGATTTTAAT 16680  
M V F G L Y K Q S C T G S P Y I D D F N  
W S L V C I N N L A R V H L I \* M I L I  
Y G L W F V \* T I L H G F T L Y R \* F \*

16681 AAGATAGCTAGTTGTAAATGGACAGAAGTTGATGATTATGTTCTGGCAAATGAGTGTATT 16740  
K I A S C K W T E V D D Y V L A N E C I  
R \* L V V N G Q K L M I M F W Q M S V L  
\* D S \* L \* M D R S \* \* L C S G K \* V Y

FIG. 2 CONT.

33/201

16741 GAACGTTTAAAGTTATTTGCTGCAGAACTCAAAAGGCAACTGAAGAGGCTTTTAAACAA 16800  
E R L K L F A A E T Q K A T E E A F K Q  
N V \* S Y L L Q K L K R Q L K R L L N K  
\* T F K V I C C R N S K G N \* R G F \* T

16801 AGCTATGCTTCTGCTACCATTCAAGAGATTGTTAGTGATAGAGAAGTTATTTTGTGTTGG 16860  
S Y A S A T I Q E I V S D R E V I L C W  
A M L L L P F K R L L V I E K L F C V G  
K L C F C Y H S R D C \* \* \* R S Y F V L

16861 GAGACAGGTAAAGTTAAACCACCACTTAATAAAAATTATGTTTTCACAGGCTACCATTTT 16920  
E T G K V K P P L N K N Y V F T G Y H F  
R Q V K L N H H L I K I M F S Q A T I L  
G D R \* S \* T T T \* \* K L C F H R L P F

16921 ACTAGTACTGGTAAGACAGTTTTAGGTGAGTATGTTTTGATAAAGTGAATTAACAACTAAC 16980  
T S T G K T V L G E Y V F D K S E L T N  
L V L V R Q F \* V S M F L I K V N \* L T  
Y \* Y W \* D S F R \* V C F \* \* K \* I N \*

16981 GGTGTGTATTACCGCGCTACAACACTTATAAACTTTCTATAGGTGATGTTTTGTTTTTA 17040  
G V Y Y R A T T T Y K L S I G D V F V L  
V C I T A L Q L L I N F L \* V M F L F \*  
R C V L P R Y N Y L \* T F Y R \* C F C F

17041 ACATCACATTCTGTAGCTAGTTTAAAGTGCACCTACACTTGTCCCAAGAGAACTATGCT 17100  
T S H S V A S L S A P T L V P Q E N Y A  
H H I L \* L V \* V H L H L S H K R T M L  
N I T F C S \* F K C T Y T C P T R E L C

17101 AGTATAAGATTTTCTAGTGTTTATAGTGTTCATTGGTGTTCAAAATAATGTTGCTAAT 17160  
S I R F S S V Y S V P L V F Q N N V A N  
V \* D F L V F I V F H W C F K I M L L I  
\* Y K I F \* C L \* C S I G V S K \* C C \*

17161 TATCAGCACATTGGAATGAAACGTTATTGCACTGTTCAAGGTCCCCCTGGTACGGGAAG 17220  
Y Q H I G M K R Y C T V Q G P P G T G K  
I S T L E \* N V I A L F K V P L V R E S  
L S A H W N E T L L H C S R S P W Y G K

17221 TCTCATCTTGCTATAGGTCTAGCTGTTTATTACTACACAGCACGTGTAGTTTATACTGCT 17280  
S H L A I G L A V Y Y Y T A R V V Y T A  
L I L L \* V \* L F I T T Q H V \* F I L L  
V S S C Y R S S C L L L H S T C S L Y C

FIG. 2 CONT.



34/201

17281 GCTAGTCATGCTGCTGTAGATGCATTGTGTGAAAAAGCTTATAAGTTTTTAAATATTAAC 17340  
A S H A A V D A L C E K A Y K F L N I N  
L V M L L \* M H C V K K L I S F \* I L T  
C \* S C C C R C I V \* K S L \* V F K Y \*

17341 GATTGTACACGTATTATTCCTGCTAAAGTTCGTGTAGATTGTTATGATAAGTTTAAATTT 17400  
D C T R I I P A K V R V D C Y D K F K I  
I V H V L F L L K F V \* I V M I S L K L  
R L Y T Y Y S C \* S S C R L L \* \* V \* N

17401 AATGATACCACTTGTAAAGTATGTTTTTACCACAATAAATGCATTACCAGAGTTGGTTACA 17460  
N D T T C K Y V F T T I N A L P E L V T  
M I P L V S M F L P Q \* M H Y Q S W L Q  
\* \* Y H L \* V C F Y H N K C I T R V G Y

17461 GATATTGTTGTTGTGATGAAGTTAGTATGCTTACTAATTATGAATTGCTGTGTATAAAT 17520  
D I V V V D E V S M L T N Y E L S V I N  
I L L L L M K L V C L L I M N C L L \* M  
R Y C C C \* \* S \* Y A Y \* L \* I V C Y K

17521 GCTCGTATTAAAGCTAAACATTATGTATATATTGGAGATCCTGCTCAATTACCTGCACCA 17580  
A R I K A K H Y V Y I G D P A Q L P A P  
L V L K L N I M Y I L E I L L N Y L H H  
C S Y \* S \* T L C I Y W R S C S I T C T

17581 CGTGTGCTGTTGAGCAAGGGTTCTTTAGAACCTAGGCACCTCAATTCATTACTAAAATA 17640  
R V L L S K G S L E P R H F N S I T K I  
V C C \* A R V L \* N L G T S I L L L K \*  
T C A V E Q G F F R T \* A L Q F Y Y \* N

17641 ATGTGTTGTTTAGGTCCTGATATCTTTTTTGGGAAATGTTATAGGTGTCCTAAAGAAATT 17700  
M C C L G P D I F L G N C Y R C P K E I  
C V V \* V L I S F W E I V I G V L K K L  
N V L F R S \* Y L F G K L L \* V S \* R N

17701 GTAGAAACTGTTTCAGCATTGGTTTATGATAATAAACTCAAGGCTAAAAATGATAATAGT 17760  
V E T V S A L V Y D N K L K A K N D N S  
\* K L F Q H W F M I I N S R L K M I I V  
C R N C F S I G L \* \* \* T Q G \* K \* \* \*

17761 TCATTATGTTTTAAAGTATATTTTAAGGGACAGACAACATGAGAGTTCAAGTGCTGTA 17820  
S L C F K V Y F K G Q T T H E S S S A V  
H Y V L K Y I L R D R Q H M R V Q V L \*  
F I M F \* S I F \* G T D N T \* E F K C C

FIG. 2 CONT.

35/201

17821 AATATTCAACAGATATATCTAATTAGTAAATTTTAAAGCTAATCCAGTTTGGGAATAGT 17880  
N I Q Q I Y L I S K F L K A N P V W N S  
I F N R Y I \* L V N F \* K L I Q F G I V  
K Y S T D I S N \* \* I F K S \* S S L E \*

17881 GCTGTTTTTATTAGTCCTTATAATAGTCAGAATTATGTTGCTAAGCGTGTTTTAGGTGTT 17940  
A V F I S P Y N S Q N Y V A K R V L G V  
L F L L V L I I V R I M L L S V F \* V F  
C C F Y \* S L \* \* S E L C C \* A C F R C

17941 CAAACACAAACTGTAGATTCTGCTCAAGGTTCCGAATATGATTATGTTATATATTACAA 18000  
Q T Q T V D S A Q G S E Y D Y V I Y S Q  
K H K L \* I L L K V R N M I M L Y I H K  
S N T N C R F C S R F G I \* L C Y I F T

18001 ACAGCAGAAACAGCCCATTTCTGTTAATGTTAATCGATTATGTTGCCATAACTAGAGCC 18060  
T A E T A H S V N V N R F N V A I T R A  
Q Q K Q P I L L M L I D L M L P \* L E P  
N S R N S P F C \* C \* S I \* C C H N \* S

18061 AAGAAGGGCATTTTTTGTGTTATGAGTAATATGCAATTATTTGAATCTCTTAATTTTATT 18120  
K K G I F C V M S N M Q L F E S L N F I  
R R A F F V L \* V I C N Y L N L L I L L  
Q E G H F L C Y E \* Y A I I \* I S \* F Y

18121 ACTCTACCTTTAGATAAAATTCAAAATCAAACCTTACCTCGTTTGCAATGCACAACATAAT 18180  
T L P L D K I Q N Q T L P R L H C T T N  
L Y L \* I K F K I K L Y L V C I A Q L I  
Y S T F R \* N S K S N F T S F A L H N \*

18181 CTTTTTAAAGATTGTAGTAAAAGTTGCTTAGGTTATCATCCAGCGCATGCCCCCTCATT 18240  
L F K D C S K S C L G Y H P A H A P S F  
F L K I V V K V A \* V I I Q R M P P H F  
S F \* R L \* \* K L L R L S S S A C P L I

18241 TTAGCAGTTGATGATAAATATAAGGTTAATGAAAATTTGGCTGTTAAATTTAAATATTTGT 18300  
L A V D D K Y K V N E N L A V N L N I C  
\* Q L M I N I R L M K I W L \* I \* I F V  
F S S \* \* \* I \* G \* \* K F G C K F K Y L

18301 GAACCTGTTTTAACATATTCTCGTTTAATATCTCTTATGGGTTTTAAATTAGATTGACT 18360  
E P V L T Y S R L I S L M G F K L D L T  
N L F \* H I L V \* Y L L W V L N \* I \* L  
\* T C F N I F S F N I S Y G F \* I R F D

FIG. 2 CONT.

36/201

18361 CTTGATGGTTATTCCTAAATTGTTTATTACTAAAGATGAAGCCATTAAACGTGTTAGAGGT 18420  
L D G Y S K L F I T K D E A I K R V R G  
L M V I L N C L L L K M K P L N V L E V  
S \* W L F \* I V Y Y \* R \* S H \* T C \* R

18421 TGGGTTGGTTTTGATGTTGAGGGCGCTCATGCTACTCGCGAAAACATTGGAACAACTTT 18480  
W V G F D V E G A H A T R E N I G T N F  
G L V L M L R A L M L L A K T L E Q T F  
L G W F \* C \* G R S C Y S R K H W N K L

18481 CCACTGCAAAATAGGTTTTTCAACTGGTGTGGATTTTGTAGTTGAAGCTACTGGCTTTATTT 18540  
P L Q I G F S T G V D F V V E A T G L F  
H C K \* V F Q L V W I L \* L K L L A Y L  
S T A N R F F N W C G F C S \* S Y W L I

18541 GCTGAGAGAGATTGTTATACTTTTAAAAAACTGTAGCTAAAGCTCCTCCTGGTGAAAAA 18600  
A E R D C Y T F K K T V A K A P P G E K  
L R E I V I L L K K L \* L K L L L V K N  
C \* E R L L Y F \* K N C S \* S S S W \* K

18601 TTTAAACATTTAATACCCCTTATGTCAAAAGGTCAAAAGTGGGATATTGTTAGAAATAGA 18660  
F K H L I P L M S K G Q K W D I V R I R  
L N I \* Y P L C Q K V K S G I L L E L E  
I \* T F N T P Y V K R S K V G Y C \* N \*

18661 ATTGTTCAAATGTTATCTGATTATCTTTTAGACCTTTCTGATAGTGTAGTATTTATTACT 18720  
I V Q M L S D Y L L D L S D S V V F I T  
L F K C Y L I I F \* T F L I V \* Y L L L  
N C S N V I \* L S F R P F \* \* C S I Y Y

18721 TGGTCTGCCAGTTTTGAACCTACTTGTTTAAGGTATTTTGCTAAATTAGGCAGAGAGCTT 18780  
W S A S F E L T C L R Y F A K L G R E L  
G L P V L N L L V \* G I L L N \* A E S L  
L V C Q F \* T Y L F K V F C \* I R Q R A

18781 AATTGTAATGTGTGTTCTAATCGTGCTACATGCTACAATTCTAGAACTGCTTATTATGGT 18840  
N C N V C S N R A T C Y N S R T G Y Y G  
I V M C V L I V L H A T I L E L V I M V  
\* L \* C V F \* S C Y M L Q F \* N W L L W

18841 TGTGGCGCCATAGTTATACTTGTGATTATGTGTATAATCCACTTATTGTAGATATACAA 18900  
C W R H S Y T C D Y V Y N P L I V D I Q  
V G A I V I L V I M C I I H L L \* I Y N  
L L A P \* L Y L \* L C V \* S T Y C R Y T

FIG. 2 CONT.

37/201

18901 CACTGGGGTTATACAGGTTCTTTAACTAGTAATCAGCATATAATTTGTAATGTACATAAA 18960  
Q W G Y T G S L T S N H D I I C N V H K  
S G V I Q V L \* L V I T I \* F V M Y I K  
T V G L Y R F F N \* \* S R Y N L \* C T \*

18961 GGTGCACATGTTGCGTCAGCTGATGCAATTATGACTCGTTGTTAGCAATCTATGATTGT 19020  
G A H V A S A D A I M T R C L A I Y D C  
V H M L R Q L M Q L \* L V V \* Q S M I V  
R C T C C V S \* C N Y D S L F S N L \* L

19021 TTTTGTAATCTGTGAATTGGAATTTAGAGTATCCAATAATTTCTAATGAGGTCAGTATA 19080  
F C K S V N W N L E Y P I I S N E V S I  
F V N L L I G I \* S I Q \* F L M R S V \*  
F L \* I C \* L E F R V S N N F \* \* G Q Y

19081 AATACATCTTGTAGGTTATTGCAGCGTGTCTGCTTAAAGCTGCCATGCTATGTAATAGA 19140  
N T S C R L L Q R V M L K A A M L C N R  
I H L V G Y C S V S C L K L P C Y V I D  
K Y I L \* V I A A C H A \* S C H A M \* \*

19141 TACAACCTTATGTTATGACATAGGCAATCCTAAAGGTTTAGCTTGTGTCAAAGATTATGAA 19200  
Y N L C Y D I G N P K G L A C V K D Y E  
T T Y V M T \* A I L K V \* L V S K I M N  
I Q L M L \* H R Q S \* R F S L C Q R L \*

19201 TTTAAATTTTATGATGCTTTTCCTGTAGCCAGTCTGTAAACAGTTATTTTATGCTAT 19260  
F K F Y D A F P V A K S V K Q L F Y V Y  
L N F M M L F L \* P S L L N S Y F M S M  
I \* I L \* C F S C S Q V C \* T V I L C L

19261 GATGTGCATAAAGATAATTTTAAAGATGGTTTATGTATGTTTGGAAATTGTAATGTTGAT 19320  
D V H K D N F K D G L C M F W N C N V D  
M C I K I I L K M V Y V C F G I V M L I  
\* C A \* R \* F \* R W F M Y V L E L \* C \*

19321 AAATATCCATCTAATTCAATTGTTTGTAGATTTGACACTCGAGTGTTAAATAAATTAAAC 19380  
K Y P S N S I V C R F D T R V L N K L N  
N I H L I Q L F V D L T L E C \* I N \* T  
\* I S I \* F N C L \* I \* H S S V K \* I K

19381 CTTCTGGATGTAATGGTGGTAGTTTGTATGTTAATAAACATGCATCCATACTAATCCT 19440  
L P G C N G G S L Y V N K H A F H T N P  
F L D V M V V V C M L I N M H S I L I L  
P S W M \* W W \* F V C \* \* T C I P Y \* S

FIG. 2 CONT.

38/201

19441 TTTACTAGAACTGTTTTTGAAAATCTTAAGCCTATGCCTTTTTTCTATTATTCAGATACG 19500  
F T R T V F E N L K P M P F F Y Y S D T  
L L E L F L K I L S L C L F S I I Q I R  
F Y \* N C E \* K S \* A Y A F F L L F R Y

19501 CCTTGTGTGTACGTAGATGGTTTGAATCTAAACAAGTTGATTACGTTCCCTTTAAGAAGC 19560  
P C V Y V D G L E S K Q V D Y V P L R S  
L V C T \* M V \* N L N K L I T F L \* E A  
A L C V R R W F R I \* T S \* L R S F K K

19561 GCCACTTGTATCACACGGTGTAATCTAGGTGGAGCTGTTTGTTCAAAGCATGCTGAAGAA 19620  
A T C I T R C N L G G A V C S K H A E E  
P L V S H G V I \* V E L F V Q S M L K N  
R H L Y H T V \* S R W S C L F K A C \* R

19621 TATTGTAACCTACCTTGAGTCTTATAATATAGTTACTACAGCAGGCTTTACTTTTTGGGTT 19680  
Y C N Y L E S Y N I V T T A G F T F W V  
I V T T L S L I I \* L L Q Q A L L F G F  
I L \* L P \* V L \* Y S Y Y S R L Y F L G

19681 TATAAGAATTTTGATTTTTATAATTTATGGAACACTTTTACTACGTTACAGAGTTTAGAA 19740  
Y K N F D F Y N L W N T F T T L Q S L E  
I R I L I F I I Y G T L L L R Y R V \* K  
L \* E F \* F L \* F M E H F Y Y V T E F R

19741 AACGTAATATATAACTTGGTTAATGTTGGTCATTATGATGGACGTACAGGTGAATTACCT 19800  
N V I Y N L V N V G H Y D G R T G E L P  
T \* Y I T W L M L V I M M D V Q V N Y L  
K R N I \* L G \* C W S L \* W T Y R \* I T

19801 TGTGCTATTATGAATGACAAAGTTGTTGTTAAGATTAATAATGTAGATACTGTTATTTTT 19860  
C A I M N D K V V V K I N N V D T V I F  
V L L \* M T K L L L R L I M \* I L L F L  
L C Y Y E \* Q S C C \* D \* \* C R Y C Y F

19861 AAAAAATAACATCATTTCTACTAATATAGCTGTTGAATTGTTTACAAAACGTAGTATC 19920  
K N N T S F P T N I A V E L F T K R S I  
K I I H H F L L I \* L L N C L Q N V V S  
\* K \* Y I I S Y \* Y S C \* I V Y K T \* Y

19921 CGGCACCACCTGAACCTAAGATTCTTAGAAAATTGAACATTGATATTTGTTGGAAGCAT 19980  
R H H P E L K I L R N L N I D I C W K H  
G T T L N L R F L E I \* T L I F V G S M  
P A P P \* T \* D S \* K F E H \* Y L L E A

FIG. 2 CONT.

## 39/201

19981 GTCCTGTGGGATTATGTTAAAGATAGTTTGTGTTTGTAGTTCCACTTATGGTGTGTTGTAAA 20040  
V L W D Y V K D S L F C S S T Y G V C K  
S C G I M L K I V C F V V P L M V F V N  
C P V G L C \* R \* F V L \* F H L W C L \*

20041 TACACAGATTTGAAGTTCATCGAAAATTTGAATATACTTTTTGATGGTCGTGACACTGGC 20100  
Y T D L K F I E N L N I L F D G R D T G  
T Q I \* S S S K I \* I Y F L M V V T L A  
I H R F E V H R K F E Y T F \* W S \* H W

20101 GCTTTAGAAGCTTTTAGAAAAGCAAGAATGGTGTGTTTATTAGTACTGAAAAATTAAGT 20160  
A L E A F R K A R N G V F I S T E K L S  
L \* K L L E K Q E M V F L L V L K N \* V  
R F R S F \* K S K K W C F Y \* Y \* K I K

20161 AGGTTATCAATGATTAAAGGTCCGCAACGAGCTGATTAAATGGTGTGATTGTGGATAAA 20220  
R L S M I K G P Q R A D L N G V I V D K  
G Y Q \* L K V R N E L I \* M V \* L W I K  
\* V I N D \* R S A T S \* F K W C D C G \*

20221 GTTGGAGAACTCAAAGTTGAGTTTGGTTCGCTATGAGAAAAGATGGTGACGATGTTATC 20280  
V G E L K V E F W F A M R K D G D D V I  
L E N S K L S F G S L \* E K M V T M L S  
S W R T Q S \* V L V R Y E K R W \* R C Y

20281 TTCAGCCGAACAGACAGCCTATGCTCAAGCCATTACTGGAGCCACAAGGTAATCTAGGT 20340  
F S R T D S L C S S H Y W S P Q G N L G  
S A E Q T A Y A Q A I T G A H K V I \* V  
L Q P N R Q P M L K P L L E P T R \* S R

20341 GGTAATTGCGCGGTAATGTCATTGGTAATGATGCTCTAACACGTTTACTATCTTTACT 20400  
G N C A G N V I G N D A L T R F T I F T  
V I A R V M S L V M M L \* H V L L S L L  
W \* L R G \* C H W \* \* C S N T F Y Y L Y

20401 CAGAGTCGTGATTGTCAAGTTTGAACCTCGCTCAGATTTAGAACGGGATTTATTGAT 20460  
Q S R V L S S F E P R S D L E R D F I D  
R V V Y C Q V L N L A Q I \* N G I L L I  
S E S C I V K F \* T S L R F R T G F Y \*

20461 ATGGATGATAATCTGTTTATTGCTAAATATGGTTTAGAAGACTATGCATTGATCATATA 20520  
M D D N L F I A K Y G L E D Y A F D H I  
W M I I C L L L N M V \* K T M H L I I \*  
Y G \* \* S V Y C \* I W F R R L C I \* S Y

FIG. 2 CONT.

40/201

20521 GTTTATGGTAGTTTAAACCATAAAGTTATAGGAGGTTTGCATTGCTTATAGGCTTATTT 20580  
V Y G S F N H K V I G G L H L L I G L F  
F M V V L T I K L \* E V C I C L \* A Y F  
S L W \* F \* P \* S Y R R F A F A Y R L I

20581 CGTAGGAAAAAATCTAATTTGTTAATTCAGAGTTTTTACAGTATGATTCTAGTATT 20640  
R R K K K S N L L I Q E F L Q Y D S S I  
V G K K N L I C \* F K S F Y S M I L V F  
S \* E K K I \* F V N S R V F T V \* F \* Y

20641 CATTCATATTTTATTACTGATCAGGAGTGTTGGTAGTAGTAAGAGTGTTTGTACAGTTATT 20700  
H S Y F I T D Q E C G S S K S V C T V I  
I H I L L L I R S V V V V R V F V Q L L  
S F I F Y Y \* S G V W \* \* \* E C L Y S Y

20701 GATTTATTATTAGATGATTTTGTTCATTGTTAAGTCATTAAATTTGAGTTGTGTTAGT 20760  
D L L L D D E V S I V K S L N L S C V S  
I Y Y \* M I L F L L L S H \* I \* V V L V  
\* F I I R \* F C F Y C \* V I K F E L C \*

20761 AAAGTTGTTAATATTAAATGTTGATTTTAAAGGATTTTCATTTATGTTGGTGTAATGAT 20820  
K V V N I N V D F K D F Q F M L W C N D  
K L L I L M L I L R I F N L C C G V M I  
\* S C \* Y \* C \* F \* G F S I Y V V V \* \*

20821 AATAAAATTATGACTTTTATCCTAAATGCAAGCCACTAATGATTGGAAACCTGGCTAT 20880  
N K I M T F Y P K M Q A T N D W K P G Y  
I K L \* L F I L K C K P L M I G N L A I  
\* \* N Y D F L S \* N A S H \* \* L E T W L

20881 TCTATGCCTGTTTGTATAAGTATTTGAATGTTCCATTAGAGAGAGTCTCTTTATGGAAT 20940  
S M P V L Y K Y L N V P L E R V S L W N  
L C L F C I S I \* M F H \* R E S L Y G I  
F Y A C F V \* V F E C S I R E S L F M E

20941 TATGGTAAACCTATTAATTTGCCTACAGGCTGATGATGAATGTTGCTAAGTACACTCAA 21000  
Y G K P I N L P T G C M M N V A K Y T Q  
M V N L L I C L Q A V \* \* M L L S T L N  
L W \* T Y \* F A Y R L Y D E C C \* V H S

21001 TTATGTCAGTATTTGAATACTACAACATTAGCTGTTCTGTTAATATGCGTGTTTTACAT 21060  
L C Q Y L N T T T L A V P V N M R V L H  
Y V S I \* I L Q H \* L F L L I C V F Y I  
I M S V F E Y Y N I S C S C \* Y A C F T

FIG. 2 CONT.

41/201

21061 TTAGGTGCAGGCTCTGATAAAGAAGTAGCTCCAGGTTCTGCTGTTTTAAGACAGTGGTTA 21120  
 L G A G S D K E V A P G S A V L R Q W L  
 \* V Q G L I K K \* L Q V L L F \* D S G Y  
 F R C R V \* \* R S S S R F C C F K T V V

21121 CCATCTGGTAGTATTCTTGTAGATAATGATTTAAACCCATTGTTAGCGATAGTTAGTT 21180  
 P S G S I L V D N D L N P F V S D S L V  
 H L V V F L \* I M I \* T H L L A I V \* L  
 T I W \* Y S C R \* \* F K P I C \* R \* F S

21181 ACTTATTTTGGAGATTGTATGACTTTACCATTTGATTCATTGGGATTTGATAATATCT 21240  
 T Y F G D C M T L P F D C H W D L I I S  
 L I L E I V \* L Y H L I V I G I \* \* Y L  
 Y L F W R L Y D F T I \* L S L G F D N I

21241 GATATGTATGATCCTCTTACTAAAAATATTGGTGATTATAATGTGAGTAAGGATGGGTTT 21300  
 D M Y D P L T K N I G D Y N V S K D G F  
 I C M I L L L K I L V I I M \* V R M G F  
 \* Y V \* S S Y \* K Y W \* L \* C E \* G W V

21301 TTACTTACATTTGTCAATTAATTCGTGATAAATTATCTTTGGGTGGTAGTGTAGCTATA 21360  
 F T Y I C H L I R D K L S L G G S V A I  
 L L T F V I \* F V I N Y L W V V V \* L \*  
 F Y L H L S F N S \* \* I I F G W \* C S Y

21361 AAAATTACAGAGTTTCTTGAATGCTGATTTATATAAATTAATGAGTTGTTTGCATT 21420  
 K I T E F S W N A D L Y K L M S C F A F  
 K L Q S F L G M L I Y I N \* \* V V L H F  
 K N Y R V F L E C \* F I \* I N E L F C I

21421 TGGACAGTTTTTGTACTAATGTAAATGCTTCTTCTAGTGAAGGGTTTTTAATAGGTATA 21480  
 W T V F C T N V N A S S S E G F L I G I  
 G Q F F V L M \* M L L L V K G F \* \* V \*  
 L D S F L Y \* C K C F F \* \* R V F N R Y

21481 AATTACCTGGGTAAATCTTCTTTGAAATAGATGGCAATGTTATGCATGCTAACTATTG 21540  
 N Y L G K S S F E I D G N V M H A N Y L  
 I T W V N L L L K \* M A M L C M L T I C  
 K L P G \* I F F \* N R W Q C Y A C \* L F

21541 TTTTGGAGAAATAGTACAACATGGAATGGCGGTGCTTATAGTTTATTTGATATGACTAAA 21600  
 F W R N S T T W N G G A Y S L F D M T K  
 F G E I V Q H G M A V L I V Y L I \* L N  
 V L E K \* Y N M E W R C L \* F I \* Y D \*

FIG. 2 CONT.



42/201

21601 TTTTCTTTGAAATGGGCTGGCACTGCTGTTGTTAATTTAAGACCAGATCAATTAATGAT 21660  
F S L K L A G T A V V N L R P D Q L N D  
F L \* N W L A L L L L I \* D Q I N \* M I  
I F F E I G W H C C C \* F K T R S I K \*

21661 TTAGTTTATTCTCTTATTGAAAGAGGTAAATTATTAGTTCGCGATACGCGTAAAGAGATT 21720  
L V Y S L I E R G K L L V R D T R K E I  
\* F I L L L K E V N Y \* F A I R V K R F  
F S L F S Y \* K R \* I I S S R Y A \* R D

21721 TTTGTTGGFGATAGTCTTGTAATACTTGTTAGATCTCATTAAATCTAAACTATGTTAAT 21780  
F V G D S L V N T C \* I S L N L N Y V N  
L L V I V L \* I L V R S H \* I \* T M L I  
F C W \* \* S C K Y L L D L I K S K L C \*

21781 TATTTTTTTATTTTTTTTATTCTGTTATGGTTTTAATGAACCTCTTAATGTTGTGCTCA 21840  
Y F F I F L F L L W F \* \* T S \* C C V S  
I F L F F Y F C Y G F N E P L N V V S H  
L F F Y F F I S V M V L M N L L M L C L

21841 TTTAAACCATGACTGGTTTTTATTGGTGATAGTCGTTCTGATTGTAACCATATTAATAA 21900  
F K P \* L V F I W \* \* S F \* L \* P Y \* \*  
L N H D W F L F G D S R S D C N H I N N  
I \* T M T G F Y L V I V V L I V T I L I

21901 TTTAAAAATTAAAAATTTTGATTATTGGATATTCACCCCTAGTTTGTGCAACAATGGTAA 21960  
F K N \* K F \* L F G Y S P \* F V Q Q W \*  
L K I K N F D Y L D I H P S L C N N G K  
I \* K L K I L I I W I F T L V C A T M V

21961 GATTTCATCTAGTGCCGGTGATTCTATTTTTTAAGAGTTTTTCATTTCACTCGATTTTATAA 22020  
D F I \* C R \* F Y F \* E F S F H S I L \*  
I S S S A G D S I F K S F H F T R F Y N  
R F H L V P V I L F L R V F I S L D F I

22021 TTACACTGGCGAAGGTGATCAATTATTTTTTATGAGGGTGTTAATTTTAATCCTTATCA 22080  
L H W R R \* S N Y F L \* G C \* F \* S L S  
Y T G E G D Q I I F Y E G V N F N P Y H  
I T L A K V I K L F F M R V L I L I L I

22081 TAGATTTAAGTGTTTTCCTAATGGTAGTAATGATGTATGGCTTCTTAACAAGGTAAGATT 22140  
\* I \* V F S \* W \* \* \* C M A S \* Q G K I  
R F K C F P N G S N D V W L L N K V R F  
I D L S V F L M V V M M Y G F L T R \* D

FIG. 2 CONT.

43/201

22141 TTATCGTGCCTTATATCTAATATGGCCTTTTCGTTATCTTACTTTTGGTGATATTCC 22200  
 L S C L I F \* Y G L F S L S Y F C \* Y S  
 Y R A L Y S N M A F F R Y L T F V D I P  
 F I V P Y I L I W P F F V I L L L L I F

22201 TTATAATGTTTCTCTTTCTAAGTTAATTCTTGTAAGTGATATTTATCACTTAACAA 22260  
 L \* C F S F \* V \* F L \* K \* Y F I T \* Q  
 Y N V S L S K F N S C K S D I L S L N N  
 L I M F L F L S L I L V K V I F Y H L T

22261 TCCTATTTTATTAATTATCTAAGGAAGTTATTTTACTTTATAGGTGTTCTCTTTA 22320  
 S Y F Y \* L F \* G S L F Y F I R L F S L  
 P I F I N Y S K E V Y F T L L G C S L Y  
 I L F L L I I L R K F I L L Y \* V V L F

22321 TTTAGTACCGCTTTCGCTTTTAAATCTAAGTTAGTCAGTACTATTATAACATAGATAC 22380  
 F S T A L P F \* I \* L \* S V L L \* H R Y  
 L V P L C L F K S N F S Q Y Y Y N I D T  
 I \* Y R F A F L N L T L V S T I I T \* I

22381 TGGCTCTGTTTATGGTTTCTAATGTTGTTTATCCTGATTTAGACTGTATTTATATTC 22440  
 W L C L W F F \* C C L S \* F R L Y L Y F  
 G S V Y G F S N V V Y P D L D C I Y I S  
 L A L F M V F L M L F I L I \* T V F I F

22441 TCTTAAACCAGGTTCTTATAAAGTTCCACCACTGCACCTTTTATCCTTACCTACTAA 22500  
 S \* T R F L \* S F H H C T F F I L T Y \*  
 L K P G S Y K V S T T A P F L S L P T K  
 L L N Q V L I K F P P L H L F Y P Y L L

22501 AGCTCTCTGTTTGTAAATCTAACAATTTGTACCTGTACAGGTTGTTGATTCTAGATG 22560  
 S S L F \* \* I \* T I C T C T G C \* F \* M  
 A L C F D K S K Q F V P V Q V V D S R W  
 K L S V L I N L N N L Y L Y R L L I L D

22561 GAACAACGAGCGTGCCTCAGATATTTCTTTATCTGTTGCATGTCAATTGCCATATTGTTA 22620  
 E Q R A C L R Y F F I C C M S I A I L L  
 N N E R A S D I S L S V A C Q L P Y C Y  
 G T T S V P Q I F L Y L L H V N C H I V

22621 TTTTCGCAATTCTCTGCTAATTATGTTGGCAAGTATGATATTAACCACGGTGATAGTGG 22680  
 F S Q F F C \* L C W Q V \* Y \* P R \* \* W  
 F R N S S A N Y V G K Y D I N H G D S G  
 I F A I L L L I M L A S M I L T T V I V

FIG. 2 CONT.

44/201

22681 TTTTATTTCTATTTTATCTGGTCTTTTATATAATGTTTCTTGTATTTCATATTATGGTGT 22740  
F Y F Y F I W S F I \* C F L Y F I L W C  
F I S I L S G L L Y N V S C I S Y Y G V  
V L F L F Y L V F Y I M F L V F H I M V

22741 ATTTTATATGATAATTTTACATCCATTGGCCCTATTATTCTTTTGGTAGGTGTCCTAC 22800  
I F I \* \* F Y I H L A L L F F W \* V S Y  
F L Y D N F T S I W P Y Y S F G R C P T  
Y F Y M I I L H P F G P I I L L V G V L

22801 ATCTTCTATTATTAACATCCAATTTGTGTTTATGATTTTTCCTATTATTTTACAAGG 22860  
I F Y Y \* T S N L C L \* F F A Y Y F T R  
S S I I K H P I C V Y D F L P I I L Q G  
H L L L L N I Q F V F M I F C L L F Y K

22861 TATTTTATTATGTTTAGCTTTACTTTTGTGTTTCTATTTTGTATATAACGA 22920  
Y F I M F S F T F C C F S I I F V I \* R  
I L L C L A L L F V V F L L F L L Y N D  
V F Y Y V \* L Y F L L F F Y Y F C Y I T

22921 TAAATCTCATTAAATCTAAACATGTTATTAATTATTTTATTTTGCCTACAACATTAGCT 22980  
\* I S L N L N M L L I I F I L P T T L A  
K S H \* I \* T C Y \* L F L F C L Q H \* L  
I N L I K S K H V I N Y F Y F A Y N I S

22981 GTTATAGGTGATTTTAATTGTTACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCT 23040  
V I G D F N C T N F A I N D L N T T V P  
L \* V I L I V L I L L L M I \* T P Q F L  
C Y R \* F \* L Y \* F C Y \* \* F K H H S S

23041 CGCATAAGTGAGTATGTTTGGATGTTTCTTATGGTTTGGGTACATATTATATACTTGAT 23100  
R I S E Y V V D V S Y G L G T Y Y I L D  
A \* V S M L W M F L M V W V H I I Y L I  
S H K \* V C C G C F L W F G Y I L Y T \*

23101 CGTGTFTTTTAAATACTACTATATTATTACTGTTATTTCCCTAAATCTGGTGCCAAT 23160  
R V Y L N T T I L F T G Y F P K S G A N  
V F I \* I L L Y Y L L V I S L N L V P I  
S C L F K Y Y Y I I Y W L F P \* I W C Q

23161 TTTAGGGATCTATCTTTAAAAGGTACTACATATTGAGTACTCTTTGGTATCAGAAACCC 23220  
F R D L S L K G T T Y L S T L W Y Q K P  
L G I Y L \* K V L H I \* V L F G I R N P  
F \* G S I F K R Y Y I F E Y S L V S E T

FIG. 2 CONT.

45/201

23221 TTTTATCTGATTTAATAATGGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTT 23280  
F L S D F N N G I F S R V K N T K L Y V  
F Y L I L I M V F F L E L R I L S C M L  
L F I \* F \* \* W Y F F \* S \* E Y \* V V C

23281 AATAAACTTTGTATAGTGAGTTTACTACTATAGTTATAGGTAGTGTATTTATTAACAAC 23340  
N K T L Y S E F S T I V I G S V F I N N  
I K L C I V S L V L \* L \* V V F L L T T  
\* \* N E V \* \* V \* Y Y S Y R \* C F Y \* Q

23341 TCTTACTATTTGTTGTTCAACCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATATAC 23400  
S Y T I V V Q P H N G V L E I T A C Q Y  
L I L L L F N L I M V F W R L Q L V N T  
L L Y Y C C S T S \* W C F G D Y S L S I

23401 ACTATGTGTGAGTATCCTCATACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCT 23460  
T M C E Y P H T I C K S K G S S R N E S  
L C V S I L I L F V N L K V V L V M N L  
H Y V \* V S S Y Y L \* I \* R \* F S \* \* I

23461 TGGCATTGTTGATAAATCTGAACCTTTGTGTCGTTCAGAAAAATTTTACTTATAATGTT 23520  
W H F D K S E P L C L F K K N F T Y N V  
G I L I N L N L C V C S R K I L L I M F  
L A F \* \* I \* T F V S V Q E K F Y L \* C

23521 TCTACAGATTGGTTGTATTTTCATTTTATCAAGAACGTGGCACTTTTATGCTTATTAT 23580  
S T D W L Y F H F Y Q E R G T F Y A Y Y  
L Q I G C I F I F I K N V A L F M L I M  
F Y R L V V F S F L S R T W H F L C L L

23581 GCTGATTCTGGCATGCCTACTACTTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCT 23640  
A D S G M P T T F L F S L Y L G T L L S  
L I L A C L L L F Y L V C I L V L F Y L  
C \* F W H A Y Y F F I \* F V S W Y S F I

23641 CATTATTATGTTTGCCTTTGACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACT 23700  
H Y Y V L P L T C N A I S S N T D N E T  
I I M F C L \* L V M L Y L L I L I M R L  
S L L C F A F D L \* C Y I F \* Y \* \* \* D

23701 TTACAATATTGGGTCACACCTTTGTCTAAACGCCAATATCTTCTTAAATTGACAACCGT 23760  
L Q Y W V T P L S K R Q Y L L K F D N R  
Y N I G S H L C L N A N I F L N L T T V  
F T I L G H T F V \* T P I S S \* I \* Q P

FIG. 2 CONT.

46/201

23761 GGTGTTATTACTAATGCTGTTGATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAA 23820  
G V I T N A V D C S S S F F S E I Q C K  
V L L L M L L I V L V V S L A R F N V K  
W C Y Y \* C C \* L F \* \* F L \* R D S M \*

23821 ACTAAATCTTTATTACCTAATACTGGTGGTTTATGACTTATCTGGTTTACTGTTAAGCCT 23880  
T K S L L P N T G V Y D L S G F T V K P  
L N L Y Y L I L V F M T Y L V L L L S L  
N \* I F I T \* Y W C L \* L I W F Y C \* A

23881 GTTGCAACTGTACATCGTCGTATTCCTGATTACCTGATTGTGACATTGATAAATGGCCTT 23940  
V A T V H R R I P D L P D C D I D K W L  
L Q L Y I V V F L I Y L I V T L I N G L  
C C N C T S S Y S \* F T \* L \* H \* \* M A

23941 AACAAATTTAATGTACCCTCACCTCTTAATTGGGAACGTAAAATTTTCTAATGCAAC 24000  
N N F N V P S P L N W E R K I F S N C N  
T I L M Y P H L L I G N V K F F L I A T  
\* Q F \* C T L T S \* L G T \* N F F \* L Q

24001 TTTAATTTGAGTACTTTGCTTCGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTT 24060  
F N L S T L L R L V H T D S F S C N N F  
L I \* V L C F V \* F I L I L F L V I I L  
L \* F E Y F A S F S S Y \* F F F L \* \* F

24061 GATGAATCTAAGATATATGGTAGTTGTTTAAAGAGTATTGTTTATAGATAAATTGCCATA 24120  
D E S K I Y G S C F K S I V L D K F A I  
M N L R Y M V V V L R V L F \* I N L P Y  
\* \* I \* D I W \* L F \* E Y C F R \* I C H

24121 CCCAACTCCAGACGATCTGATTTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAAT 24180  
P N S R R S D L Q L G S S G F L Q S S N  
P T P D D L I C S W A V L V F C N L L I  
T Q L Q T I \* F A V G Q F W F S A I F \*

24181 TATAAAATTGACACTACTTCTAGTTCTTGTCGAATTGTATTATAGTTTGCCTGCAATTAAT 24240  
Y K I D T T S S S C Q L Y Y S L P A I N  
I K L T L L L V L V N C I I V C L Q L M  
L \* N \* H Y F \* F L S I V L \* F A C N \*

24241 GTTACTATTAATAATTATAATCCTTCTTCTTGAATAGAAGGTATGGTTTAAATAATTTT 24300  
V T I N N Y N P S S W N R R Y G F N N F  
L L L I I I I L L L G I E G M V L I I L  
C Y Y \* \* L \* S F F L E \* K V W F \* \* F

FIG. 2 CONT.

47/201

24301 AATTTGAGCTCTCATAGTGTGTTTACTCACGTTATTGTTTTCTGTTAATAATACTTTT 24360  
N L S S H S V V Y S R Y C F S V N N T F  
I \* A L I V L F T H V I V F L L I I L F  
\* F E L S \* C C L L T L L F F C \* \* Y F

24361 TGTCTTGTGCTAAACCTTCTTTTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCT 24420  
C P C A K P S F A S S C K S H K P P S A  
V L V L N L L L L Q V A R V I N H L L L  
L S L C \* T F F C F K L Q E S \* T T F C

24421 TCCTGTCCTATTGGTACTAATTATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACT 24480  
S C P I G T N Y R S C E S T T V L D H T  
P V L L V L I I V L V R V L L Y S T T L  
F L S Y W Y \* L S F L \* E Y Y C T R P H

24481 GACTGGTGTAGGTGTTCTTGTGTTTACCTGATCCTATAACTGCTTATGACCCTAGGTCTTGT 24540  
D W C R C S C L P D P I T A Y D P R S C  
T G V G V L V Y L I L \* L L M T L G L V  
\* L V \* V F L F T \* S Y N C L \* P \* V L

24541 TCTCAAAAAAGTCTCTGGTTGGTGGTGAACATTGTGCAGGGTTCGGTGTGATGAA 24600  
S Q K K S L V G V G E H C A G F G V D E  
L K K S L W L V L V N I V Q G S V L M K  
F S K K V S G W C W \* T L C R V R C \* \*

24601 GAAAAGTGTGGTGTATGGATGGATCATATAATGTTTCTTGTCTTGTAGTACTGATGCC 24660  
E K C G V L D G S Y N V S C L C S T D A  
K S V V Y W M D H I M F L V F V V L M P  
R K V W C I G W I I \* C F L S L \* Y \* C

24661 TTCTAGGTGGTCTTATGACACTTCCGTCAGTAACAACCGTTGTAATATTTTCTAAT 24720  
F L G W S Y D T C V S N N R C N I F S N  
F \* V G L M T L A S V T T V V I F F L I  
L S R L V L \* H L R Q \* Q P L \* Y F F \*

24721 TTTATTTTAAATGGTATCAATAGTGGTACCACTTGTCTAATGATTTATTGCAGCCTAAT 24780  
F I L N G I N S G T T C S N D L L Q P N  
L F \* M V S I V V P L V L M I Y C S L I  
F Y F K W Y Q \* W Y H L F \* \* F I A A \*

24781 ACTGAAGTTTTACTGATGTTTGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGT 24840  
T E V F T D V C V D Y D L Y G I T G Q G  
L K F L L M F V L I T T F M V L Q D K V  
Y \* S F Y \* C L C \* L R P L W Y Y R T R

FIG. 2 CONT.

48/201

24841 ATTTTAAAGAAGTTTCTGCTGTTTATTATAATAGTTGGCAAATCTTTGTATGATTCT 24900  
I F K E V S A V Y Y N S W Q N L L Y D S  
F L K K F L L F I I I V G K I F C M I L  
Y F \* R S F C C L L \* \* L A K S F V \* F

24901 AATGGCAACATTATTGGTTTAAAGATTTTGTACTAATAAAACATATAATATTTCCCT 24960  
N G N I I G F K D F V T N K T Y N I F P  
M A T L L V L K I L L L I K H I I F S L  
\* W Q H Y W F \* R F C Y \* \* N I \* Y F P

24961 TGTATGTCAGGAAGAGTTTCTGCTGCTTTTCATCAAATGCTTCCTCTTTGGCTTTACTT 25020  
C Y A G R V S A A F H Q N A S S L A L L  
V M Q E E F L L L F I K M L P L W L Y F  
L L C R K S F C C F S S K C F L F G F T

25021 TATCGTAATTTAAATGTAGCTATGTTTGAATAATATTTCTTTAACTACTCAGCCATAT 25080  
Y R N L K C S Y V L N N I S L T T Q P Y  
I V I \* N V A M F \* I I F L \* L L S H I  
L S \* F K M \* L C F E \* Y F F N Y S A I

25081 TTTGATAGTTATCTTGGTTGCGTTTAAATGCTGATAATTTAACTGATTATCTGTTTCT 25140  
F D S Y L G C V F N A D N L T D Y S V S  
L I V I L V A F L M L I I \* L I I L F L  
F \* \* L S W L R F \* C \* \* F N \* L F C F

25141 TCTTGTGCTCTTCGCGTAGGTTTGTGTTGATTATAACTCACCTTCTTCTCC 25200  
S C A L R M G S G F C V D Y N S P S S S  
L V L F A W V V V F V L I I T H L L L P  
F L C S S H G \* W F L C \* L \* L T F F F

25201 TCTTCGCGTCGTAACGTAGAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCC 25260  
S S R R K R R S I S A S Y R F V T F E P  
L R V V N V E V F L L L I V L L L L N P  
L F A S \* T \* K Y F C F L S F C Y F \* T

25261 TTTAATGTCAGTTTGTAAATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAA 25320  
F N V S F V N D S I E S V G G L Y E I K  
L M S V L L M T V L S L W V V F M R S K  
L \* C Q F C \* \* Q Y \* V C G W S L \* D Q

25321 ATCCCACTAACTTACTATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAA 25380  
I P T N F T I V G Q E E F I Q T N S P K  
F P L T L L \* L V K R N L F K L I L L K  
N S H \* L Y Y S W S R G I Y S N \* F S \*

FIG. 2 CONT.

49/201

25381 GTTACTATTGATTGTTCTTTATTTGTCCTGTTCTAATTATGCAGCTTGCCATGACTTATTG 25440  
V T I D C S L F V C S N Y A A C H D L L  
L L L I V L Y L S V L I M Q L A M T Y C  
S Y Y \* L F F I C L F \* L C S L P \* L I

25441 TCAGAGTATGGCACTTTTTGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTA 25500  
S E Y G T F C D N I N S I L D E V N G L  
Q S M A L F V I I L I V F \* M K L M V Y  
V R V W H F L \* \* Y \* \* Y F R \* S \* W F

25501 CTTGATACTACTCAATTGCATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCC 25560  
L D T T Q L H V A D T L M Q G V T L S S  
L I L L N C M \* L I L L C K V S H L A P  
T \* Y Y S I A C S \* Y S Y A R C H T \* L

25561 AATCTTAATACTAATTTGCATTTTGATGTTGATAATATTAAATTTTAAATCCCTAGTTGGA 25620  
N L N T N L H F D V D N I N F K S L V G  
I L I L I C I L M L I I L I L N P \* L D  
Q S \* Y \* F A F \* C \* \* Y \* F \* I P S W

25621 TGTTTAGGTCCCACTGCGGTTCTTCTCTCGTTCTTTTTTGAAGATTATTGTTTGAC 25680  
C L G P H C G S S S R S F F E D L L F D  
V \* V H T A V L L L V L F L K I Y C L T  
M F R S T L R F F F S F F F \* R F I V \*

25681 AAAGTTAACTTTTCAGATGTTGGTTTGTGTTGAAGCTTATAACAATTGTACTGGTGGTAGT 25740  
K V K L S D V G F V E A Y N N C T G G S  
K L N F Q M L V L L K L I T I V L V V V  
Q S \* T F R C W F C \* S L \* Q L Y W W \*

25741 GAAATTAGAGATCTTCTTTGTGTACAATCCTTTAATGGTATTAAAGTTTGCCTCCTATT 25800  
E I R D L L C V Q S F N G I K V L P P I  
K L E I F F V Y N P L M V L K F C L L F  
\* N \* R S S L C T I L \* W Y \* S F A S Y

25801 TTGTCTGAATCTCAAATTTCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCA 25860  
L S E S Q I S G Y T T A A T V A A M F P  
C L N L K F L V T P Q P L L L L L C F H  
F V \* I S N F W L H H S R Y C C C Y V S

25861 CCATGGTCAGCAGCAGCTGGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGT 25920  
P W S A A A G I P F S L N V Q Y R I N G  
H G Q Q Q L A Y H F L L M Y N I E L M V  
T M V S S S W H T I F S \* C T I \* N \* W

FIG. 2 CONT.



50/201

25921 TTGGGTGTTACTATGGATGTTCTTAATAAAAATCAAAAGTTGATAGCTACTGCTTTTAAT 25980  
 L G V T M D V L N K N Q K L I A T A F N  
 W V L L W M F L I K I K S \* \* L L L L I  
 F G C Y Y G C S \* \* K S K V D S Y C F \*

25981 AATGCTCTTCTTTCTATTTCAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATA 26040  
 N A L L S I Q N G F S A T N S A L A K I  
 M L F F L F R M V L V L P T L H L L K Y  
 \* C S S F Y S E W F \* C Y Q L C T C \* N

26041 CAAAGTGTGTTAATTCTAATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAAT 26100  
 Q S V V N S N A Q A L N S L L Q Q L F N  
 K V L L I L M L K H L I V C Y S N Y L I  
 T K C C \* F \* C S S T \* \* F V T A I I \*

26101 AAATTGTTGCAATTAGTTCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAG 26160  
 K F G A I S S S L Q E I L S R L D A L E  
 N L V Q L V L L Y K K F Y L V S M L \* R  
 \* I W C N \* F F F T R N F I S S R C F R

26161 GCTCAGGTTTCAGATTGATAGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTC 26220  
 A Q V Q I D R L I N G R L T A L N A Y V  
 L R F R L I G L L M V V \* L L \* M L M S  
 G S G S D \* \* A Y \* W S F N C F K C L C

26221 TCTCAACAGCTTAGTGATATTTCTCTGTAAAAATTTGGTGCTGCTTTAGCTATGGAGAAG 26280  
 S Q Q L S D I S L V K F G A A L A M E K  
 L N S L V I F L L \* N L V L L \* L W R R  
 L S T A \* \* Y F S C K I W C C F S Y G E

26281 GTTAATGAGTGTGTTAAAAGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCAT 26340  
 V N E C V K S Q S P R I N F C G N G N H  
 L M S V L K V N L L V L I F V V M V I I  
 G \* \* V C \* K S I S S Y \* F L W \* W \* S

26341 ATTTTGTCATTAGTTCAAAATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAA 26400  
 I L S L V Q N A P Y G L L F M H F S Y K  
 F C H \* F K M L L M V C C L C I L V I N  
 Y F V I S S K C S L W F V V Y A F \* L \*

26401 CCTATTCTTTTAAAACTGTTTTAGTAAGTCCTGGTTTGTGTATATCAGGTGATGTAGGT 26460  
 P I S F K T V L V S P G L C I S G D V G  
 L F L L K L F \* \* V L V C V Y Q V M \* V  
 T Y F F \* N C F S K S W F V Y I R \* C R

FIG. 2 CONT.

## 51/201

26461 ATTCACCTAAACAAGGGTATTTTATTAACATAATGATCATTTGGATGTTCACTGGTAGT 26520  
I A P K Q G Y F I K H N D H W M F T G S  
L H L N K G I L L N I M I I G C S L V V  
Y C T \* T R V F Y \* T \* \* S L D V H W \*

26521 TCTTACTATTATCCTGAACCAATTTTCAGATAAAAATGTTGTTTTATGAATACTTGTCT 26580  
S Y Y Y P E P I S D K N V V F M N T C S  
L T I I L N Q F Q I K M L F L \* I L V L  
F L L L S \* T N F R \* K C C F Y E Y L F

26581 GTTAATTTTACTAAAGCGCCTCTTGTATTGATCATTCTGTACCAAAATGTTCTGAT 26640  
V N F T K A P L V Y L N H S V P K L S D  
L I L L K R L L F I \* I I L Y Q N C L I  
C \* F Y \* S A S C L F E S F C T K I V \*

26641 TTTGAATCTGAGTTATCTCATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACT 26700  
F E S E L S H W F K N Q T S I A P N L T  
L N L S Y L I G L K I K H P L R L I \* L  
F \* I \* V I S L V \* K S N I H C A \* F D

26701 TTAAATCTTCATACTATTAATGCTACTTTTTTAGATTGTATTATGAGATGAATCTTATT 26760  
L N L H T I N A T F L D L Y Y E M N L I  
\* I F I L L M L L F \* I C I M R \* I L F  
F K S S Y Y \* C Y F F R F V L \* D E S Y

26761 CAAGAGTCTATTAAGTCTTTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATAT 26820  
Q E S I K S L N N S Y I N L K D I G T Y  
K S L L S L \* I I V I S I L K I \* V H M  
S R V Y \* V F E \* \* L Y Q S \* R Y R Y I

26821 GAAATGTATGTAAATGGCCTTGGTATGTTTGGCTACTAATTTCTTTTCATTATAATA 26880  
E M Y V K W P W Y V W L L I S F S F I I  
K C M \* N G L G M F G Y \* F L F H L \* Y  
\* N V C K M A L V C L A T N F F F I Y N

26881 TTCCTTGATTGCTCTTTTTATATGTTTGTGACTGGTTGTGGTTCTGCATGTTTGTAGT 26940  
F L V L L F F I C C C T G C G S A C F S  
S L Y C S F L Y V V V L V V V L H V L V  
I P C I A L F Y M L L Y W L W F C M F \*

26941 AAATGTCATAATTGTTGTGATGAGTATGGTGGTCATCATGATTTTGTATCAAAACATCT 27000  
K C H N C C D E Y G G H H D F V I K T S  
N V I I V V M S M V V I M I L L S K H L  
\* M S \* L L \* \* V W W S S \* F C Y Q N I

FIG. 2 CONT.

## 52/201

27001 CATGATGATTAGAATCTCTTGTTCAGATCTCATTAAATCTAAACTTTATTTATGGACGTTT 27060  
H D D \* N L L S D L I K S K L Y L W T F  
M M I R I S C Q I S L N L N F I Y G R L  
S \* \* L E S L V R S H \* I \* T L F M D V

27061 GGAGACCTAGCTACACACATTCTCTTGTATTAGAGAATTTGGTGTACAAACCTTGAAG 27120  
G D L A T H I L L L L E N L V L Q T L K  
E T \* L H T F S C Y \* R I W C Y K P \* R  
W R P S Y T H S L V I R E F G V T N L E

27121 ATTTGTGTCTAAAGTATAATTACTGTCAACCTATTGTIGGTTACTGTATTGTACCTTTAA 27180  
I C V \* S I I T V N L L L V T V L Y L \*  
F V S K V \* L L S T Y C W L L Y C T F K  
D L C L K Y N Y C Q P I V G Y C I V P L

27181 ATGTTTGGTGTGCAAGTTTGGCAAATTGCTTCTCACTTTACATTACGTAGTCACGATA 27240  
M F G V A S L A N L L L T L H Y V V T I  
C L V S Q V W Q I C F S L Y I T \* S R Y  
N V W C R K F G K F A S H F T L R S H D

27241 TTTCCCATAGTAATAATTTTGGTGTGTAAGTACTTTTACTACTTATGGTAATACTGTTT 27300  
F P I V I I L V L \* L V L L L M V I L F  
F P \* \* \* F W C C N \* F Y Y L W \* Y C F  
I S H S N N F G V V T S F T T Y G N T V

27301 CTGAGGCTGTGTCTAGATTAGTTGAATCAGCTTCTGAATTTATTGTTTGGCGTGCAGAGG 27360  
L R L C L D \* L N Q L L N L L F G V Q R  
\* G C V \* I S \* I S F \* I Y C L A C R G  
S E A V S R L V E S A S E F I V W R A E

27361 CACTTAATAAGTATGGTTGATTTATTTTCAATGATACTGCTTGGTACATAGGACAGATT 27420  
H L I S M V D L F F N D T A W Y I G Q I  
T \* \* V W L I Y F S M I L L G T \* D R F  
A L N K Y G \* F I F Q \* Y C L V H R T D

27421 TTAGTTTATAGTTTATTTTGTCTTATTTCTTAACTTTGTTGTTGCTTTTATAGCACT 27480  
L V L V L F C L I S L I F V V A F L A T  
\* F \* F Y F V L F L \* S L L L L F \* Q L  
F S F S F I L S Y F F N L C C C F F S N

27481 ATTAAGCTTTGTATGCAACTTTTGTGGTTTTGTAAATTTCTTATTATTTTACCTTCGGCT 27540  
I K L C M Q L C G F C N F F I I S P S A  
L S F V C N F V V F V I S L L F H L R L  
Y \* A L Y A T L W F L \* F L Y Y F T F G

FIG. 2 CONT.

53/201

27541 TACGTTTATAAAAGAGGTATGCAGTTGTATAAGTCTTATAGTGAACAAGTTATACCACCC 27600  
Y V Y K R G M Q L Y K S Y S E Q V I P P  
T F I K E V C S C I S L I V N K L Y H P  
L R L \* K R Y A V V \* V L \* \* T S Y T T

27601 ACTTCAGATTATTTAATCTAAATCTAAACATTATGAATAAATCTTTCTTCCTCAATTTA 27660  
T S D Y L I \* I \* T L \* I N L F F L N L  
L Q I I \* S K S K H Y E \* I F S S S I Y  
H F R L F N L N L N I M N K S F L P Q F

27661 CTTCTGATCAAGCTGTTACATTCTTAAAAGAATGGAATTTCTCTTTGGGTGTAATACTAC 27720  
L L I K L L H S \* K N G I S L W V \* Y Y  
F \* S S C Y I L K R M E F L F G C N T T  
T S D Q A V T F L K E W N F S L G V I L

27721 TTTTATTACTATCATATTGCAGTTCGGTTATACGAGCCGTAGTATGTTGTTTATCTTA 27780  
F L L L S Y C S S V I R A V V C L F I L  
F Y Y Y H I A V R L Y E P \* Y V C L S Y  
L F I T I I L Q F G Y T S R S M F V Y L

27781 TCAAGATGATTATTCCTTTGGCTTATGTGGCCATTGACTATCACCTTGACTATATTTAATT 27840  
S R \* L F F G L C G H \* L S P \* L Y L I  
Q D D Y S L A Y V A I D Y H L D Y I \* L  
I K M I I L W L M W P L T I T L T I F N

27841 GTTTTATGCTTTGAATAATGCTTTTCTTGCAATTTCTATAGTGTACTATTATTCTTA 27900  
V F M L \* I M L F L H F L \* C L L L F L  
F L C F E \* C F S C I F Y S V Y Y Y F Y  
C F Y A L N N A F L A F S I V F T I I S

27901 TTGTTATATGGATTCTTTATTTTGTAAATAGTATTCGGCTTTTATTAGAACTGGCAGTT 27960  
L L Y G F F I L L I V F G F L L E L A V  
C Y M D S L F C \* \* Y S A F Y \* N W Q L  
I V I W I L Y F V N S I R L F I R T G S

27961 GGTGGAGTTTAAATCCAGAGACCAATAATCTTATGTGTATTGATATGAAAGGCAAGATGT 28020  
G G V L I Q R P I I L C V L I \* K A R C  
V E F \* S R D Q \* S Y V Y \* Y E R Q D V  
W W S F N P E T N N L M C I D M K G K M

28021 TTGTTAGGCCAGTTATTGAGGACTATCACACATTAACCTGCTACTGTTATTCGTGGTCATC 28080  
L L G Q L L R T I T H \* L L L L F V V I  
C \* A S Y \* G L S H I N C Y C Y S W S S  
F V R P V I E D Y H T L T A T V I R G H

FIG. 2 CONT.

54/201

28081 TTTATATACAGGGTGTCAAACCTGGCACTGGTTATACTCTTTCAGATTGCCCGTATATG 28140  
F I Y R V S N L A L V I L F Q I C P Y M  
L Y T G C Q T W H W L Y S F R F A R I C  
L Y I Q G V K L G T G Y T L S D L P V Y

28141 TTACTGTAGCTAAGGTGCAAGTACTTTGTACCTATAAACGTGCCTTTTATAGATAAGTTAG 28200  
L L \* L R C K Y F V P I N V P F \* I S \*  
Y C S \* G A S T L Y L \* T C L F R \* V R  
V T V A K V Q V L C T Y K R A F L D K L

28201 ATGTTAATAGTGGTTTTGCTGTTTTGTTAAGTCTAAAGTTGGTAACTATCGTTTACCGT 28260  
M L I V V L L F L L S L K L V T I V Y R  
C \* \* W F C C F C \* V \* S W \* L S F T V  
D V N S G F A V F V K S K V G N Y R L P

28261 CTAGTAAACCTAGTGGTATGGATACTGCCTTGTTAAGAGCTTAAATCTAAACTATTAGGA 28320  
L V N L V V W I L P C \* E L K S K L L G  
\* \* T \* W Y G Y C L V K S L N L N Y \* D  
S S K P S G M D T A L L R A \* I \* T I R

28321 TGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTTCAGGAA 28380  
C L I L P V I M L E V E A P L E I V Q E  
V L Y S R S L C W K \* K L L W K S F R N  
M S Y T P G H Y A G S R S S S G N R S G

28381 TCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGAG 28440  
S S R K L L G L T N L S E I T K P L I E  
P Q E N F L G \* P I \* A K L P N L \* \* R  
I L K K T S W A D Q S E R N Y Q T F N R

28441 GCAGAAAACCCACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCAC 28500  
A E K P N L N S L C L L N H K E I L S H  
Q K N P T \* I H C V Y S T T R K Y Y P T  
G R K T Q P K F T V S T Q P Q G N T I P

28501 ATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCAG 28560  
I I P G S P G S L N F K K V E T L N F Q  
L F L V L R D H S I S K R \* R L \* I F R  
H Y S W F S G I T Q F Q K G R D F K F S

28561 ATGGTCAAGGAGTTCCCATTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGGT 28620  
M V K E F P L L S E Y P L L K Q K D I G  
W S R S S H C F R S T P F \* S K R I L V  
D G Q G V P I A F G V P P S E A K G Y W

FIG. 2 CONT.

## 55/201

28621 ATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCGA 28680  
I D T A G V L L K Q L M V N K S S C Y R  
\* T Q P A F F \* N S \* W S T K A V V T E  
Y R H S R R S F K T A D G Q Q K Q L L P

28681 GATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCCC 28740  
D G I S T I S V P A H M P M H P M V N P  
M V F L L S R Y R P I C Q C I L W \* I P  
R W Y F Y Y L G T G P Y A N A S Y G E S

28741 TCGAAGGGGTCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTTT 28800  
S K G S S G L L I T K L T L L L P P M F  
R R G L L G C \* S P S \* H F Y S L R C F  
L E G V F W V A N H Q A D T S T P S D V

28801 CGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATTT 28860  
R Q G I L L L K K L S L L G F R L V R F  
V K G S Y Y S R S Y P Y \* V S A W Y D F  
S S R D P T T Q E A I P T R F P P G T I

28861 TGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAAGTCGACCAGGTT 28920  
C L K A I M L K A Q E G L L L I V D Q V  
A S R L L C \* R L R K V C F \* \* S T R F  
L P Q G Y Y V E G S G R S A S N S R P G

28921 CACGTTCTCAATCAGCTGGACCCAATAATCGTTCATTAAAGTAGAAGTAATTCTAATTTTA 28980  
H V L N H V D P I I V H \* V E V I L I L  
T F S I T W T Q \* S F I K \* K \* F \* F \*  
S R S Q S R G P N N R S L S R S N S N F

28981 GACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATCGCTAATCTTGTTTTAG 29040  
D I Q I L \* \* N L I W L M R S L I L F \*  
T F R F Y S K T \* Y G \* \* D R \* S C F S  
R H S D S I V K P D M A D E I A N L V L

29041 CCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGGAATCA 29100  
P S L V K I L N L S K S L S K M P R K S  
Q A W \* R F \* T S A S H \* A K C Q G N Q  
A K L G K D S K P Q Q V T K Q N A K E I

29101 GGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTTTC 29160  
G I K F \* Q N L A K S E L L I N I V M F  
A \* N F N K T S P K A N S \* \* T L \* C S  
R H K I L T K P R Q K R T P N K H C N V

FIG. 2 CONT.

## 56/201

29161 AACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAGC 29220  
N S V L V K E D L L K I L V M L K C \* S  
T V F W \* K R T F S K F W \* C \* N V K A  
Q Q C F G K R G P S Q N F G N A E M L K

29221 TTGGTACTAATGATCCTCAGTTTCCTATTCTTGCGAGAATTAGCTCCTACACCAGGTGCTT 29280  
L V L M I L S F L F L Q N \* L L H Q V L  
W Y \* \* S S V S Y S C R I S S Y T R C F  
L G T N D P Q F P I L A E L A P T P G A

29281 TTTTCTTTGGTTCTAAATTAGACTTGGTAAAAGAGATTCCGAGGCTGACTCACCTGTTA 29340  
F S L V L N \* T W L K E I P R L T H L L  
F L W F \* I R L G \* K R F R G \* L T C \*  
F F F G S K L D L V K R D S E A D S P V

29341 AAGATGTTTTGAACTTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGCT 29400  
K M F L N F I I L V L L G L I V L Y Q A  
R C F \* T S L F W F Y \* V \* \* Y F T R L  
K D V F E L H Y S G S I R F D S T L P G

29401 TTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATTCATCAGA 29460  
L R Q L \* K F L K R I \* M L T L I L I R  
\* D N Y E S S \* R E F K C L R \* F \* S E  
F E T I M K V L E E N L N A Y V N S N Q

29461 ACACTGATTCTGATTTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTAC 29520  
T L I L I R \* V L N L S V K E V L N N Y  
H \* F \* F V E F \* T S A \* K R C \* T I T  
N T D S D S L S S K P Q R K R G V K Q L

29521 CAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTTA 29580  
Q N S L T L L I \* V L V L S T F Q M I L  
R T V \* L S \* F K C W Y S A H F K \* F Y  
P E Q F D S L N L S A G T Q H I S N D F

29581 CTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTTG 29640  
L L R I I V Y L L L L M I L M \* K T L L  
S \* G S \* F T C Y S \* \* S L C R R L C C  
T P E D H S L L A T L D D P Y V E D S V

29641 CTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTCGCTATTATTTCGGAAT 29700  
L N E N E S \* F D T R W \* P L A I I R N  
L M R M N P N S T L G G N P S L L F G I  
A \* \* E \* I L I R H \* V V T P R Y Y S E

FIG. 2 CONT.

57/201

29701 AGGACACTCTCTATCAGAAATGAAATCTTGCTGTAATAACAGATAGAGTAGGTTGTTACAG 29760  
R T L S I R M N S C C N N R \* S R L L Q  
G H S L S E \* I L A V I T D R V G C Y R  
\* D T L Y Q N E F L L \* \* Q I E \* V V T

29761 ACTATATATTAATTAGTAGAAATTTTATATTTAGACATTTGATTGTTAGAGTAGTTATAA 29820  
T I Y \* L V E I L Y L D I \* L L E \* L \*  
L Y I N \* \* K F Y I \* T F D C \* S S Y K  
D Y I L I S R N F I F R H L I V R V V I

29821 GGTTTAGCTGTAGTATAAACGCCCTCCGGGAAGAGCTATCAATTGTAGTGTTTAATATATA 29880  
G L A V V \* T P P G R A I N C S V \* Y I  
V \* L \* Y K R L R E E L S I V V F N I Y  
R F S C S I N A S G K S Y Q L \* C L I Y

29881 TATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTACAAAAAAAAAAAAAA 29940  
Y \* Y M I E I N Y S L L E E L Q K K K K  
I S I \* L K L I I A F W R N Y K K K K K  
I L V Y D \* N \* L \* P F G G I T K K K K

29941 AA 29942

K

FIG. 2 CONT.



58/201

1 CTTATTCTCGCTTAACGCAGGCATGGCAGATAGTCGAATGCTAGAGAACAGTCTAGAGTA 60  
Y S R I A D T G D I L K R D R T L D \*  
I L A F Q T R V T \* \* S V I E Q \* I E  
F L L S N R G Y R R D A \* S R K D S R M

61 ATTTAGATTTGAAAAATTTGTTCTAAGGGACAATAGGTACGAACACTCAGACCAAATTAG 120  
\* I \* V K \* V L N G T I W A Q S H P K I  
N F R F K K F L I G Q \* G H K H T H N L  
L D L S K L C S E R N D M S T L T T \* D

121 TATTAGAACATAAAATGAAAGGTGTGAAAAGTAGAGAGACGGTCACTGCACAACCAACAG 180  
M I K Y K V K W V K \* R E A L S T N T T  
\* L R T N \* K G C K E D R Q W H R T P Q  
Y D Q I K S E V S K M E R G T V H Q N D

181 GAGTCGCAGGGAGGGTATCCAGCGTTACTAATTTTGGTCGTTATGCCAGAGCCGAAGTT 240  
R L T G G M P R L S \* F W C I R D R S \*  
G \* R G E W L D C H N F G A F V T E A E  
E A D R G Y T A I I L V L L Y P R P K L

241 CACCCGCGGTCTTAAAGCAACCGACGAAGGCCTACGTCGCCTCCTCAACCGATCAGGATA 300  
T P A L I E N A A E P H L P P T P \* D \*  
L P R W F K T P Q K R I C R L L Q S T R  
H A G S N R Q S S G S A A S S N A L G I

301 CTTCACTCTACTCCCACCAATACGGGGAGATGACCAAGTTCGCTACCTTTCACAACCTAA 360  
S T L H P H T I G R \* Q D L S P F H Q I  
H L \* I L T P \* A G R S T L R H F T N S  
F D S S P P N H G E V P \* A I S L T P N

361 GCAAATACTATTAGTACACTTCTATCTAACAGCGACGTAAGAACCTGTTCTTACCGTACA 420  
R K H Y D H S S L N D S C E Q V L I A H  
E N I I I M H L Y I T A A N K S L F P M  
T \* S L \* T F I S Q R Q M R P C S H C T

421 CGTCAGTTTAGAATAGGCACTATAAAAAACAAGTACTTCTAGATGTACAACATCTTCAAGA 480  
A T L D \* G H Y K Q E H L D V H Q L L E  
H L \* I K D T I N K N M F I \* M N Y F N  
C D F R I R S I K T \* S S R C T T S T R

481 TTGATTTTGTGCGGCATTTTCAGGCCATGCCGTTAAAAATTAATTTAGTGGAACGTATCGAA 540  
L \* F L R L T R Y P L K L \* I V K A Y S  
\* S F C G Y L G T R C N \* N F \* R Q M A  
V L V A T F D P V A I K I L D G K C L K

FIG. 3

59/201

541 CCCACCAAAGGATTTCCCATACAATACCCGAACAAGGCAAGTATGTTCTGATTTGCAAT 600  
P H N E \* L T H \* P S T G N M C S \* V N  
Q T T K R F P I N H A Q E T \* V L S F T  
P P K G L P Y T I P K N R E Y L V L R \*

601 ACAACATGTAGTAGAAGATACTGATGTAGATGATGATTAACCACTTCTAAAAACCC 660  
H Q V D D K \* S \* M \* \* \* N Q H L N K P  
I N Y M M K R H S C R S S I K T F I K Q  
T T C \* R E I V V D V V L K P S S K K P

661 AACCTAACATGGAAAACCAAAATACGGTAGAATACAAGTGTTTACCAAAGTTAAGACATC 720  
N S Q V K Q N \* A M K H E C I T E I R Y  
T P N Y R K T K H W R I N V F P K L E T  
Q I T G K P K I G D \* T \* L H N \* N Q L

721 CAACATATAACTTCTCTCACTAAATTATTAAAGTTTAAAAATTTAACTACTAATACTAAA 780  
T T Y Q L S H N L L K L N \* I Q H N H N  
P Q I N F L T I \* Y N \* I K F K I I I I  
N Y I S S L S K I I E F K L N S S \* S K

781 ATCACATCTTCTACGAATACGACTCCAAGTACGACTCGGATTTCCATTATAAGTGTTTT 840  
\* H L L H K H Q P E H Q A \* L Y I N V F  
K T Y F I S I S L N M S L R F T F I \* L  
L T S S A \* A S T \* A S G L P L Y E C F

841 TCGAATACGAAATGAATCTGTTATAGCACCATAATTGGGCATGAAAAACATCTGGTCAT 900  
L K H K V \* V I D H Y \* V R V K Q L G T  
F S I S \* K S L I T T N F G Y K K Y V L  
A \* A K S L C Y R P I L G T S K T S W Y

901 ACCAACACTGATAAGACCATTTAATCGTCTAACAGAAGTTCGAATACCAGTAATAAGAAA 960  
H N H S N Q Y I L L N D E L K H D N N K  
I T T V I R T F \* C I T K L S I T M I R  
P Q S \* E P L N A S Q R \* A \* P \* \* E K

961 CGTTCTATACTCTGTTTTTCGTCAGACATACCGAACGGTTAACTGAACTATAACATCA 1020  
A L Y S V F A T Q I A Q W N H S Q Y Q L  
Q L I H S L L L R Y P K G I T V K I N Y  
C S I L C F C D T H S A L Q S K S I T T

1021 CCGAACCGTACATCAAGCACTAAGTGCTAAACAATACGCGGACGTCTGATATCGATGATA 1080  
P K A H L E H N V I Q \* A G A S \* L \* \*  
H S P M Y N T I \* S K N H A Q L S Y S S  
A Q C T T R S E R N T I R R C V I A V I

FIG. 3 CONT'D

60/201

1081 AACACCATAATTTATACAACGTGTTGGATGTCTTCTACATCATCTACCTCTACATCAATA 1140  
K H Y \* I H Q V V \* L L H L L H L H L \*  
N T T N F I N C L R C F I Y Y I S I Y N  
Q P I L Y T A C G V S S T T S P S T T I

1141 TGCACCTTGGACATGTAAATAATAGACGACTACGTTATCAAAATTTGGAAGGATCAAACTA 1200  
V H V Q V N I I Q Q H L L K L A E \* N S  
Y T F R Y M \* \* R S I C Y N \* L K R T Q  
R S G T C K N D A S A I T K F S G L K I

1201 CTTTCAATACTGAGTATACCTACTAAAAAGATAATTTAGATATATATTACAACTAAACAC 1260  
S L \* S E Y P H N K \* \* I \* I Y H Q N T  
H F N H S M H I I K R N F R Y I I N I Q  
F T I V \* I S S K E I L D I Y L T S K H

1261 ACTAACACCAAAACAATACGTCATACCAATACATCTAACAAAATTACTATTAACTAAAC 1320  
H N H N Q \* A T H N H L N N \* H Y N H N  
T I T T K N H L I T I Y I T K I I I T I  
S Q P K T I C Y P \* T S Q K L S L Q S K

1321 AATACCAACCCAAAGTCCATTATACTACCTACCAAAAAGAACAGGTAACACAACATGTCA 1380  
K H N P K L Y Y S P H N K K D M T N Y L  
K I T P N \* T I H H I T K R T W Q T T C  
\* P Q T E P L I I S P K E Q G N H Q V T

1381 AATACTGAGATCGCTTCAATTTTCGGGTTAGTAGACCACAATAAGGACTTTTAGGACACAA 1440  
K H S \* R L \* L G I M Q H \* E Q F D Q T  
N I V R A F N F G L \* R T N N R F I R H  
\* S E L S T L A W D D P T I G S F G T N

1441 TAAATGATTATCATGACTATGACAATTGGTACTAAGAAAATTAACATACCAATAAGACA 1500  
I \* \* Y Y Q Y Q \* G H N K \* N T H N N Q  
\* K S I T S I S N V M I R K I Q I T I R  
N V L L V S V T L W S E K L K Y P \* E T

1501 GTGTGGTAAACCAAGAACATATATAACCAGCGGCGCAGGACCTAACACCTAAGGATATTA 1560  
\* V M Q N K Y I N T A A D Q I T S E \* L  
D C W K T R T Y I P R R T R S Q P N R Y  
V G N P E Q I Y Q D G R G P N H I G I I

1561 ATTTAGAAGTCAGTTCAGAATACTACTAAACCAATAAGTCCACATCATCCAACATTAG 1620  
\* I K L \* T K H H N P K N L H L L N Y I  
N F R \* D L R I I I Q N I \* T Y Y T T F  
L D E T L D \* S S K T \* E P T T P Q L D

FIG. 3 CONT'D

61/201

1621 ATAACAATTTCTTTGACGAGAATAATGAGTACGTGAAATGAATCTAATACAAGTTACATT 1680  
\* Q \* L F Q E \* \* E H V K S L N H E I Y  
R N N F F S S K N S M C K V \* I I N L T  
I T L S V A R I V \* A S \* K S \* T \* H L

1681 CACACCATTAGAACTTGTTTGTAGTATAAGAACCGCAATTATTAAGAACCACATCCGTGTA 1740  
T H Y D Q V F D Y E Q R \* Y N K T Y A V  
L T T I K F L I M N K A N I I R P T P L  
H P L R S C F \* I R P T L L E Q H L C S

1741 CAACGAATTATCTCCACTAATATTATACGAAGATTTTTTATAACTGAACAAACAATTCGC 1800  
T A \* Y L H N Y Y A E L F Y Q S T Q \* A  
Q Q K I S T I I I H K \* F I N V Q K N L  
N S L L P S \* L I S R F F I S K N T L R

1801 AGCAGACTAAAACGAACGTTCAAACGTCAAACACCTCTACCAAAACATGGAAAAATGA 1860  
D H Q N Q K C T Q L K H L H N Q V K K V  
T T S I K S A L K C N T S I T K Y R K \*  
R A S K A Q L N A T Q P S P K T G K K S

1861 TCTACCAAAATTAAGGGGCATCAATAATAGATTAAGTCTCACCATAAAAGAAATGTAGAAA 1920  
L H N L E G Y N N D L E S H Y K R \* M K  
\* I T \* N G T T I I \* N L T T N E K C R  
S P K I G R L \* \* R I \* L P I K K V D K

1921 CTACAGAGTTAAAAGTGTTC'TTCAAAGACTATACACAAATTTTTACACATAAAACAAATA 1980  
S T E I K V L L K Q Y T N L F T Y K T \*  
Q H R L K \* L F N R I H T \* F H T N Q K  
I D \* N E C S T E S I H K F I H I K N I

1981 CCTGTCTCAAAGTCAACGATGTAAAATATATCTCGTAATACAATTATCCAACCAATGAGT 2040  
P C L K L Q \* M K Y L A N H \* Y T P \* E  
H V S N \* N S C K I Y L M I N I P Q N S  
S L T E T A V N \* I S C \* T L L N T V \*

2041 TAAATTCATAAACCATGATGTGAACAATTATTTTACCAATTAACCAAAATTATGGTACAA 2100  
I \* T I P Y \* V Q \* Y F P \* N T \* Y W T  
L K L \* Q T S C K N I F H N I P K I G H  
N L N N P V V S T L L I T L Q N L V M N

2101 TCTACGATCACGTGGACGATGTCCGACCGAAGAAATGGTTAATAACTTACCAGAAAAACA 2160  
L H \* H V Q \* L S A E K G I I S H D K Q  
\* I S T C R S C A P K K V L \* Q I T K K  
S A L A G A V P Q S R \* W N N F P R K T

FIG. 3 CONT'D

62/201

2161 TCATAGAGTTCGGTTGAAATTAAACACGAAATTATGGACTAATACGATTTTAAATCA 2220  
L I E L W S \* N Q Q K L V Q N H \* F K L  
Y Y R L G V K I K N S \* Y R I I S F N \*  
T D \* A L K L K T A K I G S \* A L I K T

2221 ATTATTTAAATGTGAAAAAATTCATAATAATCTCACACAATGTCAACTACAAAATTT 2280  
\* Y I K C K K \* T I I L T H \* L Q H K L  
N I F K V S K K L \* \* \* L T N C N I N \*  
L L N \* V K K L N N N S H T V T S T K F

2281 TCTATACGGACAAGAATTTTGATAATTACCAAATCAAACATAACATCCGTTATTCAAAT 2340  
L Y A Q E \* F \* \* H N L K Y Q L C Y T K  
F I H R N K F S N I T \* N T N Y A I L K  
S I G T R L V I L P K T Q I T P L L N \*

2341 ATTGCAATCATGTCCCAATTAAGGACCAAAACAAAATGGTACATTACGTGTCCTTGTGT 2400  
Y R \* Y L T L E Q N Q K V M Y H V P V V  
I V N T C P \* N R T K N \* W T I C L F L  
L T L V P N I G P K T K G H L A C S C C

2401 TTAAATAAAAAAACTTCCGCAACGCTCTTAGACAATATCATCTTCTACTACAATAACTCTT 2460  
F K N K Q L R Q L I Q \* L L L H H \* Q S  
L N I K K F A N C F R N Y Y F I I N N L  
I \* K K S P T A S D T I T S S S T I S F

2461 ACAGTTTAGAAGAAATAGTAGAATACTCATAACAGTTGGTGGATTAGACATCTTTTTA 2520  
H \* I K K I M K H T N D V V \* I Q L F F  
I D F R R \* \* R I L I T L W R F R Y F F  
T L D E K D D \* S Y Q \* G G L D T S F I

2521 AACATAATATCTATTATACATGTACCCATTACACCACTATTTAAAAGGGATAACAGTA 2580  
K Y \* L Y Y T C P Y T H H Y I K G \* Q \*  
N T N Y I I H V H T L T T I F K E R N D  
Q I I S L I Y M P L H P S L N K G I T M

2581 CTTACTATTTTATAAACAGAAAATCTAGTCCGACCGCAAAAGGTACACGTCCATCTTT 2640  
S H Y F Y K D K L D P K A N E M H L Y F  
H I I F I N T K \* I L S P T K W T C T S  
F S L F I Q R K S \* A Q R K G H A P L F

2641 TCAATTAAAATGCTCTTTGGACAACAACTACCTCTAAGGCAGAACTACTGTCAATTCCA 2700  
L \* N \* R S V Q Q \* P S E T K S S L \* P  
F N I K V L F R N N H L N R R Q H C N L  
T L K L S F G T T I S I G D K I V T L T

FIG. 3 CONT'D

63/201

2701 ATACAACTAAATCTAAGATGAAACTACTATAAAATCCATTTCAAACAAGTCTTAACT 2760  
\* T Q N L N \* K Q H Y K L Y L K N L I Q  
N H K I \* I R S K I I N \* T F N T \* F K  
I N S K S E V K S S I K P L T Q E S N S

2761 TCATCTTTCCACAAATGACATCTACTAAAACAACGACAACAACTACGATATCTCTT 2820  
L L F P H \* Q L H N Q Q Q Q K H H \* L S  
F Y F L T N S Y I I K N S N N T I S Y L  
T S F P T V T S S K T A T T Q S A I S F

2821 ACGAAATTGAGAACATTTCTCGTAGGTCAACCAACCAATAGTTCAAGCAGTAAAAATTT 2880  
H K L S K Y L A D L P Q N D L E H M K L  
I S \* V R T F L M W H N T I L N T C K \*  
A K F E Q L S C G T T P \* \* T R A N K F

2881 ATTTGAATTACTCTTACAACAAATAAATAAACTACTCCGACCACTACTTCGTTACCGGAG 2940  
Y V \* H S H Q K N I Q H P Q H H L L P R  
I F K I L I N N I \* K I L S T I F C H G  
L S L S F T T \* K N S S A P S S A I A E

2941 AGCATACATAACATGAAAACGATAACTCCTACAACCTCTGCAATAGTCATCACTTCGACA 3000  
E Y T N Y K Q \* Q P H Q L R \* \* Y H L Q  
R T H I T S K S N L I N F V N D T T F S  
R I Y Q V K A I S S T S S T I L L S A T

3001 GCTTCTATGATAACTACCAAGCAACTTCTGTGATAATTACTGCTACTTCTACAACAATG 3060  
R L Y \* Q H H R Q L C \* \* H R H L H Q \*  
D F I S N I T D N F V S N I V I F I N N  
S S V I S P T T S S V I L S S S S T T V

3061 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3120  
Q H C H R H L H Q \* Q H C H R H L H Q \*  
S T V I V I F I N N S T V I V I F I N N  
P S L S S S S T T V P S L S S S S T T V

3121 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3180  
Q H C H R H L H Q \* Q H C H R H L H Q \*  
S T V I V I F I N N S T V I V I F I N N  
P S L S S S S T T V P S L S S S S T T V

3181 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3240  
Q H C H R H L H Q \* Q H C H R H L H Q \*  
S T V I V I F I N N S T V I V I F I N N  
P S L S S S S T T V P S L S S S S T T V

FIG. 3 CONT'D

64/201

3241 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3300  
Q H C H R H L H Q \* Q H C H R H L H Q \*  
S T V I V I F I N N S T V I V I F I N N  
P S L S S S S T T V P S L S S S S T T V

3301 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3360  
Q H C H R H L H Q \* Q H C H R H L H Q \*  
S T V I V I F I N N S T V I V I F I N N  
P S L S S S S T T V P S L S S S S T T V

3361 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3420  
Q H C H R H L H Q \* Q H C H R H L H Q \*  
S T V I V I F I N N S T V I V I F I N N  
P S L S S S S T T V P S L S S S S T T V

3421 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTATTGCTACTTCTCTAACAATG 3480  
Q H C H R H L H Q \* Q H C Y R H L S Q \*  
S T V I V I F I N N S T V I V I F L N N  
P S L S S S S T T V P S L L S S S I T V

3481 ACCACTGTTACTACTGGTTTAAACAACAATGACCACTACTACATCTACTATACTTTTCATA 3540  
Q H C H H G F Q Q \* Q H H H L H Y Q F Y  
S T V I I V L N N N S T I I Y I I N F T  
P S L S S W I T T V P S S T S S I S L I

3541 AATACTGAACTATGAATATTTTCGAGAAAATCAAAAATTACTACAGATATTACTACGAAA 3600  
K H S Q Y K Y L E K L K \* H H R Y H H K  
N I V K I S I F S K \* N K I I D I I I S  
\* S K S V \* L A R K T K L S T \* L S A K

3601 CAAACAATCAATACCAAGATCACAACCTTTGTCTTTGTATAAAATTTCAATTACCAAAATAC 3660  
T Q \* N H N \* H Q F L F M N \* L \* H N I  
Q K N T I T R T N F C F C I K F N I T \*  
N T L \* P E L T S V S V Y K L T L P K H

3661 CAGTGGATGATAATGTGTATGATTAACAACCAACGCAAGACACAATGAACATTACGTCTT 3720  
T V \* \* \* V Y \* N N T A N Q T V Q L A S  
P \* R S N C M S I T P Q T R H \* K Y H L  
D G V I V C V L Q Q N R E T N S T I C F

3721 TAATGGAAAATTCAAATTCCTAAATCGATAACTTTTATACACCAATAGAATATTCACCCC 3780  
I V K \* T \* P N L \* Q F Y T T I K Y P P  
F \* R K L K L I \* S N F I H P \* R I L H  
N G K L N L S K A I S F I H N D \* L T P

FIG. 3 CONT'D

65/201

3781 AATATTAGTTTCAAAACAATAAATGACTGGTGATAAGGATTTGATAACAAAACGG 3840  
N Y D F N Q Q N N V S W \* E \* L \* Q K A  
T I I L T K N I I \* Q G S N R F S N N Q  
\* L \* L K T S \* K S V V I G L A I T K G

3841 AGTTCACCAAAACATCGACTAAAACGAATAACCAAAAATTTGGTCAAATAATACG 3900  
E L H N Q L Q N Q K N T K L G T Q Y \* H  
R L T T K Y S I K S I P K \* V L K I N I  
\* P P K T A S K A \* Q N K F W N S I L A

3901 CATACGATTACCAACAACAATTTACACCAAAAAGAAAATAAATTTACCAAACTACG 3960  
T H \* N T N N L I H N K K Q N L H N P H  
R I S I P T T \* F T T K R K I \* I T Q I  
Y A L Q H Q K F H P K E K S K F P K S A

3961 AAACAAAAAATACCTCTATAACACAGAGTACAAACATTCACACCTGTATTATACTGAGA 4020  
K T K K H L Y Q T E H K Y T H V Y Y S E  
S Q K K I S I N H R M N T L T S M I H S  
K N K \* P S I T D \* T Q L H P C L I V R

4021 TTATCGTCGCCTGAATGGAACATGTAATGTAAAAAGTAATAAACTACTGTAAAAACACG 4080  
L L L P S V K Y M V N K M I Q H C N K H  
\* Y C R V \* R T C \* M K \* \* K I V I K T  
I A A S K G Q V N C K E N N S S L K Q A

4081 AAAAAAGTGGGGATTTTTTAAAAATAACGACGTACACGACACCTACATTTGCAAAACAGT 4140  
K K C G \* F F K \* Q Q M H Q P H L R K D  
S K A G R F F N K N S C T S H I Y V N T  
K Q V G L F I K I A A H A T S T F T Q \*

4141 AAGACATCGACAATATCCACTACTTGTATTATCTACCATTCAACAATGATTTAAATCACC 4200  
N Q L Q \* L H H V F L H Y T Q \* \* I \* H  
M R Y S N Y T I F L Y I T L K N S F K T  
E T A T I P S S C I S P L N T V L N L P

4201 ACTATTTAAACTAAAATATCATCCAATACCTTACAGTAAATCATACAGAAGAAAACCTCAA 4260  
H Y I Q N \* L L N H F T M \* Y T K K Q T  
T I F K I K Y Y T I S H \* K T H R R K L  
S L N S K I T P \* P I D N L I D E K S N

4261 TGGAGTTAACATACCAAAACACATATTGTGGATTACATACAAAACAATTTCCACTATAATA 4320  
V E I T H N T Y L V \* H I N Q \* L H Y \*  
\* R L Q I T Q T Y C R I Y T K N F T I N  
G \* N Y P K H I V G L T H K T L P S I I

FIG. 3 CONT'D



66/201

4321 TTTACACGATCTGAACAATTTGACTACAATAACAATTAGGACGATTACCCGTATACGA 4380  
L H Q \* V Q \* L Q H \* Q \* D Q \* H A Y A  
Y I N S S K N F S I N N N I R S I P M H  
F T A L S T L A S T I T L G A L P C I S

4381 GGTACCACCACCTCAACGTTTTTCGATATCGACATCGACGTCCATTTTTTAAAGATTTC 4440  
G H H H L Q L L \* L Q L Q L Y F I K \* L  
E M T T S N C F S Y S Y S C T F F K R F  
W P P P T A F A I A T A A P L F N E L S

4441 TTGACGACGATACCAATTTAGATTTCCACAAACGGTTCATCCTCTAACAATACAAAGATG 4500  
F Q Q \* P \* I \* L H K G L L L N N H K \*  
F S S S H N F R F T N A L Y S I T I N R  
V A A I T L D L P T Q W T P S Q \* T E V

4501 GCCACCATTTAATACATTTTGTGAAGAATTATAACATCCGGGACTACGATCTGTTCTACC 4560  
R H Y I I Y F L E \* Y Q L G Q H \* V L H  
G T T F \* T F C N K I N Y A R I S S L I  
P P L N H L V I R L I T P G S A L C S P

4561 TTCTGTTAGAATAACAAACAATCGTGCACGAATATTGTTAGAATTATTAATACTAACAAC 4620  
F V I K H K T L V H K Y A D \* Y N H N N  
S S L R I N Q \* C T S I L M K I I I I T  
L C D \* T K N A R A \* L C R L L \* S Q Q

4621 AAACAGATGAGAGTATAGCCGACCATATAAATCACAAGGACGACTACACAGTAATTGAAT 4680  
N T \* E \* I P Q Y I \* H E Q Q H T M L K  
T Q R S E Y R S T Y K T N R S I H \* \* S  
K D V R M D A P I N L T G A S T D N V \*

4681 GGAAGATCCACAACAACTATTGTTCATAGGAACAATCATTATTATTCTTCTAAAACT 4740  
G E L H Q Q Y V L \* G Q \* Y Y Y L L N Q  
V K \* T N N I F L N D K N T I I F F I K  
R R P T T S L C T I R T L L L L S S K S

4741 ATAATAAGTTTTTACAGTTTAATGAAGTCAACAACCATGATTTCGTAACCGACAATCTAA 4800  
Y \* E F I D F \* K L Q Q Y \* L M P Q \* I  
I N N L F T L N S \* N N T S F C Q S N S  
I I \* F H \* I V E T T P V L A N A T L N

4801 TTGACGATTACATCCGGCACAATAATTTAAACTCTGTCTACGTATGTTTGAAAAAACTC 4860  
L Q \* H L G H \* \* I Q S L H M C V K K S  
\* S S I Y A T N N F K L C I C V F K K Q  
V A L T P R T I L N S V S A Y L S K K L

FIG. 3 CONT'D

67/201

4861 ACCACTACTAACAAAACAAAGTTTAAGAAGACAATATGTTCTTCAAAATAACGAAGCAGT 4920  
H H H N N Q K L N K Q \* V L L K I A E D  
T T I I T K N \* I R R N Y L F N \* Q K T  
P S S Q K T E F E E T I C S T K N S R \*

4921 ACTATATGTTAACTTATTACTGCAAGCACTAATAAACAACAGATTCTACTGATCAGAAGG 4980  
H Y V I S Y H R E H N N T T \* S S \* D E  
M I Y L Q I I V N T I I Q Q R L H S T K  
S I C N F L S T R S \* K N D L I V L R G

4981 ATTTCTAACCGCAGAATAGTTATTTAAACTACAATAATTGCCACAATTTTGACAATTCAT 5040  
\* L N A D \* \* Y I Q H \* \* R H \* F Q \* T  
R F I P T K D I F K I N N V T N F S N L  
L S Q R R I L L N S T I L P T L V T L Y

5041 AAAACTCACAGGATTAAGATAAATATATACATCAGTCCCATTCTGAAACCAATACATAC 5100  
N Q T D \* N \* K Y I Y D F Y L S Q N H I  
I K L T R I R N I Y T T L T F V K T I Y  
K S H G L E I \* I H L \* P L S K P \* T H

5101 ACTACCAAGAAAAATATTTTCGTTGACAATTAGTTCAAACACAAAATAATCGATTCTTCTA 5160  
H H N K K Y L L Q \* D L K H K I L \* S S  
T I T R K I F C S N I L N T N \* \* S L L  
S P E K \* L A V T L \* T Q T K N A L F I

5161 TCTACAAAACGAATGACATCTACCACAATTAAAATTTAGATAAGAGAATGACATCCACT 5220  
L H K A \* Q L H H \* N \* I \* K E \* Q L H  
Y I N Q K S Y I T N I K F R N R K S Y T  
S T K S V T S P T L K L D I E R V T P S

5221 TCAAAAACCATTTTATGAACCATTAACAAAAGACACTACCGTAACTACAATGATTCAATTT 5280  
L K Q Y F V Q Y H K R H H C Q H \* \* T L  
F N K T F Y K T I N E T I A N I N S L \*  
T K P L I S P L T K Q S P M S T V L N F

5281 CACATCACTAAAAATACGGCTATTTTAAAAATATAGTCATACTTTTAAACAGAAATCGACT 5340  
T Y H N K H R Y F K I D T H F N T K L Q  
L T T I K I G I F N \* I L I F I Q R \* S  
H L S K \* A S L I K Y \* Y S F K D K A S

5341 ATAAAGACGACATGTTTCAAGTAAACCCAAACTAGTCGTTGTTAACGAACGAATAATATT 5400  
Y K Q Q V F N M Q T Q D A V I A Q K N Y  
I N R S Y L T \* K P K I L L L Q K S I I  
I E A T C L E N P N S \* C C N S A \* \* L

FIG. 3 CONT'D

68/201

5401 AAAAAATTGTCATACATTTACCAGACATCAACAATTGCCAGGTAAAAAAGAAAAC1TGT 5460  
N K L L I Y I T Q L Q \* R D M K K K Q V  
I K \* C Y T F P R Y N N V T W K K R K F  
K K V T H L H D T T T L P G N K E K S C

5461 CAGAGTATTATTACAATACTTACATCGAACAGAATACAACGTCGTATAATTAGAATT 5520  
T E Y Y N N H S H L K D \* T A A Y \* D \*  
L R M I I T I H I Y S T K H Q L M N I K  
D \* L L Q \* T F T A Q R I N C C I L R L

5521 TAAATTATTTACCGTCACCGTCCTTCGTACCATACTTAAAGCACGACCGTCTGGTGTATC 5580  
I \* Y I A T A P L M T H I E H Q C V V Y  
F K I F P L P L F C P I F K T S A S W M  
N L L H C H C S A H Y S N R A P L G C L

5581 CAATCAACGAGAACAAAATCGATTTCAGTAAAATTTAAACTACTTGGTAGTCTACGATG 5640  
T L Q E Q K L \* L D N \* I Q H V M L H \*  
P \* N S K N \* S F T M K F K I F W \* I S  
N T A R T K A L P \* K L N S S G D S A V

5641 ACTAAAAAAGCACACAAAAC1TTGTTTCGACTAAATAGTCCACGTTAAACACTTAATCT 5700  
Q N \* E H Q K S V L Q N I L H L K H I L  
S I K N T N N Q F L S I \* \* T C N T F \*  
S K I R T T K F C A S K D P A I Q S N S

5701 TGAATAAACACTAACCATAATTTGTTCTTTCAGCACAAACCACAACTACGACAATACGT 5760  
V \* K H N H Y \* V L F D H Q H Q H Q \* A  
F K N T I T T N F L F T T N T N I S N H  
S I Q S Q P I L C S L R T P T S A T I C

5761 AAAACCATGTAATCGTTTCTGACTAGAAAAATTACCAATATTCTAACCGACATTACACG 5820  
N Q Y M L L S Q D K \* H N Y S Q S Y N H  
M K T C \* C L S I K K I T I L N A T I T  
K P V N A F V S R K L P \* L I P Q L Q A

5821 TCCATCTTAACAGGTAACATGATTTAACTTACATGGTAAAACTAAACAAGATTATGAGG 5880  
L Y F Q G N Y \* I S H V M K S K N \* Y E  
C T S N D M T S F Q I Y W K Q N T R I S  
P L I T W Q V L N F T G N K I Q E L V G

5881 AGACTCATTCCTAATGGACTACTACAACAACGTCGATTGTACAAAATACCCACATCCACA 5940  
E S Y P N V Q H H Q Q L \* C T \* P H L H  
R Q T L I \* R I I N N C S V H K H T Y T  
R L L S K G S S T T A A L M N I P T P T

FIG. 3 CONT'D

69/201

5941 TCCGGTAATATGTGTAACTTTACACCAAGTGGAAATGGTTGTAACTACTACGAACATCACA 6000  
 L G N Y V N S I H N V K G V N H H K Y H  
 Y A M I C M Q F T T \* R V L M I I S T T  
 P W \* V C K F H P E G \* W C \* S A Q L T

6001 ATTTTTTATATGTCCACAATCACCACAAATTGACTGACGAACATAGAATTTTAAATTG 6060  
 \* F I Y L H \* H N N L Q S S T D \* F N L  
 N F F I C T N T T T \* S V A Q I K F I \*  
 L F Y V P T L P Q K V S Q K Y R L F K V

6061 GGTCTGAAAAATGATAGATACAACCTGATTAAATAAAAAACCTACTACAACCTTTACCAACGAAT 6120  
 G S K \* M \* T S \* N N K P H H Q F P Q K  
 G L S K C R H Q S I I K Q I I N F H N S  
 W V K V D I N V L \* K K S S T S I T A \*

6121 ATTGGGACTAGAAAGTGTATAATAACACTATTACCATTCATAATATGTTTGGATAATA 6180  
 Y G Q D K V I N N H Y H Y T N Y L V \* \*  
 I V R I K \* L I I T I I T L I I C F R N  
 L G S R E C Y \* Q S L P L Y \* V F G I I

6181 TTTCCGAGTCAAATTTGGTAAACGATTTCAACTGCCACAAATATGATTGAAATTCAATCA 6240  
 L P E T \* V M Q \* L Q R H K Y \* S \* T L  
 Y L S L K F W K S F N V T N I S V K L \*  
 F A \* N L G N A L T S P T \* V L K L N T

6241 ACCTGTACTATAAACACGAGTTAACTTACTATTCAATCCAAAATTACATCTAAACGGCAA 6300  
 Q V H Y K H E I S H Y T L N \* H L N A T  
 N S M I N T S L Q I I L \* T K I Y I Q R  
 P C S I Q A \* N F S L N P K L T S K G N

6301 ACAACTCATGTTTCATTGTCAGACCGGACATCGATGACCACTACAACAAAACCGTAGACT 6360  
 Q Q T C L L L R A Q L \* Q H H Q K P M Q  
 K N L V F Y C D P R Y S S T I N N Q C R  
 T S Y L T V T Q G T A V P S T T K A D S

6361 ACTAAATATACACTTTGCAATAAAATTTCTACACTTTGAAAACCATTCGGACAATAAAC 6420  
 H N I H S V N N \* L I H F K Q Y A Q \* K  
 I I \* I H F T I K F S T F S K T L R N N  
 S K Y T F R \* K L P H S V K P L G T Q

6421 CAAAACAGTACTACTTCGTAGTAACCTAAGAGAATGAATAAAATTTATTGGATCAAAATT 6480  
 T K D H H L M M S N E \* K N \* Y V \* N \*  
 P K T M I F C \* Q I R K S I K I F R T K  
 N Q \* S S A D N F E R V \* K L L G L K L

FIG. 3 CONT'D

70/201

6481 TAGACTTTTATCTATATACAAAAACAGACAACCTAAGACATAGACTCCTCAGTGTTCCATT 6540  
I Q F Y L Y H K T Q Q N Q I Q P T V L Y  
F R F I S I T N Q R N I R Y R L L \* L T  
D S F L Y L T K D T S E T D S S D C P L

6541 ACACCAATGAAGACAATACCTTAGCGTCTAATCATGATTTCTCCAATTCAATTTCCCACA 6600  
H P \* K Q \* P I A S \* Y \* L P \* T L P H  
I H N S R N H F R L N T S F L N L \* L T  
T T V E T I S D C I L V L S T L N F P T

6601 ATCTTTCTGACAATTTTATCTTCTACGATAATAACAATTACTACTTTTATCAAGATAATT 6660  
\* F S Q \* F L L H \* \* Q \* H H F Y N \* \*  
N S L S N F Y F I S N N N I I F I T R N  
L F V T L I S S A I I T L S S F L E I L

6661 CCAACAATTTTCAAATAGAAATCAACTACAAACCTATACATAAACTGTCCAACACTAAT 6720  
P Q \* F N I K L Q H K P Y T N S L N H N  
L N N F T \* R \* N I N P I H I Q C T T I  
T T L L K D K T S T Q S I Y K V P Q S \*

6721 ACAACAAACCAACGATTACTTAACAGTGCGGATCAATTTAGTGGTGTGCAATCCCTTAT 6780  
H Q K P Q \* H I T V G L \* I V L L \* P I  
I N N P N S I F Q \* A \* N F \* W C N P F  
T T Q T A L S N D R R T L D G V T L S Y

6781 ATATGCTATACCATAATTTGGATAATGATATGGATATCTAAACAATACAAATCTCTACT 6840  
Y V I H Y \* V \* \* \* V \* L N T I N L L H  
I Y S I T N F R N S Y R Y I Q \* T \* S I  
I R Y P I L G I V I G I S K N H K L S S

6841 ATTAGTTTGAGAAAATCAAGGATTTTAAAAATTCGTTCTCGATATCTTAAAAATACCAA 6900  
Y D F E K L E \* F K \* L L L \* L I K H N  
I I L S K \* N R F N K F C S S Y F K I T  
L \* V R K T G L I K L A L A I S N \* P K

6901 AAACCTTCAACCAACAAATAAATACAAAAATCAAATAATGTAAAAATGTTTACTATTTTGGTA 6960  
K S T T T \* K H K \* N I V N \* L H Y F W  
K Q L P Q K N I N K T \* \* M K C I I F G  
K F H N N I \* T K L K N C K V F S L V M

6961 AAAAAATATGATGTCTTTATCGAAGATTCAAATGAAAATTAACAAAACAAACCGAGAATT 7020  
K K Y \* L F L K \* T \* K \* N T K N P E \*  
N K I S C F Y S R L K S K I Q K T Q S K  
K \* V V S I A E L N V K L K N Q K A R L

FIG. 3 CONT'D

71/201

7021 TTTACGAAAAGTCTGTAAATCTACCTCATATAAATATTTTCCAAAAGAACAACATCGGTG 7080  
F H K E S M \* I S Y I \* L L N E Q Q L W  
F I S K L C K S P T Y K Y F T K K N Y G  
F A K \* V N L H L I N I F P K R T T A V

7081 ACACAAAACAAAACCAATTAATAACATATATTACAAATAAAAACTACTGAAAATAGA 7140  
Q T K T K T \* N K T Y L H \* K \* H S K D  
S H K Q K P K I K Q I Y I N N K T V K I  
T N K N Q N L K K Y I F T I K L S K \* R

7141 AGGATTATAATCACAAAAGGATAAAAACACCCCTTCTTAACAATACACCTATTTCCGATG 7200  
E \* Y \* H K E \* K Q P F F Q \* T S L P \*  
K R I N T N K R N K H S S N N H P Y L S  
G L I L T K G I K T P L I T I H I F A V

7201 AAAACCAACCAATGTAAACACTAAAAATAAGATTCAATCCACATCCAAAATGTTTCAGT 7260  
K Q N P \* L K H N K N \* T L H L N \* L D  
S K T Q N C N T I K I R L \* T Y T K C T  
K P K T V I Q S K \* E L N P T P K V L \*

7261 AAAACATTACCATCAAAATATACACTTAACACAGTAAGACCAAACTATACAACTATG 7320  
N K Y H Y N \* I H I T D N Q N Q Y T P Y  
M K T I T T K Y T F Q T M R T K I H Q I  
K Q L P L K I H S N H \* E P K S I N S V

7321 TATACGTCGATATCTAAAACAAGTCATACTTCATCTATCTGCACAAAATAAACTAACTACA 7380  
M H L \* L N Q E T H L L Y V H K I Q N H  
C I C S Y I K N L I F Y I S T N \* K I I  
Y A A I S K T \* Y S T S L R T K N S \* T

7381 ATCAAATCAGTTTAATTAACAACCTTGAGCAATAACCAATAAGTAATATGTGTCATACCAA 7440  
\* N L \* I L Q Q V R \* Q N N M I C L I T  
N T \* D F \* N N F E N N T I \* \* V C Y P  
L K T L N I T S S T I P \* E N Y V T H N

7441 AATAGGTAATAAAACAGAATAACCAATGTTAATAAATGATGTACCAACGGACTAAACAA 7500  
K D M I K D \* Q N V I I \* \* M T A Q N T  
K I W \* K T K N T \* L \* K S C P Q R I Q  
\* G N N Q R I P K C N N V V H N G S K N

7501 ATACAATCTTTGATACGTAACCAACTAATCTAAATAACATAAACATCGATTATACAATGG 7560  
\* T L F \* A N T S \* I \* Q I Q L \* Y T V  
K H \* F S H M F Q N S K N Y K Y S I H \*  
I N S V I C Q N I L N I T N T A L I N G

FIG. 3 CONT'D

72/201

7561 ACGAAAACAGAACACGCCAAAATATATCAACAATGACGATACATATTTTCATCAACCCAAA 7620  
Q K Q R T A T K Y L Q \* Q \* T Y L L Q N  
R S K D Q Q P K I Y N N S S H I F Y N T  
A K T K N R N \* I T T V A I Y L T T P K

7621 ATAATCCGTATAACAGATACCAACATTATTTTCGACCAACAAATAAAACAATATTTGCTTT 7680  
\* \* A Y Q R H N Y Y L Q N N I K N Y V F  
K N P M N D I T T I F S T T \* K T I F S  
I L C I T \* P Q L L A P Q K N Q \* L R F

7681 AACATCACAAGCACAAATTCACATCATGATAACAACCACCACATTAAGCAATAATACTATA 7740  
N Y H E H \* T Y Y \* Q Q H H L E N N H Y  
I T T N T N L T T S N N T T Y N T I I I  
Q L T R T L H L V I T P P T I R \* \* S I

7741 ATGACGATTACCACCATGACCAAAAACACAATTTGTAGTTACCTTAACAAAATTAACGGT 7800  
\* Q \* H H Y Q N K H \* V D I S N N \* N G  
N S S I T T S T K T N F M L P I T K I A  
V A L P P V P K Q T L C \* H F Q K L Q W

7801 AAGAAAATTTGGTCCATTGTGAAAATATTGACATCTTCGACGATATCTTGAAAGATTTCT 7860  
N K \* V L Y C K \* L Q L L Q \* L V K \* L  
M R K F W T V S K Y S Y F S S Y F K R F  
E K L G P L V K I V T S A A I S S E L S

7861 CGAATTTGCTGGACATTTAGGTTGACTACGAAGTGTAATACATCAATGACTATAATTTCGT 7920  
A \* V V Q L D L Q H K V N H L \* Q Y \* A  
L K F S R Y I W S I S \* M I Y N S I N L  
S L R G T F G V S A E C \* T T V S I L C

7921 TCAACCAACATACTACGCAAAACAAGATACTATCTCTACCTGTCGCACAAATGCTACTACA 7980  
L Q N Y S A N T R H Y L H V A H K R H H  
L N T T H H T Q E I I S I S L T N V I I  
T P Q I I R K N \* S L S P C R T \* S S T

7981 ACTACGATCAAATAAACATCTATAATTATTAGACAATGTAAGATTTCAATTTCAACAAGG 8040  
Q H \* N I Q L Y \* Y D T V N \* L \* L Q E  
N I S T \* K Y I N I I Q \* M R F N F N N  
S A L K N T S I L L R N C E L T L T T G

8041 ATTAAAGATACATCAACATCATCTCTCACTACGACTATCTCGATTAAAAGACTTACGACA 8100  
\* N T H L Q L L S H H Q Y L \* N E S H Q  
R I Q I Y N Y Y L T I S I S S I K Q I S  
L K Y T T T T S I S A S L A L K R F A T

FIG. 3 CONT'D

73/201

8101 ACACAAAATACGTGTTAGTAACATATCCGGATATAATGAACATCTGTTTTCAATTAATG 8160  
Q T K H V I M T Y A \* I V Q L C F T L \*  
N H K I C L \* Q I P R Y \* K Y V F L \* N  
T N \* A C D N Y L G I N S T S L F N I V

8161 ATGTCGAACATTACCATAGAGACATTGGGTCTGATACAAACTACAAATACAACTATGAAA 8220  
\* L K Y H Y R Q L G S \* T Q H K H Q Y K  
S C S T I T D R Y G L S H K I N I N I S  
V A Q L P I E T V W V I N S T \* T S V K

8221 ATACAGAGTAAACTACAACTATCTTCTCAAATTTATAAACAATTGTAACGAGTACG 8280  
\* T E N Q H Q Y F S N \* Y N Q \* C Q E H  
K H R M K I N I S L T K I I K N V N S M  
I D \* K S T S L F L K L L K T L M A \* A

8281 AAGAGAATCTCTCCACACGTTAATCTTTTCCAAAATCTATGAAAACACCCCTACACATGC 8340  
K E \* L P H A I L F P K L Y K Q P I H V  
S R K S L T H L \* F L N \* I S K H S T Y  
E R L S P T C N S F T K S V K T P H T R

8341 ATTTACAACAAGGTAAGTCTACAACCTTTGTCTAAATAATGATTTAGATACTATAG 8400  
Y I N N W Q N L H Q F L I \* \* \* I \* S I  
T F T T G N I \* I N F C S K N S F R H Y  
L H Q E M S E S T S V L N I V L D I I D

8401 ACGTCATCGACGACCAACCTTAAATGACTACTTTTAATATTGTTAAACCATGGATGTAT 8460  
Q L L Q Q N P I \* Q H F N Y C N P V \* M  
R C Y S S T Q F K S I F I I V I Q Y R C  
A T A A P K S N V S S F \* L L K T G V Y

8461 AAATTTCTCACTATTATAACATCGACGACTAAATCCACAAGAATATGTCTTACCACGATT 8520  
N L S H Y Y Q L Q Q N L H E \* V S H H \*  
I \* L T I I N Y S S I \* T N K Y L I T S  
K F L S L I T A A S K P T R I C F P A L

8521 CGTACATGTCCATTACAACGATTCCGTGATTATAAAGAACATATACCAAATAACTACG 8580  
A H V P Y H Q \* P L \* Y K K Y I T \* Q H  
L M Y L T I N S L C S I N R T Y P K N I  
C T C P L T A L A A L I E Q I H N I S A

8581 AAAATTAGTTGAATGACGACTAAATGTCGTATTTAATTTTTTCGTACACAATTTTGACC 8640  
K \* D V \* Q Q N V A Y I L F L M H \* F Q  
S K I L K S S I \* L M F \* F F C T N F S  
K L \* S V A S K C C L N F F A H T L V P

FIG. 3 CONT'D



74/201

8641 GAACTTCAATTTTAACTGAAAATTATTCGTTCTCCGTTACAGGGATAAGAATGTTGTGG 8700  
 S S T L I S K \* Y A L P L H G \* E \* L V  
 A Q L \* F Q S K I L L L C T D R N K C C  
 K F N F N V K L L C S A L T G I R V V G

8701 GAAAAGTGAATTTCTCCACAACATAACTCATTAACAATATATATAATAAAAAACAATC 8760  
 R K V \* L L H Q I S Y N T I Y I I K Q \*  
 G K \* K F S T N Y Q T I Q \* I Y \* K K N  
 K E S L P P T T N L L K N Y I N N K T L

8761 AAATTAGACAAAATATAATAACACCCGAAATAACGGATGTATATCACAATATTCAGACT 8820  
 N L R N \* I I T P K I A \* M Y H K Y T Q  
 T \* D T K Y \* Q P S \* Q R C I T N I L R  
 K I Q K I N N H A K N G V Y L T \* L D S

8821 ATAAGTAAACGGACGAATACGATCAAAATTTCAATAACTATTACCACAACAATCTCTATA 8880  
 Y E N A Q K H \* N \* L \* Q Y H H Q \* L Y  
 I N M Q R S I S T K F N N I I T N N S I  
 I \* K G A \* A L K L T I S L P T T L S I

8881 AAGTCAATTACTAAATACAAAACGATTATTTAAAAGGTTAAACTAGTTACCATACTCAG 8940  
 K L \* H N I N Q \* Y I K G I Q D I T H T  
 N \* N I I \* T K S I F K E L K I L P I L  
 E T L S K H K A L L N K W N S \* H Y S D

8941 GTGAAAACCCAGACAAATGATAGTATTAAGATACCTAACGGGATAACATCACCGTCAATA 9000  
 W K Q T Q K S D Y N \* P N G \* Q L P L \*  
 G S K P R N V I M I R H I A R N Y H C N  
 V K P D T \* \* \* L E I S Q G I T T A T I

9001 CCTACTTCTATAGCCAAGATGATACAAATTACAGGATGATTCAAAACTCTGTACCGAA 9060  
 P H L Y R N \* \* T \* H E \* \* L K S V H S  
 H I F I D T R S H K I N R S F N Q S M A  
 S S S I P E V I N L T G V L T K L C P K

9061 AGTACAAAATGTAAAAAATTGAATACGTAAACGATCACTATCACAAGTCACGATATGTGG 9120  
 E H K V N K L K H M Q \* H Y H E T S Y V  
 K M N \* M K \* S I C K S T I T N L A I C  
 \* T K C K K V \* A N A L S L T \* H \* V G

9121 TGTATAAGTCTAAAGAATATTACTAAAAATACGATCACCAACACAAAATAGTAGAAACAC 9180  
 V Y E S K K Y H N K H \* H N H K I M K T  
 W M N L N R I I I K I S T T T N \* \* R Q  
 C I \* I E \* L S K \* A L P Q T K D D K H

FIG. 3 CONT'D

75/201

9181 ATGATACAAATTTTCTCCACTACCATGTGGTGTAGGAATAACAATAAGTCTACCACAATA 9240  
Y \* T \* F L H H Y V V D K N N N L H H \*  
T S H K F S T I T C W M R I T I \* I T N  
V I N L L P S P V G C G \* Q \* E S P T I

9241 CTTCTTACGAAGAAACATATGTAGAAACCAAGGTGTATGTGCAATATCGGAACGATTAAG 9300  
S S H K K T Y M K P E V Y V N Y G Q \* N  
H L I S R Q I C R Q N W M C T I A K S I  
F F A E K Y V D K T G C V R \* L R A L E

9301 ATTACCAAAATATTCTAAAGGACTACAATAATCACTTCCATAACATGCATAACATTCTTG 9360  
\* H N \* L I E Q H \* \* H L Y Q V Y Q L F  
R I T K Y S K R I N N T F T N Y T N Y S  
L P K I L N G S T I L S P I T R I T L V

9361 CGGAGATACTGAATAACATCTCACCCACGTACACTTATGCGGCTTCTCCCATATACAAA 9420  
A S \* S K N Y L P H M H I R R L P Y I N  
R A R H S I T S H T C T F V G F L T Y T  
R E I V \* Q L T P A H S Y A S S P I H K

9421 ATTAAATTTATCAAGGACCCAAAACCTATTACTAATAATATCTTCATACGGACCTTGAAA 9480  
\* N \* Y N R P K S Y H N N Y F Y A Q F K  
K I K I T G P N Q I I I I I S T H R S S  
L K L L E Q T K F L S \* \* L L I G P V K

9481 AACACCATCTCTAGAAAACTAAACAAAATAGTTAAAAATCATCAATTAAGCAGGATA 9540  
K H Y L D K Q N T K D I K \* Y N L E D \*  
K T T S I K K I Q K I L K K T T \* N T R  
Q P L S R K S K N \* \* N K L L K I R G I

9541 TCTAAAGAAAAGAGAATGACGATCAAGATAAAAACCTCGATATAACCGATATCAACAACA 9600  
L N R K E \* Q \* N \* K Q L \* I P \* L Q Q  
Y I E K R K S S T R N K S S Y Q S Y N N  
S K K E R V A L E I K P A I N A I T T T

9601 GAACCAAAAAATAATAAATTATTTTGAATTGCGACGAAAACCTCTAATATGATCACAACA 9660  
R P K K N N L L V \* A H K Q L N Y \* H Q  
D Q N K I I \* Y F K L T S K S I I S T N  
K T K \* \* K I F S L R A K P S \* V L T T

9661 TCAATATTTACAACAACAACACACATAATTAAGAATAACGAAAAACAAAAGTTCAAT 9720  
L \* L H Q Q K T Y \* N E \* A K Q K E L K  
Y N Y I N N N P T N I K K H K K N K L N  
T I F T T T Q H I L K R I S K T K \* T \*

FIG. 3 CONT'D

76/201

9721 AGGATAAACACGTACACAAATACGAACAAAAATAAAAAATACATTGTACATAAAAGGAAG 9780  
D \* K H M H K H K N K N K H L M T N E K  
I R N T C T N I S T K I K I Y C Q I K R  
G I Q A H T \* A Q K \* K \* T V N Y K G E

9781 ACTTTAATCACATTAATACGTAAACGTTACCTAACATAACACGATATTACGGAAA 9840  
Q F \* H L \* A N A I S Q \* T H H \* L A K  
R F N T Y N H M Q L P N N H I T S Y H R  
S I L T I I C K C H I T I Y P A I I G K

9841 AACCAAAACACAGTGTATACATCGATACCAATAACGTTTGGTACAAAATACCAATAAAAG 9900  
K T K H \* M H L \* P \* Q L G H K I T I K  
K P K T D C I Y S H N N C V M N \* P \* K  
Q N Q T V Y T A I T I A F W T K H N N E

9901 TATAACATCCTTTTAACCACAATTACATACATCACTATCATGTAACTTCTTTGTAGAGA 9960  
M N Y S F Q H \* H I Y H Y Y M Q L F M E  
\* I T P F N T N I Y T T I T C K F F C R  
Y Q L F I P T L T H L S L V N S S V D R

9961 ATGATGAAAATACTAATGATTCTAAGAATAACATCTAATTTCTTAAGACAAAGACTACA 10020  
\* \* K \* S \* \* L N K N Y I L S N Q K Q H  
K S S K H N S F I R I T S \* L I R N R I  
V V K I I V L S E \* Q L N F F E T E S T

10021 ACGGATGTTATCTATAAACTCAAACATATTATTCATAGCAATGATATCACCATTTTACCT 10080  
Q R C Y I N S N T Y Y T D N S Y H Y F P  
N G V I S I Q T Q I I L I T V I T T F H  
A \* L L Y K L K Y L L Y R \* \* L P L I S

10081 ATGACGACGGATATCTCTTCGCCGCACAAGAGTCAATCGATTTCGATACCTTTGTAAATT 10140  
Y Q Q R Y L L P T N E T L \* L \* P F M \*  
I S S G I S F R R T R L \* S F S H F C K  
V A A \* L S A A H E \* N A L A I S V N L

10141 AGTGTTATTACCATTAACAGAAATATGGTTGGAGGATGTCGTAGACAAAGATGTAGAAA 10200  
D C Y H Y H H R I G V E \* L M Q K \* M K  
I V I I T I I D \* V L R R C C R N R C R  
\* L L P L S T K Y W G G V A D T E V D K

10201 AAACGTTAGTCCATAACATTTCTACCATAGAGGATGCAGTTTAACTTGGAACATAACA 10260  
K A I L Y Q L S P I E \* T L F Q V K Y Q  
K Q L \* T N Y L H Y R R R \* F N F R T N  
K C D P I T F I T D G V D F I S G Q I T

FIG. 3 CONT'D

77/201

10261 ATCACAAATGAATACCATCATACTGAAACTTACCAAATACCAATCTACTGTTTCAAATAAC 10320  
\* H \* K H Y Y S K S H N I T L H C L K N  
N T N S I T T H S Q I T \* P \* I V F N I  
L T V \* P L I V K F P K H N S S L T \* Q

10321 AGGAGCAGTACAATATACAAGTAGGAGATTATACTTGCTTGGACTAATAAGACGGAATAA 10380  
D E D H \* I N M R \* Y S R V Q N N Q R I  
T R T M N Y T \* G R I H V F R I I R G \*  
G R \* T I H E D E L I F S G S \* E A K N

10381 CACATCTCAATGAGATCCACTAAAATGATATTACAGACCAGCCTACTCAAATTGTCAACA 10440  
T Y L \* E L H N \* \* L T Q D S S N L L Q  
Q T S N S \* T I K S Y H R T P H T \* C N  
H L T V R P S K V I I D P R I L K V T T

10441 CAGAATGGTCTACGTCCCGACAGTTGAACAAAACGTGCAGAGAAATGTTTATAGGAATGTG 10500  
T K G S A P S D V Q K S L R K V F D K C  
H R V L H L A T L K N Q C D R \* L I R V  
D \* W I C P Q \* S T K V T E K C F G \* V

10501 AGETTTTATATGAAAACCATTTACAATTTGGACCACTTTGAAAATGACAAAATCGACGCAT 10560  
E L I Y K Q Y H \* V Q H F K \* Q K L Q T  
S W F I S K T I N F R T F S K S N \* S R  
G F Y V K P L T L G P S V K V T K A A Y

10561 ATTACCGGCTGGTGTTCCTGTAAGTACAATGATACGCATCATCAATATGATAATTTC 10620  
Y H G V V L P M E H \* \* A Y Y N Y \* \* L  
I I A S W L P C K M N S H T T T I S N F  
L P R G C P A N \* T V I R L L \* V I L P

10621 AAGAAAAACACACCCAGTACACCTAGACAACCAATACATAATTGTCCACTATCACAAAT 10680  
N K K T H T M H I Q Q N H I L L H Y H \*  
T R K Q T P \* T S R N T I Y \* C T I T N  
E K K H P D H P D T P \* T N V P S L T L

10681 CAAACATATATACGTAGTTAATCTCGAGTCATGACCAACAGTGTGACCGTGACTAAAATG 10740  
T Q I Y A D I L A \* Y Q N D C Q C Q N \*  
L K Y I H M L \* L E T S T T V S A S I K  
N T Y I C \* N S S L V P Q \* V P V S K V

10741 ACCATTAAAAATACCAGGTATATCTCTACGAGTCAACATGTCAACGGTCAATTCCTGAT 10800  
Q Y N K H D M Y L H E L Q V T A L \* P S  
S T I K I T W I S I S L N Y L Q W N L V  
P L K \* P G Y L S A \* T T C N G T L S \*

FIG. 3 CONT'D

78/201

10801 GCAGGTCTGACAATTACAATAACGAACCGAGATACGTCGATATGAATTATTACACGAAC 10860  
R G S Q \* H \* Q K A R H L \* V \* Y N H K  
V D L S N I N N S P E I C S Y K I I T S  
T W V T L T I A Q S \* A A I S L L Q A Q

10861 CAAACATGTTTTACTACAAACAAGATGACTTCTAAAATTACAAACCGATACCGTTTACC 10920  
T Q V F H H K N \* Q L N \* H K P \* P L H  
P K Y L I I N T R S F I K I N P S H C I  
N T C F S T Q E V S S K L T Q A I A F P

10921 AAAATCGGTTTCATTTTCGTCTAGAACAGAATCTACGAAACCGAAGTTACTGTCCACAAAG 10980  
N \* G L L L L D Q R L H K P K L S L H K  
T K A L Y F C I K D \* I S Q S \* H C T N  
K L W T F A S R T K S A K A E I V P T E

10981 ATAACCTTGAAATAACCGACGATAATTCGAGATATATACCCCTAAAGTTCCAGCAGTTTA 11040  
\* Q F K I P Q \* \* A D I Y P I E L D D F  
R N F S \* Q S S N L T \* I H S K L T T L  
I S V K N A A I L R R Y I P N \* P R \* I

11041 TGATCCTTCAACATGAAAACTTCTACTTAACCGTGGAGACTGCAAATAGTTGTTAACCG 11100  
V L F N Y K Q L H I P V K Q R K D V I P  
Y \* S T T S K F I F Q C R R V N I L L Q  
S P L Q V K S S S N A G E S T \* \* C N A

11101 ACCACAATTTAACGTTAGATTTTGTGTTTTCTAAATAATTTCTTTGTTAAATAACCTAAAA 11160  
Q H \* I A I \* F L F I \* \* L F L K N S K  
S T N F Q L R F C F S K N F F C N I P N  
P T L N C D L V F L N I L S V I \* Q I K

11161 CTATAGATGTA AAAACAAATCAACATATTAAGACGTAAACAATTTACCTGATATAAATA 11220  
S I \* M K T \* N Y L K Q M Q \* I S \* I \*  
Q Y R C K Q K T T Y N R C K N F P S Y K  
I D V N K N L Q I I E A N T L H V I N I

11221 CATATAATTATGTGTATACTAACCACAATGTAATACACATGAACAAAACAATCAAAATA 11280  
T Y \* Y V Y S Q H \* M I H V K N Q \* N \*  
H I N I C M H N T N C \* T Y K T K N T K  
Y I L V C I I P T V N H T S Q K T L K I

11281 CTACAATGATCAATTTGTATTTCGTAAAAATAAACTGATACATATATTAAGGACATGAGAC 11340  
S T V L \* V Y A N K N S \* T Y L E Q V R  
H H \* \* N F M L M K I Q S H I Y N R Y E  
I N S T L C L C K \* K V I Y I I G T S Q

FIG. 3 CONT'D

79/201

11341 ATGGAACAAAATACATTTAATAAATCAACAAATATTCTTCCAAAATCTCCAAAATGAAT 11400  
Y R T K H L N N L Q K Y P L N \* L N \* K  
T G Q K I Y I I \* N N I L F T K S T K S  
V K N \* T F \* K T T \* L S P K L P K V \*

11401 ACAGACCGAGAGTATAAAACAAGGACGACACTTAAATGAATACAAATACTTCATAAAAT 11460  
H R A R M N Q E Q Q S N \* K H K H L I K  
I D P E \* I K N R S H I K S I N I F Y K  
T Q S E Y K T G A T F K V \* T \* S T N \*

11461 ACCAACATAAAATACACAAAAACGATAAAAAATTTGATACGTATCATAATTAGTACTGTA 11520  
H N Y K I H K Q \* K \* L \* A Y Y \* D H C  
I T T N \* T N K S N K Y S H M T N I M V  
P Q I K H T K A I K I V I C L I L \* S M

11521 AAAAAGAACTACAAAAACCAACCATCTTATCAATGAAATTAAAGATACACCATAAAACC 11580  
K K K S T K P Q Y F L \* K L K \* T T N Q  
N K R Q H K Q N T S Y N S \* N R H P I K  
K E K I N K T P L I T V K I E I H Y K P

11581 CAGCTTAAATCTTCTCCTACAAAACAATAAATAATGT'CGGAAAAATCCATGAATATGTAC 11640  
T S N L L P H K T I \* \* L R K L Y K Y M  
P R I \* F L I N Q \* K N C G K \* T S I C  
D F K S S S T K N N I V A K K P V \* V H

11641 CTGGTGATAAAACAGTAATCGATATCGTTT'TTAAACAACGATTAACCAACAGACAATTATA 11700  
S W \* K T M L \* L L F Q Q \* N T T Q \* Y  
P G S N Q \* \* S Y C F N N S I P Q R N I  
V V I K D N A I A F I T A L Q N D T L I

11701 TAAAATAAAATGTCTACATGGAATATAATTTAACTAAGAGAACTCAATGAATAAATATCC 11760  
I K N \* L H V K Y \* I S E R S N S I \* L  
Y K I K C I Y R I N F Q N E Q T V \* K Y  
N \* K V S T G \* I L N I R K L \* K N I P

11761 CATATAAAATAGAACATAACCCCTAAAAAGAGAGAAAATTTGTACAAAAATCTTACGG 11820  
T Y K I K N N P I K R E K L C H K \* F A  
P I N \* R T I P S K E R K \* V T N K S H  
Y I K D Q \* Q P N K E R K F L T K L I G

11821 ATACCCACAAATATTAAATATTTTAAAGACAAGTTCTTAACGCAATATACTTACGATTACC 11880  
\* P H K Y N Y F K Q E L I A N Y S H \* H  
R H T N I I I F N R N L F Q T I H I S I  
I P T \* L \* L I E T \* S N R \* I F A L P

FIG. 3 CONT'D

80/201

11881 GAATGCAGGTGGAGCATTATCAAACTCCGATAAAACAATTAAATTTGACGAACCTTA 11940  
S V D V E Y Y N Q P \* K T L N L V A Q F  
A \* T W R T I T K L S N Q \* I \* F Q K S  
K R G G R L L K S A I K N F K F S S P I

11941 TCCACCGCACGGTCAATAACTTCAGAGGGTTTAAAGTTAGTTTAACTGACTACACTTTAC 12000  
L H R A L \* Q L R G F E I L I S Q H S I  
Y T A H W N N F D G L N L \* F Q S I H F  
P P T G T I S T E W I \* D F N V S T F H

12001 ACGATTACAACAAAACAATTAAACAAATGTCGTAAACGTACAACGAAGATTAAAGATTCAA 12060  
H \* H Q K T L N N V A N A H Q K \* N \* T  
T S I N N Q \* I T \* L M Q M N S R I R L  
A L T T K N F Q K C C K C T A E L E L N

12061 CACCGTCATAACATCACAAAATGTATTACTTTATGATAGATGAAGTCTAAACTCACATCG 12120  
T A T N Y H K V Y H F V I \* K L N S H L  
Q P L I T T N \* M I F Y \* R S \* I Q T Y  
H C Y Q L T K C L S I S D V E S K L T A

12121 AAAACTATTGCAACGAGTTAATAACTAACAAAATAAGCGGTTAGGACGACGTCAACTATG 12180  
K Q Y A Q E I I S Q K I R W D Q Q L Q Y  
S K I L K S L \* Q N N \* E G I R S C N I  
K S L S A \* N N I T K N A L G A A T S V

12181 ATTACAGAACGTTTCATATCTACTTCAATCGCTACTAATACAAGTTCTATCATGGCAAAA 12240  
\* T D Q L Y L H L \* R H N H E L Y Y R K  
S L T K C T Y I F N A I I I N L I T G N  
L H R A L I S S T L S S \* T \* S L V T K

12241 CGTCCGAAACGTTTCACTCAAACATTTATACCGATCAAAACAACCTTACTTCAGCGTTT 12300  
A P K A F H T Q L Y P \* N Q Q I H L R L  
Q L S Q L T L K Y I H S T K N F I F D C  
C A K C L S N T F I A L K T S Y S T A F

12301 CTTTTTAAACCGACTACGATTTTATCACCAAGACAATTAGTTGTTGTCTATTTTGTCAA 12360  
S F N P Q H \* F Y H N Q \* D V V S L V T  
L F I Q S I S F I T T R N I L L L Y F L  
F F K A S A L F L F E T L \* C C I F C N

12361 TCTTTTTCGTACATTATATCGATTTCAGACACATACTTGCCTATTTTCGACATCGAGCGTT 12420  
L F L M Y Y L \* T Q T H V H Y L Q L E C  
\* F F C T I Y S L R H I F T I F S Y S A  
S F A H L I A L D T Y S R S L A T A R L

FIG. 3 CONT'D

81/201

12421 TGAACCTGCAATACCGTCTGGATCGTGAATGATGTACATATTTCTCCGAGCCTAATTACT 12480  
V Q V Y P L G L V \* \* C T Y L P E S \* H  
F K F T H C V \* C K S V H I F L S P N I  
S S R I A S R A S V L M Y L S A R I L S

12481 ATTCTTCTCATTTCACAAAGGCGAAACGTCTGTACGAAAAATCGTACCAAGCATTTAA 12540  
Y S S Y L Q K R K A S L A K \* C P E Y I  
I L L T F N N G S Q L C H K K A H N T F  
L F L L T T E A K C V I S K L M T R L N

12541 CCTATTAGTCCGAAATTTAAGATAAGACCTATTACGACAATTTCCAACACATGGAAACTC 12600  
P Y D P K L N \* E P Y H Q \* L N H V K S  
Q I I L S \* I R N Q I I S N F T T Y R Q  
S L \* A K F E I R S L A T L P Q T G K L

12601 ACGATAAGGTCGTAACCGACGATTATGAAATTGATATCATTATGGTCTATTTGTTCAAAA 12660  
H \* E L M P Q \* Y K L \* L L V L Y V L K  
T S N W C Q S S I S \* S Y Y Y W I F L N  
A I G A N A A L V K V I T I G S L C T K

12661 ACTATTTCAACAACCTATTACAAATACAATGTATACGACCATCACATACCGTATATGTCTG 12720  
Q Y L Q Q Y H K H \* M H Q Y H I A Y V S  
K I F N N I I N I N C I S T T Y P M Y L  
S L T T S L T \* T V Y A P L T H C I C V

12721 ACAAGTTCTACGACTACCATAATTATTTGTCAATTGACTATAATCACAACCTAAGATTAAAC 12780  
Q E L H Q H Y \* Y V T L Q Y \* H Q N \* N  
S N L I S I T N I F L \* S I N T N I R I  
T \* S A S P I L L C N V S I L T S E L Q

12781 CGGAGAACAAATAGTAACGCTTGTCCATATTACTTCAACGATTACGACAATACGTCTTATT 12840  
A E Q \* \* Q S C T Y H L Q \* H Q \* A S Y  
P R K N D N R V P I I F N S I S N H L I  
G R T I M A F L Y L S T A L A T I C F L

12841 ACTCAACTACGGAGTATTTAATTTTATGTTCACAATTATCACCAAGACTATACTTAAC 12900  
H T S A E Y I L F V L Q \* Y H N Q Y S N  
I L Q H R M F \* F Y L N N I T T R I H I  
S N I G \* L N F I C T T L L P E S I F Q

12901 ATTATAAGGATGAGTTACAATAATATTATTACCATCATCACCATCTTATCAAATACGACA 12960  
Y Y E \* E I N N Y Y H Y Y H Y F L K H Q  
T I N R S L T I I I I T T T T S Y N I S  
L I G V \* H \* \* L L P L L P L I T \* A T

FIG. 3 CONT'D



82/201

12961 AGAATCACTACAACCTACCAGAATTCATATGATTCTATTACTTTCTACTACCTTTAACACA 13020  
E \* H H Q H D \* T Y \* S L S L H H F N H  
N K T I N I T K L I S L Y H F I I S I T  
R L S T S P R L Y V L I I F S S P F Q T

13021 ACAAAATCTCGAACTAGGAGGAACATTTAAAGATATGTTCTACAATCCCTGAATTTTA 13080  
Q K L A Q D E K Y I K \* V L H \* P V \* F  
N N \* L K I R R T F K R Y L I N L S K F  
T K S S S G G Q L N E I C S T L P S L I

13081 ATTCATAGAAATAAAATAATTTCTACATTTGTGAAATCGATCTCCACCCCAACAACCATG 13140  
\* T D K N \* \* L I Y C K L \* L T P Q Q Y  
N L I K I K N F S T V S \* S S P P N N T  
L Y R \* K I L P H L V K A L P H T T P V

13141 AAATAGAAGTTGTTAATCTAACGTCGACCAACAACGATGACTCATACGTCGATTAGAAG 13200  
K I K L L \* I A P Q H Q \* Q T H L \* N K  
S \* R \* C N S Q L S T N S S L I C S I R  
K D E V I L N C A P T A V S Y A A L E E

13201 ATATGAAAGTAATACACGTAAGACATCTAGGATTCTTTTGAATAAATCTAATATATGT 13260  
\* V K M I H M K Q L D \* S F K N L N Y V  
R Y K \* \* T C K R Y I R L F S I \* I I Y  
I S E N H A N E T S G L F V \* K S \* I C

13261 TGTTCACCCACATGGATATTAATTAACACAATTTTACGAGACACTAGTACGACCATGACC 13320  
V L H H V \* L \* N H \* F A R H D H Q Y Q  
L L T T Y R Y N I T N F H E T I M S T S  
C P P T G I I L Q T L I S Q S \* A P V P

13321 ATACCGGTAAATGATAATTTGGACTCCGATGATAATTGGTTCTAAGAATACCACCACGGAG 13380  
Y P W \* \* \* V Q P \* \* \* G L N K H H H R  
T H G N S N F R L S S N V L I R I T T G  
I A M V I L G S A V I L W S E \* P P A E

13381 TCAAACATAAATAACGGCACGTGCACATCTCGTAGGTCTACATCTACCATATACATTTAA 13440  
L K Y K N G H V H L A D L H L H Y I Y I  
\* N T N I A T C T Y L M W I Y I T Y T F  
T Q I \* Q R A R T S C G S T S P I H L N

13441 TGCACCATTTAAACATGTTTCAGGGAAACCATATTTTCTAGGATAAGAAATACACAATTG 13500  
V H Y I Q V L G K P Y L L D \* E K H T L  
\* T T F K Y L D R Q T Y F I R N K I H \*  
R P L N T C T G K P I F S G I R \* T N V

FIG. 3 CONT'D

83/201

13501 TGTACTACAAACAGTTTCTAGACACCAAAAACCTCTCTACCGTCAACAAGGACACATCCAAG 13560  
V H H K D L R H N K S L H C N N R H L N  
C M I N T L D T T K P S I A T T G T Y T  
C S T Q \* T Q P K Q L S P L Q E Q T P E

13561 TTCACAGCGACAAGTTAGATTTCTAAATTTAAAAAATTTGCCAAGCCCCATGATCACAC 13620  
L H R Q E I \* L N L N K L R T R P V L T  
\* T D S N L R F I \* I K \* V P E P Y \* H  
L T A T \* D L S K F K K F P N P T S T H

13621 TTACGGGCCGATCATGGGACACGATCACCAAATAGATGACTACAAGTTAATTCCTGTA 13680  
F A R S T G Q A L P K D V S T \* N L A N  
S H G A L V R H \* H N I \* Q H E I L P M  
I G P \* Y G T S T T \* R S I N L \* P C K

13681 CTGTAAACATTATGGTTATCTCGACCATATCCAATATAATATTTCACTTAACAACGGCA 13740  
S M Q L V L L A P I P K Y \* L T F Q Q R  
Q C K Y Y W Y L Q Y L N I N Y L S N N G  
V N T I G I S S T Y T \* I I F H I T A T

13741 AAAGTCGCATATCTACTGCTGCCATTATTTAACCTATTCAAGAAACAACAGTTTCTTGA 13800  
K \* R I S S S P L L N S L N K T T L L V  
N E A Y L H R R Y Y I P Y T R Q Q \* F F  
K L T Y I V V T I F Q I L E K N D F S S

13801 TTAAATCTTCAATATTATTTCTCTTTTGAATAATACTCAACTGATTTTCAACACCACAA 13860  
L K S T \* L L S F V \* \* S N V L L Q P T  
\* N L L K Y Y L S F K N H T S \* F N H H  
I \* F N I I F L F S I I L Q S F T T T N

13861 CACCGACTTGTAATAAGAAATGTAACTATACTACCATCAGCGCACGGTGTATATCAA 13920  
T A S C S K K V N S I S P L R T G C I T  
Q P Q V H N R \* M Q Y Q H Y D R A V Y L  
H S F M I E K C K I N I T T A H W M Y N

13921 GCATCCTTAGAAAAGTTTCATATGATACAATCTAGAAAACGATACGTAACGCAGTAAACTA 13980  
R L F R E F Y V I N S R Q \* A N R \* K S  
E Y S D K L T Y \* T L D K S H M A D N Q  
T P I K \* L I S H \* I K A I C Q T M K I

13981 GCATTACTAACAAGTTATAACACACTTTAAGAAACACTCATACGACTAACATTTCTTAGG 14040  
R L S Q E I N H S I R Q S Y A S Q L S D  
D Y H N N L I T H F E K H T H Q N Y L I  
T I I T \* Y Q T F N K T L I S I T F F G

FIG. 3 CONT'D

84/201

14041 ATGAAAAGATTCTTTCTAACCATACTAAAACAACCTTTTAGGACTATAATAATTATATATA 14100  
\* K E L F S Q Y S K T S F G S I I L I Y  
R S K \* S L N T H N Q Q F D Q Y \* \* Y I  
V K R L F I P I I K N F I R I N N I Y I

14101 TTTTAAATCCGGGATAAAAATTATCTCGAAATGAATTATGACAGTAAAAACGTCTGTGG 14160  
L F N P G I K L L A K S L V T M K A S V  
Y F I L G \* K \* Y L K V \* Y Q \* K Q L C  
F F \* A R N K I S S \* K I S D N K C V G

14161 AATCAACTTCATCCAAATCAACCACAAAATTGAAATCTATTGGTTCTAAACATACCAGTT 14220  
K T S T P K T P T K V K S L W S K Y P \*  
R L Q L L N L Q H K L K L Y G L N T H D  
\* N F Y T \* N T N \* S \* I V L I Q I T L

14221 ACCATACTAAACCACTAAAATATGTTTGTGGGGTCCCAAACCACACCGTCAACGTCTA 14280  
H Y S K P S K I C V A G P N P T A T A S  
I T H N Q H N \* V F L G L T Q H P L Q L  
P I I K T I K Y L C G W P K T H C N C I

14281 AGAATGATAAGAATATACTACGGATACAACCTGATACACAGTACATAAATCTAACACTTAAT 14340  
E \* \* E \* I I G I N V I H \* T N S Q S N  
N K S N K Y S A \* T S \* T D H I L N H I  
R V I R I H H R H Q S H T M Y \* I T F \*

14341 AAACAATTACTATCAATATCTGTTAAGCTAGAACATGTCATACTAAAATGACTAATGTTC 14400  
N T L S L \* L C N S R T C Y S K V S \* L  
I Q \* H Y N Y V I R D Q V T H N \* Q N C  
K N I I T I S L E I K Y L I I K S I V L

14401 AATCTCAACAAATTATTCATAAAATTCATAACCCCATACTTCATAGTAGGATTATGACAC 14460  
N S N N L L Y K L Y Q P I F Y \* G L V T  
T L T T \* Y T N \* T N P Y S T D D \* Y Q  
\* L Q K I L I K L I P T H L I M R I S H

14461 CTAACACTATTACTATCCACATAATAAGTAACACGATTAAAATTATATGATAAATCATAC 14520  
S Q S L S L H I I \* Q A L K L I S N L I  
P N H Y H Y T Y \* E N H \* N \* Y V I \* Y  
I T I I I P T N N M T S I K I Y \* K T H

14521 CAAAATGGATTATGAACAAAACCAGGGGAACAATCTGTTTAAAAACATCTACCACATGGC 14580  
T K G L V Q K P G R T L C I K T S P T G  
P K V \* Y K N Q D G Q \* V F K Q L H H V  
N \* R I S T K T G K N S L N K Y I T Y R

FIG. 3 CONT'D

## 85/201

14581 AAACAACAAAGATAACCAATGGTAATGTTTCTCAATCCACATCAATACTTGAATCTACAA 14640  
N T T E I P \* W \* L S N P T T I F K S T  
T Q Q K \* Q N G N C L T L H L \* S S L H  
K N N R N T V M V F L \* T Y N H V \* I N

14641 CTGTGTGTGGCAATAGCAAACAGAGAATTTCTAAATGAAGAAATACGTCGTCTAGGACGA 14700  
S V C R \* R K D R L S K S R \* A A S G A  
Q C V G N D N T E \* L N V E K H L L D Q  
V C V T I T Q R K F I \* K K I C C I R S

14701 TACGTGCAACGTAGACGATCAGAGACGAACTAAATGCTTGAACAACAAAATCACATCGA 14760  
I C T A D A L A R S S K R V Q Q K L T A  
\* A R Q M Q \* H E A Q N V F K N N \* H L  
H V N C R S T S Q K I \* S S T T K T Y S

14761 CGGTAATGTTTACCATAATTTTAAAGTTTGACATTTTGGTCCATTGAAATGGTTCTGAAA 14820  
A M V L F I F N \* V T F G P L K L W S K  
Q W \* L H Y L I E F Q L V L Y S \* G L S  
G N C T T Y F K L S Y F W T V K V L V K

14821 ATGCTCAAACAATTTTCATTTCCGAACAAATTTCTCCCATCATGTCAACTAAACTTTGTA 14880  
\* S N T L L L P K N L S P L V T S K F C  
K R T Q \* F Y L S T \* L P Y Y L Q N S V  
V L K N F T F A Q K F L T T C N I Q F M

14881 AAAAAGAAATGAGTTCTACCATTACGACGTTAATGACTAATATTAATAATATTCATATTA 14940  
K K K V \* S P L A A I V S \* L \* \* L Y L  
N K R \* E L H Y H Q L \* Q N Y N N Y T Y  
K E K S L I T I S C N S I I I I I L I I

14941 AATGGATGATACCAACTATAATTTCGTCAATAACAAACATAATCTTCAACAAATATTATA 15000  
K G V I T S I L C N N N T N S T T \* L Y  
N V \* \* P Q Y \* A T I T Q I L L Q K Y I  
\* R S H N I N L L \* Q K Y \* F N N I F I

15001 AAACTTTAAATACTACCACCAACATATGGTCGTAGTGTCAATAACAATTATTAATACTA 15060  
K S I \* S P P Q I G A D C T I T L L \* S  
N Q F K H H N Y V L M V L \* Q \* Y N H  
K F N I I T T T Y W C \* L N N N I I I I

15061 TTTTCACGACCAATAGSTAATTTTAAACCATTTCGGTCTGAAATAATACTCCGTAAT 15120  
L L A P \* G N L L N P L A L S \* \* S A N  
Y F H Q N D M \* Y I Q Y L W V K N H P M  
F T S T I W K I F K T F G S K I I L C \*

FIG. 3 CONT'D

86/201

15121 AGTAAACTCCTTGTCTTACTTTTAAATACGTATATGATTTCATTACAAGACGGGTGGAAT 15180  
D N S S C F S I \* A Y V L R L T R G V K  
I M Q P V S H F K H M Y \* V Y H E A W R  
\* K L F L I F N I C I S F T I N Q G G \*

15181 TGAGTTTACTTAAATTTTATACGATAGTCACGATTCTTATCTCGAGCGTGACATCGTCCA 15240  
V \* I F K F Y A I L A L F L A R V T A P  
L E F S N L I H \* \* H \* S Y L E C Q L L  
S L H I \* F I S D T S L I S S A S Y C T

15241 CAAAGATAAGAATCATGATACTGTCCGGCTTACAAGGTAGTTTTTACAAACTTCTCATAT 15300  
T E I R L V I V P R I N W \* F H K F L I  
H K \* E \* Y \* S L G F T G D F I N S S Y  
N R N K T S H C A S H E M L F T Q L T Y

15301 CGTCGATGGGCTCCACAAGGACAACAATATCCTTGGTGATTTTAAATACCACCAACCGTG 15360  
A A V R P T G T T I P V V L N \* P P Q S  
L L \* G L H E Q Q \* L F W \* I K H H N P  
C S G S T N R N N Y S G S F K I T T P V

15361 CTATACAATGCAGTAGAATATTTCTTACAACTGTTGGGACAAGAATACCCAACCCCTAATA 15420  
S I N R \* R I F S T S L G T R I P Q S \*  
R Y T V D D \* L P H Q C G Q E \* P N P N  
I H \* T M K Y L I N V V R N K H T P I I

15421 GGATTTTACACTAGCACGATACGGTTTATAAAACGCATAACAATCATCAAATCAAACCGG 15480  
G L H S R A I G F I K R I T L L K T K A  
D \* I H D H \* A L Y K A Y Q \* Y N L K P  
R F T I T S H W I N Q T N N T T \* N Q G

15481 GCGTTTGTACTTAAACAACAAGTGTACCACTATCTAAAATAGCGGAACGCTTACTTACA 15540  
R L C S N Q Q E C P S L N \* R R A F S H  
G C V H I K N N V H H Y I K D G Q S H I  
A F M F K T T \* M T I S K I A K R I F T

15541 CGAGTTCAAAACTCACTTTATCAATACACACCGCCAACGATAATACAATTTCGGACCACCA 15600  
A \* T K L S I T I H P P Q \* \* T L G P P  
H E L K S H F L \* T H R N S N H \* A Q H  
S L N Q T F Y N H T A T A I I N L R T T

15601 TGATCGTCACCACTACGTTGATGACGAAAACGATTAGACAAAAATTATATACAGTCCGA 15660  
V L L P S A V V A K A L E T K L I H \* A  
Y \* C H H H L \* Q K Q \* N Q K \* Y I D P  
S A T T I C S S S K S I R N K I Y T L S

FIG. 3 CONT'D

87/201

15661 CAATGACGATTACAAACAAGAGAATACCGGACATTACCGGTATTCTAACTTCTAAATTCA 15720  
T V A L T Q E R I A Q L P W L I S S K L  
Q \* Q \* H K N E \* P R Y H G Y S Q L N L  
N S S I N T R K H G T I A M, L N F I \* T

15721 TATGCGTTAAATGTTTTGCGAATATGAGATTACAAATAGCATGTCTAATACAACATAA 15780  
I R L K C F R K Y E L T \* R V S \* T S \*  
Y V C N V E V S I S \* H K D Y L N H Q N  
Y A I \* L F A \* V R I N I T C I I N I I

15781 TGTAAACAATTACTCATAATACTTAAAAATACATTCGTAATCATACTACTAAACTCA 15840  
V N T L S Y \* S N K H L C K L I I I K L  
Y M Q \* H T N H I K I Y A N \* Y S S K S  
C K N I L I I F K \* T L M K T H H N Q T

15841 CTACTACCACACAGACAATATGAGACTAATACGATCATTCCTCAATATATCGATTATAT 15900  
S S P T T Q \* L E S \* A L L P \* I A L I  
H H H H Q R N Y S Q N H \* Y P N Y L \* Y  
I I T N D T I V R I I S T L T I Y S I Y

15901 TCACAAAAGTTGTTCAAAACATGATAGTCTTATTACAGAAATACAGACTTAGATTTACA 15960  
L T K \* C T K Y \* \* F L T K I D S D L H  
L H K E V L K T S D S Y H R \* T Q I \* I  
T N K L L N Q V I L I I D K H R F R F T

15961 ACCCAACTTTTACTATAATGATTACCAGGAGTACTTAAAACAAGGGTTGTATGATACAAT 16020  
Q T S F S I V L P G \* S N Q E W C V I N  
N P Q F H Y \* \* H D E H I K N G V Y \* T  
P N F I I N S I T R M F K T G L M S H \*

16021 CAATTCTATCTACCACTAATACAAATAAATGGTATAGGTCTAGGAAGATCTTAAATCCT 16080  
T L I S P S \* T \* K G Y G S G E L I K P  
L \* S L H H N H K N V M D L D K \* F K L  
N L Y I T I I N I \* W I W I R R S N \* S

16081 CGACCAACAAAACAACTACTAAATAACTTCTGACTGTCACAAGAAAATATCTCGCGAAA 16140  
A P Q K T S S K N F V S L T R K I S R K  
L Q N N Q Q H N I S S Q C H E K S L A S  
S T T K N I I \* Q L S V T N K Q Y L A K

16141 CATTGAGATCGATATCTACGAATGGGAAATCATGTAGTACTTTTACTTCTTATGGTTTTT 16200  
T L R A I S A \* G K T C \* S F S S Y W F  
Q L D L \* L H K G K L V D H F H L I G F  
Y T \* S Y I S V R \* Y M M F I F F V L F

FIG. 3 CONT'D

88/201

16201 CAGAAAGCACATATAAATCTTATATATTTTTTTGACATATTACTAGAACCATGAGTCTAG 16260  
T K R T Y K S Y I F F S Y L S R P V \* I  
L R E H I N L I Y L F V T Y H D Q Y E S  
D K T Y I \* F I Y F F Q I I I K T S L D

16261 AATCTATCAATATCACAATAAAATTCATGAACACTACCAAATTTCAAATGACTTCTTAGT 16320  
K S L \* L T I K L V Q S P K F N V S S D  
R L Y N Y H \* K L Y K H H N L T \* Q L I  
\* I T I T N N \* T S T I T \* L K S F F \*

16321 AAAATGTTCTTATACATAAATTTTCACGGCACTACGTCTCACATCCACGTACGCAACAA 16380  
N \* L F I Y K F L A T I C L T P A H T T  
M K C S Y T N L F H R S A S H L H M R Q  
K V L I H I \* F T G H H L T Y T C A N N

16381 ACAAGTAGTGTTTGAAGAAACGCAACACCGTCAACATATGCATTGCGAAACAATACACA 16440  
Q E D C V E K R Q P L Q I R L G K N H Q  
K N M V F K K A N H C N Y V Y A K T I N  
T \* \* L S R Q T T A T T Y T L R Q \* T T

16441 TTTACAACAA'ACTGGTACAATACCGTTGATTAGTATTTTATACAAA'CTCACAGAGTGG 16500  
L H Q \* S W T I A V L \* L Y T K L T E G  
Y I N N H G H \* P L \* D Y I H K S H R V  
F T T I V M N H C S I M F I N Q T D \* R

16501 ATGCAAAACATTACGTGGATTGACACTACACTCACTACAGTGGTTTAAATATAAACCCGCCA 16560  
\* T Q L A G L Q S T L S T V L N Y K P P  
K R K Y H V \* S H H S H H \* W I I N P R  
V N T I C R V T I H T L D G F \* I Q A T

16561 TACAGAATGATAACACTTTTGGTATTTGGGGTAATAAGTAAATTCATCAATACTTACCA 16620  
I D \* \* Q S F W L G W \* E N L N T I F P  
Y T K S N H F G Y V G N N M \* T L \* S H  
H R V I T F V M F G M I \* K L \* N H I T

16621 TACCAGAAACCAAACATATTTGTTAGAACGTGCCCAAGTGGAAATATATCTACTAAAATTA 16680  
I T K P K Y L C D Q V P E G \* I S S K L  
Y P R Q N T Y V I K C P N V K Y L H N \*  
H D K T Q I F L R A R T \* R I Y I I K I

16681 TTCTATCGATCAACATTTACCTGTCTTCAACTACTAATACAAGACCGTTTACTCACATAA 16740  
L I A L Q L H V S T S S \* T R A F S H I  
Y S L \* N Y I S L L Q H N H E P L H T Y  
L Y S T T F P C F N I I I N Q C I L T N

FIG. 3 CONT'D

89/201

16741 CTTGCAAAATTCAATAAACGACGTCCTTGAGTTTTCCGTTGACTTCTCCGAAAATTGT 16800  
S R K F N N A A S V \* F A V S S A K L C  
Q V N L T I Q Q L F E F P L Q L P K \* V  
F T \* L \* K S C F S L L C S F L S K F L

16801 TCGATACGAAGACGATGGTAAGTTCTCTAACAATCACTATCTCTTCAATAAAACACAACC 16860  
L \* A E A V M \* S I T L S L S T I K H Q  
F S H K Q \* W E L S Q \* H Y L L \* K T N  
A I S R S G N L L N N T I S F N N Q T P

16861 CTCTGTCCATTTCAATTTGGTGGTGAATTATTTTAAACAAAAGTGTCCGATGGTAAAA 16920  
S V P L T L G G S L L F \* T K V P \* W K  
P S L Y L \* V V V \* Y F N H K \* L S G N  
L C T F N F W W K I F I I N E C A V M K

16921 TGATCATGACCATTCTGTCAAAATCCACTCATACAAAACACTATTTTCACTTAATTGATTG 16980  
V L V P L V T K P S Y T K S L L S N V L  
\* \* Y Q Y S L K L H T H K Q Y F H I L \*  
S T S T L C N \* T L I N K I F T F \* S V

16981 CCACACATAATGGCGCGATGTTGATGAATATTTGAAAGATATCCACTACAAAACAAAAT 17040  
P T Y \* R A V V V \* L S E I P S T K T K  
R H T N G R \* L \* K Y V K \* L H H K Q K  
T H I V A S C S S I F K R Y T I N K N \*

17041 TGTAGTGTAAGACATCGATCAAATTCACGTGGATGTGAACAGGGTGTCTCTTGATACGA 17100  
V D C E T A L K L A G V S T G C S F \* A  
L M V N Q L \* N L H V \* V Q G V L S S H  
C \* M R Y S T \* T C R C K D W L L V I S

17101 TCATATTCATAAAGATCACAATATCACAAGGTAACCACAAAAGTTTATTACAAACGATTA 17160  
L I L N E L T \* L T G N T N \* F L T A L  
\* Y L I K \* H K Y H E M P T E F Y H Q \*  
T Y S K R T N I T N W Q H K L I I N S I

17161 ATAGTCGTGTAACCTTACTTTGCAATAACGTGACAAGTTCAGGGGGACCATGCCCTTTC 17220  
\* \* C M P I F R \* Q V T \* P G G P V P F  
N D A C Q F S V N N C Q E L D G Q Y P F  
I L V N S H F T I A S N L T G R T R S L

17221 AGAGTAGAACGATATCCAGATCGACAAATAATGATGTGTGTCGACATCAAATATGACGA 17280  
D \* R A I P R A T \* \* \* V A R T T \* V A  
T E D Q \* L D L Q K N S C L V H L K Y Q  
R M K S Y T \* S N I V V C C T Y N I S S

FIG. 3 CONT'D



90/201

17281 CGATCAGTACGACGACATCTACGTAACACACTTTTCGAATATTCAAAAATTATAATTG 17340  
A L \* A A T S A N H S F A \* L N K F I L  
Q \* D H Q Q L H M T H F L K Y T K L Y \*  
S T M S S Y I C Q T F F S I L K \* I N V

17341 CTAACATGTGCATAATAAGGACGATTTCAGGCACATCTAACAATACTATTCAAATTTTAA 17400  
S Q V R I I G A L T R T S Q \* S L N L I  
R N Y V Y \* E Q \* L E H L N N H Y T \* F  
I T C T N N R S F N T Y I T I I L K F N

17401 TTACTATGGTGAACATTCATACAAAATGGTGTATTACGTAATGGTCTCAACCAATGT 17460  
L S V V Q L Y T K V V I F A N G S N T V  
\* H Y W K Y T H K \* W L L H M V L T P \*  
I I G S T L I N K G C Y I C \* W L Q N C

17461 CTATAACAACAACAACACTTCAATCATACGAATGATTAATACTTAACAGACAATATTTA 17520  
S I T T T S S T L I S V L \* S N D T I F  
L Y Q Q Q Q H L \* Y A \* \* N H I T Q \* L  
I N N N N I F N T H K S I I F Q R N Y I

17521 CGAGCATAATTTTCGATTTGTAAATACATATAAACCTCTAGGACGAGTTAATGGACGTGGT 17580  
A R I L A L C \* T Y I P S G A \* N G A G  
H E Y \* L \* V N H I Y Q L D Q E I V Q V  
S T N F S F M I Y I N S I R S L \* R C W

17581 GCACACGACAACCTCGTTCCCAAGAAATCTTGGATCCGTGAAGTTAAGATAATGATTTTAT 17640  
R T S N L L P E K S G L C K L E I V L I  
V H A T S C P N K L V \* A S \* N \* \* \* F  
T H Q Q A L T R \* F R P V E I R N S F Y

17641 TACACAACAAATCCAGGACTATAGAAAAACCCTTTAACAATATCCACAGGATTCTTTTAA 17700  
I H Q K P G S I K K P F Q \* L H G L S I  
L T N N L D Q Y R K P F N N Y T D \* L F  
H T T \* T R I D K Q S I T I P T R F F N

17701 CAATCTTTGACAAAGTCGTAACCAAATACTATTATTTGAGTTCCGATTTTACTATTATCA 17760  
T S V T E A N T \* S L L S L A L F S L L  
Q L F Q K L M P K H Y Y V \* P \* F H Y Y  
Y F S N \* C Q N I I I F E L S F I I I T

17761 AGTAATACAAAATTCATATAAAATCCCTGTCTGTGTGTACTCTCAAGTTCACGACAT 17820  
E N H K L T Y K L P C V V C S L E L A T  
N M I N \* L I N \* P V S L V H S N L H Q  
\* \* T K E Y I K L S L C C M L T \* T S Y

FIG. 3 CONT'D

91/201

17821 TTATAAGTTGTCTATATAGATTAATCATTTAAAAATTTTCGATTAGGTCAAACCTTATCA 17880  
F I \* C I Y R I L L N K F A L G T Q F L  
L Y E V S I D L \* Y I K L L \* D L K S Y  
I N L L Y I \* N T F K \* F S I W N P I T

17881 CGACAAAAATAATCAGGAATATTATCAGTCTTAATACAACGATTTCGCACAAAATCCACAA 17940  
A T K I L G \* L L \* F \* T A L R T K P T  
H Q K \* \* D K Y Y D S N H Q \* A H K L H  
S N K N T R I I T L I I N S L T N \* T N

17941 GTTTGTGTTTGACATCTAAGACGAGTTCCAAGCCTTATACTAATACAATATATAAGTGTT 18000  
\* V C V T S E A \* P E S Y S \* T I Y E C  
E F V F Q L N Q E L N P I H N H \* I N V  
L C L S Y I R S L T R F I I I N Y I \* L

18001 TGTCGTCCTTTGTCGGGTAAAGACAATTACAATTAGCTAAATTACAACGGTATTGATCTCGG 18060  
V A S V A W E T L T L R N L T A M V L A  
F L L F L G N Q \* H \* D I \* H Q W L \* L  
C C F C G M R N I N I S K I N G Y S S G

18061 TTCTTCCCGTAAAAAACACAATACTCATTTATACGTTAATAAACTTAGAGAATTAAATAA 18120  
L F P M K Q T I L L I C N N S D R L K I  
W S P C K K H \* S Y Y A I I Q I E \* N \*  
L L A N K T N H T I H L \* K F R K I K N

18121 TGAGATGGAATCTATTTTAAGTTTGTAGTTTGAAATGGAGCAAACGTAACGTGTTGATTA 18180  
V R G K S L I \* F \* V K G R K C Q V V L  
\* E V K L Y F E F D F K V E N A N C L \*  
S \* R \* I F N L I L S \* R T Q M A C S I

18181 GAAAAATTTCTAACATCATTTTCAACGAATCCAATAGTAGGTTCGCGTACGGGGGAGTAAA 18240  
R K L S Q L L L Q K P \* \* G A C A G E N  
D K \* L N Y Y F N S L N D D L A H G R M  
K K F I T T F T A \* T I M W R M G G \* K

18241 AATCGTCAACTACTATTTATATTCCAATTACTTTTAAACCGACATTTAAATTTATAAACA 18300  
K A T S S L Y L T L S F K A T F K F I Q  
K L L Q H Y I Y P \* H F N P Q L N L Y K  
\* C N I I F I L N I F I Q S Y I \* I N T

18301 CTTGGACAAAATTGTATAAGAGCAAATTATAGAGAATACCCAAAATTTAATCTAAACTGA 18360  
S G T K V Y E R K I D R I P K L N S K V  
H V Q K L M N E N L I E \* P N \* I L N S  
F R N \* C I R T \* Y R K H T K F \* I Q S

FIG. 3 CONT'D

92/201

18361 GAACTACCAATAAGATTTAACAAATAATGATTTCTACTTCGGTAATTTGCACAATCTCCA 18420  
R S P \* E L N N I V L S S A M L R T L P  
E Q H N N \* I T \* \* \* L H L W \* V H \* L  
K I T I R F Q K N S F I F G N F T N S T

18421 ACCCAACCAAACTACAACCTCCCGGAGTACGATGAGCGCTTTTGTAACCTTGTGTTGAAA 18480  
Q T P K S T S P A \* A V R S F M P V F K  
N P Q N Q H Q P R E H \* E R F C Q F L S  
P N T K I N L A S M S S A F V N S C V K

18481 GGTGACGTTTATCCAAAAAGTTGACCACACCTAAAACATCAACTTCGATGACCGAATAAA 18540  
G S C I P K E V P T S K T T S A V P K N  
E V A F L N K L Q H P N Q L Q L \* Q S I  
W Q L Y T K \* S T H I K Y N F S S A \* K

18541 CGACTCTCTCTAACAATATGAAAATTTTTTTGACATCGATTTTCGAGGAGGACCACTTTTT 18600  
A S L S Q \* V K L F V T A L A G G P S F  
Q Q S L N N Y K \* F F Q L \* L E E Q H F  
S L S I T I S K F F S Y S F S R R T F F

18601 AAATTGTAAATTATGGGGAATACAGTTTCCAGTTTTCACCCTATAACAATCTTAATCT 18660  
N L C K I G R I D F P \* F H S I T L I L  
I \* V N L V G \* T L L D F T P Y Q \* F \*  
K F M \* Y G K H \* F T L L P I N N S N S

18661 TAACAAGTTTACAATAGACTAATAGAAAATCTGGAAGACTATCACATCATAAATAATGA 18720  
I T \* I N D S \* R K S R E S L T T N I V  
F Q E F T I Q N D K L G K Q Y H L I \* \*  
N N L H \* R I I K \* V K R I T Y Y K N S

18721 ACCAGACGGTCAAACTTGAATGAACAAATCCATAAACGATTTAATCCGTCTCTCGAA 18780  
Q D A L K S S V Q K L Y K A L N P L S S  
K T Q W N Q V \* K N L T N Q \* I L C L A  
P R G T K F K S T \* P I K S F \* A S L K

18781 TTAACATTACACACAAGATTAGCACGATGTACGATGTTAAGATCTTGACCAATAATACCA 18840  
L Q L T H E L R A V H \* L E L V P \* \* P  
\* N Y H T N \* D H \* M S C N \* F Q N N H  
I T I H T R I T S C A V I R S S T I I T

18841 ACAACCGCGGTATCAATATGAACACTAATACACATATAGGTGAATAACATCTATATGTT 18900  
Q Q R W L \* V Q S \* T Y L G S I T S I C  
N N A G Y N Y K H N H T Y D V \* Q L Y V  
T P A M T I S T I I H I I W K N Y I Y L

FIG. 3 CONT'D

93/201

18901 GTCACCCCAATATGTCCAAGAAATTGATCATTAGTGCTATATTAAACATTACATGTATTT 18960  
C H P \* V P E K V L L \* S I I Q L T C L  
V T P N Y L N K L \* Y D R Y L K Y H V Y  
L P T I C T R \* S T I V I Y N T I Y M F

18961 CCACGTGTACAACGCAGTCGACTACGTTAATACTGAGCAACAAATCGTTAGATACTAACA 19020  
P A C T A D A S A I I V R Q K A I \* S Q  
L H V H Q T L Q H L \* S E N N L L R H N  
T C M N R \* S I C N H S T T \* C D I I T

19021 AAAACATTTAGACAATTAACCTTAAATCTCATAGGTTATTAAAGATTACTCCAGTCATAT 19080  
K Q L D T L Q F K S Y G I I E L S T L I  
N K Y I Q \* N S N L T D L L K \* H P \* Y  
K T F R N I P I \* L I W Y N R I L D T Y

19081 TTATGTAGAACATCCAATAACGTCGCACAGTACGAATTTGACGGTACGATACATTATCT 19140  
F V D Q L N N C R T M S L A A M S H L L  
L Y M K Y T I A A H \* A \* L Q W A I Y Y  
I C R T P \* Q L T D H K F S G H \* T I S

19141 ATGTTGAATACAATACTGTATCCGTTAGGATTTCCAAATCGAACACAGTTTCTAATACTT 19200  
Y L K H \* S M P L G L P K A Q T L S \* S  
I C S I N H C L C D \* L N L K H \* L N H  
V V \* T I V Y A I R F T \* S T D F I I F

19201 AAATTTAAAATACTACGAAAAGGACATCGGTTGAGACAATTTGTCAATAAAATACAGATA 19260  
N L N \* S A K G T A L D T L C N N \* T \*  
I \* I K H H K E Q L W T Q \* V T I K H R  
K F K I I S K R Y G L R N F L \* K I D I

19261 CTACAGTATTTCTATTAAAAATTTCTACCAAATACATACAAAACCTTAACATTACAATA 19320  
S T C L S L K L S P K H I N Q F Q L T S  
H H A Y L Y N \* L H N I Y T K S N Y H Q  
I H M F I I K F I T \* T H K P I T I N I

19321 TTTATAGGTAGATTAAGTTAACAAACATCTAAACTGTGAGCTCACATTTATTTAATTTG 19380  
L Y G D L E I T Q L N S V R T N F L N F  
Y I D M \* N L Q K Y I Q C E L T L Y I L  
F I W R I \* N N T S K V S S H \* I F \* V

19381 GAAGGACCTACATTACCACCATCAAACATACAATTATTTGTACGTAAGGTATGATTAGGA 19440  
R G P H L P P L K Y T L L C A N W V L G  
G E Q I Y H H Y N T H \* Y V H M G Y \* D  
K R S T I T T T Q I N I F M C E M S I R

FIG. 3 CONT'D

94/201

19441 AAATGATCTTGACAAAACTTTTAGAATTCGGATACGGAAAAAGATAATAAGTCTATGC 19500  
K V L V T K S F R L G I G K K \* \* E S V  
K \* \* F Q K Q F D \* A \* A K K R N N L Y  
K S S S N K F I K L R H R K E I I \* I R

19501 GGAACACACATGCATCTACCAATCTTAGATTGTTCAACTAATGCAAGGAAATTCCTCG 19560  
G Q T Y T S P K S D L C T S \* T G K L L  
A K H T R L H N L I \* V L Q N R E K L F  
R T H V Y I T \* F R F L N I V N R \* S A

19561 CGGTGAACATAGTGTGCCACATTAGATCCACCTCGACAAACAAGTTTCGTACGACTTCTT 19620  
A V Q I V R H L R P P A T Q E F C A S S  
R W K Y \* V T Y D L H L Q K N L A H Q L  
G S T D C P T I \* T S S N T \* L M S F F

19621 ATAACATTGATGGAACCTCAGAATATTATATCAATGATGTCGTCCGAAATGAAAAACCCAA 19680  
Y Q L \* R S D \* L I T V V A P K V K Q T  
I N Y S G Q T K Y Y L \* \* L L S \* K K P  
I T V V K L R I I Y N S C C A K S K P N

19681 ATATTCTTAAACTAAAAATATTAAATACCTTGTGAAAATGATGCAATGTCTCAAATCTT 19740  
\* L F K S K \* L K H F V K V V N C L K S  
K Y S N Q N K Y N I S C K \* \* T V S N L  
I L I K I K I I \* P V S K S R \* L T \* F

19741 TTGCATTATATATTGAACCAATTACAACAGTAATACTACCTGCATGTCCACTTAATGGA 19800  
F T I Y L K T L T P \* \* S P R V P S N G  
F R L I Y S P \* H Q D N H H V Y L H I V  
V Y Y I V Q N I N T M I I S T C T F \* R

19801 ACACGATAATACTTACTGTTTCAACAACAATTCTAATTATTACATCTATGACAATAAAAA 19860  
Q A I I F S L T T T L I L L T S V T I K  
K H \* \* S H C L Q Q \* S \* Y H L Y Q \* K  
T S N H I V F N N N L N I I Y I S N N K

19861 TTTTATTATGTAGTAAAGGATGATTATATCGACAACTTAACAAATGTTTTCATCATAG 19920  
L F L V D N G V L I A T S N N V F R L I  
\* F Y Y M M E \* \* Y L Q Q I T \* L V Y Y  
F I I C \* K R S I Y S N F Q K C F T T D

19921 GCCGTGGTGGGACTTGAATTCTAAGAATCTTTAAACTTGTAACATAAACAACCTTCGTA 19980  
R C W G S S L I R L F K F M S I Q Q F C  
G A G G Q V \* S E \* F N S C Q Y K N S A  
P V V R F K L N K S I Q V N I N T P L M

FIG. 3 CONT'D

95/201

19981 CAGGACACCCCTAATACAATTTCTATCAAACAAAACATCAAGGTGAATACCACAAACATTT 20040  
 T R H S \* T L S L K N Q L E V \* P T Q L  
 H G T P N H \* L Y N T K Y N W K H H K Y  
 D Q P I I N F I T Q K T T G S I T N T F

20041 ATGTGTCTAAACTTCAAGTAGCTTTTAACTTATATGAAAACTACCAGCACTGTGACCG 20100  
 Y V S K F N M S F K F I S K S P R S V P  
 I C L N S T \* R F N S Y V K Q H D H C Q  
 V C I Q L E D F I Q I Y K K I T T V S A

20101 CGAAATCTTCGAAAATCTTTTCGTTCTTTACCACAAAATAATCATGACTTTTAAATCA 20160  
 A K S A K L F A L F P T K I L V S F N L  
 R K L L K \* F L L F H H K \* \* Y Q F I L  
 S \* F S K S F C S I T N K N T S F F \* T

20161 TCCAATAGTTACTAATTTCCAGGCGTTGCTCGACTAAATTTACCACACTAACACCTATTT 20220  
 L N D I I L P G C R A S K F P T I T S L  
 Y T I L S \* L D A V L Q N L H H S Q P Y  
 P \* \* H N F T R L S S I \* I T H N H I F

20221 CAACCTCTTGAGTTTCAACTCAAAACCAAGCGATACTCTTTCTACCACTGCTACAATAG 20280  
 T P S S L T S N Q N A I L F S P S S T I  
 L Q L V \* L Q T K T R \* S F L H H R H \*  
 N S F E F N L K P E S H S F I T V I N D

20281 AAGTCGGCTTGTCTGTCGGATACGAGTTTCGGTAATGACCTCGGGTGTTCATTAGATCCA 20340  
 K L R V S L R H E L W \* Q L G C P L R P  
 R \* G F L C G I S L G N S S G V L Y D L  
 E A S C V A \* A \* A M V P A W L T I \* T

20341 CCATTAACGCGCCCATTAACAGTAACCATTAACGAGATTGTGCAAAATGATAGAAATGA 20400  
 P L Q A P L T M P L S A R V R K V I K V  
 H Y N R P Y H \* Q Y H H E L V N \* \* R \*  
 T I A R T I D N T I I S \* C T K S D K S

20401 GTCTCAGCACATAACAGTTCAAACTTGGAGCGAGTCTAAATCTTGCCCTAAAATAACTA 20460  
 \* L R T N D L K S G R E S K S R S K I S  
 E S D H I T L N Q V E S L N L V P N \* Q  
 L T T Y Q \* T K F R A \* I \* F P I K N I

20461 TACCTACTATTAGACAAATAACGATTATACCAAATCTTCTGATACGTAACTAGTATAT 20520  
 I S S L R N I A L Y P K S S \* A N S \* I  
 Y P H Y D T \* Q \* I H N L L S H M Q D Y  
 H I I I Q K N S F I T \* F V I C K I M Y

FIG. 3 CONT'D

96/201

20521 CAAATACCATCAAAATTTGGTATTTCAATATCCTCCAAACGTAAACGAATATCCGAATAAA 20580  
T \* P L K L W L T I P P K C K S I P K N  
L K H Y N \* G Y L \* L L N A N A \* L S I  
N I T T K V M F N Y S T Q M Q K Y A \* K

20581 GCATCCTTTTTTTTAGATTAAACAATTAAGTTCCTCAAAAATGTCACTAAGATCATAA 20640  
R L F F F D L K N I \* S N K C Y S E L I  
E Y S F F I \* N T L E L T K V T H N \* Y  
T P F F F R I Q \* N L L K \* L I I R T N

20641 GTAAGTATAAAATAATGACTAGTCCTCACACCATCATCATTCTCACAAACATGTCAATAA 20700  
\* E Y K I V S \* S H P L L L L T Q V T I  
E N M N \* \* Q D P T H Y Y Y S H K Y L \*  
M \* I K N S I L L T T T T L T N T C N N

20701 CTAAATAATAATCTACTAAAACAAGATAACAATTCAGTAATTTAAACTCAACACAATCA 20760  
S K N N S S K T E I T L D N F K L Q T L  
Q N I I L H N Q K \* Q \* T M L N S N H \*  
I \* \* \* I I K N R N N L \* \* I Q T T N T

20761 TTTCAACAAATTATAATTACAACATAAAATTCCTAAAAGTTAAATACAACACCACATTACTA 20820  
L T T L I L T S K L S K \* N I N H H L S  
Y L Q \* Y \* H Q N \* P N E I \* T T T Y H  
F N N I N I N I K L I K L K H Q P T I I

20821 TTATTTTAATACTGAAAAATAGGATTTTACGTTCCGGTGATTACTAACCTTTGGACCGATA 20880  
L L I I V K \* G L I C A V L S Q F G P \*  
Y Y F \* S K K D \* F A L W \* H N S V Q S  
I F N H S K I R F H L G S I I P F R A I

20881 AGATACGGACAAAACATATTCATAAACTTACAAGGTAATCTCTCTCAGAGAAATACCTTA 20940  
E I G T K Y L Y K F T G N S L T E K H F  
N \* A Q K T Y T N S H E M L S L R K I S  
R H R N Q I L I Q I N W \* L S D R \* P I

20941 ATACCATTTGGATAAATTAAACGGATGTCCGACATACTACTTACAACGATTCATGTGAGTT 21000  
\* P L G I L K G V P Q I I F T A L Y V \*  
N H Y V \* \* N A \* L S Y S S H Q \* T C E  
I T F R N I Q R C A T H H I N S L V S L

21001 AATACAGTCATAAACTTATGATGTTGTAATCGACAAGGACAATTATACGCACAAAATGTA 21060  
N H \* Y K F V V V N A T G T L I R T K C  
I I D T N S Y \* L M L Q E Q \* Y A H K V  
\* T L I Q I S C C \* S N R N I H T N \* M

FIG. 3 CONT'D

97/201

21061 AATCCACGTCCAGACTATTTCTTCATCGAGGTCCAAGACGACAAAATTCTGTACCAAT 21120  
K P A P D S L S T A G P E A T K L C H N  
N L H L T Q Y L L L E L N Q Q K L V T T  
\* T C P R I F F Y S W T R S N \* S L P \*

21121 GGTAGACCATCATAAGAACATCTATTACTAAATTTGGGTAAACAATCGCTATCAAATCAA 21180  
G D P L I R T S L S K F G N T L S L K T  
V M Q Y Y E Q L Y H N L G M Q \* R Y N L  
W R T T N K Y I I I \* V W K N A I T \* N

21181 TGAATAAAACCTCTAACATACTGAAATGGTAAACTAACAGTAACCCTAAACTATTATAGA 21240  
V \* K P S Q I V K G N S Q \* Q S K I I D  
\* K N Q L N Y S K V M Q N D N P N S L I  
S I K S I T H S \* W K I T M P I Q Y Y R

21241 CTATACATACTAGGAGAAATGATTTTATAACCACTAATATTACACTCATTCCTACCCAAA 21300  
S I Y S G R V L F I P S \* L T L L S P N  
Q Y T H D E \* \* F Y Q H N Y H S Y P H T  
I H I I R K S F I N T I I I H T L I P K

21301 AAATGAATGTAAACAGTAAATTAAGCACTATTTAATAGAAACCCACCATCACATCGATAT 21360  
K V \* M Q \* K I R S L N D K P P L T A I  
K \* K C K D N L E H Y I I K P H Y H L \*  
K S V N T M \* N T I F \* R Q T T T Y S Y

21361 TTTTAATGTCTCAAAGAACCTTACGACTAAATATATTTAATTACTCAACAAAACGTAAA 21420  
F I V S N E Q F A S K Y L N I L Q K A N  
L F \* L T K K S H Q N I Y I L S N N Q M  
F N C L K R P I S I \* I F \* H T T K C K

21421 ACCTGTCAAAAACATGATTACATTTACGAAGAAGATCACTTCCAAAAATTATCCATAT 21480  
Q V T K Q V L T F A E E L S P N K I P I  
K S L K K Y \* H L H K K \* H L T K L L Y  
P C N K T S I Y I S R R T F P K \* Y T Y

21481 TTAATGGACCCATTTAGAAGAAAACCTTTATCTACCGTTACAATACGTACGATTGATAAAC 21540  
F \* R P L D E K S I S P L T I C A L \* K  
L N G P Y I K K Q F L H C H \* A H \* S N  
I V Q T F R R K F Y I A I N H M S V I Q

21541 AAAACCTCTTTATCATGTTGTACCTTACCGCCACGAATATCAAATAAACTATACTGATTT 21600  
N Q L F L V V H F P P A \* L K N S I V L  
T K S F Y Y L M S H R H K Y N I Q Y S \*  
K P S I T C C P I A T S I T \* K I H S F

FIG. 3 CONT'D



98/201

21601 AAAAGAACTTTAACCGACCGTGACGACAACAATTAATTCTGGTCTAGTTAATTTACTA 21660  
N E K F N A P V A T T L K L G S \* N F S  
I K K S I P Q C Q Q Q \* N L V L D I L H  
K R Q F Q S A S S N N I \* S W I L \* I I

21661 AATCAAATAAGAGAATAACTTTCTCCATTTAATAATCAAGCGCTATGCGCATTCTCTAA 21720  
K T \* E R I S L P L N N T R S V R L S I  
N L K N E \* Q F L Y I I L E R Y A Y L S  
\* N I R K N F S T F \* \* N A I R T F L N

21721 AAACAACCACTATCAGAACATTTATGAACAATCTAGAGTAATTTAGATTGATACAATTA 21780  
K T P S L R T F V Q \* I E N F R F \* T L  
K Q Q H Y D Q L Y K N S R M L D L S H \*  
K N T I T K Y I S T L D \* \* I \* V I N I

21781 ATAAAAAATAAAAAATAAGACAATACCAAAATTACTTGGAGAATTACAACACAGAGT 21840  
\* K K I K K N R N H N \* H V E \* H Q T E  
N N K \* K K I E T I T K I F R K I N H R  
I K K N K \* K Q \* P K L S G R L T T D \*

21841 AAATTTGGTACTGACCAAAAAATAAACCACTATCAGCAAGACTAACATTGGTATAATTATT 21900  
N L G H S T K I Q H Y D N Q N Y G Y \* Y  
M \* V M V P K \* K T I T T R I T V M N I  
K F W S Q N K N P S L R E S Q L W I L L

21901 AAATTTTAAATTTTAAAACTAATAAACCTATAAGTGGGATCAAACACGTTGTTACCATT 21960  
N L F \* F N Q N N P Y E G \* N T C C H Y  
I \* F N F I K I I Q I N V R T Q A V I T  
K F I L F K S \* K S I \* G L K H L L P L

21961 CTAAAGTAGATCACGGCCACTAAGATAAAAAATCTCAAAGTAAAGTGAGCTAAAATATT 22020  
S K M \* H R H N \* K \* S N E N \* E I K Y  
L N \* R T G T I R N K L T K M E S S K I  
I E D L A P S E I K L L K \* K V R N \* L

22021 AATGTGACCGCTTCCACTAGTTTAATAAAAAATACTCCACAATTAAAATTAGGAATAGT 22080  
N C Q R L H D F \* K K H P H \* N \* D K D  
I V S A F T I L N N K I L T N I K I R I  
\* V P S P S \* I I K \* S P T L K L G \* \*

22081 ATCTAAATTCACAAAAGGATTACCATCATTACTACATACCGAAGAATTGTTCCATTCTAA 22140  
Y I \* T N E \* H Y Y H H I A E \* C P L I  
M S K L T K R I T T I I Y P K K V L Y S  
L N L H K G L P L L S T H S R L L T L N

FIG. 3 CONT'D

99/201

22141 AATAGCACGGAATATAAGATTATACCGGAAAAAAGCAATAGAATGAAAACAACATATAAGG 22200  
K D H R I N \* Y P R K E N D \* K Q Q Y E  
K I T G \* I R I H G K K T I K S K N I N  
\* R A K Y E L I A K K R \* R V K T S I G

22201 AATATTACAAAGAGAAAGATTCAAATTAAGAACATTTTCACTATAAAATAGTGAATTGTT 22260  
K Y H K E K \* T \* N K Y F H Y K I V \* C  
R I I N R K R L K I R T F T I N \* \* K V  
\* L T E R E L N L E Q L L S I K D S L L

22261 AGGATAAAAATAATTAATAAGATTCTTCAAATAAAATGAAATAATCCAACAAGAGAAAT 22320  
D \* K \* \* N N \* P L K N \* K I L N N E K  
I R N K N I I R L F N I K S \* \* T T R K  
G I K I L \* E L S T \* K V K N P Q E R \*

22321 AAATCATGGCGAAACGGAAAAATTTAGATTGAAATCAGTCATGATAATATTGTATCTATG 22380  
N L V A K G K \* I \* S \* D T S N Y C L Y  
I \* Y R K A K K F R V K T L V I I V Y I  
K T G S Q R K L D L K L \* Y \* \* L M S V

22381 ACCGAGACAAATACCAAAAAGATTACAACAAATAGGACTAAATCTGACATAAATATAAAG 22440  
Q S Q K H N K \* H Q K D Q N L S Y K Y K  
S A R N I T K R I N N I R I \* V T N I N  
P E T \* P K E L T T \* G S K S Q I \* I E

22441 AGAATTTGGTCCAAGAATATTTCAAAGGTGGTGACGTGGAAAAAATAGGAATGGATGATT 22500  
E \* V L N K Y L K W W Q V K K I R V \* \*  
R K F W T R I F N G G S C R K \* G \* R S  
R L G P E \* L T E V V A G K K D K G V L

22501 TCGAGAGACAAACTATTTAGATTGTGTTAAACATGGACATGTCCAACAACATAAGATCTAC 22560  
L E R N Q Y I \* V I Q V Q V P Q Q N \* I  
F S E T K I F R F L K Y R Y L N N I R S  
A R Q K S L D L C N T G T C T T S E L H

22561 CTTGTTGCTCGCACGGAGTCTATAAAGAAATAGACAACGTACAGTTAACGGTATAACAAT 22620  
S C R A H R L Y K K I Q Q M D I A M N N  
P V V L T G \* I N R \* R N C T L Q W I T  
F L S R A E S I E K D T A H \* N G Y Q \*

22621 AAAAGCGTTAAGAAGACGATTAATACAACCGTTCATACTATAATTGGTGCCACTATCACC 22680  
N E C N K Q \* N H Q C T H Y \* G R H Y H  
I K A I R R S I I N A L I I N V V T I T  
K R L E E A L \* T P L Y S I L W P S L P

FIG. 3 CONT'D

100/201

22681 AAAATAAAGATAAAATAGACCAGAAAATATATTACAAGAACATAAAGTATAATACCACA 22740  
N \* K \* K I Q D K I Y H K K Y K M N H H  
T K N R N \* R T K \* I I N R T N \* I I T  
K I E I K D P R K Y L T E Q I E Y \* P T

22741 TAAAAATATACTATTAAATGTAGGTAAACCGGGATAATAAGAAAACCATCCACAGGATG 22800  
I K I H Y N \* M W K A R N N K Q Y T D \*  
Y K \* I I I K C G N P G I I R K T P T R  
N K Y S L K V D M Q G \* \* E K P L H G V

22801 TAGAAGATAATAATTTGTAGGTAAACACAAATACTAAAAACGATAATAAAATGTTCC 22860  
M K \* \* \* V D L K H K H N K A \* \* K V L  
C R R N N F M W N T N I I K Q R N N \* L  
D E I I L C G I Q T \* S K K G I I K C P

22861 ATAAATAATACAAATCGAAATGAAAAACAACAAAAGATAATAAAAACAATATATTGCT 22920  
Y K I I N L K V K Q Q K E I I K T I Y R  
T N \* \* T \* S \* K K N N K \* \* K Q \* I V  
I K N H K A K S K T T K R N N K N Y L S

22921 ATTTAGAGTAATTTAGATTTGTACAATAATTAATAAAAAATAAACGGATGTTGTAATCGA 22980  
Y I E N F R F M N N I I K I K G V V N A  
I F R M L D L C T I L \* K \* K A \* L M L  
L D \* \* I \* V H \* \* N N K N Q R C C \* S

22981 CAATATCCACTAAAAATTAACATGATTAAACGATAATTACTAAATTTGTGGTGTCAAGGA 23040  
T I P S K L Q V L K A I L S K F V V T G  
Q \* L H N \* N Y \* N Q \* \* H N L C W L E  
N Y T I K I T S I K S N I I \* V G C N R

23041 GCGTATTCACCTCATACACACCTACAAGAATACCAAACCCATGTATAATATATGAAC TA 23100  
R M L S Y T T S T E \* P K P V Y \* I S S  
E C L H T H Q P H K K H N P Y M N Y V Q  
A Y T L I N H I N R I T Q T C I I Y K I

23101 GCACAAATAAATTTATGATGATATAATAAATGACCAATAAAGGATTTAGACCACGGTTA 23160  
R T \* K F V V I N N V P \* K G L D P A L  
D H K N L Y \* \* I I \* Q N N G \* I Q H W  
T N I \* I S S Y \* K S T I E R F R T G I

23161 AAATCCCTAGATAGAAAATTTCCATGATGTATAAACTCATGAGAAAACCATAGTCTTTGGG 23220  
K L S R D K F P V V Y K L V R Q Y \* F G  
N \* P D I K L L Y \* M N S Y E K T D S V  
K P I \* R \* F T S C I Q T S K P I L F G

FIG. 3 CONT'D

101/201

23221 AAAAATAGACTAAAATTATTACCATAAAAAAGATCTCAATTCCTTATGATTCAACATACAA 23280  
K K D S K L L P I K E L T L F V L N Y T  
R K I Q N \* Y H Y K K \* L \* S Y \* T T H  
K \* R I K I I T N K R S N L I S L Q I N

23281 TTATTTTGAAACATATCACTCAAATCATGATATCAATATCCATCACAAAAATAATTGTTG 23340  
L L V K Y L S N L V I T I P L T K I L L  
\* Y F K T Y H T \* Y \* L \* L Y H K \* \* C  
I F S Q I T L K T S Y N Y T T N K N V V

23341 AGAATATGATAACAACAAGTTGGAGTATTACCACAAAACCTCTAATGTCGAACAGTTATG 23400  
E \* V I T T \* G \* L P T K S I V A Q \* Y  
S K Y \* Q Q E V E Y H H K P S \* L K D I  
R I S N N N L R M I T N Q L N C S T L V

23401 TGATACACTCATAGGAGTATGATAAACATTTAGATTTCCATCAAGAGCATTACTTAGA 23460  
V I H S Y G \* V I Q L D L P L E R L S D  
C \* T H T D E Y \* K Y I \* L Y N E Y H I  
S H T L I R M S N T F R F T T R T I F R

23461 ACCGTAAACTATTTAGACTTGGAAACACAGACAAGTTCTTTTAAAAATGAATATTACAA 23520  
Q C K S L D S G K H R N L F F K V \* L T  
K A N Q Y I Q V K T D T \* S F N \* K Y H  
P M K I F R F R Q T Q E L F I K S I I N

23521 AGATGTCTAACCAACATAAAAGTAAAAATAGTTCTTGCACCGTGAAAAATACGAATAATA 23580  
E V S Q N Y K \* K \* \* S R P V K \* A \* \*  
K \* L N T T N E N K D L V H C K K H K N  
R C I P Q I K M K I L F T A S K I S I I

23581 CGACTAAGACCGTACGGATGATGAAAAATAAATCAAACATAGAACCATGAGAAAAATAGA 23640  
A S E P M G V V K K N L K Y R P V R K D  
H Q N Q C A \* \* K K I \* N T D Q Y E K I  
S I R A H R S S K \* K T Q I K T S K \* R

23641 GTAATAATACAAAACGGAAACTGAACATTACGATATAGAAGATTATGACTATTACTCTGA 23700  
\* \* \* T K G K V Q L A I D E L V S L S V  
E N N H K A K S K Y H \* I K \* Y Q Y H S  
M I I N Q R Q S T I S Y R R I S I I L S

23701 AATGTTATAACCCAGTGTGGAAACAGATTGCGGTTATAGAAGAATTTAAACTGTTGGCA 23760  
K C Y Q T V G K D L R W Y R R L N S L R  
K V I N P \* V K T \* V G I D E \* I Q C G  
\* L I P D C R Q R F A L I K K F K V V T

FIG. 3 CONT'D

102/201

23761 CCACAATAATGATTACGACAACAAAGATCATCAAAGAAATCGCTCTAAGTTACATT 23820  
P T I V L A T S Q E L L K K L S I \* H L  
H H \* \* \* H Q Q N N \* Y N R \* R S E I Y  
T N N S I S N I T R T T E K A L N L T F

23821 TGATTTAGAAATAATGGATTATGACCACAAATACTGAATAGACCAAAATGACAATTCGGA 23880  
V L D K N G L V P T \* S K D P K V T L G  
F \* I K I V \* Y Q H K H S I Q N \* Q \* A  
S F R \* \* R I S T N I V \* R T K S N L R

23881 CAACGTTGACATGTAGCAGCATAAGGACTAAATGGACTAACACTGTAACATTTACCGAA 23940  
T A V T C R R I G S K G S Q S M S L H S  
Q Q L Q V D D Y E Q N V Q N H C Q Y I A  
N C S Y M T T N R I \* R I T V N I F P K

23941 TTGTTAAATACATGGGAGTGGAGAATTAACCCCTGCATTTTAAAAAGATTACGTTG 24000  
L L K L T G E G R L Q S R L I K E L Q L  
\* C N \* H V R V E \* N P V Y F K K \* N C  
V I K I Y G \* R K I P F T F N K R I A V

24001 AAATTAACTCATGAAACGAAGCAAATCAAGTATGACTAAGAAAAAGAACATTATTAATA 24060  
K L K L V K S R K T \* V S E K E Q L L K  
S \* N S Y K A E N L E Y Q N K K K Y Y N  
K I Q T S Q K T \* N M S I R K R T I I K

24061 CTAATTAGATTCTATATACCATCAACAAAATTCTCATAACAAAATCTATTTAAACGGTAT 24120  
S S D L I Y P L Q K L L I T K S L N A M  
Q H I \* S I H Y N N \* S Y Q K L Y I Q W  
I F R L Y I T T T K L T N N \* I F K G Y

24121 GGGTTGAGGTCTGCTAGACTAAACGTCACCCGTCAGACCAAAAGACGTTAGAAGATTA 24180  
G L E L R D S K C N P L E P K R C D E L  
V W S W V I Q N A T P C N Q N E A I K \*  
G V G S S R I Q L Q A T R T K Q L R R I

24181 ATATTTTAACTGTGATGAAGATCAAGAACAGTTAACATAATATCAAACGGACGTTAATTA 24240  
\* L I S V V E L E Q \* N Y \* L K G A I L  
N Y F Q C \* K \* N K D I T N Y N A Q L \*  
I F N V S S R T R T L Q I I T Q R C N I

24241 CAATGATAATTATTAATATTAGGAAGAAGAACCTTATCTCCATACCAAAATTATTAATA 24300  
T V I L L \* L G E E Q F L L Y P K L L K  
H \* \* \* Y N Y D K K K S Y F T H N \* Y N  
N S N I I I I R R R P I S P I T K I I K

FIG. 3 CONT'D

103/201

24301 TTAAACTCGAGAGTATCACACAAATGAGTGCAATAACAAAAAGACAATTATTATGAAAA 24360  
L K L E \* L T T \* E R \* Q K E T L L V K  
\* N S S E Y H Q K S V N N N K Q \* Y Y K  
I Q A R M T N N V \* T I T K R N I I S K

24361 ACAGGAACACGATTGGAAGAAAACGAAGTTCAACGTTCTCAGTATTTGGTGAAGACGA 24420  
Q G Q A L G E K A E L Q L L \* L G G E A  
K D K H \* V K K Q K L N C S D Y V V K Q  
T R T S F R R K S \* T A L T M F W R R S

24421 AGGACAGGATAACCATGATTAATAGCAAGAACAACCTCTCATGATGACATGAGCTGGTGTGA 24480  
E Q G I P V L \* R E Q S L V V T S S W V  
K R D \* Q Y \* N D N K H S Y \* Q V R G C  
G T R N T S I I T R T L T S S Y E V V S

24481 CTGACCACATCCACAAGAACAATGGACTAGGATATTGACGAATACTGGGATCCAGAACA 24540  
S Q H L H E Q K G S G I V A \* S G L D Q  
Q S T Y T N K N V Q D \* L Q K H G \* T K  
V P T P T R T \* R I R Y S S I V R P R T

24541 AGAGTTTTTTTCAGAGACCAACCACAACCACTTGTAACACGTCCCAAGCCACAACACTACTT 24600  
E \* F F D R T P T P S C Q A P N P T S S  
N E F F T E P Q H Q H V N H L T R H Q H  
R L F L R Q N T N T F M T C P E T N I F

24601 CTTTTCACACCACATAACCTACCTAGTATATTACAAAGAACAGAAACATCATGACTACGG 24660  
S F H P T N S P D Y L T E Q R Q L V S A  
L F T H H I P H I M Y H K K D K Y Y Q H  
F L T T Y Q I S \* I I N R T K T T S I G

24661 AAAGATCCAACCAGAATACTGTGAACGCAGTCATTGTTGGCAACATTATAAAAAAGATTA 24720  
K R P Q D \* S V Q T L L L R Q L I K E L  
R E L N T K H C K R \* Y C G N Y Y K K \*  
K \* T P R I V S A D T V V T T I N K R I

24721 AAATAAAATTTACCATAGTTATCACCATGGTGAACAAGATTACTAAATAACGTCGGGATTA 24780  
K I K F P I L L P V V Q E L S K N C G L  
N \* K L H Y \* Y H Y W K N \* H N I A A \*  
K N \* I T D I T T G S T R I I \* Q L R I

24781 TGACTTCAAAAATGACTACAAACACAACCTAATGCTGGAAATACCATAATGTCCTGTCCA 24840  
V S T K V S T Q T S \* S R \* P I V P C P  
Y Q L K \* Q H K H Q N R G K H Y \* L V L  
S F N K S I N T N I V V K I T N C S L T

FIG. 3 CONT'D

104/201

24841 TAAAAATTTCTTCAAAGACGACAAATAATATTATCAACCGTTTGTAGAAAACATACTAAGA 24900  
I K L S T E A T \* \* L L Q C F R K Y S E  
Y K \* L L K Q Q K N Y Y N A F D K T H N  
N K F F N R S N I I I T P L I K Q I I R

24901 TTACCGTTGTAATAACCAAAATTTCTAAAACAATGATTATTTGTATATATATAAGGGA 24960  
L P L M I P K L S K T V L L V Y L I K G  
\* H C C \* Q N \* L N Q \* \* Y F M Y Y K G  
I A V N N T K F I K N S I F C I I N E R

24961 ACAATACGTCCTTCTCAAAGACGACGAAAAGTAGTTTACGAAGGAGAAACCGAAATGAA 25020  
Q \* A P L T E A A K \* \* F A E E K A K S  
K N H L F L K Q Q K E D F H K R K P K V  
T I C S S N R S S K M L I S G R Q S \* K

25021 ATAGCATTAAATTTTACATCGATACAAAACCTATTATAAAGAAATGATGAGTCGGTATA 25080  
\* R L K F H L \* T K F L I E K V V \* G Y  
K D Y N L I Y S H K S Y Y K K L \* E A M  
I T I \* F T A I N Q I I N R \* S S L W I

25081 AAATATCAATAGAACCAACGCAAAAATTACGACTATTAAATTGACTAATAAGACAAAGA 25140  
K S L \* R P Q T K L A S L K V S \* E T E  
N Q Y N D Q N R K \* H Q Y N L Q N N Q K  
K I T I K T A N K I S I I \* S I I R N R

25141 AGAACACGAGAAGCGTACCCATCACCAAAAACACAATAATATTGAGTGGAAGAAGAAGG 25200  
E Q A R R M P L P K Q T S \* L E G E E E  
K K H E E C P Y H N K H Q N Y S V K K K  
R T S K A H T T T K T N I I V \* R R R G

25201 AGAAGCGCAGCATTTCATCTTCATAAAGACGAAGAATAGCAAAACAATGAAAACCTGGG 25260  
E E R R L R L L I E A E \* R K T V K S G  
R K A D Y V Y F Y K Q K K D N Q \* K Q V  
R R T T F T S T N R S R I T K N S K F G

25261 AAATTACAGTCAAAACAATTACTGTCACTCACTCAGACACCCACCAGAAATACTCTAGTTT 25320  
K L T L K T L S L I S D T P P R \* S I L  
R \* H \* N Q \* H C Y Q T Q P H D K H S \*  
K I D T K N I V T N L R H T T K I L D F

25321 TAAGGGTGATTGAAATGATATCAACGAGTTCTCCTTAAATAAGTTTGATTAGAGGATTT 25380  
I G V L K V I T P \* S S N I \* V L E G L  
F E W \* S \* \* L Q D L P I \* E F \* N E \*  
N G S V K S Y N T L L F K N L S I R R F

FIG. 3 CONT'D

105/201

25381 CAATGATAACTAACAAGAAATAAACAGACAAGATTAAATACGTGGAACGGTACTGAATAAC 25440  
T V I S Q E K N T Q E L \* A A Q W S K N  
L \* \* Q N N K I Q R N \* N H L K G H S I  
N S N I T R \* K D T R I I C S A M V \* Q

25441 AGTCTCATACCGTGAAAAACACTATTATAATTATCATAAAATCTACTTCAATTACCAAAT 25500  
D S Y P V K Q S L I L L I K S S T L P K  
T L T H C K K H Y Y \* Y Y K L H L \* H N  
\* L I A S K T I I N I T N \* I F N I T \*

25501 GAACTATGATGAGTTAACGTACATCGACTATGAGAATACGTTCCACAGTGTGAATCGAGG 25560  
S S V V \* N C T A S V R I C P T V S L E  
V Q Y \* E I A H L Q Y E \* A L H \* V \* S  
K I S S L Q M Y S I S K H L T D C K A G

25561 TTAGAATTATGATTAAACGTAAACTACAACTATTATAATTAAAATTTAGGGATCAACCT 25620  
L R L V L K C K S T S L I L K L D R T P  
W D \* Y \* N A N Q H Q Y Y \* N \* I G L Q  
I K I S I Q M K I N I I N I K F G \* N S

25621 ACAAATCCAGGTGTGACGCCAAGAAGAAGAGCAAGAAAAAACTTCTAAATAACAACTG 25680  
H K P G C Q P E E E R E K K S S K N N S  
I N L D V S R N K K E N K K Q L N I T Q  
T \* T W V A T R R R R T R K K F I \* Q K V

25681 TTTCAATTTGAAAGTCTACAACCAAAACAACTTCGAATATTGTTAACATGACCACCATCA 25740  
L T L S E S T P K T S A \* L L Q V P P L  
C L \* V K L H Q N Q Q L K Y C N Y Q H Y  
F N F K \* I N T K N F S I V I T S T T T

25741 CTTTAATCTCTAGAAGAAACACATGTTAGGAAATTACCATAATTTCAAAACGGAGGATAA 25800  
S I L S R R Q T C D K L P I L T K G G I  
H F \* L D E K H V I R \* H Y \* L K A E \*  
F N S I K K T Y L G K I T N F N Q R R N

25801 AACAGACTTAGAGTTTAAAGACCAATGTGGTGTGCGCGATGACAACGACGATACAAAGGT 25860  
K D S D \* I E P \* V V A A V T A A I N G  
K T Q I E F K Q N C W L R \* Q Q Q \* T E  
Q R F R L N R T V G C G S S N S S H K W

25861 GGTACCAGTCGTCGTCGACCGTATGGTAAAAGAGAATTACATGTTATATCTTAATTACCA 25920  
G H D A A A P M G N E R L T C Y L I L P  
V M T L L L Q C V M K E \* H V I Y F \* H  
W P \* C C S A Y W K R K I Y L I S N I T

FIG. 3 CONT'D



106/201

25921 AACCCACAATGATACCTACAAGAATTATTTTAGT'TTTCAACTATCGATGACGAAAATTA 25980  
K P T V I S T R L L F \* F N I A V A K L  
N P H \* \* P H E \* Y F D F T S L \* Q K \*  
Q T N S H I N K I F I L L Q Y S S S K I

25981 TTACGAGAAGAAAAGATAAGTCTTACCAAAATCAGATGGTTGAGACGTGAACGATTTTAT 26040  
L A R R E I \* F P K L A V L E A S A L I  
Y H E E K \* E S H N \* H \* W S Q V Q \* F  
I S K K R N L I T K T S G V R C K S F Y

26041 GTTTCACAACAATTAAGATTACGAGTTCGTGAATTATCAAACAATGTCGTTAATAAATTA 26100  
C L T T L E L A \* A S L L K N C C N N L  
V F H Q \* N \* H E L V \* Y N T V A I I \*  
L T N N I R I S L C K I T Q \* L L \* K I

26101 TTAAACCACGTTAATCAAGAAGAAATGTTCTTTAAATAGAGCAGAGCTACGAAATCTC 26160  
L N P A I L E E K C S I K D R R S A K S  
Y I Q H L \* N K K V L F K I E D R H K L  
F K T C N T R R \* L F N \* R T E I S \* L

26161 CGAGTCCAAGTCTAACTATCCGAATAATTACCAGCAAATTGACGAAATTTACGAATACAG 26220  
A \* T \* I S L S I L P R K V A K F A \* T  
P E P E S Q Y A \* \* H D N L Q K L H K H  
S L N L N I P K N I T T \* S S \* I S I D

26221 AGAGTTGTGGAATCACTATAAAGAGAACATTTTAAACCACGACGAAATCGATACCTCTTC 26280  
E \* C S L S I E R T F N P A A K A I S F  
R E V A \* H Y K E Q L I Q H Q K L \* P S  
R L L K T I N R K Y F K T S S \* S H L L

26281 CAATTACTCACACAATTTTCAGTTAGAGGAGCATAATTAAAAACACCATTAACATTAGTA 26340  
T L S H T L L \* D G R I L K Q P L F L \*  
P \* H T H \* F D I E E Y \* N K H Y H Y D  
N I L T N F T L R R T N I K T T I T I M

26341 TAAAACAGTAATCAAGTTTTCAGGGAATACCAAACAACAAATACGTAAAAATCAATATTT 26400  
I K D N T \* F A G \* P K N N I C K L \* L  
Y K T M L E F H E K H N T T \* A N \* N Y  
N Q \* \* N L I S R I T Q Q K H M K T I F

26401 GGATAAAGAAAAATTTTGACAAAATCATTCAGGACCAACACATATAGTCCACTACATCCA 26460  
G I E K L V T K T L G P K H I D P S T P  
V \* K K \* F Q K L L D Q N T Y I L H H L  
R N R K F S N \* Y T R T Q T Y \* T I Y T

FIG. 3 CONT'D

107/201

26461 TAACGTGGATTGTGCCATAAAATAATTTGTATTACTAGTAACCTACAAGTGACCATCA 26520  
I A G L C P Y K I L C L S \* Q I N V P L  
Y Q V \* V L T N \* \* V Y H D N S T \* Q Y  
N C R F L P I K N F M I I M P H E S T T

26521 AGAATGATAATAGGACTTGGTTAAAGTCTATTTTTACAACAAAATACTTATGAACAAGA 26580  
E \* \* \* G S G I E S L F T T K I F V Q E  
N K S N D Q V L K L Y F H Q K \* S Y K N  
R V I I R F W N \* I F I N N K H I S T R

26581 CAATTAAATGATTTCGCGGAGAACAAATAAACTTAGTAAGACATGGTTTAAACAGACTA 26640  
T L K V L A G R T \* K F \* E T G F N D S  
Q \* N \* \* L A E Q K N S D N Q V L I T Q  
N I K S F R R K N I Q I M R Y W F Q R I

26641 AAACCTAGACTCAATAGAGTAACCAAATTTTGTAGTTGTAGGTAAACGCGGATTAAACTGA 26700  
K S D S N D \* Q N L F \* V D M A G L K V  
N Q I Q T I E N T \* F D F M W Q A \* N S  
K F R L \* R M P K F I L C G N R R I Q S

26701 AATTTAGAAGTATGATAATTACGATGAAAAATCTAACATAATACCTACTTAGAATAA 26760  
K F R \* V I L A V K K S K Y \* S I F R I  
K L D E Y \* \* H \* K K L N T N H S S D \*  
\* I K M S N I S S K \* I Q I I L H I K N

26761 GTTCTCAGATAATTCAGAACTTATTATCAATATAGTTAGAATTCTATATCCATGTATA 26820  
\* S D I L D K F L L \* I L R L S I P V Y  
E L T \* \* T K S Y Y N Y \* D \* L Y L Y M  
L L R N L R Q I I T I D I K F I Y T C I

26821 CTTTACATACATTTTACCGGAACCATACAAACCGATGATTAAAGAAAAAGTAAATATTAT 26880  
S I Y T F H G Q Y T Q S S I E K E N I I  
H F T H L I A K T H K A V L K K K M \* L  
F H I Y F P R P I N P \* \* N R K \* K Y Y

26881 AAGGAACATAACGAGAAAAATATACAACAACATGACCAACACCAAGACGTACAAAATCA 26940  
N R T N S K K I H Q Q V P Q P E A H K L  
I G Q I A R K \* I N N Y Q N H N Q M N \*  
E K Y Q E K K Y T T T S T T T R C T K T

26941 TTTACAGTATTAACAACACTACTCATACCACAGTAGTACTAAAACAATAGTTTGTAGA 27000  
L H \* L Q Q S S Y P P \* \* S K T I L V D  
Y I D Y N N H H T H H D D H N Q \* \* F M  
F T M I T T I L I T T M M I K N D F C R

FIG. 3 CONT'D

108/201

27001 GTACTACTAATCTTAGAGAACAGTCTAGAGTAATTTAGATTGAAATAAATACCTGCAAA 27060  
\* S S \* F R K D S R M L D L S \* K H V N  
E H H N S D R T L D \* \* I \* V K N I S T  
M I I L I E Q \* I E N F R F K I \* P R K

27061 CCTCTGGATCGATGTGTGTAAGAGAACAAATAATCTCTTAAACCACAATGTTTGGAACTTC 27120  
P S R A V C M R K N N S F K T N C V K F  
Q L G L \* V C E R T I L S N P T V F R S  
S V \* S C V N E Q \* \* L I Q H \* L G Q L

27121 TAAACACAGATTTTCATATTAATGACAGTTGGATAACAACCAATGACATAACATGGAAATT 27180  
I Q T \* L I I V T L R N N T V T N Y R \*  
S K H R F Y L \* Q \* G I T P \* Q I T G K  
N T D L T Y N S D V \* Q Q N S Y Q V K L

27181 TACAAACCACAGCGTTCAAACCGTTTAAACGAAGAGTGAAATGTAATGCATCAGTGCTAT 27240  
I N P T A L K A F K S R V K C \* T T V I  
F T Q H R L N P L N A E \* K V N R L \* S  
H K T D C T Q C I Q K E S \* M V Y D R Y

27241 AAAGGGTATCATTATTAAAACCAACATGATCAAAATGATGAATACCATTTATGACAAA 27300  
N G M T I I K T N Y S T K S S I T I S N  
I E W L L L K P T T V L K V V \* P L V T  
K G Y Y Y N Q H Q L \* N \* \* K H Y Y Q K

27301 GACTCCGACACAGATCTAATCAACTTAGTCGAAGACTTAAATAACAAACCGCACGTC?CC 27360  
R L S H R S \* N F \* S R F K N N P T C L  
E S A T D L N T S D A E S N I T Q R A S  
Q P Q T \* I L Q I L K Q I \* Q K A H L P

27361 GTGAATTATTCATACCACTAAATAAAAAAGTTACTATGACGAACCATGTATCCTGTCTAA 27420  
C K I L I T S K N K L S V A Q Y M P C I  
A S L L Y P Q N I K \* H Y Q K T C L V S  
V \* Y T H N I \* K E I I S S P V Y S L N

27421 AATCAAAATCAAAATAAAACAGAATAAAGAAATTAGAAACAACAACGAAAAAATCGTTGA 27480  
K T K T K N Q R I E K I K T T A K K A V  
K L K L K I K D \* K K L R Q Q Q K K L L  
\* N \* N \* K T K N R \* D K N N S K \* C S

27481 TAATTCGAAACATACGTTGAAACACCAAAAACATTAAGAAATAATAAAGTGGAAGCCGA 27540  
I L S Q I C S Q P K Q L K K I I E G E A  
\* \* A K Y A V K H N K Y N R \* \* K V K P  
N L K T H L K T T K T I E K N N \* R R S

FIG. 3 CONT'D

109/201

27541 ATGCAATATTTTCTCCATACGTCAACATATTCAGAATATCACTTGTTC AATATGGTGGG 27600  
\* T \* L L P I C N Y L D \* L S C T I G G  
K R K Y F L Y A T T Y T K Y H V L \* V V  
V N I F S T H L Q I L R I T F L N Y W G

27601 TGAAGTCTAATAAATTAGATTTAGATTTGTAATACTTATTTAGAAAAGAAGGAGTTAAAT 27660  
V E S \* K I \* I \* V N H I F R K K R L K  
W K L N N L R F R F M I F L D K R G \* N  
S \* I I \* D L D L C \* S Y I K E E E I \*

27661 GAAGACTAGTTCGACAATGTAAGAATTTTCTTACCTTAAGAGAAACCCACATTATGATG 27720  
S R I L S N C E \* F F P I E R Q T Y Y \*  
V E S \* A T V N K F S H F K E K P T I S  
K Q D L Q \* M R L L I S N R K P H L V V

27721 AAAAATAATGATAGTATAACGTCAAGCCAATATGCTCGGCATCATACAAAACAAATAGAAT 27780  
K K N S D Y Q L E T I R A T T H K N I K  
S K I V I M N C N P \* V L R L I N T \* R  
K \* \* \* \* I A T R N Y S G Y Y T Q K D \*

27781 AGTTCTACTAATAAGAAACCGAATACACCGGTAACGTAGTAGTGGAACTGATATAAATTAA 27840  
D L H N N K P K H P W Q S D G Q S Y K I  
I L I I I R Q S I H G N V I V K V I N L  
\* S S \* E K A \* T A M S \* \* R S \* I \* N

27841 CAAAAATACGAACTTATTACGAAAAGAACGTAAAAGATATCACAATGATAATAAAGAT 27900  
T K I S Q I I S K K C K R Y H K S N N R  
Q K \* A K F L A K R A N E I T N V I I E  
N K H K S Y H K E Q M K \* L T \* \* \* K \*

27901 AACAAATACCTAAGAAATAAAACAATTATCATAAGCCGAAAAATAATCTTGACCGTCAA 27960  
N N Y P N K I K N I T N P K K N S S A T  
I T I H I R \* K T L L I R S K I L V P L  
Q \* I S E K N Q \* Y Y E A K \* \* F Q C N

27961 CCACCTCAAAATTAGGTCTCTGGTTATTAGAAATACACATAACTATACTTTCCGTTCTACA 28020  
P P T K I W L G I I K H T N I H F A L H  
Q H L K L G S V L L R I H I S I F P L I  
T S N \* D L S W Y D \* T Y Q Y S L C S T

28021 AACAAATCCGGTCAATAACTCCTGATAGTGTGTAATTGACGATGACAATAAGCACCAGTAG 28080  
K N P W N N L V I V C \* S S S N N T T M  
N T L G T I S S \* \* V N V A V T I R P \*  
Q \* A L \* Q P S D C M L Q \* Q \* E H D D

FIG. 3 CONT'D

110/201

28081 AAATATATGTCCACAGTTTGAACCGTGACCAATATGAGAAAGTCTAAACGGGCATATAC 28140  
K I Y L T D F K A S T I S K \* I Q G Y I  
R \* I C P T L S P V P \* V R E S K G T Y  
K Y V P H \* V Q C Q N Y E K L N A R I H

28141 AATGACATCGATTCCACGTTTCATGAAACATGGATATTTGCACGGAAAAATCTATTCAATC 28200  
N S Y S L H L Y K T G I F T G K \* I L \*  
T V T A L T C T S Q V \* L R A K K S L N  
\* Q L \* P A L V K Y R Y V H R K L Y T L

28201 TACAATTATCACCAAAACGACAAAACAATTAGATTTCAACCATTGATAGCAAATGGCA 28260  
I N I T T K S N K N L R F N T V I T \* R  
S T L L P K A T K T L D L T P L \* R K G  
H \* Y H N Q Q K Q \* T \* L Q Y S D N V T

28261 GATCATTGGATCACCATACCTATGACGGAACAATTCGAAATTTAGATTTGATAATCCT 28320  
R T F R T T H I S G Q \* S S L D L S N P  
D L L G L P I S V A K N L A \* I \* V I L  
\* Y V \* H Y P Y Q R T L L K F R F \* \* S

28321 ACAGAATATGAGGGCCAGTAATACGACCTTCATCTTCGAGGAGACCTTTAGCAAGTCCTT 28380  
H R I S G T M I S S T S A G R S I T \* S  
I D \* V G P \* \* A P L L L E E P F R E P  
T K Y E R D N H Q F Y F S R Q F D N L F

28381 AGGAGTTCTTTTGAAGAACCGACTGGTTAGACTCGCTTTAATGGTTGGAAATATATCTC 28440  
D E L F S R P S V L R L S I V L G K I S  
I R L F V E Q A S W D S R F \* W V K L L  
G \* S F K K P Q G I Q A F N G F R \* Y L

28441 CGTCTTTTGGGTTGGATTTAAGTGACACAGATGAGTTGGTGTTCCTTTATGATAGGGTG 28500  
A S F G L R F E S H R S L W L S I S D W  
P L F V W G L N V T D V \* G C P F V I G  
C F F G V \* I \* Q T \* E V V L F Y \* G V

28501 TAATAAGGACCAAGAGGCCCTAGTGAGTTAAAGTTTTTCCATCTCTGAAATTTAAAAGTC 28560  
M I G P E G P D S L K L F T S V K F K \*  
C \* E Q N E P I V \* N \* F P L S K L N E  
N N R T R R S \* E I E F L Y L S \* I K L

28561 TACGAGTTCTCAAGGGTAACGAAAGCCTCATGGGGGAAGACTTCGTTTTCTATAACCA 28620  
I T L S N G N S E S Y G R R F C F S I P  
S P \* P T G M A K P T G G E S A F P Y Q  
H D L L E W Q K R L V G K Q L L L I N T

FIG. 3 CONT'D

111/201

28621 TATCTGTGTCGGCCGCAAGAAAATTTGTGCGACTACCGTTGTTTTCGTCAACAATGGCT 28680  
I S V A P T R K F C S I T L L L L Q \* R  
Y L C L R R E K L V A S P \* C F C N N G  
Y V C G A N K \* F L Q H D V F A T T V S

28681 CTACCATAAAGATGATAGAGCCATGGCCGGGTATACGGTTACGTAGGATACCACTTAGGG 28740  
S P I E V I E T G A W I G I C G I T F G  
L H Y K \* \* R P V P G Y A L A D \* P S D  
I T N R S D R Y R G M H W H M R H H I G

28741 AGCTTCCCCAGAAGACCCAACGATTAGTGGTTCGACTGTGAAGATGAGGGAGGCTACAAA 28800  
E F P D E P N S I V L S V S R S G G I N  
R S P T K Q T A L \* W A S V E V G E S T  
R L P R R P Q \* D G L Q C K \* E R R H K

28801 GCAGTTCCTTAGGATGATGAGTTCTTCGATAGGGATGATCCAAAGGCGGACCATGCTAAA 28860  
R \* P I R S S L F S D R S P K R R T R N  
E D L S G V V \* S A I G V L N G G P V I  
T L P D \* \* E L L \* G \* \* T E A Q Y S K

28861 ACGGAGTTCGGATAATAACAACCTCCGAGTCCTTCAGACGAAGATTATCAGCTGGTCCAA 28920  
Q R L A I I N F A \* S P R S R I T S W T  
K G \* P \* \* T S P E P L D A E L L R G P  
A E L S N H Q L S L F T Q K \* Y D V L N

28921 GTGCAAGAGTTAGTGCACCTGGGTATTAGCAAGTAATTCATCTTCATTAAGATTAAAAAT 28980  
\* T R L \* T S G I I T \* \* T S T I R I K  
E R E \* D R P G L L R E N L L L L E L K  
V N E I V H V W Y D N M L Y F Y N \* N \*

28981 CTGTAAGTCTAAGATATCATTTTGGACTATACCGACTACTCTAGCGATTAGAACAAAATC 29040  
S M \* I R Y Y F R I H S I L D S I K N \*  
L C E S E I T F G S I A S S I A L R T K  
V N L N \* L L V Q Y P Q H S R \* D Q K L

29041 GGTTCGAACCATTTCTAAGATTGGAGTCGTTTCAGTGATTTCGTTTACGGTTCCTTTAGT 29100  
G L K T F I R F R L L D S L L I G L F D  
A L S P L S E L G \* C T V L C F A L S I  
W A Q Y L N \* V E A L \* \* A F H W P F \*

29101 CCGTATTTTAAAAATTGTTTGGAGCGGTTTTCGCTTGAGGATTATTTGTAACATTACAAG 29160  
P M F N \* C F R A L L S S R I F M T I N  
L C L I K V F G R W F R V G L L C Q L T  
A Y F K L L V E G F A F E \* Y V N Y H E

FIG. 3 CONT'D

112/201

29161 TTGTCACAAAACCATTTTCTCCTGGAAGAGTTTTAAACCATTACGACTTTACAATTTG 29220  
L L T K T F S S R R L I K T I S F H \* L  
\* C H K P L L P G E \* F K P L A S I N F  
V T N Q Y F L V K E F N Q Y H Q F T L A

29221 AACCATGATTACTAGGAGTCAAAGGATAAGAACGCTTTAATCGAGGATGTGGTCCACGAA 29280  
K T S I I R L K R N K C F \* S R C W T S  
S P V L S G \* N G I R A S N A G V G P A  
Q Y \* H D E T E \* E Q L I L E \* V L H K

29281 AAAAGAAACCAAGATTTAATCTGAACCAATTTTCTCTAAGGCTCCGACTGAGTGGACAAT 29340  
K E K T R F \* V Q N F S I G L S V \* R N  
K K K F E L N S K T L L S E S A S E G T  
K R Q N \* I L S P \* F L N R P Q S V Q \*

29341 TTCTACAAAACCTGAAGTAATAAGACCAAGATAATCCAACTATCATGAAATGGTCCGA 29400  
F I N K F K M I R T R N P K I T S \* W A  
L S T K S S \* \* E P E I L N S L V K G P  
L H K Q V E N N Q N \* \* T Q Y Y K V L S

29401 AACTCTGTTAATACTTTCAAGAAGCTTCTCTTAAATTACGAATGCAATTAAGATTAGTCT 29460  
K L C N H F N K F L I \* I S V N I R I L  
K S V I I F T R S S F K F A \* T L E L \*  
Q S L \* S L E Q L S N L H K R \* N \* D S

29461 TGTGACTAAGACTAAGCAACTCAAGATTTGGAGTCGCATTTTCTCCACAATTTGTTAATG 29520  
V S I R I R Q T R F R L T F S T N F L \*  
F V S E S E N L E L G \* R L L P T L C N  
C Q N Q N T S N \* V E A Y F L H \* V I V

29521 GTCTTGTCAAACCTGAGAGAATTAAATTCACGACCATGAGTCGTGTAAAGTTTACTAAAAT 29580  
W F L K V R K I \* T S T S L V N \* I I K  
G S C N S E R L K L A P V \* C M E F S K  
L V T Q S E \* N L H Q Y E A C K L H N \*

29581 GAGGACTCCTAGTATCAAATGAACGATGAGAACTACTAGGAATACATCTTCTGAGACAAC 29640  
S R L I M T \* K S S K I I R I Y F V R N  
V G S S \* L K S A V R S S G \* T S S E T  
E Q P D Y N V Q \* E Q H D K H L L S Q Q

29641 GAATTACTCTTACTTAGGATTAAGCTGTGATCCACCATTGGGGAGCGATAATAAGCCTTA 29700  
S L S F S D \* N S V L H Y G R A I I R F  
A \* H S H I R I R C \* T T V G R \* \* E S  
K I L I F G L E V S P P L G E S N N P I

FIG. 3 CONT'D

113/201

29701 TCCTGTGAGAGATAGTCTTACTTAAGAACGACATTATTGTCTATCTCATCCAACAATGTC 29760  
L V S E I L I F E Q Q L L L Y L L N N C  
Y S V R \* \* F S N K S Y Y C I S Y T T V  
P C E R D S H I R A T I V S L T P Q \* L

29761 TGATATATAATTAATCATCTTTAAATATAAATCTGTAAACTAACAATCTCATCAATATT 29820  
V I Y \* N T S I K Y K S M Q N N S Y N Y  
S \* I N I L L F K I N L C K I T L T T I  
S Y I L \* Y F N \* I \* V N S Q \* L L \* L

29821 CCAAATCGACATCATATTTGCGGAGGCCCTTCTCGATAGTTAACATCACAAATTATATAI 29880  
P K A T T Y V G G P L A I L Q L T \* Y I  
L N L Q L I F A E P F L \* \* N Y H K I Y  
T \* S Y Y L R R R S S S D I T T N L I Y

29881 ATAATCATATACTAACTTTAATTAATATCGGAAAACCTCCTTAATGTTTTTTTTTTTTTT 29940  
Y \* Y I I S I L \* L R K S S N C F F F F  
I N T Y S Q F \* N Y G K P P I V F F F F F  
I L I H N F N I I A K Q L F \* L F F F F

29941 TT 29942  
F  
F

FIG. 3 CONT'D



114/201




FIG. 4

115/201




FIG. 5A

116/201




FIG. 5B

117/201




FIG. 6

118/201




FIG. 7

119/201




FIG. 8

120/201

1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGAGATCTCAT 60  
E \* E R I A S V P S I S L R S L V R S H  
N K S E L R P Y R L S A Y D L L S D L I  
I R A N C V R T V Y Q L T I S C Q I S L

61 TAAATCTAAACTTTTAAACAAGATTCCTGTTATCCATGCTTGTGAGTGTGGTTAATC 120  
\* I \* T F \* T R F P V I H A C E C G L I  
K S K L F K Q D S L L S M L V S V V \* S  
N L N F L N K I P C Y P C L \* V W F N H

121 ATAATCTTGTATTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTTGGTTGTC 180  
I I L Y F T F H T F H L S A S D V L V V  
\* S C I L L S T L F I S L P V T C W L S  
N L V F Y F P H F S S L C Q \* R V G C P

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAAACCAGCAAATACGGTCTCGGCTTCAA 240  
L S V P P I G R N D \* N Q Q I R S R L Q  
S A S L P \* V A M I K T S K Y G L G F K  
Q R P S H R S Q \* L K P A N T V S A S S

241 GTGGGCGCCAGAATTTTCGTTGGCTGCTTCCGGATGCAGCGGAGGAGTTGGCTAGTCCTAT 300  
V G A R I S L A A S G C S G G V G \* S Y  
W A P E F R W L L P D A A E E L A S P M  
G R Q N F V G C F R M Q R R S W L V L \*

301 GAAGTCAGATGAGGGTGGGTTATGCCCCCTCTACTGGTCAAGCGATGGAAAGTGTGGATT 360  
E V R \* G W V M P L Y W S S D G K C W I  
K S D E G G L C P S T G Q A M E S V G F  
S Q M R V G Y A P L L V K R W K V L D L

361 TGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420  
C L \* \* S C E D R L S L H S W T R M A C  
V Y D N H V K I D C R C I L G Q E W H V  
F M I I M \* R \* I V A A F L D K N G M C

421 GCAGTCAAATCTTATCCGTGATATTTTGTTCATGAAGATCTACATGTTGTAGAAGTTCT 480  
A V K S Y P \* Y F C S \* R S T C C R S S  
Q S N L I R D I F V H E D L H V V E V L  
S Q I L S V I F L F M K I Y M L \* K F \*

481 AACTAAACAGCCGTAAAGTCCGGTACGGCAATTTTAAATTAATCACCTTTGCATAGCTT 540  
N \* N S R K V R Y G N F N \* I T F A \* L  
T K T A V K S G T A I L I K S P L H S L  
L K Q P \* S P V R Q F \* L N H L C I A W

FIG. 9

## 121/201

541 GGGTGGTTTTCCTAAAGGGTATGTTATGGGCTTGTTCGGTTCATACAAGACTAAACGTTA 600  
G W F S \* R V C Y G L V P F I Q . D \* T L  
G G F P K G Y V M G L F R S Y K T K R Y  
V V F L K G M L W A C S V H T R L N V M

601 TGTGTACATCATCTTTCTATGACTACATCTACTACTAATTTTGGTGAAGATTTTTTGGG 660  
C C T S S F Y D Y I Y Y \* F W \* R F F G  
V V H H L S M T T S T T N F G E D F L G  
L Y I I F L \* L H L L L I L V K I F W V

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTACAAAATGGTTTCAATTCTGTAG 720  
L D C T F W F Y A I L C S Q M V S I L \*  
W I V P F G F M P S Y V H K W F Q F C R  
G L Y L L V L C H L M F T N G F N S V G

721 GTTGTATATTGAAGAGAGTGATTTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780  
V V Y \* R E \* F N N F K F \* I \* \* L \* F  
L Y I E E S D L I I S N F K F D D Y D F  
C I L K R V I \* \* F Q I L N L M I M I L

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAAATATTCACAAAA 840  
\* C R R C L C \* G S C \* A \* R \* I F T K  
S V E D A Y A E V H A E P K G K Y S Q K  
V \* K M L M L R F M L S L K V N I . H K K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAAACCCGTACTCTTTGTAGACCAGTA 900  
S L C F T \* T I S W Y \* T R T L C R P V  
A Y A L L R Q Y R G I K P V L F V D Q Y  
L M L Y L D N I V V L N P Y S L \* T S M

901 TGGTTGTGACTATTCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATTCTTT 960  
W L \* L F W \* I S R L S S S L W S L F F  
G C D Y S G K L A D C L Q A Y G H Y S L  
V V T I L V N \* Q I V F K L M V I I L C

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGCGACTTTGATATTGTAGT 1020  
A R Y E T K A V C M A C Q L R L \* Y C S  
Q D M R Q K Q S V W L A N C D F D I V V  
K I \* D K S S L Y G L P I A T L I L \* W

1021 GGCTTGGCATGTAGTTCGTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080  
G L A C S S \* F T I C Y A P A D Y S Y Y  
A W H V V R D S R F V M R L Q T I A T I  
L G M \* F V I H D L L C A C R L \* L L F

FIG. 9 CONT.



## 122/201

1081 TTGTGGTATTAAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGCTGTAGTTAT 1140  
L W Y \* I C C T T Y R R C S R W S C S Y  
C G I K Y V A Q P T E D V V D G A V V I  
V V L N M L H N L Q K M \* \* M E L \* L Y

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTTAAAGCTTCCTAGTTTGAT 1200  
T \* T C T F I I C \* C N S F K A S \* F D  
R E P V H L L S A D A I V L K L P S L M  
V N L Y I Y Y L L M Q \* F \* S F L V \* \*

1201 GAAAGTTATGACTCATATGGATGATTTTCTATTAAATCTATATACAATGTTGATTTGTG 1260  
E S Y D S Y G \* F F Y \* I Y I Q C \* F V  
K V M T H M D D F S I K S I Y N V D L C  
K L \* L I W M I F L L N L Y T M L I C V

1261 TGATTGTGGTTTTGTTATGCAGTATGGTTATGTAGATTGTTTTAATGATAATTGTGATT 1320  
\* L W F C Y A V W L C R L F \* \* \* L \* F  
D C G F V M Q Y G Y V D C F N D N C D F  
I V V L L C S M V M \* I V L M I I V I F

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTTCTTGCCATTGTGTTGTACAGT 1380  
L W L G F R \* Y D G W F F L S I V L Y S  
Y G W V S G N M M D G F S C P L C C T V  
M V G F Q V I \* W M V F L V H C V V Q F

1381 TTATGACTCTAGTGAAGTTAAAGCCCAATCATCTGGTGTATTTCCTGAGAATCCTGTGTT 1440  
L \* L \* \* S \* S P I I W C Y S \* E S C V  
Y D S S E V K A Q S S G V I P E N P V L  
M T L V K L K P N H L V L F L R I L C Y

1441 ATTTACTAATAGTACTGATACTGTTAACCCCTGATTCTTTTAATTTGTATGGTTATTCTGT 1500  
I Y \* \* Y \* Y C \* P \* F F \* F V W L F C  
F T N S T D T V N P D S F N L Y G Y S V  
L L I V L I L L T L I L L I C M V I L L

1501 TACACCATTGGTTCTTGTATATATTGGTCACCGCGTCCTGGATTGTGGATTCCATATCAT 1560  
Y T I W F L Y I L V T A S W I V D S Y H  
T P F G S C I Y W S P R P G L W I P I I  
H H L V L V Y I G H R V L D C G F L S L

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTTCAGGTGTAGTAGGTTGTAAATC 1620  
\* I F S Q V L \* \* F G L F R C S R L \* I  
K S S V K S Y D D L V Y S G V V G C K S  
N L Q S S L M M I W F I Q V \* \* V V N L

FIG. 9 CONT.

123/201

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACTTTACTTAGATTATGTTCAATGTAA 1680  
Y C \* R N C S Y Y S C T L L R L C S M \*  
I V K E T A L I T H A L Y L D Y V Q C K  
L L K K L L L L L M H F T \* I M F N V S

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGTGTAAATAATTCTTGGTGTAGGCAACT 1740  
V W \* S \* T K S Y S W C \* \* F L V \* A T  
C G N L E Q N H I L G V N N S W C R Q L  
V V I L N K I I F L V L I I L G V G N C

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTTTAAAAAATATTGACTTGTTTGTAAAGCG 1800  
V A \* \* R \* L \* Y A F K K Y \* L V C \* A  
L L N R G D Y N M L L K N I D L F V K R  
C L I E V I I I C F \* K I L T C L L S V

1801 TCGTGCTGATTTTGCTTGCAAGTTTGCAAGTTTGTGGAGATGGTTTGTACCTTTTTTACT 1860  
S C \* F C L Q V C S L W R W F C T F F T  
R A D F A C K F A V C G D G F V P F L L  
V L I L L A S L Q F V E M V L Y L F Y \*

1861 AGATGGTTTAATCCCCGTAGTTATTATCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920  
R W F N S P \* L L S N S E W Y F L Y I F  
D G L I P R S Y Y L I Q S G I F F T S L  
M V \* F P V V I I \* F R V V F S L H L \*

1921 GATGTCTCAATTTTCACAAGAAGTTTCTGATATGTGTTTAAAAATGTGTATTTTGTATTAT 1980  
D V S I F T R S F \* Y V F K N V Y F V Y  
M S Q F S Q E V S D M C L K M C I L F M  
C L N F H K K F L I C V \* K C V F C L W

1981 GGACAGAGTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040  
G Q S F S C Y I L Y R A L C \* \* V G Y S  
D R V S V A T F Y I E H Y V N R L V T Q  
T E F Q L L H F I \* S I M L I G W L L N

2041 ATTTAAGTTATTGGGTACTACACTTGTAAATAAAATGGTTAATTGGTTTAAATACCATGTT 2100  
I \* V I G Y Y T C \* \* N G \* L V \* Y H V  
F K L L G T T L V N K M V N W F N T M L  
L S Y W V L H L L I K W L I G L I P C \*

2101 AGATGCTAGTGCACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTTGT 2160  
R C \* C T C Y R L A S L P I I E W S F C  
D A S A P A T G W L L Y Q L L N G L F V  
M L V H L L Q A G F F T N Y \* M V F L \*

FIG. 9 CONT.

124/201

2161 AGTATCTCAAGCCAACTTTAATTTTGGTTGCTTTAATACCTGATTATGCTAAAATTTTAGT 2220  
S I S S Q L \* F C C F N T \* L C \* N F S  
V S Q A N F N F V A L I P D Y A K I L V  
Y L K P T L I L L L \* Y L I M L K F \* L

2221 TAATAAATTTTACACTTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTTAAA 2280  
\* \* I L H F F \* V I I R V C Y S \* C F K  
N K F Y T F F K L L L E C V T V D V L K  
I N F T L F L S Y Y \* S V L Q L M F \* K

2281 AGATATGCCTGTTCTTAAACTATTAATGGTTTAGTTTGTATTGTAGGCAATAAGTTTTA 2340  
R Y A C S \* N Y \* W F S L Y C R Q \* V L  
D M P V L K T I N G L V C I V G N K F Y  
I C L F L K L L M V \* F V L \* A I S F I

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTTGTTTTACCATGTAATGCACAGGAACAACA 2400  
\* R \* Y R V N S W F C F T M \* C T G T T  
N V S T G L I P G F V L P C N A Q E Q Q  
T L V Q G \* F L V L F Y H V M H R N N K

2401 AATTTATTTTTTTGAAGGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAGAA 2460  
N L F F \* R R C R I C Y S R R \* C Y \* E  
I Y F F E G V A E S V I V E D D V I E N  
F I F L K A L Q N L L \* \* K M M L L R M

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAAT 2520  
C Q I F F I I L \* V L S T T \* I C R K N  
V K S S L S S Y E Y C Q P P K S V E K I  
S N L L Y H L M S I V N H L N L \* K K F

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTTCCCTATTGTCAT 2580  
L Y Y R \* Y V H G \* V W \* \* I F P Y C H  
C I I D N M Y M G K C G D K F F P I V M  
V L \* I I C T W V S V V I N F S L L S \*

2581 GAATGATAAAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTCCATGTGCAGGTAGAAA 2640  
E \* \* K Y L S F R S G L A F S M C R \* K  
N D K N I C L L D Q A W R F P C A G R K  
M I K I F V F \* I R L G V F H V Q V E K

2641 AGTTAATTTTAACGAGAAACCTGTTGTTATGGAGATTCCGTCTTTGATGACAGTTAAGGT 2700  
S \* F \* R E T C C Y G D S V F D D S \* G  
V N F N E K P V V M E I P S L M T V K V  
L I L T R N L L L W R F R L \* \* Q L R L

FIG. 9 CONT.

125/201

2701 TATGTTTGATTTAGATTCTACTTTTGATGATATTTTAGGTAAAGTTTGTTCAGAATTGA 2760  
Y V \* F R F Y F \* \* Y F R \* S L F R I \*  
M F D L D S T F D D I L G K V C S E F E  
C L I \* I L L L M I F \* V K F V Q N L K

2761 AGTAGAAAAGGTGTTACTGTAGATGATTTTGTGCTGTTGTTTGTGATGCTATAGAGAA 2820  
S R K G C Y C R \* F C R C C L \* C Y R E  
V E K G V T V D D F V A V V C D A I E N  
\* K R V L L \* M I L S L L F V M L \* R M

2821 TGCTTTAAACTCTTGTAAGATCATCCAGTGGTTGTTATCAAGTTCGTGCATTTTTTAAA 2880  
C F K L L \* R S S S G W L S S S C I F K  
A L N S C K D H P V V G Y Q V R A F L N  
L \* T L V K I I Q W L V I K F V H F \* I

2881 TAACTTAATGAGAACGTTGTTTATTTATTTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940  
\* T \* \* E R C L F I \* \* G W \* \* S N G L  
K L N E N V V Y L F D E A G D E A M A S  
N L M R T L F I Y L M R L V M K Q W P L

2941 TCGTATGTATTGTACTTTTGCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000  
S Y V L Y F C Y \* G C \* R R Y Q \* \* S C  
R M Y C T F A I E D V E D V I S S E A V  
V C I V L L L L R M L K T L S V V K L L

3001 TGAAGATACTATTGATGGTGTGCTGAAGACACTATTAATGATGATGAAGATGTTGTTAC 3060  
\* R Y Y \* W C R \* R H Y \* \* \* \* R C C Y  
E D T I D G V V E D T I N D D E D V V T  
K I L L M V S L K T L L M M M K M L L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3181 TGGTGATAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240  
W \* \* \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V I M T M K M L L L V T M T M K M L L L

FIG. 9 CONT.

126/201

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3361 TGGTGACAATGACGATGAAGAGATTGTTACTGGTGACAATGATGACCAAATTGTTGTTAC 3420  
W \* Q \* R \* R D C Y W \* Q \* \* P N C C Y  
G D N D D E E I V T G D N D D Q I V V T  
V T M T M K R L L L V T M M T K L L L L

3421 TGGTGATGATGTAGATGATATTGAAAGTGTCTATGATTTTGATACTTATAAAGCTCTTTT 3480  
W \* \* C R \* Y \* K C L \* F \* Y L \* S S F  
G D D V D D I E S V Y D F D T Y K A L L  
V M M \* M I L K V S M I L I L I K L F \*

3481 AGTTTTTAATGATGTCTATAATGATGCTTTGTTTGTAGTTATGGTTCTAGTGTGAAAC 3540  
S F \* \* C L \* \* C F V C \* L W F \* C \* N  
V F N D V Y N D A L F V S Y G S S V E T  
F L M M S I M M L C L L V M V L V L K Q

3541 AGAAACATATTTTAAAGTTAATGGTTTATGGTCACCTACTATTACACATACTAACTGTTG 3600  
R N I F \* S \* W F M V T Y Y Y T Y \* L L  
E T Y F K V N G L W S P T I T H T N C W  
K H I L K L M V Y G H L L L H I L T V G

3601 GTTGCGTTCTGTGTTACTTGTAAATGCAGAAATTACCTTTTAAGTTTAAGGATTTAGCTAT 3660  
V A F C V T C N A E I T F \* V \* G F S Y  
L R S V L L V M Q K L P F K F K D L A I  
C V L C Y L \* C R N Y L L S L R I \* L L

3661 TGAAAAATATGTGGTTATCTTATAAGGTGGGTTATAATCAAAGTTTTGTTGATTATTTACT 3720  
\* K Y V V I L \* G G L \* S K F C \* L F T  
E N M W L S Y K V G Y N Q S F V D Y L L  
K I C G Y L I R W V I I K V L L I I Y \*

3721 GACCACTATTCCTAAAGCTATTGTTTTGCCTCAAGGTGGTTATGTAGCTGACTTTGCTTA 3780  
D H Y S \* S Y C F A S R W L C S \* L C L  
T T I P K A I V L P Q G G Y V A D F A Y  
P L F L K L L F C L K V V M \* L T L L I

FIG. 9 CONT.

127/201

3781 TTGGTTTTTAAACCAGTTTGATATTAATGCGTATGCTAATTGGTGTGTTTAAATGTGG 3840  
L V F K P V \* Y \* C V C \* L V L F K M W  
W F L N Q F D I N A Y A N W C C L K C G  
G F \* T S L I L M R M L I G V V \* N V V

3841 TTTTCTTTTGATTAAATGGTTTGGATGCTGTGTTTTTTATGGAGATATTGTGTCTCA 3900  
F F F \* F K W F G C C V F L W R Y C V S  
F S F D L N G L D A V F F Y G D I V S H  
F L L I \* M V W M L C F F M E I L C L M

3901 TGTTTGTAAGTGTGGACATAATATGACTCTAATAGCAGCGGACTTACCTTGACATTACA 3960  
C L \* V W T \* Y D S N S S G L T L Y I T  
V C K C G H N M T L I A A D L P C T L H  
F V S V D I I \* L \* \* Q R T Y L V H Y I

3961 TTTTTCATTATTTGATGACAAATTTTGTGCTTTTGCACCCCTAAAAAATTTTATTGC 4020  
F F I I \* \* Q F L C F L H P \* K N F Y C  
F S L F D D N F C A F C T P K K I F I A  
F H Y L M T I F V L F A P L K K F L L L

4021 TGCATGTGCTGTGGATGTAAACGTTTGTCTTCTGTAGCTGTTATAGGTGATGAACAAAT 4080  
C M C C G C K R L S F C S C Y R \* \* T N  
A C A V D V N V C H S V A V I G D E Q I  
H V L W M \* T F V I L \* L L \* V M N K \*

4081 AGATGGTAAGTTTGTTACTAAATTTAGTGGTGATAAATTTGATTTTATAGTAGGTTATGG 4140  
R W \* V C Y \* I \* W \* \* I \* F Y S R L W  
D G K F V T K F S G D K F D F I V G Y G  
M V S L L L N L V V I N L I L \* \* V M E

4141 AATGTCATTTAGTATGTCTTCTTTTGAGTTAGCTCAATTGTATGGTTTGTGTATAACACC 4200  
N V I \* Y V F F \* V S S I V W F V Y N T  
M S F S M S S F E L A Q L Y G L C I T P  
C H L V C L L L S \* L N C M V C V \* H L

4201 TAATGTATGTTTTGTTAAAGGTGATATTATAAATGTTGCTAGACTTGTTAAAGCTGATGT 4260  
\* C M F C \* R \* Y Y K C C \* T C \* S \* C  
N V C F V K G D I I N V A R L V K A D V  
M Y V L L K V I L \* M L L D L L K L M L

4261 TATTGTTAACCCTGCTAATGGGCATATGCTCCATGGTGGTGGAGTTGCAAAAGCTATAGC 4320  
Y C \* P C \* W A Y A P W W W S C K S Y S  
I V N P A N G H M L H G G G V A K A I A  
L L T L L M G I C S M V V E L Q K L \* L

FIG. 9 CONT.

128/201

4321 TGTAGCTGCAGGTAAAAAATTTTCTAAAGAACTGCTGCTATGGTTAAATCTAAAGGTGT 4380  
C S C R \* K I F \* R N C C Y G \* I \* R C  
V A A G K K F S K E T A A M V K S K G V  
\* L Q V K N F L K K L L L W L N L K V F

4381 TTGCCAAGTAGGAGATTGTTATGTTTCTACCGGTGGTAAATTATGTAAACAATTCTTAA 4440  
L P S R R L L C F Y R W \* I M \* N N S \*  
C Q V G D C Y V S T G G K L C K T I L N  
A K \* E I V M F L P V V N Y V K Q F L I

4441 TATTGTAGGTCCTGATGCTAGACAAGATGGAAGACAATCTTATGTTTTGTAGCACGTGC 4500  
Y C R S \* C \* T R W K T I L C F V S T C  
I V G P D A R Q D G R Q S Y V L L A R A  
L \* V L M L D K M E D N L M F C \* H V L

4501 TTATAAGCATCTTAATAATTATGATTGTTGTTTGTCTACTCTCATATCGGCTGGTATATT 4560  
L \* A S \* \* L \* L L F V Y S H I G W Y I  
Y K H L N N Y D C C L S T L I S A G I F  
I S I L I I M I V V C L L S Y R L V Y L

4561 TAGTGTTCCTGCTGATGTGTCATTAACTTACCTTCTAGGTGTTGTTGATAACAAGTTAT 4620  
\* C S C \* C V I N L P S R C C \* \* T S Y  
S V P A D V S L T Y L L G V V D K Q V I  
V F L L M C H \* L T F \* V L L I N K L S

4621 CCTTGTTAGTAATAATAAAGAAGATTTTGATATTATTCAAAAATGTCAAATTACTTCAGT 4680  
P C \* \* \* \* R R F \* Y Y S K M S N Y F S  
L V S N N K E D F D I I Q K C Q I T S V  
L L V I I K K I L I L F K N V K L L Q L

4681 TGTGTTACTAAAGCATTGGCTGTTAGATTAACTGCTAATGTAGGCCGTGTTATTAAATT 4740  
C W Y \* S I G C \* I N C \* C R P C Y \* I  
V G T K A L A V R L T A N V G R V I K F  
L V L K H W L L D \* L L M \* A V L L N L

4741 TGAGACAGATGCATACAACTTTTCTTGAGTGGTGATGATTGTTTTGTTTCAAATTCCTTC 4800  
\* D R C I Q T F L E W \* \* L F C F K F F  
E T D A Y K L F L S G D D C F V S N S S  
R Q M H T N F S \* V V M I V L F Q I L L

4801 TGTTATACAAGAAGTTTTATTGCTTCGTCATGATATACAATTGAATAATGACGTTTCGTGA 4860  
C Y T R S F I A S S \* Y T I E \* \* R S \*  
V I Q E V L L L R H D I Q L N N D V R D  
L Y K K F Y C F V M I Y N \* I M T F V I

FIG. 9 CONT.

129/201

4861 TTATTTGTGTCTAAGATGACTAGTCTTCCCAAAGATTGGCGTCTTATCAATAAATTTGA 4920  
L F V V \* D D \* S S Q R L A S Y Q \* I \*  
Y L L S K M T S L P K D W R L I N K F D  
I C C L R \* L V F P K I G V L S I N L M

4921 TGTTATTAACGGTGTAAACTGTAAAGTACTTTGAGTGTCTAATTCTATTTATATATG 4980  
C Y \* R C \* N C \* V L \* V S \* F Y L Y M  
V I N G V K T V K Y F E C P N S I Y I C  
L L T V L K L L S T L S V L I L F I Y V

4981 TAGTCAGGGTAAAGACTTTGGTTATGTATGTGATGGTCTTTTTATAAAGCAACTGTTAA 5040  
\* S G \* R L W L C M \* W F F L \* S N C \*  
S Q G K D F G Y V C D G S F Y K A T V N  
V R V K T L V M Y V M V L F I K Q L L I

5041 TCAAGTTTGTGTGTTATTAGCTAAGAAGATAGATGTTTGGCTTACTGTAGATGGTGTAA 5100  
S S L C V I S \* E D R C F A Y C R W C \*  
Q V C V L L A K K I D V L L T V D G V N  
K F V C Y \* L R R \* M F C L L \* M V L I

5101 TTTTAAATCTATTTCTTCTTACTGTAGGTGAAGTTTTGGTAAATACTTGGTAATGTTTT 5160  
F \* I Y F S Y C R \* S F W \* N T W \* C F  
F K S I S L T V G E V F G K I L G N V F  
L N L F L L L \* V K F L V K Y L V M F S

5161 CTGTGATGGCATTGATGTTACTAAGTTAAAGTGTAGTGATTTTTATGCCGATAAAATTTT 5220  
L \* W H \* C Y \* V K V \* \* F L C R \* N F  
C D G I D V T K L K C S D F Y A D K I L  
V M A L M L L S \* S V V I F M P I K F Y

5221 ATATCAGTATGAAAATTTGTCTTTAGCTGATATTTCTGCTGTACAAAGTTCATTGGGGT 5280  
I S V \* K F V F S \* Y F C C T K F I W V  
Y Q Y E N L S L A D I S A V Q S S F G F  
I S M K I C L \* L I F L L Y K V H L G L

5281 TGATCAGCAACAATTGCTTGCTTACTATAATTTTTTAACAGTATGTAAATGGTCTGTAGT 5340  
\* S A T I A C L L \* F F N S M \* M V C S  
D Q Q Q L L A Y Y N F L T V C K W S V V  
I S N N C L L T I I F \* Q Y V N G L \* L

5341 TGTTAACGGTCCATTTTTTTCTTTGAACAGTCTCATAATAATTGTTATGTGAATGTAGC 5400  
C \* R S I F F F \* T V S \* \* L L C E C S  
V N G P F F S F E Q S H N N C Y V N V A  
L T V H F F L L N S L I I I V M \* M \* L

FIG. 9 CONT.



130/201

5401 TTGTCTTATGTTGCAGCATATTAATCTTAAATTTAATAAATGGCAGTGGCAGGAAGCATG 5460  
L S Y V A A Y \* S \* I \* \* M A V A G S M  
C L M L Q H I N L K F N K W Q W Q E A W  
V L C C S I L I L N L I N G S G R K H G

5461 GTATGAATTTCTGCTGGCAGACCACATAGGTTAGTTGCTCTTGTGTTTAGCTAAAGGTCA 5520  
V \* I S C W Q T T \* V S C S C F S \* R S  
Y E F R A G R P H R L V A L V L A K G H  
M N F V L A D H I G \* L L L F \* L K V I

5521 TTTTAAATTTGATGAACCATCAGATGCTACTGATTTTATTCGTGTTGTTTGAACAAGC 5580  
F \* I \* \* T I R C Y \* F Y S C C F E T S  
F K F D E P S D A T D F I R V V L K Q A  
L N L M N H Q M L L I L F V L F \* N K L

5581 TGATTATCAGGTGCAATTTGTGAATTAGAACTTATTTGTGATTGTGGTATTAAACAAGA 5640  
\* F I R C N L \* I R T Y L \* L W Y \* T R  
D L S G A I C E L E L I C D C G I K Q E  
I Y Q V Q F V N \* N L F V I V V L N K K

5641 AAGTCGTGTTGGTGTGATGCTGTTATGCATTTTGGTACATTAGCAAAGACTGATCTTTT 5700  
K S C W C \* C C Y A F W Y I S K D \* S F  
S R V G V D A V M H F G T L A K T D L F  
V V L V L M L L C I L V H \* Q R L I F L

5701 TAATGGTTATAAGATTGGCTGTAATTGTGCAGGTAGAATTGTCCATTGTACTAAATTGAA 5760  
\* W L \* D W L \* L C R \* N C P L Y \* I E  
N G Y K I G C N C A G R I V H C T K L N  
M V I R L A V I V Q V E L S I V L N \* M

5761 TGTACCATTTTGTGTTGTTCTAATACTCCTCTGAGTAAGGATTTACCTGATGATGTTGT 5820  
C T I F D L F \* Y S S E \* G F T \* \* C C  
V P F L I C S N T P L S K D L P D D V V  
Y H F \* F V L I L L \* V R I Y L M M L L

5821 TGCAGCTAACATGTTTATGGGTGTAGGTGTAGGCCATTATACACATTTGAAATGTGGTTC 5880  
C S \* H V Y G C R C R P L Y T F E M W F  
A A N M F M G V G V G H Y T H L K C G S  
Q L T C L W V \* V \* A I I H I \* N V V H

5881 ACCTTACCAACATTATGATGCTTGTAGTGTTAAAAAATATACAGGTGTTAGTGGTTGTTT 5940  
T L P T L \* C L \* C \* K I Y R C \* W L F  
P Y Q H Y D A C S V K K Y T G V S G C L  
L T N I M M L V V L K N I Q V L V V V \*

FIG. 9 CONT.

## 131/201

5941 AACTGACTGCTTGTATCTTAAAAATTTAACCAGACTTTTACATCTATGTTGACTAATTA 6000  
N \* L L V S \* K F N P D F Y I Y V D \* L  
T D C L Y L K N L T Q T F T S M L T N Y  
L T A C I L K I \* P R L L H L C \* L I I

6001 TTTTTGGATGATGTTGAAATGGTTGCTTATAACCCTGATCTTTCACAATATTATTGTGA 6060  
F F G \* C \* N G C L \* P \* S F T I L L \*  
F L D D V E M V A Y N P D L S Q Y Y C D  
F W M M L K W L L I T L I F H N I I V I

6061 TAATGGTAAGTATTATACAAAACCTATTATAAAGGCTCAGTTTAAACCATTGCTAAAGT 6120  
\* W \* V L Y K T Y Y K G S V \* T I C \* S  
N G K Y Y T K P I I K A Q F K P F A K V  
M V S I I Q N L L \* R L S L N H L L K L

6121 TGACGGTGTTTATACTAACTTTAAGTTAGTTGGACATGATATTTGTGCTCAATTGAATGA 6180  
\* R C L Y \* L \* V S W T \* Y L C S I E \*  
D G V Y T N F K L V G H D I C A Q L N D  
T V F I L T L S \* L D M I F V L N \* M I

6181 TAAGTTAGGTTTTAATGTAGATTTGCCGTTTGTGAGTACAAAGTAACAGTCTGGCCTGT 6240  
\* V R F \* C R F A V C \* V Q S N S L A C  
K L G F N V D L P F V E Y K V T V W P V  
S \* V L M \* I C R L L S T K \* Q S G L \*

6241 AGCTACTGGTGATGTTGTTTTGGCATCTGATGATTTATATGTTAAACGTTATTTTAAAGG 6300  
S Y W \* C C F G I \* \* F I C \* T L F \* R  
A T G D V V L A S D D L Y V K R Y F K G  
L L V M L F W H L M I Y M L N V I L K D

6301 ATGTGAACTTTTGGTAAGCCTGTTATTTGGCTTTGTGTCATGATGAAGCATCATTGAATTC 6360  
M \* N F W \* A C Y L A L S \* \* S I I E F  
C E T F G K P V I W L C H D E A S L N S  
V K L L V S L L F G F V M M K H H \* I L

6361 TCTTACTTATTTTAAATAAACCTAGTTTTAAATCTGAAAATAGATATAGTGTGTTGTCTGT 6420  
S Y L F \* \* T \* F \* I \* K \* I \* C F V C  
L T Y F N K P S F K S E N R Y S V L S V  
L L I L I N L V L N L K I D I V F C L L

6421 TGATTCTGTATCTGAGGAGTCACAAGGTAATGTGGTTACTTCTGTTATGGAATCGCAGAT 6480  
\* F C I \* G V T R \* C G Y F C Y G I A D  
D S V S E E S Q G N V V T S V M E S Q I  
I L Y L R S H K V M W L L L L W N R R L

FIG. 9 CONT.

132/201

6481 TAGTACTAAAGAGGTTAAGTTAAAGGGTGTAGAAAGACTGTAAAAATAGAAGATGCTAT 6540  
\* Y \* R G \* V K G C \* K D C \* N R R C Y  
S T K E V K L K G V R K T V K I E D A I  
V L K R L S \* R V L E R L L K \* K M L L

6541 TATTGTTAATGATGAAAAATAGTTCTATTAAAGGTTGTTAAAAGTTTATCTTTAGTTGATGT 6600  
Y C \* \* \* K \* F Y \* G C \* K F I F S \* C  
I V N D E N S S I K V V K S L S L V D V  
L L M M K I V L L R L L K V Y L \* L M F

6601 TTGGGATATGTATTTGACAGGTTGTGATTATGTTGTTTGGGTTGCTAATGAATTGTCACG 6660  
L G Y V F D R L \* L C C L G C \* \* I V T  
W D M Y L T G C D Y V V W V A N E L S R  
G I C I \* Q V V I M L F G L L M N C H A

6661 CCTAGTTAAATCACCAACAGTTAGGGAATATATACGATATGGTATTAAACCTATTACTAT 6720  
P S \* I T N S \* G I Y T I W Y \* T Y Y Y  
L V K S P T V R E Y I R Y G I K P I T I  
\* L N H Q Q L G N I Y D M V L N L L L Y

6721 ACCTATAGATTTGTTATGTTTAAAGAGATGATAATCAAACCTCTTTTAGTTCCTAAAATTTT 6780  
T Y R F V M F K R \* \* S N S F S S \* N F  
P I D L L C L R D D N Q T L L V P K I F  
L \* I C Y V \* E M I I K L F \* F L K F L

6781 TAAAGCAAGAGCTATAGAATTTTATGTTTTTGAAGTGGTTGTTTATTTATGTTTTTAG 6840  
\* S K S Y R I L W F F E V V V Y L C F \*  
K A R A I E F Y G F L K W L F I Y V F S  
K Q E L \* N F M V F \* S G C L F M F L V

6841 TTTATTACATTTTACAAATGATAAAACCATTTTATATACTACAGAAATAGCTTCTAAGTT 6900  
F I T F Y K \* \* N H F L Y Y R N S F \* V  
L L H F T N D K T I F Y T T E I A S K F  
Y Y I L Q M I K P F F I L Q K \* L L S L

6901 TACTTTTAATTTGTTTTGTTTGGCTCTTAAAAATGCTTTTCAGACATTAGATGGAGTAT 6960  
Y F \* F V L F G S \* K C F S D I \* M E Y  
T F N L F C L A L K N A F Q T F R W S I  
L L I C F V W L L K M L F R H L D G V Y

6961 ATTTATAAAAGGTTTTCTTGTGTAGCCACTGTGTTTTGTTTTGGTTTAATTTTTTGTA 7020  
I Y K R F S C C S H C V F V L V \* F F V  
F I K G F L V V A T V F L F W F N F L Y  
L \* K V F L L \* P L C F C F G L I F C I

FIG. 9 CONT.

133/201

7021 TATAAATGTTATTTTGTAGTATTTTATCTTCCTAATATTAGTGTTCCTATTTTGT 7080  
Y K C Y F \* \* F L S S \* Y \* C F S Y F C  
I N V I F S D F Y L P N I S V F P I F V  
\* M L F L V I F I F L I L V F F L F L W

7081 GGGAGAATTGTTATGTGGATAAAGGCTACTTTTGGTTTGGTTACAATTTGTGATTTT 7140  
G K N C Y V D K G Y F W F G Y N L \* F L  
G R I V M W I K A T F G L V T I C D F Y  
E E L L C G \* R L L L V W L Q F V I F I

7141 TTCTAAGTTAGGTGTAGGTTTACAGTCATTTTGTAAATGGTAGTTTATATGTGAATT 7200  
F \* V R C R F Y K S F L \* W \* F Y M \* I  
S K L G V G F T S H F C N G S F I C E L  
L S \* V \* V L Q V I F V M V V L Y V N C

7201 GTGTTATTCTGGTTTGTATGTTGGATACATATGCAGCTATAGATTTTGTTCAGTATGA 7260  
V L F W F \* Y V G Y I C S Y R F C S V \*  
C Y S G F D M L D T Y A A I D F V Q Y E  
V I L V L I C W I H M Q L \* I L F S M K

7261 AGTAGATAGACGTGTTTATTTGATTATGTTAGTTTAGTCAAATTAATTGTTGAACTCGT 7320  
S R \* T C F I \* L C \* F S Q I N C \* T R  
V D R R V L F D Y V S L V K L I V E L V  
\* I D V F Y L I M L V \* S N \* L L N S L

7321 TATTGGTTATTCATTATATACAGTATGGTTTATCCATTATTTGTCTTATTGGTTTACA 7380  
Y W L F I I Y S M V L S I I L S Y W F T  
I G Y S L Y T V W F Y P L F C L I G L Q  
L V I H Y I Q Y G F I H Y F V L L V Y N

7381 ATTATTTACTACATGGTTGCCTGATTTGTTTATGTTAGAACTATGCATTGGTTGATTAG 7440  
I I Y Y M V A \* F V Y V R N Y A L V D \*  
L F T T W L P D L F M L E T M H W L I R  
Y L L H G C L I C L C \* K L C I G \* L D

7441 ATTTATTGTATTTGTAGCTAATATGTTACCTGCTTTTGTCTTGTTCGGGTTTATATAGT 7500  
I Y C I C S \* Y V T C F C L V A V L Y S  
F I V F V A N M L P A F V L L R F Y I V  
L L Y L \* L I C Y L L L S C C G F I \* L

7501 TGTTACTGCTATGTATAAAGTAGTTGGTTTATTAGGCATATTGTTTATGGTTGTAATAA 7560  
C Y C Y V \* S S W F Y \* A Y C L W L \* \*  
V T A M Y K V V G F I R H I V Y G C N K  
L L L C I K \* L V L L G I L F M V V I K

FIG. 9 CONT.

134/201

7561 AGCTGGTTGTTTGTGTTTGTATATAAACGAAATTGTAGTGTTCGTGTTAAGTGTAGTACTAT 7620  
S W L F V L L \* T K L \* C S C \* V \* Y Y  
A G C L F C Y K R N C S V R V K C S T I  
L V V C F V I N E I V V F V L S V V L L

7621 TGTGTTGGTGTAAATTCGTTATTATGATATTACTGCTAATGGTGGTACTGGTTTTGTGT 7680  
C W W C N S L L \* Y Y C \* W W Y W F L C  
V G G V I R Y Y D I T A N G G T G F C V  
L V V \* F V I M I L L L M V V L V F V L

7681 TAAACATCAATGGAATTGTTTTAATTGCCATTCTTTTAAACCAGGTAACACTTTTATAAC 7740  
\* T S M E L F \* L P F F \* T R \* H F Y N  
K H Q W N C F N C H S F K P G N T F I T  
N I N G I V L I A I L L N Q V T L L \* L

7741 TGTAGAAGCTGCTATAGAACTTCTAAAGAGCTTAAACGACCTGTAAACCCAACTGATGC 7800  
C R S C Y R T F \* R A \* T T C K P N \* C  
V E A A I E L S K E L K R P V N P T D A  
\* K L L \* N F L K S L N D L \* T Q L M L

7801 TTCACATTATGTAGTTACTGATATTAAGCAAGTTGGTTGTATGATGCGTTTGTCTATGA 7860  
F T L C S Y \* Y \* A S W L Y D A F V L \*  
S H Y V V T D I K Q V G C M M R L F Y D  
H I M \* L L I L S K L V V \* C V C S M I

7861 TAGAGATGGACAGCGTGTTTACGATGATGTTGATGCTAGTTTATTTGTAGATATTAATAA 7920  
\* R W T A C L R \* C \* C \* F I C R Y \* \*  
R D G Q R V Y D D V D A S L F V D I N N  
E M D S V F T M M L M L V Y L \* I L I I

7921 TCTGTTACATTCTAAAGTCAAAGTTGTTCCCTAATTGTATGTAGTTGTAGTAGAGAGTGA 7980  
S V T F \* S Q S C S \* F V C S C S R E \*  
L L H S K V K V V P N L Y V V V V E S D  
C Y I L K S K L F L I C M \* L \* \* R V M

7981 TGCTGATAGAGCTAATTTTCTGAATGCTGTTGTGTTTTATGCACAATCATTGTATAGGCC 8040  
C \* \* S \* F S E C C C V L C T I I V \* A  
A D R A N F L N A V V F Y A Q S L Y R P  
L I E L I F \* M L L C F M H N H C I G L

8041 TATATTACTTGTAGACAAAAAGTTAATTACTACAGCTTGTAAATGGTATCTCTGTAACCCA 8100  
Y I T C R Q K V N Y Y S L \* W Y L C N P  
I L L V D K K L I T T A C N G I S V T Q  
Y Y L \* T K S \* L L Q L V M V S L \* P R

FIG. 9 CONT.

135/201

8101 GACTATGTTTGATGTTTATGTTGATACTTTTATGTCTCATTTTGATGTTGATAGAAAGAG 8160  
D Y V \* C L C \* Y F Y V S F \* C \* \* K E  
T M F D V Y V D T F M S H F D V D R K S  
L C L M F M L I L L C L I L M L I E R V

8161 TTTTAATAATTTTGTTAACATTGCTCATGCTTCTCTTAGAGAGGGTGTGCAATTAGAAAA 8220  
F \* \* F C \* H C S C F S \* R G C A I R K  
F N N F V N I A H A S L R E G V Q L E K  
L I I L L T L L M L L L E R V C N \* K R

8221 GGTTTTAGATACTTTTGTGGGATGTGTACGTAAATGTTGTTCATTGATTCAGATGTTGA 8280  
G F R Y F C G M C T \* M L F H \* F R C \*  
V L D T F V G C V R K C C S I D S D V E  
F \* I L L W D V Y V N V V P L I Q M L K

8281 AACAAGATTTATTACTAAATCTATGATATCTGCAGTAGCTGCTGGTTTGAATTTACTGA 8340  
N K I Y Y \* I Y D I C S S C W F G I Y \*  
T R F I T K S M I S A V A A G L E F T D  
Q D L L L N L \* Y L Q \* L L V W N L L M

8341 TGAAAATTATAACAATTTGGTACCTACATATTTAAAGAGTGATAATATTGTAGCTGCAGA 8400  
\* K L \* Q F G T Y I F K E \* \* Y C S C R  
E N Y N N L V P T Y L K S D N I V A A D  
K I I T I W Y L H I \* R V I I L \* L Q I

8401 TTTAGGTGTTCTTATACAGAATGGTGCTAAGCATGTACAGGGTAATGTTGCTAAGGCAGC 8460  
F R C S Y T E W C \* A C T G \* C C \* G S  
L G V L I Q N G A K H V Q G N V A K A A  
\* V F L Y R M V L S M Y R V M L L R Q L

8461 TAATATTCTTGATATGGTTTATTGACACTTTTAATCAACTTACTGCTGATTACAGCA 8520  
\* Y F L Y M V Y \* H F \* S T Y C \* F T A  
N I S C I W F I D T F N Q L T A D L Q H  
I F L V Y G L L T L L I N L L L I Y S I

8521 TAAATTAAAAAAGCATGTGTAAAACTGGCTTGAAGTTAAATGACTTTTAATAAGCA 8580  
\* I K K S M C \* N W L E V K I D F \* \* A  
K L K K A C V K T G L K L K L T F N K Q  
N \* K K H V L K L A \* S \* N \* L L I S K

8581 AGAGGCAAGTGTTCTTATTCTTACAACGCCCTTTTCACTTAAAGGAGGTGTTGTATTGAG 8640  
R G K C S Y S Y N A L F T \* R R C C I E  
E A S V P I L T T P F S L K G G V V L S  
R Q V F L F L Q R P F H L K E V L Y \* V

FIG. 9 CONT.

136/201

8641 TAATTTGTTATATATATTATTTTTTATTAGTTTAATCTGTTTTATATTATTGTGGGCTTT 8700  
\* F V I Y I I F Y \* F N L F Y I I V G F  
N L L Y I L F F I S L I C F I L L W A L  
I C Y I Y Y F L L V \* S V L Y Y C G L Y

8701 ACTGCCTACATATAGTGTTTATAAGTCTGATATTCATTTGCCTGCTTATGCTAGTTTTAA 8760  
T A Y I \* C L \* V \* Y S F A C L C \* F \*  
L P T Y S V Y K S D I H L P A Y A S F K  
C L H I V F I S L I F I C L L M L V L K

8761 AGTTATTGATAATGGTGTGTTAGAGATATTTCAAGTTAATGATTATGTTTTGCTAATAA 8820  
S Y \* \* W C C \* R Y F S \* \* F M F C \* \*  
V I D N G V V R D I S V N D L C F A N K  
L L I M V L L E I F Q L M I Y V L L I N

8821 ATTTTCCAAATTGATCAATGGTATGAGTCCACTTTTGGGTCTTTTACTATCATAATTC 8880  
I F P I \* S M V \* V H F W V F L L S \* F  
F F Q F D Q W Y E S T F G S F Y Y H N S  
F S N L I N G M S P L L G L F T I I I L

8881 TATGGATTGCCCTATTGTTGTGGCAGTTATGGATGAAGATATTGGTCTACTATGTTTAA 8940  
Y G L P Y C C G S Y G \* R Y W F Y Y V \*  
M D C P I V V A V M D E D I G S T M F N  
W I A L L L W Q L W M K I L V L L C L M

8941 TGTTCTACTAAAGTTTTGAGACATGGCTTTTCATGTTTACATTTTCTAACTTATGCATT 9000  
C S Y \* S F E T W L S C F T F S N L C I  
V P T K V L R H G F H V L H F L T Y A F  
F L L K F \* D M A F M F Y I F \* L M H L

9001 TGCTAGTGATAGTGTTCAGTGCTATACACCACATATTCAGATTTCTTATAATGATTTTTA 9060  
C \* \* \* C S V L Y T T Y S D F L \* \* F L  
A S D S V Q C Y T P H I Q I S Y N D F Y  
L V I V F S A I H H I F R F L I M I F M

9061 TGCTAGTGGTTGTGTTTATCATCTTTGTGTACTATGTTTAAAAGAGGTGATGGTACACC 9120  
C \* W L C F I I F V Y Y V \* K R \* W Y T  
A S G C V L S S L C T M F K R G D G T P  
L V V V F Y H L C V L C L K E V M V H H

9121 ACATCCTTATTGTTATTCAGATGGTGTATGAAGAATGCTTCTTTGTATACATCTTTGGT 9180  
T S L L L F R W C Y E E C F F V Y I F G  
H P Y C Y S D G V M K N A S L Y T S L V  
I L I V I Q M V L \* R M L L C I H L W F

FIG. 9 CONT.

137/201

9181 TCCACATACACGTTATAGCCTTGCTAATTCTAATGGTTTATAAGATTTCCTGATGTTAT 9240  
S T Y T L \* P C \* F \* W F Y K I S \* C Y  
P H T R Y S L A N S N G F I R F P D V I  
H I H V I A L L I L M V L \* D F L M L L

9241 TAGTGAAGGTATTGTACGTATTGTAAGAACGCGCTCTATGACTTATTGTAGAGTGGGTGC 9300  
\* \* R Y C T Y C K N A L Y D L L \* S G C  
S E G I V R I V R T R S M T Y C R V G A  
V K V L Y V L \* E R A L \* L I V E W V H

9301 ATGTGAATATGCCGAAGAGGGTATATGTTTAAATTTAATAGTTCCCTGGGTTTTGAATAA 9360  
M \* I C R R G Y M F \* F \* \* F L G F E \*  
C E Y A E E G I C F N F N S S W V L N N  
V N M P K R V Y V L I L I V P G F \* I M

9361 TGATTATTATAGAAGTATGCCTGGAACTTTTGTGGTAGAGATCTTTTGATTGTTTTA 9420  
\* L L \* K Y A W N F L W \* R S F \* F V L  
D Y Y R S M P G T F C G R D L F D L F Y  
I I I E V C L E L F V V E I F L I C F I

9421 TCAATTTTTTAGTAGTTTAATTCGTCCTATAGATTTCCTTCTCTTACTGCTAGTCTAT 9480  
S I F \* \* F N S S Y R F L F S Y C \* F Y  
Q F F S S L I R P I D F F S L T A S S I  
N F L V V \* F V L \* I S F L L L L V L F

9481 TTTTGGAGCTATATTGGCTATAGTCGTTGTCTTGGTTTTTTATTATTAAATAAACTTAA 9540  
F W S Y I G Y S R C L G F L L F N K T \*  
F G A I L A I V V V L V F Y Y L I K L K  
L E L Y W L \* S L S W F F I I \* \* N L S

9541 GCGTGCTTTTGGAGATTATACTAGTGTGTAGTTATAAATGTTATTGTTGGTGTATTAA 9600  
A C F W R L Y \* C C S Y K C Y C L V Y \*  
R A F G D Y T S V V V I N V I V W C I N  
V L L E I I L V L \* L \* M L L F G V L I

9601 TTTTCTTATGCTTTTTGTTTTTCAAGTTTATCCTATTTGTGCATGTGTCTATGCTTGTTT 9660  
F S Y A F C F S S L S Y L C M C L C L F  
F L M L F V F Q V Y P I C A C V Y A C F  
F L C F L F F K F I L F V H V S M L V F

9661 TTATTTTTATGTAACATTGTATTTTCCTTCTGAAATTAGTGTAAATTATGCATTTGCAATG 9720  
L F L C N I V F S F \* N \* C N Y A F A M  
Y F Y V T L Y F P S E I S V I M H L Q W  
I F M \* H C I F L L K L V \* L C I C N G

FIG. 9 CONT.



138/201

9781 TATTGCAAACCATGTTTTATGGTTATTTTCATATTGTAGGAAAATTGGTGTTAATGTATG 9840  
Y C K P C F M V I F I L \* E N W C \* C M  
I A N H V L W L F S Y C R K I G V N V C  
L Q T M F Y G Y F H I V G K L V L M Y V

9841 TAATGATAGTACATTTGAAGAAACATCTCTACTACTTTTATGATTACTAAAGATTCTTA 9900  
\* \* \* Y I \* R N I S Y Y F Y D Y \* R F L  
N D S T F E E T S L T T F M I T K D S Y  
M I V H L K K H L L L L L \* L L K I L I

9901 TTGTAGATTAAAGAATTCTGTTCTGATGTTGCTTACAATAGATATTTGAGTTGTATAA 9960  
L \* I K E F C F \* C C L Q \* I F E F V \*  
C R L K N S V S D V A Y N R Y L S L Y N  
V D \* R I L F L M L L T I D I \* V C I I

9961 TAAGTATCGTTACTATAGTGGTAAATGGATACTGCTGCCTATAGAGAAGCGGCGTGTTC 10020  
\* V S L L \* W \* N G Y C C L \* R S G V F  
K Y R Y Y S G K M D T A A Y R E A A C S  
S I V T I V V K W I L L P I E K R R V L

10021 TCAGTTAGCTAAAGCTATGGAAACATTTAATCACAATAATGGTAATGATGCTTATACCA 10080  
S V S \* S Y G N I \* S Q \* W \* \* C L I P  
Q L A K A M E T F N H N N G N D V L Y Q  
S \* L K L W K H L I T I M V M M S Y T N

10081 ACCTCCTACAGCATCTGTTTCTACATCTTTTTTGCAATCAGGTATTGTAAAGATGGTATC 10140  
T S Y S I C F Y I F F A I R Y C K D G I  
P P T A S V S T S F L Q S G I V K M V S  
L L Q H L F L H L F C N Q V L \* R W Y L

10141 TCCTACGTCAAAAATTGAACCTTGATTGTTAGTGTACTTATGGTAGTATGACTTTGAA 10200  
S Y V K N \* T L Y C \* C Y L W \* Y D F E  
P T S K I E P C I V S V T Y G S M T L N  
L R Q K L N L V L L V L L M V V \* L \* M

10201 TGGTTTATGGTTAGATGACAAAGTTTATTGTCCTCGTCATGTTATATGTTTATCCTCTAA 10260  
W F M V R \* Q S L L S S S C Y M F I L \*  
G L W L D D K V Y C P R H V I C L S S N  
V Y G \* M T K F I V L V M L Y V Y P L I

10261 TATGAATGAACCTGATTATTCTGCCTTATTATGTAGAGTTACTCTAGGTGATTTTACTAT 10320  
Y E \* T \* L F C L I M \* S Y S R \* F Y Y  
M N E P D Y S A L L C R V T L G D F T I  
\* M N L I I L P Y Y V E L L \* V I L L \*

FIG. 9 CONT.

139/201

9721 GATTGTTATGTATGGTGCTATAATGCCTTTTGGTTTTGTGTACATATGTAGCTATGGT 9780  
D C Y V W C Y N A F L V L C H I C S Y G  
I V M Y G A I M P F W F C V T Y V A M V  
L L C M V L \* C L F G F V S H M \* L W L

10321 AATGTCTGGGCGGATGAGTTTAAACAGTTGTGTCTTACCAGATGCAGGGCTGTCAACTTGT 10380  
N V W A D E F N S C V L P D A G L S T C  
M S G R M S L T V V S Y Q M Q G C Q L V  
C L G G \* V \* Q L C L T R C R A V N L F

10381 TTTGACAGTCTCTTTACAAAATCCTTACACTCCAAAATATACTTTTGGTGTGTGTTAAACC 10440  
F D S L F T K S L H S K I Y F W C C \* T  
L T V S L Q N P Y T P K Y T F G V V K P  
\* Q S L Y K I L T L Q N I L L V L L N L

10441 TGGTGAAACTTTTACTGTTTTAGCTGCGTATAATGGCCGACCACAAGGGGCATTTCATGT 10500  
W \* N F Y C F S C V \* W P T T R G I S C  
G E T F T V L A A Y N G R P Q G A F H V  
V K L L L F \* L R I M A D H K G H F M L

10501 TACTATGCGTAGTAGTTATACTATTAAAGGTTCTTTTTTGTGTGGGTCATGTGGATCTGT 10560  
Y Y A \* \* L Y Y \* R F F F V W V M W I C  
T M R S S Y T I K G S F L C G S C G S V  
L C V V V I L L K V L F C V G H V D L L

10561 TGGTTATGTATTAAACAGGTGATAGTGTAAAGTTTGTATATATGCATCAATTAGAGCTCAG 10620  
W L C I N R \* \* C \* V C I Y A S I R A Q  
G Y V L T G D S V K F V Y M H Q L E L S  
V M Y \* Q V I V L S L Y I C I N \* S S V

10621 TACTGGTTGTACACTGGCACTGATTTTACTGGTAATTTTATGGTCCATATAGAGATGC 10680  
Y W L S H W H \* F Y W \* F L W S I \* R C  
T G C H T G T D F T G N F Y G P Y R D A  
L V V T L A L I L L V I F M V H I E M L

10681 TCAAGTTGTACAGTTGCCAGTTAAGGACTACGTCCAAACTGTTAATGTTATTGCTTGGCT 10740  
S S C T V A S \* G L R P N C \* C Y C L A  
Q V V Q L P V K D Y V Q T V N V I A W L  
K L Y S C Q L R T T S K L L M L L L G S

10741 CTATGCAGCTATACTTAATAATTGTGCTTGGTTTGTACAAAATGATGTTTGTCTATTGA 10800  
L C S Y T \* \* L C L V C T K \* C L F Y \*  
Y A A I L N N C A W F V Q N D V C S I E  
M Q L Y L I I V L G L Y K M M F V L L K

FIG. 9 CONT.

140/201

10801 AGATTTTAATGTTTGGGCTATGACAAATGGTTTATAGCCAAGTAAAAGCAGATCTTGTGTTT 10860  
R F \* C L G Y D K W F \* P S K S R S C F  
D F N V W A M T N G F S Q V K A D L V L  
I L M F G L \* Q M V L A K \* K Q I L F \*

10861 AGATGCTTTGGCTTCAATGACAGGTGTTTCTATTGAACTTTATTGGCTGCTATTAAGCG 10920  
R C F G F N D R C F Y \* N F I G C Y \* A  
D A L A S M T G V S I E T L L A A I K R  
M L W L Q \* Q V F L L K L Y W L L L S V

10921 TCTATATATGGGATTTCAAGGTCGTCAAATACTAGGAAGTTGTACTTTTGAAGATGAATT 10980  
S I Y G I S R S S N T R K L Y F \* R \* I  
L Y M G F Q G R Q I L G S C T F E D E L  
Y I W D F K V V K Y \* E V V L L K M N W

10981 GGCACCTTCTGACGTTTATCAACAATTGGCTGGTGTTAAATTGCAATCTAAAACAAAAAG 11040  
G T F \* R L S T I G W C \* I A I \* N K K  
A P S D V Y Q Q L A G V K L Q S K T K R  
H L L T F I N N W L V L N C N L K Q K D

11041 ATTTATTAAAGAAACAATTTATTGGATTTTGATATCTACATTTTGTGTTAGTTGTATAAT 11100  
I Y \* R N N L L D F D I Y I F V \* L Y N  
F I K E T I Y W I L I S T F L F S C I I  
L L K K Q F I G F \* Y L H F C L V V \* F

11101 TTCTGCATTTGTTAAATGGACTATATTTATGTATATTAATACACATATGATTGGTGTTAC 11160  
F C I C \* M D Y I Y V Y \* Y T Y D W C Y  
S A F V K W T I F M Y I N T H M I G V T  
L H L L N G L Y L C I L I H I \* L V L H

11161 ATTATGTGTACTTTGTTTGTGTTAGTTTATGATGTTACTAGTTAAACATAAGCATTTT 11220  
I M C T L F C \* F Y D V T S \* T \* A F L  
L C V L C F V S F M M L L V K H K H F Y  
Y V Y F V L L V L \* C Y \* L N I S I F I

11221 TTTGACTATGTATATAATTCCTGTACTCTGTACCTTGTGTTTATGTAAATTATTTAGTTGT 11280  
F D Y V Y N S C T L Y L V L C K L F S C  
L T M Y I I P V L C T L F Y V N Y L V V  
\* L C I \* F L Y S V P C F M \* I I \* L S

11281 CTATAAGGAAGGTTTTAGAGGTCTTACTTATGTCTGGCTCTCATATTTGTTTCTGCTGT 11340  
L \* G R F \* R S Y L C L A L I F C S C C  
Y K E G F R G L T Y V W L S Y F V P A V  
I R K V L E V L L M S G S H I L F L L \*

FIG. 9 CONT.

## 141/201

11341 GAATTTTACTTATGTTTATGAAGTATTTTATGGTTGTATTTTATGTGTTTTGCTATTTT 11400  
E F Y L C L \* S I L W L Y F M C F C Y F  
N F T Y V Y E V F Y G C I L C V F A I F  
I L L M F M K Y F M V V F Y V F L L F L

11401 TATAACTATGCATAGTATTAATCATGACATTTTTCTTTGATGTTTTGGTTGGTAGAAT 11460  
Y N Y A \* Y \* S \* H F F F D V F G W \* N  
I T M H S I N H D I F S L M F L V G R I  
\* L C I V L I M T F F L \* C F W L V E \*

11461 AGTTACTTTAATTTCTATGTGGTATTTTGGGTCGAATTTAGAAGAGGATGTTTTGTATT 11520  
S Y F N F Y V V F W V E F R R G C F V I  
V T L I S M W Y F G S N L E E D V L L F  
L L \* F L C G I L G R I \* K R M F C Y L

11521 TATTACAGCCTTTTTAGGTACTTATACATGGACCACTATTTTGTTCATTAGCTATAGCAA 11580  
Y Y S L F R Y L Y M D H Y F V I S Y S K  
I T A F L G T Y T W T T I L S L A I A K  
L Q P F \* V L I H G P L F C H \* L \* Q K

11581 AATTGTTGCTAATTGGTTGTCTGTTAATATATTTTATTTTACAGATGTACCTTATATTAA 11640  
N C C \* L V V C \* Y I L F Y R C T L Y \*  
I V A N W L S V N I F Y F T D V P Y I K  
L L L I G C L L I Y F I L Q M Y L I L N

11641 ATTGATTCTTTGAGTTACTTATTTATAGGGTATATTTTATCTTGTATTGGGGATTTTT 11700  
I D S F E L L I Y R V Y F I L L L G I F  
L I L L S Y L F I G Y I L S C Y W G F F  
\* F F \* V T Y L \* G I F Y L V I G D F S

11701 CTCTCTTTTAAACAGTGTTTTTGAATGCCTATGGGTGTTTATAATTATAAAATTTCTGT 11760  
L S F K Q C F \* N A Y G C L \* L \* N F C  
S L L N S V F R M P M G V Y N Y K I S V  
L F \* T V F L E C L W V F I I I K F L F

11761 TCAAGAATGCGTTATATGAATGCTAATGGCTTACGTCCACCCGTAATAGTTTTGAGGC 11820  
S R I A L Y E C \* W L T S T P \* \* F \* G  
Q E L R Y M N A N G L R P P R N S F E A  
K N C V I \* M L M A Y V H P V I V L R L

11821 TATTTTGTAAATTTAAACTGCTTGAATAGGTGGCGTGCCAGTTATTGAAGTTTCTCA 11880  
Y F V K F K T A W N R W R A S Y \* S F S  
I L L N L K L L G I G G V P V I E V S Q  
F C \* I \* N C L E \* V A C Q L L K F L K

FIG. 9 CONT.

## 142/201

11881 AATTCAATCAAAATTGACTGATGTGAAATGTGCTAATGTTGTTTTGTTAAATTGTTTACA 11940  
N S I K I D \* C E M C \* C C F V K L F T  
I Q S K L T D V K C A N V V L L N C L Q  
F N Q N \* L M \* N V L M L F C \* I V Y S

11941 GCATTTGCATGTTGCTTCTAATTCTAGGTTGTGGCAGTATTGTAGTATTTTACATAATGA 12000  
A F A C C F \* F \* V V A V L \* Y F T \* \*  
H L H V A S N S R L W Q Y C S I L H N E  
I C M L L L I L G C G S I V V F Y I M K

12001 AATACTATCTACTTCAGATTTAAGTGTAGCTTTTGATAAGCTTGCTCAATTATTGATTGT 12060  
N T I Y F R F K C S F \* \* A C S I I D C  
I L S T S D L S V A F D K L A Q L L I V  
Y Y L L Q I \* V \* L L I S L L N Y \* L F

12061 TTTATTGCGCAATCCTGCTGCAGTTGATACTAAGTGTCTTGCAAGTATAGATGAAGTTAG 12120  
F I R Q S C C S \* Y \* V S C K Y R \* S \*  
L F A N P A A V D T K C L A S I D E V S  
Y S P I L L Q L I L S V L Q V \* M K L A

12121 CGATGATTATGTTCAAGATAGTACTGTTTTGCAGGCTTTGCAAAGTGAGTTTGTAAATAT 12180  
R \* L C S R \* Y C F A G F A K \* V C K Y  
D D Y V Q D S T V L Q A L Q S E F V N M  
M I M F K I V L F C R L C K V S L \* I W

12181 GGCTAGTTTTGTTGAATATGAAGTCGCAAGAAAAATTGGCTGATGCTAAAAATAGTGG 12240  
G \* F C \* I \* S R K E K F G \* C \* K \* W  
A S F V E Y E V A K K N L A D A K N S G  
L V L L N M K S Q R K I W L M L K I V V

12241 TTCTGTTAATCAACAACAGATAAAACAGTTAGAAAAGGCATGTAATATAGCTAAGTCTGT 12300  
F C \* S T T D K T V R K G M \* Y S \* V C  
S V N Q Q Q I K Q L E K A C N I A K S V  
L L I N N R \* N S \* K R H V I \* L S L C

12301 GTATGAACGCGATAAAGCTGTAGCTCGCAAACGTGGAACGTATGGCAGACCTAGCACTTAC 12360  
V \* T R \* S C S S Q T G T Y G R P S T Y  
Y E R D K A V A R K L E R M A D L A L T  
M N A I K L \* L A N W N V W Q T \* H L L

12361 TAACATGTATAAAGAGGCTCGGATTAATGATAAGAAGAGTAAAGTTGTTTCCGCTTTGCA 12420  
\* H V \* R G S D \* \* \* E E \* S C F R F A  
N M Y K E A R I N D K K S K V V S A L Q  
T C I K R L G L M I R R V K L F P L C R

FIG. 9 CONT.

143/201

12421 GACAATGCTTTTTAGCATGGTTCGTAAATGGATAATCAGGCTTTAAATTCTATTCTGGA 12480  
D N A F \* H G S \* I G \* S G F K F Y S G  
T M L F S M V R K L D N Q A L N S I L D  
Q C F L A W F V N W I I R L \* I L F W I

12481 TAATGCTGTTAAAGGTTGTGTACCTTTGAATGCTATTCCAGCGCTGGCTGCTAATACTTT 12540  
\* C C \* R L C T F E C Y S S A G C \* Y F  
N A V K G C V P L N A I P A L A A N T L  
M L L K V V Y L \* M L F Q R W L L I L \*

12541 AACTATAATAATACCAGATAAACAAGTTTTTGATAAAGTTGTTGATAATGTTTATGTTGC 12600  
N Y N N T R \* T S F \* \* S C \* \* C L C C  
T I I I P D K Q V F D K V V D N V Y V A  
L \* \* Y Q I N K F L I K L L I M F M L H

12601 ATATGCTGGTAGTGTATGGCATATACAGACTGTTCAAGATGCTGATGGTATTAATAAACA 12660  
I C W \* C M A Y T D C S R C \* W Y \* \* T  
Y A G S V W H I Q T V Q D A D G I N K Q  
M L V V Y G I Y R L F K M L M V L I N S

12661 GTTAACTGATATTAGTGTGATTCTAATTGGCCTCTTGTTATTATTGCTAACAGGTATAA 12720  
V N \* Y \* C \* F \* L A S C Y Y C \* Q V \*  
L T D I S V D S N W P L V I I A N R Y N  
\* L I L V L I L I G L L L L L L L T G I M

12721 TGAAGTTGCTAATGCTGTTATGCAGAATAATGAGTTGATGCCTCATAAATTAAAAATACA 12780  
\* S C \* C C Y A E \* \* V D A S \* I K N T  
E V A N A V M Q N N E L M P H K L K I Q  
K L L M L L C R I M S \* C L I N \* K Y K

12781 AGTTGTTAATAGTGGTCTGATATGAATTGTAACATTCTACTCAATGTTATTATAATAA 12840  
S C \* \* W F \* Y E L \* H S Y S M L L \* \*  
V V N S G S D M N C N I P T Q C Y Y N N  
L L I V V L I \* I V T F L L N V I I I M

12841 TGGTAGTAGTGGTAGAATAGTTTATGCTGTTCTTAGTGATGTTGATGGTCTTAAGTATAC 12900  
W \* \* W \* N S L C C S \* \* C \* W S \* V Y  
G S S G R I V Y A V L S D V D G L K Y T  
V V V V E \* F M L F L V M L M V L S I L

12901 TAAGATAATAAAAGATGATGGAAATTGTGTTGTTTTAGAGCTTGATCCTCCTTGTAATTT 12960  
\* D N K R \* W K L C C F R A \* S S L \* I  
K I I K D D G N C V V L E L D P P C K F  
R \* \* K M M E I V L F \* S L I L L V N F

FIG. 9 CONT.

## 144/201

12961 TTCTATACAAGATGTTAAGGGACTTAAAATTAAGTATCTTTATTTTATTAAAGGATGTAA 13020  
F Y T R C \* G T \* N \* V S L F Y \* R M \*  
S I Q D V K G L K I K Y L Y F I K G C N  
L Y K M L R D L K L S I F I L L K D V T

13021 CACTTTAGCTAGAGGGTGGGTTGTTGGTACTTTATCTCAACAATTAGATTGCAGGCTGG 13080  
H F S \* R V G C W Y F I F N N \* I A G W  
T L A R G W V V G T L S S T I R L Q A G  
L \* L E G G L L V L Y L Q Q L D C R L V

13081 TGTTCGCTACTGAGTATGCAGCTAATTCTTCTATACTTTCATTATGTGCATTTTCTGTAGA 13140  
C C Y \* V C S \* F F Y T F I M C I F C R  
V A T E Y A A N S S I L S L C A F S V D  
L L L S M Q L I L L Y F H Y V H F L \* I

13141 TCCTAAGAAAACCTTATTTAGATTATATACAACAAGGTGGTGTACCTATAATTAATTGTGT 13200  
S \* E N L F R L Y T T R W C T Y N \* L C  
P K K T Y L D Y I Q Q G G V P I I N C V  
L R K L I \* I I Y N K V V Y L \* L I V L

13201 TAAAATGCTCTGTGATCATGCTGGTACTGGTATGGCTATTACTATTAAACCTGAGGCTAC 13260  
\* N A L \* S C W Y W Y G Y Y Y \* T \* G Y  
K M L C D H A G T G M A I T I K P E A T  
K C S V I M L V L V W L L L L N L R L L

13261 TATTAATCAAGATTCTTATGGTGGTGCCTCAGTTTGTATTTACTGCCGTGCACGTGTAGA 13320  
Y \* S R F L W W C L S L Y L L P C T C R  
I N Q D S Y G G A S V C I Y C R A R V E  
L I K I L M V V P Q F V F T A V H V \* S

13321 GCATCCAGATGTAGATGTTTGTGTAAATTACGTGGTAAATTTGTACAAGTCCCTTTGGG 13380  
A S R C R W F V \* I T W \* I C T S P F G  
H P D V D G L C K L R G K F V Q V P L G  
I Q M \* M V C V N Y V V N L Y K S L W V

13381 TATAAAAGATCCTATTCTCTATGTGTTAACACATGATGTTTGTCAAGTTTGTGGATTTTG 13440  
Y K R S Y S L C V N T \* C L S S L W I L  
I K D P I L Y V L T H D V C Q V C G F W  
\* K I L F S M C \* H M M F V K F V D F G

13441 GAGAGATGGCAGTTGTTCCCTGTGTAGGTTTCAGGTGTCGCTGTTCAATCTAAAGATTTAAA 13500  
E R W Q L F L C R F R C R C S I \* R F K  
R D G S C S C V G S G V A V Q S K D L N  
E M A V V P V \* V Q V S L F N L K I \* I

FIG. 9 CONT.

145/201

13501 TTTTAAACGGGTTCGGGGTACTAGTGTGAATGCCCGTCTAGTACCCTGTGCTAGTGGT 13560  
F F K R V R G T S V N A R L V P C A S G  
F L N G F G V L V \* M P V \* Y P V L V V  
F \* T G S G Y \* C E C P S S T L C \* W F

13561 TTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACTAATAGAGCTGGTATA 13620  
L S T D V Q L R A F D I C N T N R A G I  
Y L L M F N \* G H L I F V I L I E L V \*  
I Y \* C S I K G I \* Y L \* Y \* \* S W Y R

13621 GGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGATGACGACGGTAATAAA 13680  
G L Y Y K V N C C R F Q R I D D D G N K  
V Y I I K \* I V A V F S V \* M T T V I N  
F I L \* S E L L P F S A Y R \* R R \* \* I

13681 TTGGATAAGTTCTTTGTTGTTAAAAGAACTAATCTAGAAGTTTATAATAAGAGAAAAC 13740  
L D K F F V V K R T N L E V Y N K E K T  
W I S S L L L K E L I \* K F I I K R K L  
G \* V L C C \* K N \* S R S L \* \* R E N L

13741 TATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGATTCTTTACATTTGAT 13800  
Y Y E L T K S C G V V A E H D F F T F D  
I M S \* L K V V V L W L N M I S L H L I  
L \* V D \* K L W C C G \* T \* F L Y I \* Y

13801 ATTGATGGTAGTCGTGTGCCACATATAGTTTCGTAAGAACCCTCTCAAAGTATACTATGTTA 13860  
I D G S R V P H I V R K N L S K Y T M L  
L M V V V C H I \* F V R T S Q S I L C \*  
\* W \* S C A T Y S S \* E P L K V Y Y V R

13861 GATCTTTGCTATGCATTGCGCCATTTTGATTGTAATGATTGTTTCAGTATTGTGTGAAATT 13920  
D L C Y A L R H F D C N D C S V L C E I  
I F A M H C A I L I V M I V Q Y C V K F  
S L L C I A P F \* L \* \* L F S I V \* N S

13921 CTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAAGATTGGTATGATTTT 13980  
L C E Y A D C K E S Y F S K K D W Y D F  
F V S M L I V K N P T F L R K I G M I L  
L \* V C \* L \* R I L L F \* E R L V \* F C

13981 GTTGAAAATCCTGATATTATTAATATTTATAAAAAATTAGGCCCTATTTTAAATAGAGCT 14040  
V E N P D I I N I Y K K L G P I F N R A  
L K I L I L L I F I K N \* A L F L I E L  
\* K S \* Y Y \* Y L \* K I R P Y F \* \* S F

FIG. 9 CONT.



## 146/201

14041 TTA CTTAATACTGTCAGTTTTCAGATACTTTAGTAAAAGTAGGTTTAGTTGGTGTTTTA 14100  
L L N T V S F A D T L V K V G L V G V L  
Y L I L S V L Q I L \* \* K \* V \* L V F \*  
T \* Y C Q F C R Y F S K S R F S W C F N

14101 ACTTTAGATAATCAAGACTTGTATGGTCAATGGTATGATTTTGGTGATTTTATACAAACA 14160  
T L D N Q D L Y G Q W Y D F G D F I Q T  
L \* I I K T C M V N G M I L V I L Y K Q  
F R \* S R L V W S M V \* F W \* F Y T N S

14161 GCTCCAGGTTTTGGTGTTGGCAGTTGCAGATTCTTACTATTCTTATATGATGCCTATGTTG 14220  
A P G F G V A V A D S Y Y S Y M M P M L  
L Q V L V W Q L Q I L T I L I \* C L C \*  
S R F W C G S C R F L L F L Y D A Y V D

14221 ACTATGTGTCATGATTAGATTGTGAATTATTTGTTAATGATAGTTATAGACAATTCGAT 14280  
T M C H V L D C E L F V N D S Y R Q F D  
L C V M Y \* I V N Y L L M I V I D N S I  
Y V S C I R L \* I I C \* \* \* L \* T I R S

14281 CTTGTACAGTATGATTTTACTGATTATAAGTTAGAATTGTTTAATAAGTATTTTAAGTAT 14340  
L V Q Y D F T D Y K L E L F N K Y F K Y  
L Y S M I L L I I S \* N C L I S I L S I  
C T V \* F Y \* L \* V R I V \* \* V F \* V L

14341 TGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGATAGGTGATTATTTCAT 14400  
W G M K Y H P N T V D C D N D R C I I H  
G V \* S I I L I L W I V I M I G V L F I  
G Y E V S S \* Y C G L \* \* \* \* V Y Y S L

14401 TGTGCTAATTTTAATATATTATTTAGTATGGTCTTACCTAATACTTGTTTTGGTCTCTT 14460  
C A N F N I L F S M V L P N T C F G P L  
V L I L I Y Y L V W S Y L I L V L V L L  
C \* F \* Y I I \* Y G L T \* Y L F W S S C

14461 GTTAGACAAATTTTGTAGATGGTGTCCGTTTGTGTTTCAATTGGTTACCATTATAAA 14520  
V R Q I F V D G V P F V V S I G Y H Y K  
L D K F L \* M V F R L L F Q L V T I I K  
\* T N F C R W C S V C C F N W L P L \* R

14521 GAGTTAGGTGTAGTTATGAACCTGGATGTTGATACACACCGCTATCGTTTGTCTCTTAAA 14580  
E L G V V M N L D V D T H R Y R L S L K  
S \* V \* L \* T W M L I H T A I V C L L K  
V R C S Y E L G C \* Y T P L S F V S \* R

FIG. 9 CONT.

## 147/201

14581 GACTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCTGCTAGTGCTCTGCTT 14640  
D L L L Y A A D P A M H V A S A S A L L  
T Y F F M Q Q I L L C M L H L L V L C L  
L T S L C S R S C Y A C C I C \* C S A \*

14641 GATTTACGAAGTTGTTGTTTGTAGTAGCTGCCATTACAAGTGGTATAAAGTTTCAAAGT 14700  
D L R T C C F S V A A I T S G I K F Q T  
I Y E L V V L V \* L P L Q V V \* S F K L  
F T N L L F \* C S C H Y K W Y K V S N C

14701 GTTAAACCAGGTAATTTTAACCAAGATTTTATGAGTTTGTCAAAAGTAAAGGCTTGTTT 14760  
V K P G N F N Q D F Y E F V K S K G L F  
L N Q V I L T K I F M S L S K V K A C L  
\* T R \* F \* P R F L \* V C Q K \* R L V \*

14761 AAAGAGGGTAGTACAGTTGATTGAAACACTTTTCTTTACTCAAGATGGTAATGCTGCA 14820  
K E G S T V D L K H F F F T Q D G N A A  
K R V V Q L I \* N T F S L L K M V M L Q  
R G \* Y S \* F E T L F L Y S R W \* C C N

14821 ATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTTGATATTAAGCAGTTA 14880  
I T D Y N Y Y K Y N L P T M V D I K Q L  
L L I I I I I S I I Y L L W L I L S S Y  
Y \* L \* L L \* V \* F T Y Y G \* Y \* A V I

14881 TTGTTTGTATTAGAAGTTGTTTATAAGTATTTTGAAATTTATGATGGTGGTTGTATACCA 14940  
L F V L E V V Y K Y F E I Y D G G C I P  
C L Y \* K L F I S I L K F M M V V V Y Q  
V C I R S C L \* V F \* N L \* W W L Y T S

14941 GCATCACAAGTTATTGTTAATAATTATGACAAAAGTGCTGGTTATCCATTTAATAAATTT 15000  
A S Q V I V N N Y D K S A G Y P F N K F  
H H K L L L I I M T K V L V I H L I N L  
I T S Y C \* \* L \* Q K C W L S I \* \* I W

15001 GGTAAGCTAGACTTTATTATGAGGCATTATCATTTGAGGAGCAGAATGAAATTTATGCA 15060  
G K A R L Y Y E A L S F E E Q N E I Y A  
V K L D F I M R H Y H L R S R M K F M H  
\* S \* T L L \* G I I I \* G A E \* N L C I

15061 TATACTAAACGTAATGTGTTGCCCACTTTAACTCAAATGAATTTAAAATATGCTATTAGT 15120  
Y T K R N V L P T L T Q M N L K Y A I S  
I L N V M C C P L \* L K \* I \* N M L L V  
Y \* T \* C V A H F N S N E F K I C Y \* C

FIG. 9 CONT.

148/201

15121 GCTAAGAATAGAGCTCGTACTGTTGCAGGTGTTTCCATTCTTAGTACTATGACAGGTCGA 15180  
A K N R A R T V A G V S I L S T M T G R  
L R I E L V L L Q V F P F L V L \* Q V E  
\* E \* S S Y C C R C F H S \* Y Y D R S N

15181 ATGTTTCATCAAAAATGTTTGAAGAGTATAGCAGCTACTCGTGGTGTTCCCTGTTGTTATA 15240  
M F H Q K C L K S I A A T R G V P V V I  
C F I K N V \* R V \* Q L L V V F L L L \*  
V S S K M F E E Y S S Y S W C S C C Y R

15241 GGAAGTACTAAATTTTATGGTGGCTGGGATGATATGTTACGCCATCTTATAAAGGATGTT 15300  
G T T K F Y G G W D D M L R H L I K D V  
E L L N F M V A G M I C Y A I L \* R M L  
N Y \* I L W W L G \* Y V T P S Y K G C \*

15301 GACAACCTGTCTTATGGGTGGGATTATCCTAAATGTGATCGTGCATGCCAAATATT 15360  
D N P V L M G W D Y P K C D R A M P N I  
T T L F L W V G I I L N V I V P C Q I F  
Q P C S Y G L G L S \* M \* S C H A K Y F

15361 TTGCGTATTGTTAGTAGTTTAGTTTGGCTCGTAAACATGAATTTTGTGTTTCACATGGT 15420  
L R I V S S L V L A R K H E F C C S H G  
C V L L V V \* F W L V N M N F V V H M V  
A Y C \* \* F S F G S \* T \* I L L F T W \*

15421 GATAGATTCTATCGCCTTGCGAATGAATGTGCTCAAGTTTTGAGTGAAATAGTTATGTGT 15480  
D R F Y R L A N E C A Q V L S E I V M C  
I D S I A L R M N V L K F \* V K \* L C V  
\* I L S P C E \* M C S S F E \* N S Y V W

15481 GGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGATGCAACCACTGCTTTT 15540  
G G C Y Y V K P G G T S S G D A T T A F  
A V A I M L S L V V L A V V M Q P L L L  
R L L L C \* A W W Y \* Q W \* C N H C F C

15541 GCTAACTCTGTTTTTAATATATGTCAAGCTGTTACTGCTAATGTTTGTCTCTTATGGCT 15600  
A N S V F N I C Q A V T A N V C S L M A  
L T L F L I Y V K L L L L M F V L L W L  
\* L C F \* Y M S S C Y C \* C L F S Y G L

15601 TGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAAAAACGCTTATACTCT 15660  
C N G H K I E D L S I R N L Q K R L Y S  
V M A I R L K I \* V Y A I Y K N A Y T L  
\* W P \* D \* R F K Y T Q F T K T L I L \*

FIG. 9 CONT.

149/201

15661 AATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAGTATTATGAATTTT 15720  
N V Y R T D Y V D Y T F V N E Y Y E F L  
M F I V Q I M L I I H L L M S I M N F Y  
C L S Y R L C \* L Y I C \* \* V L \* I F M

15721 TGTAAGCATTTTATGATGATTTTGAGTGATGATGGTGTGTTGTTTATAACTCTGAT 15780  
C K H F S M M I L S D D G V V C Y N S D  
V S I L V \* \* F \* V M M V L F V I T L I  
\* A F \* Y D D F E \* \* W C C L L \* L \* L

15781 TATGCTAGTAAGGGTTATATAGCCAATATAAGTGTTTTCAACAAGTTTGTACTATCAG 15840  
Y A S K G Y I A N I S V F Q Q V L Y Y Q  
M L V R V I \* P I \* V F F N K F C T I R  
C \* \* G L Y S Q Y K C F S T S F V L S E

15841 AATAACGTTTTATGTCTGAATCTAAATGTTGGGTTGAAAATGATATTACTAATGGTCCT 15900  
N N V F M S E S K C W V E N D I T N G P  
I T F L C L N L N V G L K M I L L M V L  
\* R F Y V \* I \* M L G \* K \* Y Y \* W S S

15901 CATGAATTCTGTTCAACATACTATGTTGGTTAAGATAGATGGTGACTATGTTTATCTA 15960  
H E F C S Q H T M L V K I D G D Y V Y L  
M N S V H N I L C W L R \* M V T M F I Y  
\* I L F T T Y Y V G \* D R W \* L C L S T

15961 CCCTATCCAGACCCTTCTAGAATTTTAGGAGCTGTTGTTTGTGATGATTTATGAAG 16020  
P Y P D P S R I L G A G C F V D D L L K  
P I Q T L L E F \* E L V V L L M I Y \* R  
L S R P F \* N F R S W L F C \* \* F I E D

16021 ACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATAGATGCTTACCCTTTA 16080  
T D S V L L I E R F V S L A I D A Y P L  
L T V F F \* \* S A L \* V \* L \* M L T L \*  
\* Q C S F D R A L C K S S Y R C L P F S

16081 GTACACCATGAAAATGAAGAATACCAAAAAGTTTTTCGTGTATATTTAGAATATATAAAA 16140  
V H H E N E E Y Q K V F R V Y L E Y I K  
Y T M K M K N T K K F F V Y I \* N I \* K  
T P \* K \* R I P K S F S C I F R I Y K K

16141 AAACATATATAATGATCTTGGTAATCAGATCTTAGATAGTTATAGTGTATTTTAACTACT 16200  
K L Y N D L G N Q I L D S Y S V I L S T  
N Y I M I L V I R S \* I V I V L F \* V L  
T I \* \* S W \* S D L R \* L \* C Y F K Y L

FIG. 9 CONT.

## 150/201

16201 TGTGATGGTTTAAAGTTCACCTGATGAATCATTTTATAAGAATATGTATTTAAAAAGTGCC 16260  
C D G L K F T D E S F Y K N M Y L K S A  
V M V \* S S L M N H F I R I C I \* K V P  
\* W F K V H \* \* I I L \* E Y V F K K C R

16261 GTGATGCAGAGTGTAGGTGCATGTGTTGTTTGTTCATCACAGACGTCTTTGCGTTGTGGC 16320  
V M Q S V G A C V V C S S Q T S L R C G  
\* C R V \* V H V L F V H H R R L C V V A  
D A E C R C M C C L F I T D V F A L W Q

16321 AGTTGTATACGGAAGCCTTTGTGTGTTGTAAATGTTGCTATGATCATGTTATGGCAACC 16380  
S C I R K P L L C C K C C Y D H V M A T  
V V Y G S L C C V V N V A M I M L W Q P  
L Y T E A F V V L \* M L L \* S C Y G N Q

16381 AATCATAAATATGTTTTGAGTGTTCACCTTATGTGTGTAATGCACCTAACTGTGATGTG 16440  
N H K Y V L S V S P Y V C N A P N C D V  
I I N M F \* V F H L M C V M H L T V M \*  
S \* I C F E C F T L C V \* C T \* L \* C E

16441 AGTGATGTCACCAAATTATATTTGGGTGGTATGTCTTATTATTGTGAAAACCATAAACCT 16500  
S D V T K L Y L G G M S Y Y C E N H K P  
V M S P N Y I W V V C L I I V K T I N L  
\* C H Q I I F G W Y V L L L \* K P \* T S

16501 CATTATTCATTTAAGTTAGTTATGAATGGTATGGTCTTTGGTTTGTATAAACAATCTTGT 16560  
H Y S F K L V M N G M V F G L Y K Q S C  
I I H L S \* L \* M V W S L V C I N N L V  
L F I \* V S Y E W Y G L W F V \* T I L Y

16561 ACAGGTTACCTTATATAGATGATTTTAATAAGATAGCTAGTTGTAAATGGACAGAAGTT 16620  
T G S P Y I D D F N K I A S C K W T E V  
Q V H L I \* M I L I R \* L V V N G Q K L  
R F T L Y R \* F \* \* D S \* L \* M D R S \*

16621 GATGATTATGTTCTGGCAAATGAGTGTATTGAACGTTTAAAGTTATTTGCTGCAGAAACT 16680  
D D Y V L A N E C I E R L K L F A A E T  
M I M F W Q M S V L N V \* S Y L L Q K L  
\* L C S G K \* V Y \* T F K V I C C R N S

16681 CAAAAGGCAACTGAAGAAGCTTTTAAACAAAGCTATGCTTCTGCTACTATTCAAGAGATT 16740  
Q K A T E E A F K Q S Y A S A T I Q E I  
K R Q L K K L L N K A M L L L L F K R L  
K G N \* R S F \* T K L C F C Y Y S R D C

FIG. 9 CONT.

151/201

16741 GTTAGTGATAGAGAAATTATTTTGTGTTGGGAGACAGGTAAAGTTAAACCACCACTTAAT 16800  
V S D R E I I L C W E T G K V K P P L N  
L V I E K L F C V G R Q V K L N H H L I  
\* \* \* R N Y F V L G D R \* S \* T T T \* \*

16801 AAAAATTATGTTTTCTACTGGCTATCATTCTACTAGTACTGGTAAGACAGTTTTAGGTGAG 16860  
K N Y V F T G Y H F T S T G K T V L G E  
K I M F S L A I I L L V L V R Q F \* V S  
K L C F H W L S F Y \* Y W \* D S F R \* V

16861 TATGTTTTTGATAAAAGTGAATTAACATAATGGTGTATTATATCGCGCTACAACACTACTTAC 16920  
Y V F D K S E L T N G V Y Y R A T T T Y  
M F L I K V N \* L M V F I I A L Q L L T  
C F \* \* K \* I N \* W C L L S R Y N Y L Q

16921 AAACCTTCTATAGGTGATGTTTTGTCTTAACATCACATTCTGTAGCTAATCTAAGTGCA 16980  
K L S I G D V F V L T S H S V A N L S A  
N F L \* V M F L S \* H H I L \* L I \* V H  
T F Y R \* C F C L N I T F C S \* S K C T

16981 CCTACACTTGTTCCACAAGAGAACTATGCTAGTATAAGATTTTCTAGTGTATTATAGCGTT 17040  
P T L V P Q E N Y A S I R F S S V Y S V  
L H L F H K R T M L V \* D F L V F I A F  
Y T C S T R E L C \* Y K I F \* C L \* R S

17041 CCTTGCTGTTTCAAACATAATGTTGCTAACTATCAGCACATTGGAATGAAACGTTATTGC 17100  
P L L F Q T N V A N Y Q H I G M K R Y C  
L C C F K L M L L T I S T L E \* N V I A  
F A V S N \* C C \* L S A H W N E T L L H

17101 ACTGTGCAAGGTCCTCCTGGTACGGGCAAGTCTCACCTTGCTATAGGTTTAGCTGTTTAT 17160  
T V Q G P P G T G K S H L A I G L A V Y  
L C K V L L V R A S L T L L \* V \* L F I  
C A R S S W Y G Q V S P C Y R F S C L L

17161 TACTATACAGCACGTGTAGTTTATACTGCTGCTAGTCATGCTGCTGTAGATGCATTGTGT 17220  
Y Y T A R V V Y T A A S H A A V D A L C  
T I Q H V \* F I L L L V M L L \* M H C V  
L Y S T C S L Y C C \* S C C C R C I V \*

17221 GAAAAAGCTTATAAGTTTTTAAATATTAATGACTGTACACGCATTATACCTGCTAAAGTT 17280  
E K A Y K F L N I N D C T R I I P A K V  
K K L I S F \* I L M T V H A L Y L L K F  
K S L \* V F K Y \* \* L Y T H Y T C \* S S

FIG. 9 CONT.

## 152/201

17281 CGTGTAGATTGTTATGATAAGTTTAAATTAATGATACTACTTGTAAAGTATGTTTTTACT 17340  
R V D C Y D K F K I N D T T C K Y V F T  
V \* I V M I S L K L M I L L V S M F L L  
C R L L \* \* V \* N \* \* Y Y L \* V C F Y Y

17341 ACAATAAATGCATTACCAGAGTTAGTCACAGATATTGTTGTTGTTGATGAAGTTAGTATG 17400  
T I N A L P E L V T D I V V V D E V S M  
Q \* M H Y Q S \* S Q I L L L L M K L V C  
N K C I T R V S H R Y C C C \* \* S \* Y A

17401 CTTACTAATTATGAATTGTCTGTTATAAATGCTCGTGTTAAAGCTAAACATTATGTATAT 17460  
L T N Y E L S V I N A R V K A K H Y V Y  
L L I M N C L L \* M L V L K L N I M Y I  
Y \* L \* I V C Y K C S C \* S \* T L C I Y

17461 ATTGAGATCCTGCTCAGTTACCTGCACCACGTGTGCTATTGAGTAAGGGTTCTTTAGAA 17520  
I G D P A Q L P A P R V L L S K G S L E  
L E I L L S Y L H H V C Y \* V R V L \* N  
W R S C S V T C T T C A I E \* G F F R T

17521 CCTAGGCATTTTAATTCTATTACTAAAATAATGTGCTGTTTAGGTCCTGATATTTTTTTTG 17580  
P R H F N S I T K I M C C L G P D I F L  
L G I L I L L L K \* C A V \* V L I F F W  
\* A F \* F Y Y \* N N V L F R S \* Y F F G

17581 GGAAATTGTTATAGATGTCCTAAAGAAATTGTAGAAACTGTTTCAGCATTGGTTTATGAT 17640  
G N C Y R C P K E I V E T V S A L V Y D  
E I V I D V L K K L \* K L F Q H W F M I  
K L L \* M S \* R N C R N C F S I G L \* \*

17641 AATAAACTTAAGGCTAAGAATGATAATAGTTCATTATGCTTTAAAGTATATTTTAAGGGA 17700  
N K L K A K N D N S S L C F K V Y F K G  
I N L R L R M I I V H Y A L K Y I L R D  
\* T \* G \* E \* \* \* F I M L \* S I F \* G T

17701 CAGACAACACATGAGAGTTCAAGTGCTGTAAATATTCAACAAATATATTTAATTAGTAAA 17760  
Q T T H E S S S A V N I Q Q I Y L I S K  
R Q H M R V Q V L \* I F N K Y I \* L V N  
D N T \* E F K C C K Y S T N I F N \* \* I

17761 TTTTGAAGCTAATCCAGTTTGAATAGTGCTGTTTTATTAGTCCTTATAATAGTCAG 17820  
F L K A N P V W N S A V F I S P Y N S Q  
F \* K L I Q F G I V L F L L V L I I V R  
F E S \* S S L E \* C C F Y \* S L \* \* S E

FIG. 9 CONT.

153/201

17821 AACTATGTTGCTAAGCGTATTTTAGGTGTTCAAACACAACTGTTGATTCTGCTCAAGGT 17880  
N Y V A K R I L G V Q T Q T V D S A Q G  
T M L L S V F \* V F K H K L L I L L K V  
L C C \* A Y F R C S N T N C \* F C S R F

17881 TCTGAATATGATTATGTTATATATATTCACAAACAGCAGAAACAGCTCATTCTATTAATGTT 17940  
S E Y D Y V I Y S Q T A E T A H S I N V  
L N M I M L Y I H K Q Q K Q L I L L M L  
\* I \* L C Y I F T N S R N S S F Y \* C \*

17941 AATCGATTTAATGTTGCCATAACTAGAGCCAAGAAGGGTATTTTCTGTGTTATGAGTAAT 18000  
N R F N V A I T R A K K G I F C V M S N  
I D L M L P \* L E P R R V F S V L \* V I  
S I \* C C H N \* S Q E G Y F L C Y E \* Y

18001 ATGCAATTATTTGAATCTCTTAATTTTATTACTTTACCTTTAGATAAAATTCAGAATCAA 18060  
M Q L F E S L N F I T L P L D K I Q N Q  
C N Y L N L L I L L L Y L \* I K F R I K  
A I I \* I S \* F Y Y F T F R \* N S E S N

18061 ACTTTATCTCGTTTGCATTGTACTACTAATCTTTTAAAGATTGTAGTAAAAATTTTTA 18120  
T L S R L H C T T N L F K D C S K N F L  
L Y L V C I V L L I F L K I V V K I F \*  
F I S F A L Y Y \* S F \* R L \* \* K F F R

18121 GGTACCACCCAGCTCATGCTCCTTATTTTTATCAGTTGATGATAAATATAAGGTCAAC 18180  
G Y H P A H A P S F L S V D D K Y K V N  
V T T Q L M L L H F Y Q L M I N I R S T  
L P P S S C S F I F I S \* \* \* I \* G Q R

18181 GAAGATTGGCTGTTTGTAAACATTTGTGAACCTGTTTAAACATATTCTCGTTTAATA 18240  
E D L A V C L N I C E P V L T Y S R L I  
K I W L F V \* T F V N L F \* H I L V \* Y  
R F G C L F K H L \* T C F N I F S F N I

18241 TCTCTCATGGGGTTTAAATTGGATTGACTCTTGATGGTTATTCTAAATTTTTTATTACT 18300  
S L M G F K L D L T L D G Y S K F F I T  
L S W G L N W I \* L L M V I L N F L L L  
S H G V \* I G F D S \* W L F \* I F Y Y \*

18301 AAAGACGAAGCTATTAAACGTGTAGAGGTGGGTGGTTTGGATGTAGAAGGAGCCCAT 18360  
K D E A I K R V R G W V G F D V E G A H  
K T K L L N V L E V G L V L M \* K E P M  
R R S Y \* T C \* R L G W F \* C R R S P C

FIG. 9 CONT.



154/201

18361 GCTACGCGTGACAACATTGGAACAACTTTCCATTGCAAATAGGTTTTTCAACTGGTGT 18420  
A T R D N I G T N F P L Q I G F S T G V  
L R V T T L E Q T F H C K \* V F Q L V L  
Y A \* Q H W N K L S I A N R F F N W C \*

18421 GATTTTGTAGTTGAAGCTACTGGCTTATTTGCTGAGAGAGATTGTTATATATTTAAAGA 18480  
D F V V E A T G L F A E R D C Y I F K R  
I L \* L K L L A Y L L R E I V I Y L K E  
F C S \* S Y W L I C \* E R L L Y I \* K N

18481 ACTGTTGCTAAAGCTCCTCCTGGTGATAACTTTAAACATTTAATACCCCTTATGTCGAAA 18540  
T V A K A P P G D N F K H L I P L M S K  
L L L K L L L V I T L N I \* Y P L C R K  
C C \* S S S W \* \* L \* T F N T P Y V E R

18541 GGTCAAAAGTGGGATGTTGTTAGAATCAGAATTGTTCAAATGTTGTCTGATTATCTTTTG 18600  
G Q K W D V V R I R I V Q M L S D Y L L  
V K S G M L L E S E L F K C C L I I F W  
S K V G C C \* N Q N C S N V V \* L S F G

18601 GATCTTTCTGATAGTGTAGTATTTATTACTTGGTCTGCCAGTTTGAAGTTACGTGTTTA 18660  
D L S D S V V F I T W S A S F E L T C L  
I F L I V \* Y L L L G L P V L N L R V \*  
S F \* \* C S I Y Y L V C Q F \* T Y V F K

18661 AGGTATTTTGCTAAATTAGGTAGAGAGCTCAATTGTGATGTGTGTCTTAATCGTGCAACA 18720  
R Y F A K L G R E L N C D V C P N R A T  
G I L L N \* V E S S I V M C V L I V Q H  
V F C \* I R \* R A Q L \* C V S \* S C N M

18721 TGCTATAATTCTAGAACTGGTTATTACGGTTGTTGGCGCCATAGTTATACTTGTGATTAT 18780  
C Y N S R T G Y Y G C W R H S Y T C D Y  
A I I L E L V I T V V G A I V I L V I M  
L \* F \* N W L L R L L A P \* L Y L \* L C

18781 GTGTATAACCCGCTTATTGTAGATATACAACAGTGGGGTTACACAGGTTCTTTAACTAGT 18840  
V Y N P L I V D I Q Q W G Y T G S L T S  
C I T R L L \* I Y N S G V T Q V L \* L V  
V \* P A Y C R Y T T V G L H R F F N \* \*

18841 AATCATGATATAATTTGTAATGTACATAAAGGTGCACATGTTGCATCATCTGATGCAATT 18900  
N H D I I C N V H K G A H V A S S D A I  
I M I \* F V M Y I K V H M L H H L M Q L  
S \* Y N L \* C T \* R C T C C I I \* C N Y

FIG. 9 CONT.

155/201

18901 ATGACTCGGTGTTTAGCAATCTATGATTGTTTTGTAAATCTGTTAATTGGAATTTAGAG 18960  
M T R C L A I Y D C F C K S V N W N L E  
\* L G V \* Q S M I V F V N L L I G I \* S  
D S V F S N L \* L F L \* I C \* L E F R V

18961 TATCCAATAATTTCCAATGAGGTTAGTATAAATACATCTTGTAGGTTATTGCAGCGTGT 19020  
Y P I I S N E V S I N T S C R L L Q R V  
I Q \* F P M R L V \* I H L V G Y C S V L  
S N N F Q \* G \* Y K Y I L \* V I A A C Y

19021 ATGCTTAAAGCTGCCATGCTATGTAATAGATACAATTTATGTTATGACATTGGCAATCCT 19080  
M L K A A M L C N R Y N L C Y D I G N P  
C L K L P C Y V I D T I Y V M T L A I L  
A \* S C H A M \* \* I Q F M L \* H W Q S \*

19081 AAAGGTATTGCTTGTGTCAAAGATTATGAATTTAAATTCTATGATGCTTCTCCTGTTGTC 19140  
K G I A C V K D Y E F K F Y D A S P V V  
K V L L V S K I M N L N S M M L L L L S  
R Y C L C Q R L \* I \* I L \* C F S C C Q

19141 AAGTCTGTAAACAGTTGTTTTATGTTTATGATGTTTATAAAGATAATTTAAGGATGGT 19200  
K S V K Q L F Y V Y D V H K D N F K D G  
S L L N S C F M F M M F I K I I L R M V  
V C \* T V V L C L \* C S \* R \* F \* G W F

19201 TTATGTATGTTTTGGAATTGTAATGTTGATAAATATCCATCTAATTCAATTGTTTGTAGA 19260  
L C M F W N C N V D K Y P S N S I V C R  
Y V C F G I V M L I N I H L I Q L F V D  
M Y V L E L \* C \* \* I S I \* F N C L \* I

19261 TTTGATACTCGGTATTAAATAAATAAACCTCCCTGGATGTAATGGTGGTAGTTTGTAT 19320  
F D T R V L N K L N L P G C N G G S L Y  
L I L G Y \* I N \* T S L D V M V V V C M  
\* Y S G I K \* I K P P W M \* W W \* F V C

19321 GTTAATAAACATGCATTTTACTACTAATCCTTTTACCAGAACGGTCTTTGAAAATCTTAAA 19380  
V N K H A F H T N P F T R T V F E N L K  
L I N M H F I L I L L P E R S L K I L N  
\* \* T C I S Y \* S F Y Q N G L \* K S \* T

19381 CCTATGCCATTTTTTACTATTTCAGATACTCCTTGTGTGTATGTAGATGGTTTGGAAATCC 19440  
P M P F F Y Y S D T P C V Y V D G L E S  
L C H F F T I Q I L L V C M \* M V W N P  
Y A I F L L F R Y S L C V C R W F G I Q

FIG. 9 CONT.

156/201

19441 AAACAAGTTGATTATGTGCCTTTAAGAAGCGCTACTTGTATCACACGATGTAATTTAGGT 19500  
K Q V D Y V P L R S A T C I T R C N L G  
N K L I M C L \* E A L L V S H D V I \* V  
T S \* L C A F K K R Y L Y H T M \* F R W

19501 GGTGCTGTTTGTCTAAGCATGCTGAAGATTATTGTAAATATCTTGAGTCTTATAATGTA 19560  
G A V C S K H A E D Y C K Y L E S Y N V  
V L F V L S M L K I I V N I L S L I M \*  
C C L F \* A C \* R L L \* I S \* V L \* C S

19561 GCTACTACAGCAGGCTTTACTTTTTGGGTTTATAAGACTTTTGATTTTTATAATTTATGG 19620  
A T T A G F T F W V Y K T F D F Y N L W  
L L Q Q A L L F G F I R L L I F I I Y G  
Y Y S R L Y F L G L \* D F \* F L \* F M E

19621 AATACTTTCACTATGTTGCAGAGCTTAGAAAATGTAATATATAATTTGGTTAATGCTGGT 19680  
N T F T M L Q S L E N V I Y N L V N A G  
I L S L C C R A \* K M \* Y I I W L M L V  
Y F H Y V A E L R K C N I \* F G \* C W S

19681 CATTATGATGGACGTATAGGTGAATTGCCTTGTGCTATTATGAATGACAAAGTTGTTGTT 19740  
H Y D G R I G E L P C A I M N D K V V V  
I M M D V \* V N C L V L L \* M T K L L L  
L \* W T Y R \* I A L C Y Y E \* Q S C C \*

19741 AAGATTAATAATGTAGATACTGTTATTTTTAAAAATAATACATCACTTCCTACTAATATA 19800  
K I N N V D T V I F K N N T S L P T N I  
R L I M \* I L L F L K I I H H F L L I \*  
D \* \* C R Y C Y F \* K \* Y I T S Y \* Y S

19801 GCTGTTGAATTATTTACAAAACGTAGTATTCGCCATCACCTGAACCTAAGATTCTTAGA 19860  
A V E L F T K R S I R H H P E L K I L R  
L L N Y L Q N V V F A I T L N L R F L E  
C \* I I Y K T \* Y S P S P \* T \* D S \* K

19861 AATTTGAATATTGATATTTGTTGGAAGCATGTCCTTTGGGATTATGTTAAAGATAGTTTG 19920  
N L N I D I C W K H V L W D Y V K D S L  
I \* I L I F V G S M S F G I M L K I V C  
F E Y \* Y L L E A C P L G L C \* R \* F V

19921 TTTTGTAGTTCTACCTATGGTGTCTGCAAATACACAGATTTAAATTTTATTGAAAATTTG 19980  
F C S S T Y G V C K Y T D L N F I E N L  
F V V L P M V S A N T Q I \* I L L K I \*  
L \* F Y L W C L Q I H R F K F Y \* K F E

FIG. 9 CONT.

157/201

19981 AATGTACTTTTTGATGGTCGTGACAATGGTGCTTTAGAACCTTTAGAAAAGCAAGAAAT 20040  
N V L F D G R D N G A L E A F R K A R N  
M Y F L M V V T M V L \* K L L E K Q E M  
C T F \* W S \* Q W C F R S F \* K S K K W

20041 GGTGTTTTTATTAGTACTGGAAAATTAAGTAGTTTGTCTATGATTAAAGGTCCGCAACGA 20100  
G V F I S T G K L S S L S M I K G P Q R  
V F L L V L E N \* V V C L \* L K V R N E  
C F Y \* Y W K I K \* F V Y D \* R S A T S

20101 GCTGATTTAAATGGCGTAATTGTGGATAAAGTTGGAGAACTCAATGTTGAGTTTGGTTT 20160  
A D L N G V I V D K V G E L N V E F W F  
L I \* M A \* L W I K L E N S M L S F G L  
\* F K W R N C G \* S W R T Q C \* V L V C

20161 GCTATGAGAAAAGATGGTGACGATGTTATCTTCAGCCGTGCAGACAGCCTAAGCCCCAAGC 20220  
A M R K D G D D V I F S R A D S L S P S  
L \* E K M V T M L S S A V Q T A \* A Q A  
Y E K R W \* R C Y L Q P C R Q P K P K P

20221 CATTACTGGAGCCCACAAGGTAATCTAGGTGGTAATTGTGCAGGTAATGCCAGCGGTAAT 20280  
H Y W S P Q G N L G G N C A G N A S G N  
I T G A H K V I \* V V I V Q V M P A V M  
L L E P T R \* S R W \* L C R \* C Q R \* \*

20281 GATGCTCTAGCGCGTTTTACTATCTTTACTCAGAGTCGTGTATTGTCAACCTTTGAACCT 20340  
D A L A R F T I F T Q S R V L S T F E P  
M L \* R V L L S L L R V V Y C Q P L N L  
C S S A F Y Y L Y S E S C I V N L \* T S

20341 CGCTCAGATTTAGAACGGGATTTTATTGATATGGAGGATAGTCTGTTTATAGCCAAATAT 20400  
R S D L E R D F I D M E D S L F I A K Y  
A Q I \* N G I L L I W R I V C L \* P N M  
L R F R T G F Y \* Y G G \* S V Y S Q I W

20401 GGTTTAGAAGATTATGCATTTGATCATATAGTTTATGGTAGTTTAAATTATAAAGTTATA 20460  
G L E D Y A F D H I V Y G S F N Y K V I  
V \* K I M H L I I \* F M V V L I I K L \*  
F R R L C I \* S Y S L W \* F \* L \* S Y R

20461 GGAGGTTTGCACCTTGCTTATAGGTTTATTTTCGTAGACTAAAAAATCTAATTTGGTAATT 20520  
G G L H L L I G L F R R L K K S N L V I  
E V C T C L \* V Y F V D \* K N L I W \* F  
R F A L A Y R F I S \* T K K I \* F G N S

FIG. 9 CONT.

158/201

20521 CAAGAGTTTTTGCAGTATGATTCTAGTATTCATTTCATATTTTCATTACTGATCAAGAGTGT 20580  
Q E F L Q Y D S S I H S Y F I T D Q E C  
K S F C S M I L V F I H I S L L I K S V  
R V F A V \* F \* Y S F I F H Y \* S R V W

20581 GGTAGTAGTAAGAGTGTGTTGTACAGTTATTGATTTATTATTAGATGACTTTGTTGTTATT 20640  
G S S K S V C T V I D L L L D D F V V I  
V V V R V F V Q L L I Y Y \* M T L L L L  
\* \* \* E C L Y S Y \* F I I R \* L C C Y C

20641 GTTAAGTCATTAAATTTGAATTGTGTTAGTAAAGTTGTTAATATTAATGTTGACTTTAAG 20700  
V K S L N L N C V S K V V N I N V D F K  
L S H \* I \* I V L V K L L I L M L T L R  
\* V I K F E L C \* \* S C \* Y \* C \* L \* G

20701 GACTTTCAATTTATGTTGTGGTGAATGATAATAAAATTATGACTTTTTATCCTAAATG 20760  
D F Q F M L W C N D N K I M T F Y P K M  
T F N L C C G V M I I K L \* L F I L K C  
L S I Y V V V \* \* \* \* N Y D F L S \* N A

20761 CAAGCTACTAGTGACTGGAAACCTGGTTATTCTATGCCTGTTTATATAAGTATTTGAAT 20820  
Q A T S D W K P G Y S M P V L Y K Y L N  
K L L V T G N L V I L C L F Y I S I \* M  
S Y \* \* L E T W L F Y A C F I \* V F E C

20821 GTCCATTAGAGAGAGTTTCTTTATGGAATTATGGTAAAGCTATTAATTTACCAACAGGT 20880  
V P L E R V S L W N Y G K A I N L P T G  
F H \* R E F L Y G I M V K L L I Y Q Q V  
S I R E S F F M E L W \* S Y \* F T N R L

20881 TGTATGATGAATGTTGCTAAGTATACTCAATTATGTCAGTATTTAAATACTACAACATTA 20940  
C M M N V A K Y T Q L C Q Y L N T T T L  
V \* \* M L L S I L N Y V S I \* I L Q H \*  
Y D E C C \* V Y S I M S V F K Y Y N I S

20941 GCTGTTCTGTGTTAATATGCGTGTCTTACACTTAGGTGCAGGATCTGATAAAGAAGTAGCC 21000  
A V P V N M R V L H L G A G S D K E V A  
L F L L I C V S Y T \* V Q D L I K K \* P  
C S C \* Y A C L T L R C R I \* \* R S S P

21001 CCTGGTTCTGCTGTTTTAAGACAGTGGTTACCATCTGCTAGTATTCTGTAGATAATGAT 21060  
P G S A V L R Q W L P S G S I L V D N D  
L V L L F \* D S G Y H L V V F L \* I M I  
W F C C F K T V V T I W \* Y S C R \* \* F

FIG. 9 CONT.

159/201

21061 TTAAATCCTTTTGTACTGATAGTTTAGTCACTTATTTTGGAGATTGTATGACTTTACCA 21120  
L N P F V S D S L V T Y F G D C M T L P  
\* I L L L V I V \* S L I L E I V \* L Y H  
K S F C \* \* \* F S H L F W R L Y D F T I

21121 TTTGATTGTCATTGGGATCTGATAATATCTGATATGTATGATCCTCTTACTAAGAATATT 21180  
F D C H W D L I I S D M Y D P L T K N I  
L I V I G I \* \* Y L I C M I L L L R I L  
\* L S L G S D N I \* Y V \* S S Y \* E Y W

21181 GGTGATTATAATGTGAGTAAGGATGGTTTCTTTACTTATATTTGTTATTTAATTCGTGAT 21240  
G D Y N V S K D G F F T Y I C Y L I R D  
V I I M \* V R M V S L L I F V I \* F V I  
\* L \* C E \* G W F L Y L Y L L F N S \* \*

21241 AAATTATCTTTGGGTGGTAGTGTGCTATAAAAAATTACAGAATTTTCTTGGAATGCTGAC 21300  
K L S L G G S V A I K I T E F S W N A D  
N Y L W V V V L L \* K L Q N F L G M L T  
I I F G W \* C C Y K N Y R I F L E C \* L

21301 TTATATAAATTAATGAGTTATTTTGCATTCTGGACAGTTTTTTGTACTAATGTAAATGCT 21360  
L Y K L M S Y F A F W T V F C T N V N A  
Y I N \* \* V I L H S G Q F F V L M \* M L  
I \* I N E L F C I L D S F L Y \* C K C F

21361 TCTTCTAGTGAAGGGTTTTTAATAGGTATAAATTATTTGGGTAAGTCCTGCTTTGAAATA 21420  
S S S E G F L I G I N Y L G K S C F E I  
L L V K G F \* \* V \* I I W V S P A L K \*  
F \* \* R V F N R Y K L F G \* V L L \* N R

21421 GATGGCAATGTTATGCATGCCAACTATTTGTTTTGGAGAAATAGTACAACATGGAATGGT 21480  
D G N V M H A N Y L F W R N S T T W N G  
M A M L C M P T I C F G E I V Q H G M V  
W Q C Y A C Q L F V L E K \* Y N M E W W

21481 GGTGCTTATAGTTTATTTGATATGTCTAAATTTTCTTTGAAATTGGCTGGCACTGCTGTA 21540  
G A Y S L F D M S K F S L K L A G T A V  
V L I V Y L I C L N F L \* N W L A L L \*  
C L \* F I \* Y V \* I F F E I G W H C C S

21541 GTAAATTTAAGACCAGATCAATTAAATGATTTAGTTTATTCTCTTATTGAAAGAGGTAAG 21600  
V N L R P D Q L N D L V Y S L I E R G K  
\* I \* D Q I N \* M I \* F I L L L K E V S  
K F K T R S I K \* F S L F S Y \* K R \* V

FIG. 9 CONT.

160/201

21601 TTATTAGTGCCTGATACGCGTAAAGAAATTTTTGTGGTGATAGTCTTGTAACACTTGT 21660  
L L V R D T R K E I F V G D S L V N T C  
Y \* C V I R V K K F L L V I V L \* T L V  
I S A \* Y A \* R N F C W \* \* S C K H L L

21661 TAGATCTTTCAGTTTGTTAATATTAAATCTAAACTATGTTAATTATATTTTATTTT 21720  
\* I F Q F V N I K S K L C \* L Y F Y F L  
R S F S L L I L N L N Y V N Y I F I F \*  
D L S V C \* Y \* I \* T M L I I F L F F N

21721 ATTTTTGTTATGGTTTTAATGAACCTTTGAATGTTGTGCTCATTTAAACCATGACTGGT 21780  
I F V M V L M N L \* M L C L I \* T M T G  
F L L W F \* \* T F E C C V S F K P \* L V  
F C Y G F N E P L N V V S H L N H D W F

21781 TTTTATTTGGTGATAGTCGTTCTGATTGTAACCATATTAATAATTTAAAAATTAAAAATT 21840  
F Y L V I V V L I V T I L I I \* K L K I  
F I W \* \* S F \* L \* P Y \* \* F K N \* K L  
L F G D S R S D C N H I N N L K I K N Y

21841 ATGGTTATTTGGATATTACCCCTAGTTTGTGTAATAATGGTAAAATTCATCTAGTGCTG 21900  
M V I W I F T L V C V I M V K F H L V L  
W L F G Y S P \* F V \* \* W \* N F I \* C W  
G Y L D I H P S L C N N G K I S S S A G

21901 GTGATTCATTTTTTAAGAGTTATCATTTTACCGGTTTTATAATTACACTGGCGAGGGTG 21960  
V I L F L R V I I L P G F I I T L A R V  
\* F Y F \* E L S F Y P V L \* L H W R G \*  
D S I F K S Y H F T R F Y N Y T G E G D

21961 ATCAAATTATTTTTATGAGGGTGTTAATTTCAATCCTCATCATAGGTTTAAGTGCTTCT 22020  
I K L F F M R V L I S I L I I G L S A S  
S N Y F L \* G C \* F Q S S S \* V \* V L L  
Q I I F Y E G V N F N P H H R F K C F F

22021 TTAATGGTAGTAATGATGTATGGATTTTTAACAAGGTGAGGTTTTATCGTGCTTTATATT 22080  
L M V V M M Y G F L T R \* G F I V L Y I  
\* W \* \* \* C M D F \* Q G E V L S C F I F  
N G S N D V W I F N K V R F Y R A L Y S

22081 CTAATATGGCTCTTTTCGCTATCTTACCTTTGTTGATATTCTTTACAATTTTCTTTTT 22140  
L I W L F F A I L P L L I F F T I F L F  
\* Y G S F S L S Y L C \* Y S L Q F F F F  
N M A L F R Y L T F V D I L Y N F S F S

FIG. 9 CONT.

## 161/201

22141 CTATTAAGGCTAATATTTGTAATAGTAATATTTTATCACTTAATAATCCTATTTTTATTA 22200  
L L R L I F V I V I F Y H L I I L F L L  
Y \* G \* Y L \* \* \* Y F I T \* \* S Y F Y \*  
I K A N I C N S N I L S L N N P I F I S

22201 GTACTAATTATTCTAAGGACGTTTATTTCACTTTATCAGGGTGTTCTTTGTATTTAGTAC 22260  
V L I I L R T F I S L Y Q G V L C I \* Y  
Y \* L F \* G R L F H F I R V F F V F S T  
T N Y S K D V Y F T L S G C S L Y L V P

22261 CTCTTTGTCTTTTTAAATCTAATTTTAGTCAGTACTATTATAATATGGATACTGGCTTTG 22320  
L F V F L N L I L V S T I I I W I L A L  
S L S F \* I \* F \* S V L L \* Y G Y W L C  
L C L F K S N F S Q Y Y Y N M D T G F A

22321 CTTATGGTTATTCTAATTTTGTCTTCTGATTAGATTGTACATATATTTCTCTTAAAC 22380  
L M V I L I L F L L I \* I V H I F L L N  
L W L F \* F C F F \* F R L Y I Y F S \* T  
Y G Y S N F V S S D L D C T Y I S L K P

22381 CTGGTTCTTATAAAATTTTTCTACTGGTTTGTGTTTATCCATACCTACTAAAGCTCTTT 22440  
L V L I K F F L L V L F Y P Y L L K L F  
W F L \* N F F Y W F C F I H T Y \* S S L  
G S Y K I F S T G F V L S I P T K A L C

22441 GCTTTAATAAATCTAAACAATTTGTACCCGTCAGGTTGTTGATTCTAGGTGGAACAATC 22500  
A L I N L N N L Y P C R L L I L G G T I  
L \* \* I \* T I C T R A G C \* F \* V E Q S  
F N K S K Q F V P V Q V V D S R W N N L

22501 TTCGTGCATCGGATACTTCATTATCCGATGCATGTCAGTTGCCTTATTGTTATTTTCGCA 22560  
F V H R I L H Y P M H V S C L I V I F A  
S C I G Y F I I R C M S V A L L L F S Q  
R A S D T S L S D A C Q L P Y C Y F R N

22561 ATTCTTCTGGTAATTATGTTGGCAAATATGATATTAATCATGGTGATAATGGTTTTACTT 22620  
I L L V I M L A N M I L I M V I M V L L  
F F W \* L C W Q I \* Y \* S W \* \* W F Y F  
S S G N Y V G K Y D I N H G D N G F T S

22621 CTATTCTATCTGGTCTTTTATATAATGTCTCTTGTATTTCTTATTATGGCTCCTTTTTGT 22680  
L F Y L V F Y I M S L V F L I M A P F C  
Y S I W S F I \* C L L Y F L L W L L F V  
I L S G L L Y N V S C I S Y Y G S F L Y

FIG. 9 CONT.



162/201

22681 ATGACAATTTTACATCAATTGGCCTCGTTTTCTTTGGTAATTGTCCTACATCTGCTT 22740  
M T I L H Q F G L V F L L V I V L H L L  
\* Q F Y I N L A S F F F W \* L S Y I C L  
D N F T S I W P R F S F G N C P T S A Y

22741 ATATTAAATTAAATTGTTTCTATGATCCTTGCCTATTATTTTACAAGGTATTTATTAT 22800  
I L N \* I V S M I L C L L F Y K V F Y Y  
Y \* I K L F L \* S F A Y Y F T R Y F I I  
I K L N C F Y D P L P I I L Q G I L L F

22801 TTTTAGCTTTATGTTTATTGTGTTTTACTTTTTCTAGTTTACCATGGCTAATATTAAA 22860  
F \* L Y C L L C F Y F F \* F T M A N I K  
F S F I V Y C V F T F S S L P W L I L N  
L A L L F I V F L L F L V Y H G \* Y \* I

22861 TCTAAACATGTTTTAATTATTTTATTTTGCCTACAACACTAGCTGTTATAGGTGATTT 22920  
S K H V F N Y F Y F A Y N T S C Y R \* F  
L N M F L I I F I L P T T L A V I G D F  
\* T C F \* L F L F C L Q H \* L L \* V I L

22921 TAATTGTAACACTCTTTTATTAATGATTATAATAAAACCATTCCGCGTATAAGCGAGGA 22980  
\* L Y \* L F Y \* \* L \* \* N H S A Y K R G  
N C T N S F I N D Y N K T I P R I S E D  
I V L T L L L M I I I K P F R V \* A R M

22981 TGTGTGTGATGATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTTATTTAAA 23040  
C C \* C I S W F G H I L C S \* P C L F K  
V V D V S L G L G T Y Y V L N R V Y L N  
L L M Y L L V W A H I M F L T V F I \* I

23041 TACTACCTTGTTATTTACAGGTTATTTTCCTAAATCTGGTGCTAATTTTAGAGACTTGGC 23100  
Y Y L V I Y R L F S \* I W C \* F \* R L G  
T T L L F T G Y F P K S G A N F R D L A  
L P C Y L Q V I F L N L V L I L E T W L

23101 TTTAAAGGGTTCTAAATATTTGAGTACTCTCTGGTATAAACCACCTTTTCTGTCAGATTT 23160  
F K G F \* I F E Y S L V \* T T F S V R F  
L K G S K Y L S T L W Y K P P F L S D F  
\* R V L N I \* V L S G I N H L F C Q I L

23161 TAATAATGGTATTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTA 23220  
\* \* W Y F F \* G \* E Y \* V I C \* \* Y F V  
N N G I F S K V K N T K L Y V N N T L Y  
I M V F F L R L R I L S Y M L I I L C I

FIG. 9 CONT.

163/201

23221 TAGTGAATTTAGTACTATAGTTATAGGTAGTGTGTTTTGTTAATACTTCTTATACTATTGT 23280  
\* \* I \* Y Y S Y R \* C F C \* Y F L Y Y C  
S E F S T I V I G S V F V N T S Y T I V  
V N L V L \* L \* V V F L L I L L I L L L

23281 TGTTCAACCTCACAATGGTATTTTGGAGATTACAGCTTGTCTAGTATACTATGTGTGAATA 23340  
C S T S Q W Y F G D Y S L S V Y Y V \* I  
V Q P H N G I L E I T A C Q Y T M C E Y  
F N L T M V F W R L Q L V S I L C V N I

23341 TCCTCACACTGTTTGTAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCACATTGATTC 23400  
S S H C L \* V \* G \* Y S \* \* I L A H \* F  
P H T V C K S K G S I R N E S W H I D S  
L T L F V S L R V V F V M N L G T L I L

23401 TTCGGAACCTTTATGCTTGTTTAAGAAAAATTTTACTTATAATGTTTCTGCAGATTGGCT 23460  
F G T F M L V \* E K F Y L \* C F C R L A  
S E P L C L F K K N F T Y N V S A D W L  
R N L Y A C L R K I L L I M F L Q I G C

23461 GTATTTTCATTTTATCAAGAACGTGGTGTGTTTTTATGCATATTATGCAGATGTAGGTAT 23520  
V F S F L S R T W C F L C I L C R C R Y  
Y F H F Y Q E R G V F Y A Y Y A D V G M  
I F I F I K N V V F F M H I M Q M \* V C

23521 GCCTACCACTTTCTTATTTAGTTTATATTTAGGTACTATTTTATCTCATTATTATGTTAT 23580  
A Y H F L I \* F I F R Y Y F I S L L C Y  
P T T F L F S L Y L G T I L S H Y Y V M  
L P L S Y L V Y I \* V L F Y L I I M L C

23581 GCCTTTGACTTGTAAGGCTATATCTTCAAATACTGACAATGAACTTTAGAATATTGGGT 23640  
A F D L \* G Y I F K Y \* Q \* N F R I L G  
P L T C K A I S S N T D N E T L E Y W V  
L \* L V R L Y L Q I L T M K L \* N I G L

23641 TACACCGCTATCTAGACGTAGTATCTTCTTAATTTTGATGAGCACGGTGTATTACTAA 23700  
Y T A I \* T S V S S \* F \* \* A R C Y Y \*  
T P L S R R Q Y L L N F D E H G V I T N  
H R Y L D V S I F L I L M S T V L L L M

23701 TGCCGTTGATTGTTCAAGTAGTTTTCTTAGTGAGATTCAATGTAAACTCAATCTTTTGC 23760  
C R \* L F K \* F S \* \* D S M \* N S I F C  
A V D C S S S F L S E I Q C K T Q S F A  
P L I V Q V V F L V R F N V K L N L L H

FIG. 9 CONT.

164/201

23761 ACCTAATACTGGTGTATGATTTGTCTGGTTTTACTGTAAAGCCTGTTGCAACTGTTTA 23820  
T \* Y W C L \* F V W F Y C K A C C N C L  
P N T G V Y D L S G F T V K P V A T V Y  
L I L V F M I C L V L L \* S L L Q L F I

23821 TCGTCGGATTCTAATTTACCTGATTGTGACATTGACAACCTGGCTTAATAATGTTAGTGT 23880  
S S D S \* F T \* L \* H \* Q L A \* \* C \* C  
R R I P N L P D C D I D N W L N N V S V  
V G F L I Y L I V T L T T G L I M L V Y

23881 ACCTTCACCTCTTAATTGGGAACGTAGAATTTTTCTAATTGTAACCTCAATTTAAGCAC 23940  
T F T S \* L G T \* N F F \* L \* L Q F K H  
P S P L N W E R R I F S N C N F N L S T  
L H L L I G N V E F F L I V T S I \* A L

23941 TTTACTTCGTCTAGTTTCATGTTGATTCTTTTTCTGTAATAATCTTGATAAATCTAAAAT 24000  
F T S S S S C \* F F F L \* \* S \* \* I \* N  
L L R L V H V D S F S C N N L D K S K I  
Y F V \* F M L I L F L V I I L I N L K F

24001 TTTTGGTAGTTGCTTTAATAGTATTACTGTTGACAAGTTTGCTATACCTAATCGCAGACG 24060  
F W \* L L \* \* Y Y C \* Q V C Y T \* S Q T  
F G S C F N S I T V D K F A I P N R R R  
L V V A L I V L L L T S L L Y L I A D E

24061 AGATGATTTGCAATTGGGCAGTTCTGGCTTTTGGCAATCATCTAATTACAAAATAGATAT 24120  
R \* F A I G Q F W L F A I I \* L Q N R Y  
D D L Q L G S S G F L Q S S N Y K I D I  
M I C N W A V L A F C N H L I T K \* I F

24121 TTCTTCTAGTTCTTGTCAATTGTATTATAGTTTACCTTTAGTTAATGTTACTATTAATAA 24180  
F F \* F L S I V L \* F T F S \* C Y Y \* \*  
S S S S C Q L Y Y S L P L V N V T I N N  
L L V L V N C I I V Y L \* L M L L L I T

24181 CTTTAATCCATCTTCTTGAATAGGAGGTATGGTTTTGGTAGTTTAAATGTGTCTTCTTA 24240  
L \* S I F L E \* E V W F W \* F \* C V F L  
F N P S S W N R R Y G F G S F N V S S Y  
L I H L L G I G G M V L V V L M C L L M

24241 TGACGTTGTTTATTCTGATCATTGTTTTCTGTAAACAGCGACTTTTGCCCTTGTGCAGA 24300  
\* R C L F \* S L F F C \* Q R L L P L C R  
D V V Y S D H C F S V N S D F C P C A D  
T L F I L I I V F L L T A T F A L V Q I

FIG. 9 CONT.

165/201

24301 TCCGTCTGTTGTTAATTCTTGTGTTAAATCTAAGCCTCTTCTGCCATTTGTCCTGCTGG 24360  
S V C C \* F L C \* I \* A S F C H L S C W  
P S V V N S C V K S K P L S A I C P A G  
R L L L I L V L N L S L F L P F V L L V

24361 TACTAAATATCGTCATTGCGACTTGGATACTACTCTTATGTTAATAACTGGGTAGATG 24420  
Y \* I S S L R L G Y Y S L C \* \* L V \* M  
T K Y R H C D L D T T L Y V N N W C R C  
L N I V I A T W I L L F M L I T G V D V

24421 TTCTGTCTACCTGACCCCATTTCTACTTATTCCTAACACATGTCCTCAAAAGAAGGT 24480  
F L S T \* P H F Y L F S \* H M S S K E G  
S C L P D P I S T Y S P N T C P Q K K V  
L V Y L T P F L L I L L T H V L K R R S

24481 CGTTGTTGGTATAGGTGAACATTGTCCAGGTCTTGGTATTAATGAGGAAAAATGTGGTAC 24540  
R C W Y R \* T L S R S W Y \* \* G K M W Y  
V V G I G E H C P G L G I N E E K C G T  
L L V \* V N I V Q V L V L M R K N V V H

24541 ACAATTAAATCATAGTTCCTGTCTTGTAGTCCTGATGCCTTTTTGGGTTGGTCTTTTGA 24600  
T I K S \* F L F L \* S \* C L F G L V F \*  
Q L N H S S C S C S P D A F L G W S F D  
N \* I I V P V L V V L M P F W V G L L I

24601 TAGTTGTATTAGTAATAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGAATTAA 24660  
\* L Y \* \* \* S L Q Y F F \* F Y F \* W N \*  
S C I S N N R C N I F S N F I F N G I N  
V V L V I I V A I F F L I L F L M E L I

24661 TAGTGGCACCACCTTGTCTAATGATTGTTATATTCTAACACTGAAGTTTCTACTGGTGT 24720  
\* W H H L F \* \* F V I F \* H \* S F Y W C  
S G T T C S N D L L Y S N T E V S T G V  
V A P L V L M I C Y I L T L K F L L V F

24721 TTGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTAAAGAAGTTTCTGC 24780  
L C \* L \* S L W H H R P R Y F \* R S F C  
C V N Y D L Y G I T G Q G I F K E V S A  
V L I M I F M A S Q A K V F L K K F L R

24781 GGCTTATTATAATAATTGGCAGAATCTTTGTATGATTCTAATGGTAATATTATTGGTTT 24840  
G L L \* \* L A E S F V \* F \* W \* Y Y W F  
A Y Y N N W Q N L L Y D S N G N I I G F  
L I I I I G R I F C M I L M V I L L V L

FIG. 9 CONT.

166/201

24841 TAAAGATTTTTGACTAATAAACTTACACTATACTTCCTTGTTATTCTGGTAGAGTGTC 24900  
\* R F F D \* \* N L H Y T S L L F W \* S V  
K D F L T N K T Y T I L P C Y S G R V S  
K I F \* L I K L T L Y F L V I L V E C L

24901 TGCTGCATTTTATCAAAATTCTTCTTACCAGCTTTGCTTTATCGTAATTTAAAGTG TAG 24960  
C C I L S K F F F T S F A L S \* F K V \*  
A A F Y Q N S S S P A L L Y R N L K C S  
L H F I K I L L H Q L C F I V I \* S V V

24961 TTATGTTTTGAATAATATTCTTTTATCTCACAACCATTTTATTTGATAGTTATCTTGG 25020  
L C F E \* Y F F Y L T T I L F \* \* L S W  
Y V L N N I S F I S Q P F Y F D S Y L G  
M F \* I I F L L S H N H F I L I V I L V

25021 TTGTGTTTTGAATGCTGTTAATTTAACTAGCTATTCTGTATCCTCTTGATTTGCGTAT 25080  
L C F E C C \* F N \* L F C I L L \* F A Y  
C V L N A V N L T S Y S V S S C D L R M  
V F \* M L L I \* L A I L Y P L V I C V W

25081 GGGTAGTGGGTTTTGTATTGATTATGCTTTACCTCTTCTCGGCGTAAGCGTAGAGGTAT 25140  
G \* W V L Y \* L C F T L F S A \* A \* R Y  
G S G F C I D Y A L P S S R R K R R G I  
V V G F V L I M L Y P L L G V S V E V F

25141 TTCTTCTCCTTATCGCTTTGTAACCTTTGAACCTTTAATGTTAGTTTGTAAACGATAG 25200  
F F S L S L C N F \* T L \* C \* F C \* R \*  
S S P Y R F V T F E P F N V S F V N D S  
L L L I A L \* L L N P L M L V L L T I V

25201 TGTTGAAACTGTTGGTGGTTTATTTGAGATTCAGATTCCTACTAACTTTACCATAGCTGG 25260  
C \* N C W W F I \* D S D S Y \* L Y H S W  
V E T V G G L F E I Q I P T N F T I A G  
L K L L V V Y L R F R F L L T L P \* L V

25261 TCATGAAGAATTTATTCAGACTAGTTCTCCTAAAGTTACTATTGATTGTTTCAGCTTTTGT 25320  
S \* R I Y S D \* F S \* S Y Y \* L F S F C  
H E E F I Q T S S P K V T I D C S A F V  
M K N L F R L V L L K L L L I V Q L L F

25321 TTGCTCTAATTATGCTGCTTGTCATGATTTATTGTCGGAATATGGCACTTTTTCGATAA 25380  
L L \* L C C L S \* F I V G I W H F L R \*  
C S N Y A A C H D L L S E Y G T F C D N  
A L I M L L V M I Y C R N M A L F A I I

FIG. 9 CONT.

167/201

25381 TATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTGCAGGTTGC 25440  
Y \* \* Y F K \* S Q \* F T \* Y Y S V A G C  
I N S I L N E V N D L L D I T Q L Q V A  
L I V F \* M K S M I Y L I L L S C R L L

25441 TAATGCTTTAATGCAAGGTGTTACACTTAGTTCTAATCTTAATACTAATCTACACTCTGA 25500  
\* C F N A R C Y T \* F \* S \* Y \* S T L \*  
N A L M Q G V T L S S N L N T N L H S D  
M L \* C K V L H L V L I L I L I Y T L M

25501 TGTTGATAATATAGATTTTAAATCTCTCTAGGTTGTTTAGGTTACACAATGTGGTTCTTC 25560  
C \* \* Y R F \* I S S R L F R F T M W F F  
V D N I D F K S L L G C L G S Q C G S S  
L I I \* I L N L F \* V V \* V H N V V L R

25561 GTCTAGATCTTTGTTAGAGGATTTATTATTCAACAAGGTCAAACCTTTCAGATGTAGGTTT 25620  
V \* I F V R G F I I Q Q G Q T F R C R F  
S R S L L E D L L F N K V K L S D V G F  
L D L C \* R I Y Y S T R S N F Q M \* V L

25621 TGTTGAAGCTTATAATAATTGCACTGGTGGTAGTGAAATTAGAGATCTTCTCTGTGTGCA 25680  
C \* S L \* \* L H W W \* \* N \* R S S L C A  
V E A Y N N C T G G S E I R D L L C V Q  
L K L I I I A L V V V K L E I F S V C N

25681 ATCTTTTAATGGTATTAAAGTATTACCTCCCATTTTATCTGAGACTCAAATTTCTGGCTA 25740  
I F \* W Y \* S I T S H F I \* D S N F W L  
S F N G I K V L P P I L S E T Q I S G Y  
L L M V L K Y Y L P F Y L R L K F L A I

25741 TACTACAGCTGCTACTGTGGCGGCTATGTTTCCGCCATGGTCTGCTGCTGCTGGTGTACC 25800  
Y Y S C Y C G G Y V S A M V C C C W C T  
T T A A T V A A M F P P W S A A A G V P  
L Q L L L W R L C F R H G L L L L V Y H

25801 ATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGATGTTCTTAA 25860  
I F S \* C T I \* N \* W F G C Y Y G C S \*  
F S L N V Q Y R I N G L G V T M D V L N  
F L L M Y N I E L M V W V L L W M F L I

25861 TAAGAATCAAAAGTTAATAGCTAATGCTTTTAAATAAAGCTCTTCTTCTATCCAGAATGG 25920  
\* E S K V N S \* C F \* \* S S S F Y P E W  
K N Q K L I A N A F N K A L L S I Q N G  
R I K S \* \* L M L L I K L F F L S R M V

FIG. 9 CONT.

168/201

25921 TTTTACTGCTACTAACTCTGCTCTTGCTAAAATTCAAAGTGTGCTTAATGCTAATGCTCA 25980  
F Y C Y \* L C S C \* N S K C R \* C \* C S  
F T A T N S A L A K I Q S V V N A N A Q  
L L L L T L L L L K F K V S L M L M L K

25981 AGCACTTAATAGTTTGTACACAATTATTTAATAAATTTGGTGCTATTAGTCTTCTTT 26040  
S T \* \* F V T T I I \* \* I W C Y \* F F F  
A L N S L L Q Q L F N K F G A I S S S L  
H L I V C Y N N Y L I N L V L L V L L Y

26041 ACAAGAAATTTTGTCTCGCCTTGATAATTTAGAAGCTCAGGTTGAGATTGATAGGCTCAT 26100  
T R N F V S P \* \* F R S S G S D \* \* A H  
Q E I L S R L D N L E A Q V Q I D R L I  
K K F C L A L I I \* K L R F R L I G S L

26101 TAATGGTCGTTTGACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGATATTACACT 26160  
\* W S F D C F K C L C F S T A \* \* Y Y T  
N G R L T A L N A Y V S Q Q L S D I T L  
M V V \* L L \* M L M F L N S L V I L H L

26161 TATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAAAGTCAATC 26220  
Y \* G W S F S C Y \* E G \* \* V C \* K S I  
I K A G A S R A I E K V N E C V K S Q S  
L R L E L L V L L R R L M S V L K V N P

26221 CCCTCGTATAAATTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAAATGCTCC 26280  
P S Y K F L W Q W \* P H F I I G S K C S  
P R I N F C G N G N H I L S L V Q N A P  
L V \* I F V A M V T T F Y H W F K M L L

26281 TTATGGTTTGCTTTTCATTCATTTTAGTTATAAACCTACTTCTTTTAAACTGTCTTAGT 26340  
L W F A F H S F \* L \* T Y F F \* N C L S  
Y G L L F I H F S Y K P T S F K T V L V  
M V C F S F I L V I N L L L L K L S \* \*

26341 AAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGTTATTTTAT 26400  
K S R F M F I R \* \* R Y C T \* A R L F Y  
S P G L C L S G D R G I A P K Q G Y F I  
V Q V Y V Y P V I E V L H L S K V I L L

26401 TAAACAAAATGATTCCTGGATGTTTACTGGTAGTTCCTATTATTACCCAGAACCAATTC 26460  
\* T K \* F L D V Y W \* F L L L P R T N F  
K Q N D S W M F T G S S Y Y Y P E P I S  
N K M I P G C L L V V P I I T Q N Q F Q

FIG. 9 CONT.

169/201

26461 AGATAAAATGTTGTTTTCATGAATAGTTGCTCTGTTAATTTTACTAAAGCTCCATTTAT 26520  
R \* K C C F H E \* L L C \* F Y \* S S I Y  
D K N V V F M N S C S V N F T K A P F I  
I K M L F S \* I V A L L I L L K L H L F

26521 TTATCTTAATAATTCTATACCAAATTTGTCTGATTTTGAAGCCGAGTTTCTCTTTGGTT 26580  
L S \* \* F Y T K F V \* F \* S R V F S L V  
Y L N N S I P N L S D F E A E F S L W F  
I L I I L Y Q I C L I L K P S F L F G L

26581 TAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTCATATTAATGCTACTTT 26640  
\* K S Y F Y S T \* F N L \* F S Y \* C Y F  
K N H T S I A P N L T F N S H I N A T F  
K I I L L \* H L I \* P L I L I L M L L F

26641 TTTAGATCTGTATTATGAAATGAATGTTATTCAGGAATCTATTAAATCTTTGAACAGTAG 26700  
F R S V L \* N E C Y S G I Y \* I F E Q \*  
L D L Y Y E M N V I Q E S I K S L N S S  
\* I C I M K \* M L F R N L L N L \* T V V

26701 TTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGGCCTTGGTACAT 26760  
F Y \* S \* R N R Y L \* N V C \* M A L V H  
F I N L K E I G T Y E M Y V K W P W Y I  
L L I L K K \* V L M K C M L N G L G T F

26761 TTGGTTGTTAATTGTCATTTTATTTATAATTTTCTTATGATACTTTTCTTTATATGCTG 26820  
L V V N C H F I Y N F S Y D T F L Y M L  
W L L I V I L F I I F L M I L F F I C C  
G C \* L S F Y L \* F F L \* Y F S L Y A A

26821 CTGTACTGGTTGTGGTTCAGCATGTTTTAGTAAATGTCATAATTGTTGTGATGAGTATGG 26880  
L Y W L W F S M F \* \* M S \* L L \* \* V W  
C T G C G S A C F S K C H N C C D E Y G  
V L V V V Q H V L V N V I I V V M S M G

26881 GGGTCACAATGATTTTGTATTATTAAGCATCTCATGATGATTAGATTTTAAATCTAAACTT 26940  
G S Q \* F C Y \* S I S \* \* L D F K S K L  
G H N D F V I K A S H D D \* I L N L N F  
V T M I L L L K H L M M I R F \* I \* T L

26941 TATATATGGAAGTTTGGAGGCCTAGCTATAAATATTCTCTTATTACTAGAGAATTTGGTG 27000  
Y I W K F G G L A I N I L L L L E N L V  
I Y G S L E A \* L \* I F S Y Y \* R I W C  
Y M E V W R P S Y K Y S L I T R E F G V

FIG. 9 CONT.



## 170/201

27001 TCACAGATCTTGAGGATTTGTGTTTTAAATATAATTATTGCCAACCTTGTGTTGGTTATT 27060  
S Q I L R I C V L N I I I A N L V L V I  
H R S \* G F V F \* I \* L L P T L C W L L  
T D L E D L C F K Y N Y C Q P C V G Y C

27061 GTATTGTACCTTTAAACGTTTGGTGTCTAAGTTTGGTAAATTGCTTCTTATTTTGT 27120  
V L Y L \* T F G V V S L V N L L L I L F  
Y C T F K R L V S \* V W \* I C F L F C F  
I V P L N V W C R K F G K F A S Y F V L

27121 TACGTAGTCATGACACCTCTCATAAGAATAATTTGGTGTATAACTAGTTTACTAGTT 27180  
Y V V M T P L I R I I L V L \* L V L L V  
T \* S \* H L S \* E \* F W C Y N \* F Y \* L  
R S H D T S H K N N F G V I T S F T S Y

27181 ATGGTAACACTGTTTCTGAGGCTGTTTCTAAATTAGTTGAATCAGCATCTGATTTTATCG 27240  
M V T L F L R L F L N \* L N Q H L I L S  
W \* H C F \* G C F \* I S \* I S I \* F Y R  
G N T V S E A V S K L V E S A S D F I A

27241 CTTGGCGAGCTGAAGCACTTAATAAGTATGGTTGATGTATTTTCTACTGATACTGCTTGG 27300  
L G E L K H L I S M V D V F F T D T A W  
L A S \* S T \* \* V W L M Y F S L I L L G  
W R A E A L N K Y G \* C I F H \* Y C L V

27301 TATGTAGGTCAGATTTTCTTTTAGTTTTATCTTGTGTCATTTTCTTAATTTTGTGTT 27360  
Y V G Q I F F L V L S C V I F L I F V V  
M \* V R F S F \* F Y L V S F S \* F L L L  
C R S D F L F S F I L C H F L N F C C C

27361 GCACTTTTAGCAACTATTAACTTTGTATTCAAATTTGTGGTTTTGTAAATATTTTATT 27420  
A L L A T I K L C I Q I C G F C N I F I  
H F \* Q L L N F V F K F V V F V I F L L  
T F S N Y \* T L Y S N L W F L \* Y F Y Y

27421 ATTCACCTTCTGCCTATGTTTATAATAGAGGTAGACAGTTGTATAAGTCTTATAGTGAA 27480  
I S P S A Y V Y N R G R Q L Y K S Y S E  
F H L L P M F I I E V D S C I S L I V N  
F T F C L C L \* \* R \* T V V \* V L \* \* T

27481 CATGTCATACCTTCTACTTTAGATGATTTAATTTAAATCTAAACATCATGAATGAATCAA 27540  
H V I P S T L D D L I \* I \* T S \* M N Q  
M S Y L L L \* M I \* F K S K H H E \* I N  
C H T F Y F R \* F N L N L N I M N E S I

FIG. 9 CONT.

## 171/201

27541 TTTTTCCTCATTGGAATTCTGATCAAGCTATTACATTCTTAAAGAATGGAATTCTCTT 27600  
F F L I G I L I K L L H S \* K N G I S L  
F S S L E F \* S S Y Y I L K R M E F L F  
F P H W N S D Q A I T F L K E W N F S L

27601 TGGGTGTAATATTACTTCTCATTACTATCATACTGCAGTTTGGTTATACGAGTCGTAGTA 27660  
W V \* Y Y F S L L S Y C S L V I R V V V  
G C N I T S H Y Y H T A V W L Y E S \* Y  
G V I L L L I T I I L Q F G Y T S R S M

27661 TGTTTGTATTCTTATTAAGATGATTATTCTTTGGCTTATGTGGCCATTGACCATTATCT 27720  
C L F I L L R \* L F F G L C G H \* P L S  
V C L S Y \* D D Y S L A Y V A I D H Y L  
F V Y L I K M I I L W L M W P L T I I L

27721 TGA CTATATTTAATTGCTTTTATGCTTTGAATAATATCTTTCTTGGGCTTTCTATACTGT 27780  
\* L Y L I A F M L \* I I S F L G F L Y C  
D Y I \* L L L C F E \* Y L S W A F Y T V  
T I F N C F Y A L N N I F L G L S I L F

27781 TTACTATTATTCTATTGTTATATGGATTTTATATTTTGTCAACAGTATTGCGCTTTTTA 27840  
L L L F L L L Y G F Y I L S T V F G F L  
Y Y Y F Y C Y M D F I F C Q Q Y S A F Y  
T I I S I V I W I L Y F V N S I R L F I

27841 TCAGAACTGGCAGTTGGTGGAGTTTTAAACCCAGAGACTAATAATCTTATGTGTATTGATA 27900  
S E L A V G G V L T Q R L I I L C V L I  
Q N W Q L V E F \* P R D \* \* S Y V Y \* Y  
R T G S W W S F N P E T N N L M C I D M

27901 TGAAAGGTAAGATGTATGTTAGGCCAGTTATTGAGGACTATCATACTTAACGGCTACTG 27960  
\* K V R C M L G Q L L R T I I H \* R L L  
E R \* D V C \* A S Y \* G L S Y I N G Y C  
K G K M Y V R P V I E D Y H T L T A T V

27961 TTATCCGTGGTCATCTTTATATACAGGGTGTTAAACTTGGCACTGGTTACACGCTTGCCG 28020  
L S V V I F I Y R V L N L A L V T R L P  
Y P W S S L Y T G C \* T W H W L H A C R  
I R G H L Y I Q G V K L G T G Y T L A D

28021 ATTTGCCTGTTTATGTTACTGTAGCTAAGGTGCAAGTCCTCTGTACTTATAAACGTGCCT 28080  
I C L F M L L \* L R C K S S V L I N V P  
F A C L C Y C S \* G A S P L Y L \* T C L  
L P V Y V T V A K V Q V L C T Y K R A F

FIG. 9 CONT.

172/201

28081 TTTTAGATAAGTTAGATGTTAATAGTGGTTTGGCTGTTTTGTTAAGTCTAAAGTTGGTA 28140  
F \* I S \* M L I V V L L F L L S L K L V  
F R \* V R C \* \* W F C C F C \* V \* S W \*  
L D K L D V N S G F A V F V K S K V G N

28141 ACTATCGTTTACCTTCTAGTAAATCTAGTGGTATGGATACTGCCTTGTTGAGAGCTTAAA 28200  
T I V Y L L V N L V V W I L P C \* E L K  
L S F T F \* \* I \* W Y G Y C L V E S L N  
Y R L P S S K S S G M D T A L L R A \* I

28201 TCTAAACTATTAGGATGTCTTATACTCCCGGTCATCATGCTGGAAGTAGAAGCTCCTCTG 28260  
S K L L G C L I L P V I M L E V E A P L  
L N Y \* D V L Y S R S S C W K \* K L L W  
\* T I R M S Y T P G H H A G S R S S S G

28261 GAAATCGTTCAGGAATCCTCAAGAAAACCTTCTTGGGTTGACCAATCTGAGCGAAGCCATC 28320  
E I V Q E S S R K L L G L T N L S E A I  
K S F R N P Q E N F L G \* P I \* A K P S  
N R S G I L K K T S W V D Q S E R S H Q

28321 AAACCTATAATAGAGGCAGAAAACCCCAACCCAAATTCACTGTGTCTACTCAACCACAAG 28380  
K P I I E A E N P N P N S L C L L N H K  
N L \* \* R Q K T P T Q I H C V Y S T T R  
T Y N R G R K P Q P K F T V S T Q P Q G

28381 GAAACCTATCCACATTATTCCTGGTTCTCTGGGATTACCCAATTTCAAAAAGGTAGAG 28440  
E T L S H I I P G S L G L P N F K K V E  
K P Y P T L F L V L W D Y P I S K R \* R  
N P I P H Y S W F S G I T Q F Q K G R D

28441 ACTTTAAATTTCCAGATGGTCAAGGAGTACCCATTGCTTACGGGATACCCCTTCTGAAG 28500  
T L N F Q M V K E Y P L L T G Y P L L K  
L \* I S R W S R S T H C L R D T P F \* S  
F K F P D G Q G V P I A Y G I P P S E A

28501 CAAAAGGATATTGGTATAAACACAACCGGCGTTCTTTTAAACAGCTGATGGTCAACAAA 28560  
Q K D I G I N T T G V L L K Q L M V N K  
K R I L V \* T Q P A F F \* N S \* W S T K  
K G Y W Y K H N R R S F K T A D G Q Q K

28561 AGCAGTTGTTACCAAGATGGTATTTCTACTATCTCGGTACCGGTCCATATGCCAGTTCAT 28620  
S S C Y Q D G I S T I S V P V H M P V H  
A V V T K M V F L L S R Y R S I C Q F I  
Q L L P R W Y F Y Y L G T G P Y A S S S

FIG. 9 CONT.

173/201

28621 CCTATGGTGATGCCCACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGACACTTCTA 28680  
P M V M P T K V S S G S L V T K L T L L  
L W \* C P R R Y L L G R \* S P S \* H F Y  
Y G D A H E G I F W V A S H Q A D T S I

28681 TTCCCTCCGATGTTTCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTT 28740  
F P P M F R Q G I L L F K K L S L L G F  
S L R C F G K G S Y Y S R S Y P Y \* V F  
P S D V S A R D P T I Q E A I P T R F S

28741 CGCCTGGTACGATTTTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTA 28800  
R L V R F C L K A I M L K A Q E G L L L  
A W Y D F A S R L L C \* R L R K V C F \*  
P G T I L P Q G Y Y V E G S G R S A S N

28801 ATAGCCGGCCAGGTTACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAA 28860  
I A G Q V H V L N H V D P I I V H \* V E  
\* P A R F T F S I T W T Q \* S F I K \* K  
S R P G S R S Q S R G P N N R S L S R S

28861 GTAATTCTAATTTTAGACATTCTGATTCTATAGTGAAACCTGATATGGCTGATGAGATTG 28920  
V I L I L D I L I L \* \* N L I W L M R L  
\* F \* F \* T F \* F Y S E T \* Y G \* \* D C  
N S N F R H S D S I V K P D M A D E I A

28921 CTAGTCTTGCTTGGCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTTACCAAGCAAA 28980  
L V L S W P S L V K I L N L S K L P S K  
\* S C L G Q A W \* R F \* T S A S Y Q A K  
S L V L A K L G K D S K P Q Q V T K Q N

28981 ATGCTAAGGAAATTAGGCATAAAATTTTAATGAAACCTCGCCAAAAGCGAACTCCTAATA 29040  
M L R K L G I K F \* \* N L A K S E L L I  
C \* G N \* A \* N F N E T S P K A N S \* \*  
A K E I R H K I L M K P R Q K R T P N K

29041 AATTTTGTAATGTTCAACAGTGTTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATT 29100  
N F V M F N S V L V K E D R S K T L V I  
I L \* C S T V F W \* K R T A P K L W \* F  
F C N V Q Q C F G K R G P L Q N F G N S

29101 CTGAAATGTTAAAGCTTGGTACTAATGATCCTCAATTCCTATTCTTGCTGAATTAGCCC 29160  
L K C \* S L V L M I L N F L F L L N \* P  
\* N V K A W Y \* \* S S I S Y S C \* I S P  
E M L K L G T N D P Q F P I L A E L A P

FIG. 9 CONT.

174/201

29161 CTACACCAGGTGCTTTTTTCTTTGGCTCTAAATTAGAGTTGTTTAAAAGAGACTCTGATG 29220  
L H Q V L F S L A L N \* S C L K E T L M  
Y T R C F F L W L \* I R V V \* K R L \* C  
T P G A F F F G S K L E L F K R D S D A

29221 CTGATTCACCTTCTAAAGACACTTTTGAACCTTCGTTATTCTGGTTCTATTAGGTTTGATa 29280  
L I H L L K T L L N F V I L V L L G L I  
\* F T F \* R H F \* T S L F W F Y \* V \* \*  
D S P S K D T F E L R Y S G S I R F D S

29281 GTACTTTACCTGGTTTTGAGACAATTATGAAAGTTCTTAAAGAGAATTTAGATGCTTATG 29340  
V L Y L V L R Q L \* K F L K R I \* M L M  
Y F T W F \* D N Y E S S \* R E F R C L C  
T L P G F E T I M K V L K E N L D A Y V

29341 TTAATTCTAATCAGAACACTGTTTCTGGTTCGCTGAGTCCTAAACCTCAGCGTAAAAGAG 29400  
L I L I R T L F L V R \* V L N L S V K E  
\* F \* S E H C F W F A E S \* T S A \* K R  
N S N Q N T V S G S L S P K P Q R K R G

29401 GTGTAAACAATCACCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACA 29460  
V L N N H L N R L T L L I \* V L I L S T  
C \* T I T \* I V \* L S \* F K C \* Y S A H  
V K Q S P E S F D S L N L S A D T Q H I

29461 TTTCAAATGATTTTACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATG 29520  
F Q M I L L L R I I V Y L L L L M I L M  
F K \* F Y S \* G S \* F T C Y S \* \* S L C  
S N D F T P E D H S L L A T L D D P Y V

29521 TAGAAGACTCTGTTGCTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTC 29580  
\* K T L L L N E N E S \* F D T R W \* P L  
R R L C C L M R M N P N S T L G G N P S  
E D S V A \* \* E \* I L I R H \* V V T P R

29581 GCTATTAGTCGGAATAGGACACTCTCTATCAGAATGAATCTTGCTGTTACAACAGATAG 29640  
A I S R N R T L S I R M N S C C Y N R \*  
L L V G I G H S L S E \* I L A V T T D R  
Y \* S E \* D T L Y Q N E F L L L Q Q I E

29641 AGTAGGTTGTTGCAGACTATATATTAATTAGTAGAACTTTATATTTAAATATTTGATTG 29700  
S R L L Q T I Y \* L V E T L Y L N I \* L  
V G C C R L Y I N \* \* K L Y I \* I F D C  
\* V V A D Y I L I S R N F I F K Y L I V

FIG. 9 CONT.

## 175/201

29701 TTAGAGTAGTTATAAGGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTAGCAATTAT 29760  
L E \* L \* G L A V V \* T P P G R A S N Y  
\* S S Y K V \* L \* Y K R L R E E L A I I  
R V V I R F S C S I N A S G K S \* Q L \*

29761 AGTATTTAATATATATATATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTA 29820  
S I \* Y I Y \* Y M I E I N Y S L L E E L  
V F N I Y I S I \* L K L I I A F W R N Y  
Y L I Y I L V Y D \* N \* L \* P F G G I T

29821 CAAAAAAAAAAAAAAAAA 29836  
Q K K K K X  
K K K K K  
K K K K

FIG. 9 CONT.

1 400 800 1200 1600 2000 2400 2800 3200 3600 4000 4400 4800 5200 5600 6000 6400 6800 7200

HCov-CC43 p28 p85 PL1<sup>pro</sup> PL2<sup>pro</sup> nsp2 nsp3 nsp5 nsp nsp8 nsp10 nsp11 nsp12 nsp13

BCoV p28 p85 PL1<sup>pro</sup> PL2<sup>pro</sup> nsp2 nsp3 nsp5 nsp nsp8 nsp10 nsp11 nsp12 nsp13

MHV p28 p85 PL1<sup>pro</sup> PL2<sup>pro</sup> nsp2 nsp3 nsp5 nsp nsp8 nsp10 nsp11 nsp12 nsp13

CoV-HKU1 p28 p85 PL1<sup>pro</sup> PL2<sup>pro</sup> nsp2 nsp3 nsp5 nsp nsp8 nsp10 nsp11 nsp12 nsp13

AC Domain nsp1 nsp2 nsp3 nsp5 nsp nsp8 nsp10 nsp11 nsp12 nsp13

ATR nsp1

MHV VGEIEPAVFEDDVVDVVKAPLTYQGCKPFTSFSEKICIVDKLYNAKCGDQFYPVVVDNDHT 819

BCoV KSGSGDFSLADSVVEVVTSTLTPCGSYSEPPKVADKICIVDNVYNAKAGDKYYPVVVDG-H 838

HCov-CC43 KSGSGDFSLADSVVEVVTSTLTPCGSYSEPPKVADKICIVDNVYNAKAGDKYYPVVVDG-H 838

CoV-HKU1 (1st patient) EGVAESVIVEDDVIVNKSSLSSEYECQPPKSEVEKICIDNNHYMGKCGDKFEPVVDNDK 796

CoV-HKU1 (2nd patient) EGVAESVIVEDDVIVNKSSLSSEYECQPPKSEVEKICIDNNHYMGKCGDKFEPVVDNDK 796

MHV VGVLDQCNREFPCAGKKVEFNDKPKVRKIPST-RNKITFALDADFDSVLSKACSEFEVDK 878

BCoV VGLLDQAWRVPCAGRRVTFKEQPTVNEIATSTPKTIKVEYELDKDFENTLINTACGVFEVD 898

HCov-CC43 VGLLDQAWRVPCAGRRVTFKEQPTVNEIATSTPKTIKVEYELDKDFENTLINTACGVFEVD 898

CoV-HKU1 (1st patient) ICLLDQAWRVPCAGRRVTFKEQPTVNEIATSTPKTIKVEYELDKDFENTLINTACGVFEVD 898

CoV-HKU1 (2nd patient) ICLLDQAWRVPCAGRRVTFKEQPTVNEIATSTPKTIKVEYELDKDFENTLINTACGVFEVD 898

MHV DVTLDLDELVDVDAVESTLSPCKEHDVIGTKVCALLDRLAGDVYVYLFDEGGDEVIAPRM 938

BCoV TVDMEEFYAVVIDAIEEKLSPCKLEGGVAKVSAFLQKLEDNLSFLFDEAGEEVLASKLY 958

HCov-CC43 TVDMEEFYAVVIDAIEEKLSPCKLEGGVAKVSAFLQKLEDNLSFLFDEAGEEVLASKLY 958

CoV-HKU1 (1st patient) GVTVDDEFAVVCDAIENALNSCKEHVYVGYQVRAFLNKLINENVYVLFDEAGDEAMARM 915

CoV-HKU1 (2nd patient) GVTVDDEFAVVCDAIENALNSCKEHVYVGYQVRAFLNKLINENVYVLFDEAGDEAMARM 915

MHV CSFSAPODEDCVAADVVDADEN-----QDD-----DAEDSAVLVAOTQEEEDGVAKG- 984

BCoV CFTAPEDDDFLFEZSGVE-----EDDVEGEETDLTVTSAG- 993

HCov-CC43 CFTAPEDDDFLFEZSGVE-----EDDVEGEETDLTVTSAG- 993

CoV-HKU1 (1st patient) CTFATIEDVVDVTSSEAVEEDTIDGVVEDTINDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 975

CoV-HKU1 (2nd patient) CTFATIEDVVDVTSSEAVEEDTIDGVVEDTINDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 975

MHV -----QVEADSEICVAHTGSGQEELAEPOAVGSGTPIASAEETEVGEASDREGIAEAKAT 1038

BCoV -----EPCVASEQESSEILEDTLDGFCVETSD-----SQVEEDVEMSD 1034

HCov-CC43 -----QPCVASEQESSEILEDTLDGFCVETSD-----SQVEEDVEMSD 1034

CoV-HKU1 (1st patient) DDEEVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 1035

CoV-HKU1 (2nd patient) DDEEVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 1035

MHV VCADAVDACPDQVEAFEIEKVEDSILDELQTELNAPADK----- 1077

BCoV ADLESVIQDYEN-----VCPEEYTFTEPFVNVLDLYVVK 1066

HCov-CC43 VDLSEVIQDYEN-----VCPEEYTFTEPFVNVLDLYVVK 1066

CoV-HKU1 (1st patient) DDEEVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 1095

CoV-HKU1 (2nd patient) DDEEVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 1095

AC Domain PL1<sup>pro</sup>

MHV -----TYEDVLAEDAVCSEALSAEYAVPSDETTFE-KVCGFYSPFA 1115

BCoV -----VCPEEYTFTEPFVNVLDLYVVK 1066

HCov-CC43 -----VCPEEYTFTEPFVNVLDLYVVK 1066

CoV-HKU1 (1st patient) DDEEVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 1125

CoV-HKU1 (2nd patient) DDEEVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDNDDDEDVVTGDN 1125

FIG. 10

177/201

Fig. 11. Multiple alignment of the replicase genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9 and 10.

```

Patient 7      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 9      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 10     TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 6      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 4      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 8      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 2      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 5      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGGCTAGTA 60
Patient 1      TCTAAAGATTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
*****

Patient 7      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 9      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 10     CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 6      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 4      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 8      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 2      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 5      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 1      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGATATTGTAATACC 120
*****

Patient 7      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 9      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 10     AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 6      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 4      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 8      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 2      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 5      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 1      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
*****

Patient 7      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 9      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 10     GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 6      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 4      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 8      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 2      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 5      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATTTAGAAGTTTAT 240
Patient 1      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGTCAAAAGAACTAATCTAGAAGTTTAT 240
*****

Patient 7      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 9      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 10     AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 6      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 4      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 8      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 2      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 5      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 1      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
*****

Patient 7      TTCTTTATATTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 9      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 10     TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 6      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 4      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 8      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 2      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 5      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 1      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAACCTCTCA 360
*****

Patient 7      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 9      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 10     AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 6      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 4      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 8      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 2      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 5      AAGTATACATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420

```

FIG. 11



178/201

Patient 1 AAGTATACTATGTTAGATCTTTGCTATGCATTGCGCCATTTTGATTGTAATGATTGTTC 420  
\*\*\*\*\*

Patient 7 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 9 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 10 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 6 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 4 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 8 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 2 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 5 ATATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
Patient 1 GTATTGCTGAAATTCCTTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480  
\*\*\*\*\*

Patient 7 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 9 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 10 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 6 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 4 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 8 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 2 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 5 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
Patient 1 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
\*\*\*\*\*

Patient 7 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 9 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 10 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 6 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 4 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 8 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 2 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 5 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
Patient 1 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGATACCTTAGTTGAAGTAGGT 600  
\*\*\*\*\*

Patient 7 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 9 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 10 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 6 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 4 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 8 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 2 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 5 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTGTATGGTCAATGGTATGATTTTGGT 660  
Patient 1 TTAGTTGGTGTTTTAACTTTAGATAATCAAGACTTGTATGGTCAATGGTATGATTTTGGT 660  
\*\*\*\*\*

Patient 7 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 9 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 10 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 6 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 4 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 8 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 2 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 5 GATTTTATACAAACAGCCCCAGGATTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
Patient 1 GATTTTATACAAACAGCTCCAGGTTTGGTGTGGCAGTCGCAGATTCTTACTATTCTTAT 720  
\*\*\*\*\*

Patient 7 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 9 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 10 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 6 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 4 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 8 ATGATGCCATGTTAACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 2 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 5 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
Patient 1 ATGATGCCATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780  
\*\*\*\*\*

Patient 7 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
Patient 9 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
Patient 10 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
Patient 6 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
Patient 4 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
Patient 8 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840  
Patient 2 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAA 840

FIG. 11 CONT.

179/201

```
Patient 5      TATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 1      TATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTATAAGTTAGAAATTGTTTAAAT 840
*****

Patient 7      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 9      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 10     AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 6      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 4      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 8      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 2      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 5      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 1      AAGTATTTTAAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
*****

Patient 7      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 9      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 10     AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 6      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 4      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 8      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 2      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 5      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
Patient 1      AGGTGTATTATTTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960
*****

Patient 7      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 9      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 10     TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 6      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 4      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 8      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 2      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 5      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
Patient 1      TGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGGTGACCGTTTGTGTTTCTATT 1020
*****

Patient 7      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 9      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 10     GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 6      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 4      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 8      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 2      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 5      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
Patient 1      GGTACCATTACAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080
*****

Patient 7      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 9      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 10     CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 6      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 4      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 8      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 2      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 5      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 1      CGTTTGCTCTCTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
*****

Patient 7      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 9      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 10     GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 6      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 4      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 8      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 2      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 5      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 1      GCTAGTGCTCTGCTTGATTTACGAACCTGTTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
*****

Patient 7      ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260
Patient 9      ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260
Patient 10     ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260
Patient 6      ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260
Patient 4      ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260
Patient 8      ATAAAATTTCAAACCTGTAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTFAAA 1260
```

FIG. 11 CONT.

180/201

Patient 2 ATAAAAATTTCAAACGTGTAACCAAGGTAAGTTCAGAGTTGTTAAA 1260  
 Patient 5 ATAAAAATTTCAAACGTGTAACCAAGGTAAGTTCAGAGTTGTTAAA 1260  
 Patient 1 ATAAAGTTTCAAACGTGTAACCAAGGTAAGTTCAGAGTTGTTAAA 1260  
 \*\*\*\*\*  
 Patient 7 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 9 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 10 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 6 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 4 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 8 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 2 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 5 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 Patient 1 AGTAAAGGCTTGTGTTAAAGAGGGTAGTACAGTTGATTGAAACATTTTCTTTACTCAA 1320  
 \*\*\*\*\*  
 Patient 7 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 9 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 10 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 6 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 4 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 8 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 2 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 5 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 1 GATGGTAATGCTGCAATTACTGATTATAATTATATAAGTATAATTTACCTACTATGGTT 1380  
 \*\*\*\*\*  
 Patient 7 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 9 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 10 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 6 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 4 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 8 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 2 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 5 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 Patient 1 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440  
 \*\*\*\*\*  
 Patient 7 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 9 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 10 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 6 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 4 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 8 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 2 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 5 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 Patient 1 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAGTCTGGTTAT 1500  
 \*\*\*\*\*  
 Patient 7 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 9 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 10 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 6 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 4 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 8 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 2 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 5 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 1 CCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 \*\*\*\*\*  
 Patient 7 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 9 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 10 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 6 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 4 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 8 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 2 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 5 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 Patient 1 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCTCAAATGAATTTA 1620  
 \*\*\*\*\*  
 Patient 7 AAATATGCTATCAGTGCTAAGAAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 9 AAATATGCTATCAGTGCTAAGAAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 10 AAATATGCTATCAGTGCTAAGAAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 6 AAATATGCTATCAGTGCTAAGAAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 4 AAATATGCTATCAGTGCTAAGAAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680

FIG. 11 CONT.

181/201

Patient 8 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
Patient 2 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
Patient 5 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
Patient 1 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTCTATTCTTAGT 1680  
\*\*\*\*\*

Patient 7 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 9 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 10 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 6 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 4 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 8 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 2 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 5 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
Patient 1 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
\*\*\*\*\*

Patient 7 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 9 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 10 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 6 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 4 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 8 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 2 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 5 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
Patient 1 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
\*\*\*\*\*

Patient 7 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 9 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 10 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 6 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 4 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 8 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 2 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 5 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
Patient 1 CTTATAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
\*\*\*\*\*

Patient 7 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 9 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 10 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 6 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 4 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 8 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 2 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 5 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
Patient 1 GCTATGCCAAATATTTTGCCTATTGTTAGTAGTTTAGTTTTTGGCCCGCAAACATGAATTT 1920  
\*\*\*\*\*

Patient 7 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 9 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 10 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 6 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 4 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 8 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 2 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 5 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
Patient 1 TGTTGTTCCACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980  
\*\*\*\*\*

Patient 7 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 9 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 10 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 6 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 4 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 8 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 2 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 5 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
Patient 1 GAAATAGTTATGTTGTCGCGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
\*\*\*\*\*

Patient 7 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 9 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 10 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 6 GCAACTACTGCTTTTGTCTAATCTGTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100

FIG. 11 CONT.

182/201

Patient 4	GCAACTACTGCTTTTGCTAAATCTGTTTTTAATATATGTGAGGCTGTTACTGCTAACGTT	2100
Patient 8	GCAACTACTGCTTTTGCTAAATCTGTTTTTAATATATGTGAGGCTGTTACTGCTAACGTT	2100
Patient 2	GCAACTACTGCTTTTGCTAAATCTGTTTTTAATATATGTGAGGCTGTTACTGCTAACGTT	2100
Patient 5	GCAACTACTGCTTTTGCTAAATCTGTTTTTAATATATGTGAGGCTGTTACTGCTAACGTT	2100
Patient 1	GCAACCCTGCTTTTGCTAAATCTGTTTTTAATATATGTGAGGCTGTTACTGCTAACGTT	2100
*****		
Patient 7	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 9	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 10	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 6	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 4	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 8	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 2	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 5	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
Patient 1	TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA	2160
*****		
Patient 7	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 9	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 10	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 6	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 4	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 8	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 2	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 5	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
Patient 1	AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTGTTAATGAG	2220
*****		
Patient 7	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 9	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 10	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 6	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 4	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 8	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 2	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 5	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
Patient 1	TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC	2280
*****		
Patient 7	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 9	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 10	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 6	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 4	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 8	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 2	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 5	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
Patient 1	TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTTCAACAA	2340
*****		
Patient 7	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 9	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 10	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 6	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 4	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 8	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 2	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 5	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
Patient 1	GTTTTGTACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT	2400
*****		
Patient 7	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 9	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 10	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 6	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 4	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 8	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 2	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 5	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
Patient 1	ATTACTAATGGTCCTCATGAATTTTGTGCCAACATACCTATGTTGGTTAAGATAGATGGT	2460
*****		
Patient 7	GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTCTAGGAGCTGGTTGTTTGT	2520
Patient 9	GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTCTAGGAGCTGGTTGTTTGT	2520
Patient 10	GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTCTAGGAGCTGGTTGTTTGT	2520

FIG. 11 CONT.

183/201

Patient 6 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 4 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 8 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 2 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 5 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTTGTT 2520  
Patient 1 GACTATGTTTATCTACCCATATCCAGACCTTCTAGAATTTAGGAGCTGGTTGTTTTGTT 2520  
\*\*\*\*\*

Patient 7 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 9 GATGATTTATTGAAGACTGATAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 10 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 6 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 4 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 8 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 2 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 5 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
Patient 1 GATGATTTATTGAAGACTGACAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
\*\*\*\*\*

Patient 7 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 9 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 10 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 6 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 4 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 8 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 2 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 5 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
Patient 1 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
\*\*\*\*\*

Patient 7 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 9 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 10 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 6 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 4 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 8 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 2 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 5 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
Patient 1 TTAGAATATATAAAAAAAGTGTATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
\*\*\*\*\*

Patient 7 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 9 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 10 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 6 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 4 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 8 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 2 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 5 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
Patient 1 GTTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
\*\*\*\*\*

Patient 7 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 9 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 10 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 6 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 4 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 8 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 2 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 5 TATTTAAAAAGTGCCGTGATGCAG 2784  
Patient 1 TATTTAAAAAGTGCCGTGATGCAG 2784  
\*\*\*\*\*

FIG. 11 CONT.

184/201




FIG. 12

185/201

Fig. 13. Multiple alignment of the spike genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```

Patient 6      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 9      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 10     ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 5      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 4      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 7      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 2      ATGTTATTAATTATTTTATTTTGGCTACAACATTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 1      ATGTTTAAATTATTTTATTTTGGCTACAACACTAGCTGTTATAGGTGATTTTAAATTGT 60
Patient 8      ATGTTTAAATTATTTTATTTTGGCTACAACACTAGCTGTTATAGGTGATTTTAAATTGT 60
*****

Patient 6      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 9      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 10     ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 5      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 4      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 7      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 2      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 1      ACTAACTCTTTTATTAATGATTATAATAAACCATTCGCGGTATAAGCGAGGATGTTGTT 120
Patient 8      ACTAACTCTTTTATTAATGATTATAATAAACCATTCGCGGTATAAGCGAGGATGTTGTT 120
*****

Patient 6      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 9      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 10     GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 5      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 4      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 7      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 2      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 1      GATGATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTTTATTTAAATACTACC 180
Patient 8      GATGATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTTTATTTAAATACTACC 180
*****

Patient 6      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 9      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 10     ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 5      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 4      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 7      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 2      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAAATTTTAGGGATCTATCTTTAAAA 240
Patient 1      TTGTTATTTACAGGTTATTTCCCTAAATCTGGTGCTAATTTTAGAGACTTGGCTTTAAAG 240
Patient 8      TTGTTATTTACAGGTTATTTTCCTAAATCTGGTGCTAATTTTAGAGACTTGGCTTTAAAG 240
*****

Patient 6      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 9      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 10     GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 5      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 4      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 7      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 2      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCCCTTTTATCTGATTTTAAATAAT 300
Patient 1      GGTCTAAATATTTGAGTACTCTCTGGTATAAACCCCTTTTCGTCAGATTTTAAATAAT 300
Patient 8      GGTCTATATATTTGAGTACTCTCTGGTATAAACCCCTTTTCGTCAGATTTTAAATAAT 300
*****

Patient 6      GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 9      GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 10     GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 5      GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 4      GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 7      GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 2      GGTATTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAACTTTGTATAGTGAG 360
Patient 1      GGTATTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTATAGTGAA 360
Patient 8      GGTATTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTATAGTGAA 360
*****

Patient 6      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 9      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 10     TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 5      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 4      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 7      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 2      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420
Patient 1      TTTAGTACTATAGTTATAGGTAGTGTGTTTTATTAAACAACCTCTTATACTATTGTTGTTCAA 420

```

FIG. 13



186/201

Patient 8 TTTAGTACTATAGTTATAGGTAGTGTGTTTTGTTAACTTCTTATACTATTGTTGTTCAA 420  
\*\*\*\*\*

Patient 6 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 9 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 10 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 5 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 4 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 7 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 2 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCATACACTATGTTGAGTATCCTCAT 480  
Patient 1 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAGTATACTATGTTGAAATATCCTCAC 480  
Patient 8 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAGTATACTATGTTGAAATATCCTCAC 480  
\*\*\*\*\*

Patient 6 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 9 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 10 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 5 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 4 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 7 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 2 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 1 ACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
Patient 8 ACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCATTGTTGATAAATCTGAA 540  
\*\*\*

Patient 6 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 9 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 10 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 5 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 4 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 7 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 2 CCTTTGTGCTGTGTTCAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTGATTTT 600  
Patient 1 CCTTTATGCTGTGTTAAGAAAAATTTACTTATAATGTTTCTGCAGATTGGCTGTATTTT 600  
Patient 8 CCTTTATGCTGTGTTAAGAAAAATTTACTTATAATGTTTCTGCAGATTGGCTGTATTTT 600  
\*\*\*\*\*

Patient 6 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 9 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 10 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 5 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 4 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 7 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 2 CATTTTTATCAAGAACGTGGCAGCTTTTTATGCTTATTATGCTGATTCTGGCATGCCACT 660  
Patient 1 CATTTTTATCAAGAACGTGGTGTGTTTTTATGCATATTATGCAGATGTAGGTATGCCCTACC 660  
Patient 8 CATTTTTATCAAGAACGTGGTGTGTTTTTATGCATATTATGCAGATGTAGGTATGCCCTACC 660  
\*\*\*\*\*

Patient 6 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 9 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 10 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 5 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 4 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 7 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 2 ACTTTTTATTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 1 ACTTTCTTATTAGTTTATATTAGGTACTATTTTATCTCATTATTATGTTTATGCCTTTG 720  
Patient 8 ACTTTCTTATTAGTCTATATTAGGTACTATTTTATCTCATTATTATGTTTATGCCTTTG 720  
\*\*\*\*\*

Patient 6 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 9 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 10 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 5 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 4 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 7 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 2 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 1 ACTTGTAAGGCTATATCTTCTAATACTGACAATGAACTTTAGAATATTGGGTACACCG 780  
Patient 8 ACTTGTAATGCTATATCTTCTAATACTGACAATGAACTTTAGAATATTGGGTACACCG 780  
\*\*\*\*\*

Patient 6 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 9 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 10 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 5 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 4 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 7 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 2 TTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840

FIG. 13 CONT.

187/201

Patient 1 CTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTTATTACTAATGCCGTT 840  
Patient 8 CTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTTATTACTAATGCCGTT 840  
\*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \*

Patient 6 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 9 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 10 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 5 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 4 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 7 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 2 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAACTAAATCTTTATTACCTAAT 900  
Patient 1 GATTGTTCAAGTAGTTTCTTAGTGAGATTCAATGTAAACTCAATCTTTTGCACCTAAT 900  
Patient 8 GATTGTTCAAGTAGTTTCTTAGTGAGATTCAATGTAAACTCAATCTTTTGCACCTAAT 900  
\*\*\*\*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 9 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 10 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 5 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 4 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 7 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 2 ACTGGTGTTTATGACTTATCTGGTTTACTGTTAAGCCTGTTGCAACTGTACATCGTCGT 960  
Patient 1 ACTGGTGTTTATGATTGCTGCTGTTTACTGTTAAGCCTGTTGCAACTGTTTATCGTCGG 960  
Patient 8 ACTGGTGTTTATGATTGCTGCTGTTTACTGTTAAGCCTGTTGCAACTGTTTATCGTCGG 960  
\*\*\*\*\* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 9 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 10 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 5 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 4 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 7 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 2 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 1 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
Patient 8 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
\*\*\*\*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \*

Patient 6 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 9 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 10 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 5 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 4 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 7 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 2 CCTCTTAATTGGGAACGTAAAATTTTTCTAATTGCAACTTTAATTTGAGTACTTTGCTT 1080  
Patient 1 CCTCTTAATTGGGAACGTAGAATTTTTCTAATTGTAACCTCAATTTAAGCAGCTTTACTT 1080  
Patient 8 CCTCTTAATTGGGAACGTAGAATTTTTCTAATTGTAACCTCAATTTAAGCAGCTTTACTT 1080  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \*

Patient 6 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 9 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 10 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 5 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 4 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 7 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 2 CGTTTAGTTCATACTGATTCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140  
Patient 1 CGTCTAGTTCATGTTGATTCTTTTCTTGTAATAATCTTGATAAATCTAAAATTTTGGT 1140  
Patient 8 CGTCTAGTTCATGTTGATTCTTTTCTTGTAATAATCTTGATAAATCTAAAATTTTGGT 1140  
\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\* \*

Patient 6 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACTCCAGACGATCTGAT 1200  
Patient 9 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACTCCAGACGATCTGAT 1200  
Patient 10 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACTCCAGACGATCTGAT 1200  
Patient 5 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACTCCAGACGATCTGAT 1200  
Patient 4 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACTCCAGACGATCTGAT 1200  
Patient 7 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACTCCAGACGATCTGAT 1200  
Patient 2 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACTCCAGACGATCTGAT 1200  
Patient 1 AGTTGCTTTAATAGTATTACTGTTGACAAGTTTGTATACCTAATCGCAGACGAGATGAT 1200  
Patient 8 AGTTGCTTTAATAGTATTACTGTTGACAAGTTTGTATACCTAATCGCAGACGAGATGAT 1200  
\*\*\*\*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAATTATAAAATTTGACACTACTTCT 1260  
Patient 9 TTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAATTATAAAATTTGACACTACTTCT 1260  
Patient 10 TTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAATTATAAAATTTGACACTACTTCT 1260  
Patient 5 TTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAATTATAAAATTTGACACTACTTCT 1260  
Patient 4 TTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAATTATAAAATTTGACACTACTTCT 1260  
Patient 7 TTGCAGTTGGGCAGTTCTGGTTTCTGCAATCTTCTAATTATAAAATTTGACACTACTTCT 1260

FIG. 13 CONT.

188/201

Patient 2 TTGCAGTTGGGCAGTTCTGGTTTTCTGCAATCTTCTAATTATAAAATTGACACTACTTCT 1260  
Patient 1 TTGCAATTGGGCAGTTCTGGTTTTCTGCAATCATCTAATTACAAAATAGATATTTCTTCT 1260  
Patient 8 TTGCAATTGGGCAGTTCTGGTTTTCTGCAATCATCTAATTACAAAATAGATATTTCTTCT 1260  
\*\*\*\*\*  
Patient 6 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 9 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 10 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 5 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 4 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 7 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 2 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 1 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
Patient 8 AGTTCTTGTCGAATTGTATTATAGTTTGCCCTGCAATTAATGTTACTATTAAATAATTATAAT 1320  
\*\*\*\*\*  
Patient 6 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 9 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 10 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 5 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 4 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 7 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 2 CCTTCTTCTTGGGAATAGAAGGTATGGTTTTTAATAATTTTAATTTGAGCTCTCATAGTGT 1380  
Patient 1 CCATCTTCTTGGGAATAGAAGGTATGGTTTTGGTAGTTTTAATGTGCTCTTATGACGTT 1380  
Patient 8 CCATCTTCTTGGGAATAGAAGGTATGGTTTTGGTAGTTTTAATGTGCTCTTATGACGTT 1380  
\*\*  
Patient 6 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 9 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 10 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 5 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 4 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 7 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 2 GTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTTTTGCTTGTGCTAAACCTTCT 1440  
Patient 1 GTTTATCTGATCATTTGTTTTTCTGTTAACAAGCGACTTTTGCCCTTGTGCAGATCCGCT 1440  
Patient 8 GTTTATCTGATCATTTGTTTTTCTGTTAACAAGCGACTTTTGCCCTTGTGCAGATCCGCT 1440  
\*\*\*\*\*  
Patient 6 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 9 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 10 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 5 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 4 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 7 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 2 TTGCTTCAAGTTGCAAGAGTCATAAACACCTTCTGCTTCCGTCTTATTGGTACTAAT 1500  
Patient 1 GTTGTTAATCTTGTGTTAAATCTAAGCCTCTTTCTGCCATTGTCTGCTGCTACTAAA 1500  
Patient 8 GTTGTTAATCTTGTGTTAAATCTAAGCCTCTTTCTGCCATTGTCTGCTGCTACTAAA 1500  
\*\*\*  
Patient 6 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 9 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 10 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 5 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 4 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 7 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 2 TATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACTGATTGGTGTAGGTGTTCTTGT 1560  
Patient 1 TATCGTCATTGCGACTTGGATACTACTCTTTATGTTAATAACTGGTGTAGATGTTCTTGT 1560  
Patient 8 TATCGTCATTGCGACTTGGATACTACTCTTTATGTTAATAACTGGTGTAGATGTTCTTGT 1560  
\*\*\*\*\*  
Patient 6 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTT 1620  
Patient 9 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTC 1620  
Patient 10 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTT 1620  
Patient 5 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTT 1620  
Patient 4 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTT 1620  
Patient 7 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTT 1620  
Patient 2 TTACCTGATCCTATAACTGCTTATGACCTAGGCTTTGTTCTCAAAAAAGTCTCTGGTT 1620  
Patient 1 CTACCTGACCCATTCTACTTATCTCTTAACACATGCTCTCAAAAGAGGTGCTTGT 1620  
Patient 8 CTACCTGACCCATTCTACTTATCTCTTAACACATGCTCTCAAAAGAGGTGCTTGT 1620  
\*\*\*\*\*  
Patient 6 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 9 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 10 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 5 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 4 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680

FIG. 13 CONT.

189/201

Patient 7 GGTGTTGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 2 GGTGTTGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
Patient 1 GGTATAGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1675  
Patient 8 GGTATAGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1675  
\*\*\* \* \*\*\*\*\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 9 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 10 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 5 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 4 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 7 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 2 GGATCATATAATGTTCTTGCTTTGTAGTACTGATGCCCTTCTAGGTTGGTCTTATGAC 1740  
Patient 1 -AATTAATCATAGTTCCTGTTCTTGTAGTCCCTGATGCCCTTTTGGGTGGTCTTTTGAT 1734  
Patient 8 -AATTAATCATAGTTCCTGTTCTTGTAGTCCCTGATGCCCTTTTGGGTGGTCTTTTGAT 1734  
\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 9 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 10 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 5 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 4 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 7 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 2 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
Patient 1 AGTTGTATTAGTAATAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1794  
Patient 8 AGTTGTATTAGTAATAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1794  
\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 9 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 10 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 5 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 4 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 7 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 2 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1860  
Patient 1 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1854  
Patient 8 AGTGGTACCCTTGTCTAATGATTTATTGCAGCCCTAATCTGAAGTTTCTACTGATGTT 1854  
\*\*\*\*\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 9 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 10 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 5 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 4 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 7 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 2 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
Patient 1 TGTGTTAATTATGATCTTTATGGCATCAGGCCAAGGTATTTTTAAAGAAGTTTCTGCT 1914  
Patient 8 TGTGTTAATTATGATCTTTATGGCATCAGGCCAAGGTATTTTTAAAGAAGTTTCTGCT 1914  
\*\*\*\*\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 9 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 10 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 5 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 4 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 7 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 2 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
Patient 1 GCTTATTATAAATAATGGCAGAAATCTTTGTATGATTCTAATGGTAAATATTATTGGTTTT 1974  
Patient 8 GCTTATTATAAATAATGGCAGAAATCTTTGTATGATTCTAATGGTAAATATTATTGGTTTT 1974  
\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 9 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 10 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 5 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 4 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 7 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 2 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
Patient 1 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034  
Patient 8 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034  
\*\*\*\*\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Patient 6 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100  
Patient 9 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100  
Patient 10 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100  
Patient 5 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100

FIG. 13 CONT.

190/201

Patient 4 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100  
Patient 7 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100  
Patient 2 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAATGTAGC 2100  
Patient 1 GCTGCATTTTATCAAAATCTTCCTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094  
Patient 8 GCTGCATTTTATCAAAATCTTCCTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094  
\*\*\*\*\* \*\* \*\*\*\*\* \*\* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 9 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 10 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 5 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 4 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 7 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 2 TATGTTTTGAATAATATTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
Patient 1 TATGTTTTGAATAATATTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGGT 2154  
Patient 8 TATGTTTTGAATAATATTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGGT 2154  
\*\*\*\*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 9 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 10 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 5 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 4 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 7 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 2 TCGGTTTTTAATGCTGATAATTTAACTGATTATTCGTTCCTCTTGTGCTCTTCGCATG 2217  
Patient 1 TGTGTTTTGAATGCTGTTAATTTAACTAGCTATTCGTATCCTCTTGTGATTTCGCATG 2214  
Patient 8 TGTGTTTTGAATGCTGTTAATTTAACTAGCTATTCGTATCCTCTTGTGATTTCGCATG 2214  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \* \*\* \*\*\*\*\*

Patient 6 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 9 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 10 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 5 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 4 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 7 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 2 GGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCCTCTTCCTCTTCGCGTCGTAACGT 2277  
Patient 1 GGTAGTGGTTTTTGTATTGATTATGCTTTACCCCTCTTCT-----CGGCGTAAGCGT 2265  
Patient 8 GGTAGTGGATTTTGTATTGATTATGCTTTACCCCTCTTCT-----CGGCGTAAGCGT 2265  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \* \*\* \*\*\*\*\* \*\* \*\*\*\*\*

Patient 6 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 9 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 10 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 5 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 4 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 7 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 2 AGAAGTATTCTGCTTCTTATCGTTTTGTTACTTTTGAACCCCTTAATGTCAAGTTTGT 2337  
Patient 1 AGAGTATTCTCTCTCTTATCGCTTTGTAACCTTTGAACCCCTTAATGTAGTTTGT 2325  
Patient 8 AGAGTATTCTCTCTCTTATCGCTTTGTAACCTTTGAACCCCTTAATGTAGTTTGT 2325  
\*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 9 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 10 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 5 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 4 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 7 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 2 AATGACAGTATTGAGTCTGTGGGTGGTCTTTATGAGATCAAAATCCCACCTAATTTACT 2397  
Patient 1 AACGATAGTGTGAAACTGTTGGTGGTTATTTGAGATTGAGATTCCTACTAATTTACC 2385  
Patient 8 AACGATAGTGTGAAACTGTTGGTGGTTATTTGAGATTGAGATTCCTACTAATTTACC 2385  
\*\* \*\* \*\* \*\* \*\* \* \*\* \*\* \*\* \* \*\* \*\* \*\* \* \*\* \*\*

Patient 6 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 9 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 10 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 5 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 4 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 7 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 2 ATAGTTGGTCAAGAGGAATTTATTCAACTAATTCCTCTAAAGTTACTATTGATTGTTCT 2457  
Patient 1 ATAGCTGGTCATGAAGAATTTATTCAGACTAGTTCTCTCTAAAGTTACTATTGATTGTTCA 2445  
Patient 8 ATAGCTGGTCATGAAGAATTTATTCAGACTAGTTCTCTCTAAAGTTACTATTGATTGTTCA 2445  
\*\*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCAGTTTT 2517  
Patient 9 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCAGTTTT 2517  
Patient 10 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCAGTTTT 2517

FIG. 13 CONT.

191/201

Patient 5 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
Patient 4 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
Patient 7 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
Patient 2 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
Patient 1 GCTTTTGTTGCTCTAATTATGCTGCTTGTCATGATTTATTGTCGGAATATGGCACTTTT 2505  
Patient 8 GCTTTTGTTGCTCTAATTATGCTGCTTGTCATGATTTATTGTCGGAATATGGCACTTTT 2505  
\*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 9 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 10 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 5 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 4 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 7 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 2 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
Patient 1 TGCATAATATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTG 2565  
Patient 8 TGCATAATATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTG 2565  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 9 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 10 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 5 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 4 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 7 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 2 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTG 2637  
Patient 1 CAGGTTGCTAATGCTTTAATGCAAGGTGTTACACTTAGTCTAATCTTAATACTAATCTA 2625  
Patient 8 CAGGTTGCTAATGCTCTAATGCAAGGTGTTACACTTAGTCTAATCTTAATACTAATCTA 2625  
\*\* \*

Patient 6 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 9 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 10 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 5 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 4 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 7 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 2 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGGTTCCACACTGC 2697  
Patient 1 CACTCTGATGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTCCACAAATG 2685  
Patient 8 CACTCTGATGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTCCACAAATG 2685  
\*\* \*

Patient 6 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 9 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 10 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 5 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 4 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 7 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 2 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
Patient 1 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2745  
Patient 8 GGTTCTTCTCTCGTCTCTTTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2745  
\*\*\*\*\* \*\* \*

Patient 6 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 9 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 10 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 5 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 4 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 7 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 2 GTTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2817  
Patient 1 GTAGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2805  
Patient 8 GTAGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGTGAAATTAGAGATCTTCTT 2805  
\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 9 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 10 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 5 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 4 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 7 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 2 TGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATTTTGTCTGAATCTCAAATT 2877  
Patient 1 TGTGTACAATCCTTTAATGGTATTAAAGTTTACCTCCCATTTTATCTGAGACTCAAATT 2865  
Patient 8 TGTGTACAATCCTTTAATGGTATTAAAGTTTACCTCCCATTTTATCTGAGACTCAAATT 2865  
\*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 9 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937

FIG. 13 CONT.

192/201

Patient 10 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
 Patient 5 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
 Patient 4 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
 Patient 7 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
 Patient 2 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
 Patient 1 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTTCCGCCATGGTCTGCTGCTGCT 2925  
 Patient 8 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTTCCGCCATGGTCTGCTGCTGCT 2925  
 \*\*\*\*\* \*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\* \*\*

Patient 6 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 9 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 10 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 5 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 4 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 7 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 2 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
 Patient 1 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2985  
 Patient 8 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2985  
 \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 9 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 10 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 5 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 4 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 7 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 2 GTTCTTAATAAAATCAAAGTTGATAGCTACTGCTTTTAATAATGCTCTTCTTCTATT 3057  
 Patient 1 GTTCTTAATAAAGATCAAAGTTAATAGCTAATGCTTTTAATAAAGCTCTTCTTCTATC 3045  
 Patient 8 GTTCTTAATAAAGATCAAAGTTAATAGCTAATGCTTTTAATAAAGCTCTTCTTCTATC 3045  
 \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 9 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 10 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 5 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 4 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 7 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 2 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAATACAAAGTGTGTTAATTCT 3117  
 Patient 1 CAGAATGGTTTTACTGCTACTAATCTGCTCTTGCTAAAATACAAAGTGTGTTAATTCT 3105  
 Patient 8 CAGAATGGTTTTACTGCTACTAATCTGCTCTTGCTAAAATACAAAGTGTGTTAATTCT 3105  
 \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 9 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 10 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 5 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 4 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 7 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 2 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3177  
 Patient 1 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3165  
 Patient 8 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAAATTTGGTGCAATTAGT 3165  
 \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 9 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 10 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 5 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 4 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 7 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 2 TCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTTCAAGATTGAT 3237  
 Patient 1 TCTTCTTTACAAGAAATTTGTCTCGCTTGATAATTTAGAGGCTCAGGTTTCAAGATTGAT 3225  
 Patient 8 TCTTCTTTACAAGAAATTTGTCTCGCTTGATAATTTAGAGGCTCAGGTTTCAAGATTGAT 3225  
 \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 9 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 10 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 5 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 4 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 7 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 2 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
 Patient 1 AGGCTCATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGAT 3285  
 Patient 8 AGGCTCATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGAT 3285  
 \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 ATTTCTCTTGTAATAATTTGGTGCTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAA 3357

FIG. 13 CONT.

Patient	9	ATTTCTCTTGTAAAAATTGGTGCTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA	3357
Patient	10	A TTTC TCTT GTAAAA ATTGG TGCT GCTTT AGCT ATGGAGAAGGTTAATGAGTGTGTTAAA	3357
Patient	5	ATTTCTCTTGTAAAAATTGGTGCTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA	3357
Patient	4	A TTTC TCTT GTAAAA ATTGG TGCT GCTTT AGCT ATGGAGAAGGTTAATGAGTGTGTTAAA	3357
Patient	7	A TTTC TCTT GTAAAA ATTGG TGCT GCTTT AGCT ATGGAGAAGGTTAATGAGTGTGTTAAA	3357
Patient	2	ATTTCTCTTGTAAAAATTGGTGCTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA	3357
Patient	1	ATTACACTTATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAA	3345
Patient	8	ATTACACTTATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAA	3345
		*** * ** * ** *** ** *	
Patient	6	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	9	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	10	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	5	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	4	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	7	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	2	AGTCAATCCTCCGCGTATTAATTTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA	3417
Patient	1	AGTCAATCCCCGCGTATAAATTTTTTGTGGCAATGGTAACCACATTTTATCATTTGGTTCAA	3405
Patient	8	AGTCAATCCCCGCGTATAAATTTTTTGTGGCAATGGTAACCACATTTTATCATTTGGTTCAA	3405
		***** ***** ***** ***** ***** ** ***** ***** *****	
Patient	6	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	9	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	10	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	5	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	4	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	7	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	2	AATGTCCTTTATGGTTTGTGTGTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAACT	3477
Patient	1	AATGTCCTTTATGGTTTGTGTTTTCATTCATTTTAGTTATAAACCTACTTCTTTTAAAACT	3465
Patient	8	AATGTCCTTTATGGTTTGTGTTTTCATTCATTTTAGTTATAAACCTACTTCTTTTAAAACT	3465
		***** ***** * ** * ***** ***** ***** *****	
Patient	6	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	9	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	10	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	5	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	4	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	7	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	2	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3537
Patient	1	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3525
Patient	8	GTTTtagtaagtcctcggtttggtgatatacaggatgatgtaggattatgcacctaaacaagg	3525
		** ***** ***** **** ** ***** ***** ***** *****	
Patient	6	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	9	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	10	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	5	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	4	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	7	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	2	TATTTTATTAACAATAATGATCATTGGATGTTTCACGTTAGTCTTACTATTATCCTGAA	3597
Patient	1	TATTTTATTAACAATAATGATCCTCGGATGTTTACTGGTAGTTCCTATTATTACCAGAA	3585
Patient	8	TATTTTATTAACAATAATGATCCTCGGATGTTTACTGGTAGTTCCTATTATTACCAGAA	3585
		***** ***** ***** ***** ***** ** ***** ** **	
Patient	6	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	9	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	10	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	5	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	4	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	7	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	2	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCG	3657
Patient	1	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCT	3645
Patient	8	CCAATTTTCAGATAAAAAATGTTGTTTTATGAATACTTGTTCTGTTAATTTTACTAAAGCT	3645
		***** ***** ***** ***** ***** ** ***** ***** *****	
Patient	6	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	9	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	10	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	5	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	4	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	7	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	2	CCTCTTGTTTATTATTGAATCATCTCTGACCAAAATTGCTGATTTTGAATCTGAGTTATCT	3717
Patient	1	CCATTATTATTATCTTAATATCTATACCAAAATTGCTGATTTTGAAGCCGAGTTTCT	3705
Patient	8	CCATTATTATTATCTTAATATCTATACCAAAATTGCTGATTTTGAAGCCGAGTTATCT	3705
		** * ***** * ** ***** ***** ***** ***** *****	

FIG. 13 CONT.



194/201

```
Patient 6 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 9 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 10 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 5 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 4 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 7 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 2 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 1 CTTTGGTTTAAAAATCATACTTCTATAGCACCTAATTAAACCTTTAATTCTCATA---TT 3762
Patient 8 CTTTGGTTTAAAAATCATACTTCTATAGCACCTAATTAAACCTTTAATTCTCATA---TT 3762
* * * * *

Patient 6 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 9 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 10 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 5 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 4 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 7 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 2 AATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATTCAGAGTCTATTAAGTCT 3837
Patient 1 AATGCTACTTTTTAGATCTGTATTATGAATGAATGTTATTCAGGAATCTATTAATCT 3822
Patient 8 AATGCTACTTTTTAGATCTGTATTATGAATGAATGTTATTCAGGAATCTATTAATCT 3822
* * * * *

Patient 6 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 9 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 10 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 5 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 4 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 7 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 2 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAAATGG 3897
Patient 1 TTGAACAGTAGTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTAAATGG 3882
Patient 8 TTGAACAGTAGTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTAAATGG 3882
* * * * *

Patient 6 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 9 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 10 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 5 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 4 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 7 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 2 CCTTGGTATGTTTGGCTACTAATTTCTTTTTCATTATATAATATTCCTTGTATTGCTCTTT 3957
Patient 1 CCTTGGTACATTTGGTTGTTAATGTCATTTTATTTATAATTTTCTTATGATACTTTTC 3942
Patient 8 CCTTGGTACATTTGGTTGTTAATGTCATTTTATTTATAATTTTCTTATGATACTTTTC 3942
* * * * *

Patient 6 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 9 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 10 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 5 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 4 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 7 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 2 TTTATATGTTGTTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4017
Patient 1 TTTATATGCTGCTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4002
Patient 8 TTTATATGCTGCTGTACTGGTTGTGGTTCTGCATGTTTGTAGTAAATGTCATAATTGTTGT 4002
* * * * *

Patient 6 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 9 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 10 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 5 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 4 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 7 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 2 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 1 GATGAGTATGGGGTCCAAATGATTTTGTATTAAGCATCTCATGATGATTAG 4056
Patient 8 GATGAGTATGGGGTCCAAATGATTTTGTATTAAGCATCTCATGATGATTAG 4056
* * * * *
```

FIG. 13 CONT.

195/201

Fig. 14. Multiple alignment of the nucleocapsid genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```

Patient 4      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 6      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 7      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 9      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 10     ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 2      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 5      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 1      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 8      ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
*****

Patient 4      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 6      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 7      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 9      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 10     ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 2      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 5      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 1      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 8      ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
*****

Patient 4      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 6      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 7      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 9      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 10     GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 2      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 5      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 1      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
Patient 8      GGCAGAAAAACCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACATATCCCA 180
*****

Patient 4      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 6      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 7      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 9      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 10     CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 2      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 5      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 1      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 8      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
*****

Patient 4      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 6      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 7      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 9      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 10     GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 2      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 5      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 1      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
Patient 8      GATGGTCAAGGAGTTCCTTTCGCGGATACCCCTTCTGAAGCAAAAGGATATTGG 300
*****

Patient 4      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 6      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 7      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 9      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 10     TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 2      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 5      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 1      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 8      TATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
*****

Patient 4      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 6      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 7      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 9      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 10     AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 2      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 5      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 1      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 8      AGATGGTATTTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420

```

FIG. 14

196/201

Patient 8 AGATGGTATTCTACTATCTCGGTACCGGTCCATATGCCAGTTCATCCTATGGTGATGCC 420  
\*\*\*\*\*

Patient 4 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 6 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 7 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 9 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 10 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 2 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 5 CTCGAAGGGGCTTCTGGGTTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
Patient 1 CACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGACACTTCTATTCCCTCCGATGTT 480  
Patient 8 CACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGATACTTCTATTCCCTCCGATGTT 480  
\*\*\*\*\*

Patient 4 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 6 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 7 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 9 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 10 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 2 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 5 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 1 TCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
Patient 8 TCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTCCGCCGTGTACGATT 540  
\*\*\*\*\*

Patient 4 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 6 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 7 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 9 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 10 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 2 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 5 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 1 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
Patient 8 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
\*\*\*\*\*

Patient 4 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 6 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 7 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 9 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 10 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 2 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 5 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 1 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
Patient 8 TCACGTTCTCAATCACGTGGACCCAATAATCGTTTCATTAAGTAGAAGTAATCTAATTTT 660  
\*\*\*\*\*

Patient 4 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 6 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 7 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 9 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 10 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 2 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 5 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 1 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
Patient 8 AGACATTTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
\*\*\*\*\*

Patient 4 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 6 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 7 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 9 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 10 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 2 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 5 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 1 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
Patient 8 GCCAAGCTTGGTAAAGAACTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAAT 780  
\*\*\*\*\*

Patient 4 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
Patient 6 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
Patient 7 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
Patient 9 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
Patient 10 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
Patient 2 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
Patient 5 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840

FIG. 14 CONT.

197/201

```
Patient 1      AGGCATAAAATTTTAAATGAAACCTCGCCAAAAGCGAACTCCTAATAAATTTTGTAAATGTT 840
Patient 8      AGGCATAAAATTTTAAATGAAACCTCGCCAAAAGCGAACTCCTAATAAATTTTGTAAATGTT 840
*****

Patient 4      CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 6      CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 7      CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 9      CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 10     CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 2      CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 5      CAACAGTGTGTTTGGTAAAAGAGGACCTTCTCAAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 1      CAACAGTGTGTTTGGTAAAAGAGGACCGCTCCAAAACCTTTGGTAATGCTGAAATGTTAAAG 900
Patient 8      CAACAGTGTGTTTGGTAAAAGAGGACCGCTCCAAAACCTTTGGTAATGCTGAAATGTTAAAG 900
*****

Patient 4      CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 6      CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 7      CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 9      CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 10     CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 2      CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 5      CTTGGTACTAATGATCCTCAGTTTCCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 1      CTTGGTACTAATGATCCTCAATTCTTCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
Patient 8      CTTGGTACTAATGATCCTCAATTCTTCTATTCTTGCAGAAATTAGCTCCTACACCAAGGTGCT 960
*****

Patient 4      TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 6      TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 7      TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 9      TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 10     TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 2      TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 5      TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 1      TTTTCTTTGGTTCTAAATTAGAGTTGTTTAAAAGAGACTCTGATGCTGATTACCTTCT 1020
Patient 8      TTTTCTTTGGTTCTAAATTAGAGTTGTTTAAAAGAGACTCTGATGCTGATTACCTTCT 1020
*****

Patient 4      AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 6      AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 7      AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 9      AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 10     AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 2      AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 5      AAAGATGTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 1      AAAGACACTTTTGAACCTTCGTTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCTGGT 1080
Patient 8      AAAGACACTTTTGAACCTTCGTTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCTGGT 1080
*****

Patient 4      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 6      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 7      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 9      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 10     TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 2      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATCTAATCAG 1140
Patient 5      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATCTAATCAG 1140
Patient 1      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAGATGCTTATGTTAATCTAATCAG 1140
Patient 8      TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAGATGCTTATGTTAATCTAATCAG 1140
*****

Patient 4      AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 6      AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 7      AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 9      AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 10     AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 2      AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 5      AACACTGATTCGTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 1      AACACTGTTTCGGTTCGCTGAGTCTTAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200
Patient 8      AACACTGTTTCGGTTCGCTGAGTCTTAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200
*****

Patient 4      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 6      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 7      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 9      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 10     CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 2      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
```

FIG. 14 CONT.


198/201

```
Patient 5      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 1      CCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACATTTCAAATGATTTT 1260
Patient 8      CCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACATTTCAAATGATTTT 1260
** ***      *****

Patient 4      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 6      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 7      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 9      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 10     ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 2      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 5      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 1      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 8      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
*****

Patient 4      GCTTAA 1326
Patient 6      GCTTAA 1326
Patient 7      GCTTAA 1326
Patient 9      GCTTAA 1326
Patient 10     GCTTAA 1326
Patient 2      GCTTAA 1326
Patient 5      GCTTAA 1326
Patient 1      GCTTAA 1326
Patient 8      GCTTAA 1326
*****
```

FIG. 14 CONT.



200/201

	LPW1926	LPW1927	
HCoV-HKU1 (Patient 1)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 2)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 4)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 5)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 6)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 7)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 8)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 9)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 10)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-OC43 (NC_005147)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
SARS-CoV (NC_004718)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../TTACCTGTAAGCATTTTAGTATGATGAT		2270
HCoV-229E (NC_002645)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../TTATTTGTAAGCATTTTAGTATGATGAT		2255
HCoV-NL63 (NC_005831)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../TTATCTTGAAGCATTTTAGTATGATGAT		2255

FIG. 16

201/201




FIG. 17



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CN2005/001088

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup> C12N 15/50 C12N 15/63 C12N 7/00 C07K14/165 A61K39/215 A61P11/00 G01N33/53 C12Q1/68  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup> C12N, C07K, A61K, A61P, G01N, C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Data Base: EPODOC, WPI, CNPAT, CNKI, CA, BA; Search Terms: human, coronavirus, hcov, genomic sequence

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US6057436A (PFIZER INC ET-AL) 2.MAY 2000 (02.05.2000), see the whole document	1-74
A	WO0139797 A2 (CONSEJO SUPERIOR INVESTIGACIONES CIENTIF ET-AL) 7.JUN 2001 (07.06.2001), see the whole document	1-74
A	CN1450173A (BENYUAN ZHENGYANG GENE TECHNOLOGY CO LTD) 22.OCT 2003(22.10.2003), see the whole document	1-74

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance

“E” earlier application or patent but published on or after the international filing date

“L” document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)

“O” document referring to an oral disclosure, use, exhibition or other means

“P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&”document member of the same patent family

Date of the actual completion of the international search  
12.OCT 2005(12.10.2005)

Date of mailing of the international search report

27. OCT 2005 (27.10.2005)

Name and mailing address of the ISA/CN  
The State Intellectual Property Office, the P.R.China  
6 Xitucheng Rd., Jimen Bridge, Haidian District, Beijing, China  
100088  
Facsimile No. 86-10-62019451

Authorized officer

Wang Qiyang

Telephone No. (86-10)62085348

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/CN2005/001088

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
US6057436A	2.MAY 2000 (02.05.2000)	CA2096010A1	17.MAY1992 (17.05.1992)
		IE913948A1	20.MAY1992 (20.05.1992)
		WO9208487A1	29.MAY1992 (29.05.1992)
		AU9128691 A	11.JUN 1992 (11.06.1992)
		ZA9108988 A	30.JUN 1992 (30.06.1992)
		EP0557455 A1	1.SEP 1993 (01.09.1993)
		CA2135200A1	11.NOV 1993 (11.11.1993)
		WO9323423A1	25.NOV 1993 25.11.1993)
		AU4251593A	13.DEC 1993 (13.12.1993)
		JP6502768T	31.MAR 1994 (31.03.1994)
		NZ240558 A	25.NOV 1994 (25.11.1994)
		EP0640098 A1	1.MAR 1995 (01.03.1995)
		JP7508421T	21.SEP 1995 (21.09.1995)
		JP3245169B2	7.JAN 2002 (07.01.2002)
		AU666298B2	8.FEB 1996 (08.02.1996)
		AU670092B2	4.JUL 1996 (04.07.1996)
		KR204258B1	15.JUN 1999 (15.06.1999)
		US6057436A	2 .MAY 2000 (02.05.2000)
		US6280974B1	28 .AUG 2001 (28.08.2001)
		US6372224 B1	16 .APR 2002 (16.04.2002)
		AT225805T	15 .OCT 2002 (15.10.2002)
		DK640098T	28.OCT 2002 (28.10.2002)
		DE69332375 D1	14 .NOV 2002 (14.11.2002)
		PT640098T	31.JAN 2003(31.01.2003)
		DE69332375T	13 .FEB 2003 (13.02.2003)
		ES2182827T	16 .MAR 2003 (16.03.2003)
		JP2003093078 A	2 .APR 2003 (02.04.2003)
WO0139797 A2	7.JUN 2001 (07.06.2001)	AU200130051 A	12.JUN 2001 (12.06.2001)
		BR200016145 A	13.AUG 2002 (13.08.2002)
		ES2170622 A1	1.AUG 2002 (01.08.2002)
		NO200202419 A	30.JUL 2002 (30.07.2002)
		EP1234024 A2	28.AUG 2002 (28.08.2002)
		SK200200761 A3	6.NOV 2002 (06.11.2002)
		CZ200201882 A3	13.NOV 2002 (13.11.2002)
		KR2002060251 A	16.JUL 2002 (16.07.2002)
		HU200203305 A2	28.JAN 2003 (28.01.2003)
		ZA200203560 A	26.MAR 2003 (26.03.2003)
		JP2003515335T T	07.MAY 2003 (07.05.2003)
		CN1402780 A	12.MAR2003 (12.03.2003)
		US2003148325 A1	07.AUG 2003 (07.08.2003)
		NZ518990 A	26.MAR 2004 (26.03.2004)
		US2004086846 A1	6.MAY 2004 (06.05.2004)
		EP1234024 B1	19.MAY 2004 (19.05.2004)
		ES2170622 B1	16.MAY 2004 (19.05.2004)
		DE60010921E E	24.JUN 2004 (24.06.2004)
		EP1437400 A2	14.JUL 2004 (14.07.2004)
CN1450173A	22.OCT 2003(22.10.2003)	NONE	